<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.2/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.2/"
>

<channel> 
	<title>Compass</title>
	<link>http://localhost/wordpress</link>
	<description>Blah blah</description>
	<pubDate>Sun, 07 Feb 2016 14:06:19 +0000</pubDate>
	<language>en-US</language>
	<wp:wxr_version>1.2</wp:wxr_version>
	<wp:base_site_url>http://localhost/wordpress</wp:base_site_url>
	<wp:base_blog_url>http://localhost/wordpress</wp:base_blog_url>

	<wp:author>
		<wp:author_id>5</wp:author_id>
		<wp:author_login><![CDATA[spoon]]></wp:author_login>
		<wp:author_email><![CDATA[georges.guigui@spoonconsulting.com]]></wp:author_email>
		<wp:author_display_name><![CDATA[spoon]]></wp:author_display_name>
		<wp:author_first_name><![CDATA[]]></wp:author_first_name>
		<wp:author_last_name><![CDATA[]]></wp:author_last_name>
	</wp:author>

	
			<item>

	<title>Key Developments in Hepatocellular Carcinoma - Feedback From The EASL Meeting</title>
	<pubDate>2012-04-30T13:21:03+02:00</pubDate>
	<wp:post_id>3000</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Leerink &amp; Swann Analysts have published an interesting review of ongoing developments in hepatocellular cancer following the recent European Association Meeting for the Study of the Liver (EASL).<wbr> BMS's brivanib appears to have an equal but differentiated tolerability profile to Bayer's Nexavar and with a number of upcomging studies likely to be presented at ASCO, 2012 could well be a defining year for the future treatment landscape of HCC.<wbr> </div><div style="margin-bottom: 10px;">ARQL's tivantinib and Lilly's preliminary data announced on the former from a randomized Phase II trial, which is uncommon in HCC, looking positive.<wbr> ASCO data is expected to potentially generate further interest in this agent, and important new data could include biomarker data as well as OS data.<wbr> </div><div style="margin-bottom: 10px;">Ramucirumab, a VEGFR-2 antibody has also demonstrated a signal of efficacy without major toxicity.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8243_1_ScreenCapture1.jpg"> </div><div>For access to the analyst's full report on this subject please contact Jacquelyne Cantle </div><!-- Comment details --><a name="oncology8243attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8243_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(228,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8243">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-30T13:21:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-30T13:21:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Highlights New Presentation of Sandostatin LAR In Q1 Press Release</title>
	<pubDate>2012-04-30T12:56:48+02:00</pubDate>
	<wp:post_id>3001</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis recorded a solid first quarter sales and earnings picture despite the increased impact of generic competition to Femara and Diovan.<wbr> Sandostatin sales grew by 11% driven predominantly by US growth.<wbr> Importantly, it was noted that 8 countries have approved a new presentation of Sandostatin LAR, which includes a new diluent, safety needle and vial adapter improving the mixing and administration of the product.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Overall Sales Picture </STRONG> </div><div style="margin-bottom: 10px;">The contribution of new products to Novartis's overall growth picture is shown below </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6917_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The star performers amongst the group's key products were Affinitor (renal cancer and pNET), Gilenya (multiple sclerosis) and Glavus (diabetes).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sandostatin Sales Picture</STRONG> </div><div style="margin-bottom: 10px;">Sandostatin sales grew by 11% in constant currencies to reach $370 million with growth underpinned by increasing use of Sandostatin LAR in key markets to treat symptoms of patients with neuroendocrine tumors.<wbr> US sales grew by 26% in constant currencies whilst sales in the ROW by only 2% </div><div style="margin-bottom: 10px;">Based on the PROMID data, approvals have been granted in nearly 30 countries for the delay of tumor progression in patients with midgut carcinoid tumors.<wbr> These data are currently under review for inclusion in the label in more than 15 additional countries.<wbr> Additional filings are underway for the new Sandostatin LAR formulation.<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6917_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Key Development Projects/<wbr>Regulatory Timelines</STRONG> </div><div style="margin-bottom: 10px;">From a development perspective, Novartis noted that it refiled for Cushing's disease in the US in the first quarter and expects approval in the second half of 2012.<wbr> </div><div style="margin-bottom: 10px;">Everolimus was submitted to regulatory agencies around the world in the fourth quarter of 2011 as a potential treatment for postmenopausal women with advanced breast cancer that recurred or progressed despite treatment with hormonal therapies.<wbr> </div><div style="margin-bottom: 10px;">In its development update, Novartis noted that 1st filings for Afinitor in hepatocellular cancer and GI/<wbr>Lung Net are planned for 2015.<wbr> </div><div style="margin-bottom: 10px;">Novartis confirmed that the full development data from the phIII trials with pasireotide in acromegaly will be released at the upcoming ECE meeting next week </div><div>It also confirmed in its press release what had already been identified at the ENETs meeting in March that a  study of pasireotide LAR versus octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues was closed based on a futility study showing that it was unlikely to meet its primary endpoint.<wbr> It notes that no new or unexpected serious adverse events were identified for pasireotide and safety was not a factor in the decision to close the study and that other studies evaluating pasireotide as a tumor control agent continue unaffected by this decision.<wbr> </div><!-- Comment details --><a name="endocrinology6917attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6917_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6917_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(80,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6917">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-30T12:56:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-30T12:56:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Milestone for GSK's Rotarix™</title>
	<pubDate>2012-04-30T10:51:32+02:00</pubDate>
	<wp:post_id>3002</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GSK will supply to the Global Alliance for Vaccines and Immunisation (GAVI) &gt;132 million doses of the vaccine over 5 years at a 95% reduction of the price to developed Western countries.<wbr> The vaccine will be introduced into the newly started national vaccination programme in Ghana.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">GAVI's objectives are to cover &gt;40 countries by 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Has been introduced in 5 GAVI eligible countries: Nicaragua, Honduras, Bolivia, Guyana and Sudan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>April 2009 - the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) recommended that rotavirus vaccination be included in all national immunisation programmes.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120431&edate=20120101&rec=1838">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-30T10:51:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-30T10:51:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Named as One of the "Best Places to Work in New Jersey"</title>
	<pubDate>2012-04-27T19:44:59+02:00</pubDate>
	<wp:post_id>3003</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The "Best Places to Work in New Jersey" ranking is a prestigious recognition of New Jersey-based companies that show a dedication to their employees' growth and quality of life.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Will be provided in the April 30 issues of NJBIZ.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Companies from across the stNew-Jersey State entered the two-part process to determine the 100 Best Places to Work in New Jersey.<wbr> </div><div><UL><LI>The first part (consisted of evaluating each nominated company's workplace policies, practices, philosophy, systems and demographics)  was worth approx.<wbr> 25% of the total evaluation.<wbr> </LI>
<LI>The second part (consisted of an employee survey to measure the employee experience) was worth approximately 75% of the total evaluation.<wbr> </LI>
<LI>The combined scores determined the top companies and the final ranking.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9861">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-27T19:44:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-27T19:44:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Selected Key Messages on Amylin's Bydureon (Once-Weekly Exenatide) for Diabetes</title>
	<pubDate>2012-04-27T14:20:17+02:00</pubDate>
	<wp:post_id>3004</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During the release of its Q1 financial results the company reported that it is 10 wks into the launch of Bydureon in the US, and it has gained &gt;5% of the GLP-1 market.<wbr> When it comes to development, Management highligted that a pen device is expected to be launched by the end of 2012 or in early 2013).<wbr> Regarding the weekly and the monthly suspension, it was reported that Ph3 trials are expected to start mid-2012, and at the beginning of 2013 respectively.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management highlighted that Ex-US partnership negotiations are "going well".<wbr> </div><div>Amgen have put in dossiers to the Italian and Spanish authorities for pricing and reimbursement, but haven't yet approached France relative to a dossier for pricing in France.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6916">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-27T14:20:17+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-27T14:20:17+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Rejects Amgen's Application for XGEVA (denosumab) for Prevention of Bone Metastases in CRPC Patients</title>
	<pubDate>2012-04-27T12:33:39+02:00</pubDate>
	<wp:post_id>3005</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The agency has determined that the risks (including osteonecrosis of the jaw) outweigh the effect of the drug, and has requested a new trial to demonstrate a positive risk benefit profile in the broader CRPC population.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Approved for the prevention of SREs in patients with bone metastases from solid tumours </div><div>Xgeva is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8240">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-27T12:33:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-27T12:33:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Greece Publishes List of Diseases and Reimbursed Drugs</title>
	<pubDate>2012-04-26T15:15:46+02:00</pubDate>
	<wp:post_id>3006</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Greece's National Organisation for Medicines (EOF) has published a list of the diseases and disease areas and medicines that are covered 100% under the public health system, requiring no patient co-payments, and also a list of those diseases and associated drugs for which patients must pay a 10% co-payment.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>List of 100% Reimbursed Diseases</B></P> </div><div style="margin-bottom: 10px;">A list of 100% reimbursed diseases is given, with all the medicines that can be reimbursed for patients with these diseases.<wbr> The list of these diseases is as follows: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Neoplasms of all systems and leukemia 
</LI>
<LI>Type 1 diabetes 
</LI>
<LI>Psychoses 
</LI>
<LI>Epilepsy 
</LI>
<LI>Alzheimer's disease 
</LI>
<LI>Thalassemia 
</LI>
<LI>Sickle cell anaemia 
</LI>
<LI>Idiopathic thrombocytopenic purpura 
</LI>
<LI>Haemophilia 
</LI>
<LI>Dwarfism (human growth hormone deficiency) 
</LI>
<LI>Hepatitis types B and C 
</LI>
<LI>Pulmonary hypertension 
</LI>
<LI>Multiple sclerosis 
</LI>
<LI>Renal failure (nephropathy) 
</LI>
<LI>Drugs to prevent transplant rejection 
</LI>
<LI>Gaucher's disease, Nieman-Pick disease type C, Wilson disease, hyperphenylalaninaemia 
</LI>
<LI>Cystic fibrosis 
</LI>
<LI>HIV/<wbr>AIDS 
</LI>
<LI>Vaccines in a national vaccination programme (full reimbursement only in the case of certain age limits and population groups)</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>List of Diseases with 10% Co-Payment for Drugs</B></P> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Parkinson's disease 
</LI>
<LI>Type 2 diabetes 
</LI>
<LI>Lupus, vasculitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis 
</LI>
<LI>Osteoporosis and Paget disease 
</LI>
<LI>Myasthenia gravis 
</LI>
<LI>Tuberculosis 
</LI>
<LI>Chronic obstructive pulmonary disease 
</LI>
<LI>Ulcerative colitis, Crohn's disease 
</LI>
<LI>Congenital ichthyosis 
</LI>
<LI>Hereditary angioedema 
</LI>
<LI>Chronic rheumatic heart disease, chronic pulmonary heart disease</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Outlook and Implications</B></P> </div><div style="margin-bottom: 10px;">All other medicines on the positive list—and by implication, all other diseases—require a patient co-payment of 25%.<wbr> </div><div style="margin-bottom: 10px;">Among the medicines that are listed by the EOF as being 100% reimbursed and those requiring a 10% co-payment, there are considerable numbers of high-cost innovative medicines.<wbr> Clearly, for many of these medicines, particularly for cancer and rare diseases, it would not be expected for patients to contribute, considering their very high cost.<wbr> However, there may be questions about certain other medicines, for example those for the treatment of type 1 and type 2 diabetes; in Greece, a wide range of high-cost treatments are available for these conditions, where other European countries with much better economic situations than Greece faces are much more circumspect about their reimbursement.<wbr> Both major insulin analogues Lantus (insulin glargine; Sanofi, France) and Levemir (insulin detemir; Novo Nordisk, Denmark) are fully reimbursed in Greece, as are almost all the new-generation oral type 2 diabetes medicines, whereas in a country such as Poland, which has a GDP per capita almost comparable with Greece (USD20,334 in 2011, compared with Greece's USD26,294, according to the International Monetary Fund), none of these medicines are generally reimbursed.<wbr> In Germany, the two aforementioned drugs are also not subject to reimbursement.<wbr> </div><div style="margin-bottom: 10px;">Thus, it can be seen that Greece continues to have a strongly pro-innovation and generous reimbursement system, although it remains to be seen whether this is a sustainable proposition, even with improvements in efficiency from electronic prescribing and greater use of generics for off-patent medicines.<wbr> </div><div>From Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9860">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-26T15:15:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-26T15:15:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence from ESOU 2012 – Part 3 – Advanced and Metastatic PC</title>
	<pubDate>2012-04-26T14:45:30+02:00</pubDate>
	<wp:post_id>3007</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The very last session of the conference was dedicated to evolving treatment trends.<wbr> For the time being, surgery was highlighted by Pr Van Poppel as the most important first step for optimal treatment of high risk prostate cancer, and RT in the adjuvant or salvage setting.<wbr> Pr Kramer believes immunotherapy has a place at an early stage setting and, probably the future, as part of combination therapy.<wbr> For Pr Osanto, personalized medicines will change the landscape, and thus chemotherapy will be limited.<wbr> Pf Miller expected new drugs in pre and post docetaxel to completely alter the landscape for CRPC within the next 2 years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pr Van Poppel</STRONG> started his session highlighting the need to know which type of definitions has been used when it is reported on high risk (HR).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Also, depending on how high risk is defined, there is a difference in progression free probability from 35 to 76%.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">There is an increasing rate of HR patients treated with surgery, and one has moved from wondering whether surgery is an option to whether it might be the preferred therapeutic option.<wbr> Retrospective series show good OS when primarily treated with surgery (Berger et al.<wbr> Eur Urol 58:8-11, 2010).<wbr> </div><div style="margin-bottom: 10px;">Today, radical prostatectomy (RP) is optional in selected patients with low volume high risk localised disease.<wbr> Patient selection is key.<wbr> The EMPaCT-Study Group gathered a database of 1632 patients with HR PC.<wbr> Outcomes were recently published.<wbr> (Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer - Briganti et al.<wbr> Eur Urol <B>2012</B>; 61:584-592).<wbr> </div><div style="margin-bottom: 10px;">He questioned what to do (surgery or radiation) with patients having adverse pathology </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Local control matters and maybe RT is not the best option.<wbr> RP always yields the best local control (D’Amico et al.<wbr> JCO 2003; 21:2163-72).<wbr> For HR patients this is an important difference.<wbr> </div><div style="margin-bottom: 10px;">His conclusions outlined that : </div><div style="margin-bottom: 10px;"><UL><LI>RP for HR PC is increasing at high volume centers</LI>
<LI>Not all HR patients have the same prognosis</LI>
<LI>A multimodal approach is key, but surgery offers a tailoring eventual adjuvant or salvage treatment measures</LI>
<LI>Despite evidences reporting a more favourable outcome for surgically treated patients as compared to those treated with RT, prospective randomized trials remain needed.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Pr Kramer</STRONG> gave an overview of the Pros and Cons of Sipuleucel-T (Provenge) treatment.<wbr> Some areas of concern with OS benefit of the vaccine for CRPC patients were highlighted.<wbr> </div><div style="margin-bottom: 10px;">No measurable tumour response (TR) after Sipuleucel-T in CRPC </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Dendreon has not put a high priority on measuring immune response in their patients.<wbr> However, effective immune monitoring has never been shown for any immunotherapy in cancer treatment.<wbr> </div><div style="margin-bottom: 10px;">The age dependence was a major issue with the vaccine (<STRONG>unpublished data from FDA documents</STRONG>): </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Vaccination strategy is less effective in the elderly.<wbr> Age-related impairments of the immune system: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Pr Kramer believes it is probably easier to use treatments of checkpoints inhibitors in the future like CTL4-targeted antibody or PD1-targeted abtibody which block receptors on the T-cells which usually turn off the immune response.<wbr> Two studies of ipilimumab in CRPC (NCT01057810; NCT00861614) were cited.<wbr> He highlighted that combination therapy should enhance the immunogenic effects in PC patients, and thus probably be the future.<wbr> </div><div style="margin-bottom: 10px;">He concluded giving his personal perspective regarding immunotherapy for PC: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">For<STRONG> Pr Osanto</STRONG> <SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px/18px arial, verdana; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px/18px arial, verdana; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px/18px arial, verdana; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN>pointed out that CRPC treatment landscape will change to personalized medicine.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">For <STRONG>Pr Miller </STRONG>there<STRONG> </STRONG>will not be much change in hormone therapy for the next 2-3-4 years.<wbr> Regarding Provenge, he believes it ill not be available in EU within the next 2-3 years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Abiraterone (will be in the 1st place of the sequence of CRPC)</LI>
<LI>Docetaxel</LI>
<LI>MDV3100</LI>
<LI>Cabazitaxel</LI>
<LI>Zoledronic acid</LI>
<LI>Denosumab</LI>
</UL> </div><div style="margin-bottom: 10px;">Where is the place of Alpharadin ? can it be combined with abiraterone? Yes; combined with docetaxel? Yes; sequenced ? most probably Yes </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>MDV3100 (the PREVAIL trial) results expected ASCO 2013 (question will be: first use of abiraterone or first use of MDV3100 ? or both in combination (although different targets bor both drugs)</LI>
<LI>Abiraterone</LI>
<LI>TAK700</LI>
<LI>Docetaxel</LI>
<LI>Cabazitaxel</LI>
<LI>Zoledronic acid</LI>
<LI>Denosumab</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>More drugs coming (Prostvac; Cabozantinib; TOK001; OGX011)</LI>
</UL> </div><div>When it comes to predictive markers, Pr Miller highlighted that they are needed in CRPC to better tailor the therapy to the patients.<wbr> </div><!-- Comment details --><a name="oncology8238attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(47,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(58,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(121,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(103,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(82,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(36,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8238_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(60,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8238">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-26T14:45:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-26T14:45:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spanish Government Confirms Healthcare Reforms</title>
	<pubDate>2012-04-25T17:51:47+02:00</pubDate>
	<wp:post_id>3008</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Although the government has highlighted expected savings of around EUR400–450 million through defunding, in reality, the process could exceed this as the government appears intent on imposing stricter reimbursement criteria and a centralised procurement process.<wbr> </div><div style="margin-bottom: 10px;">The industry has avoided outright price cuts, but these new procedures will provide longer-term market access barriers to the Spanish market.<wbr> Clearly, the discourse since the announcement has centred on an emerging perception that the industry has been spared austerity in favour of more financially vulnerable pensioners.<wbr> The precise nature of the defunding mechanisms and centralised procurement system may eventually evolve and turn into a major problem area for the industry.<wbr> Industry association Farmindustria has issued a statement regretting that the majority of the weight of the new measures will indeed fall on the industry.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Spanish government yesterday (24 April) approved the Royal Decree-Law 16/<wbr>2012, which outlines a series of new measures to restrict demand and supply of healthcare services and products in Spain.<wbr> The measure is a direct result of the government's attempts to grapple with national and international demands for the country to balance its budget, as well as a directive that education and healthcare would be the source of enhanced savings.<wbr> Budget minister Cristóbal Montoro concomitantly presented the 2012 budget, which included EUR27 billion (USD36 billion) in austerity measures.<wbr> The outline of the reform agenda was made last week.<wbr> </div><div style="margin-bottom: 10px;">There are no major surprises in the actual decree, which was published in the Official Gazette slightly later than anticipated (it had been expected to go through on 20 April).<wbr> From 2013, pensioners will also have to pay part of their prescription costs.<wbr> Responsibility for the reforms will ultimately lie with the autonomous regions, which will have stricter criteria to reduce their budget deficits.<wbr> </div><div style="margin-bottom: 10px;">Significant uncertainty remains over the precise nature of some of the reforms, particularly around the new centralised purchasing mechanism and new health technology assessment systems.<wbr> The new cost-effectiveness body had previously been announced last August, but there are no new details of its precise methodology and remit, beyond acting as a "NICE [National Institute for Health and Clinical Excellence]-like body".<wbr> It will be composed of eight sub-groups and provide economic analysis on the therapeutic value of reimbursed medicines.<wbr> </div><div style="margin-bottom: 10px;">As a general goal, the law outlines that defunding of medicines will serve the purpose of removing drugs where funding "is not deemed necessary to meet the health needs of the Spanish population", or for drugs that may be effective but treat minor symptoms.<wbr> The new auctioning and tendering of medicines will have an adapting pricing mechanism proposed by the Ministry of Health (MoH) to the Interministerial Commission on Drug Prices.<wbr> The MoH will be able to propose an original ceiling price to drug companies, which will be followed by vendor responses and a selection process for the best price, which will be valid for two years.<wbr> These prices will also be exempt from the previous 4%, 7.<wbr>5%, and 15% price cuts that have been implemented in Spain during 2010 and 2011.<wbr> The basis for the price mechanism will include reference prices based on therapeutic groups.<wbr> </div><div>From Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9859">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-25T17:51:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-25T17:51:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medy-Tox Has Started Ph3 of Neuramis (HA Filler) for the Correction of Nasobial Folds</title>
	<pubDate>2012-04-25T17:28:50+02:00</pubDate>
	<wp:post_id>3009</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Two sites in Korea are currently recruiting approx.<wbr> 69 participants (30 to 75 years; both genders).<wbr> Efficacy is evaluated based on the change in Wrinkle Severity Rating Scale (WSRS) from baseline.<wbr> Safety will be assessed based on 24 weeks FU visits, and subject diary which will be given to subjects during the first 2 weeks after the injection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01585220?recr=Open&amp;fund=2&amp;rcv_s=04%2F11%2F2012&amp;rank=29"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: Feb.<wbr> 2012 - Completion date: Aug.<wbr> 2012 /<wbr> Oct.<wbr> 2012.<wbr> </div><div style="margin-bottom: 10px;">Design: Restylane as active comparator </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6368_1_ScreenCapture1.jpg"> </div><div>PI: Chan Yeong Heo (Seoul National U.<wbr> Bundang Hospital); Saik Bang (Samsung Medical Center).<wbr> </div><!-- Comment details --><a name="neurology6368attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6368_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(22,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6368">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-25T17:28:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-25T17:28:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Signifor® (pasireotide) Approved in EU for Cushing</title>
	<pubDate>2012-04-25T17:11:13+02:00</pubDate>
	<wp:post_id>3010</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pasireotide is the first medical treatment for Cushing's Disease that targets the pituitary gland.<wbr><WBR> It will be given by sc injection twice daily.<wbr></WBR><WBR> The drug will be launched in May 2012 as planned by the company.<wbr></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>The decision follows the positive opinion the CHMP adopted for the drug in January 2012 for the treatment of Cushing's disease and applies to all 27 EU member states, plus Iceland and Norway.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6915">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-25T17:11:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-25T17:11:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence from ESOU 2012 - Part 2 - Does White or Blue Light Cytoscopy/Resection Matter Clinically ?</title>
	<pubDate>2012-04-25T14:19:24+02:00</pubDate>
	<wp:post_id>3011</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A debate on whether the use of white or blue light cytoscopy/<wbr>resection matters clinically was organised between Professor de Reike from Netherlands and Professor O’Brien from UK.<wbr> Key messages are outlined below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">For <STRONG>Pr de Reijke</STRONG> clearly the answer is 'YES', it does matter clinically.<wbr> </div><div style="margin-bottom: 10px;">He outlined the challenges in bladder cancer management, such as increasing the detection of bladder cancer, the reduction of residual tumours and recurrent rate.<wbr> </div><div style="margin-bottom: 10px;">Photodynamic diagnosis (PDD) is a significant prognostic factor as it provides better resection vs standard endocscopy, and reduces recurrent rate.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>P O’Brien</STRONG> reported that PDD using Hexvix is clearly “a stunning diagnostic tool”.<wbr> But the question is: Does this visual clarity translate into reduced recurrence by using the technique? </div><div style="margin-bottom: 10px;">How good is the evidence ? </div><div style="margin-bottom: 10px;"><UL><LI>Studies mix up at the beginning new and recurent tumours, and it is difficult to speak about recurrence.<wbr> Very few studies in the literature which only have new tumours in.<wbr> </LI>
<LI>Controles not treated optimally (i;e no single shot MMC)</LI>
<LI>Histological endpoints not recurrence endpoints, which matter to patients</LI>
<LI>Are all of the 'extra lesions' really significant tumours ?</LI>
<LI>How many times PPD detect the only CIS ? CIS with no G3 tumour or other CIS would you have used BCG anyway ?</LI>
<LI>ALA in many trials, not Hexvix</LI>
<LI>Multiple reporting of very positive studies (i;e Filbeck) &gt; 'brilliant' piece of work, in terms of the effects</LI>
<LI>Does the surgeon try harder under blue light ? &gt; 'big issue'</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Findings of a randomised clinical trial @ the Guys Hospital</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Duration: 5 years</LI>
<LI>Recruitment: patients with newly presenting NMIBC (&gt;90% of the pts were elligible fo entry and agreed to be randomized); this is not a selected population</LI>
<LI>Regimen: TUR Blue Lignt + MitomycinC (MMC) Vs TUR White Light + MMC</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Outcomes</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">As shown below, the results show no difference in recurrence rate (RR) at 3 months and at 12 months between blue lignt and white light.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">Blue light cystoscopy detects &gt;50% more secondary CIS than white light: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">He concluded that blue light is a good training tool, and a 'brilliant training tool' to understand the pathological anatomy of bladder cancer, but 'white light technique is much better' (white light results are excellent).<wbr> </div><div style="margin-bottom: 10px;">He finally ended his presentation with the following messages: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;">Pr O'Brien is 'fan of the technique, but realistic fan of the technique'.<wbr> He advocates selective use in: </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="oncology8230attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(48,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(47,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(46,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(46,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(51,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(42,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(43,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(40 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8230_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(42 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8230">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-25T14:19:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-25T14:19:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Closure of Merck Serono’s HQs in Geneva</title>
	<pubDate>2012-04-24T17:56:46+02:00</pubDate>
	<wp:post_id>3012</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merck plans workforce reductions across all global operations in Switzerland and intends to relocate certain Geneva-based functions to existing locations in Germany, the US and China.<wbr> Biotech production facilities will continue to be maintained in Aubonne and Corsier-sur-Vevey.<wbr> Details will be announced on May 15.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Merck plans to transfer 750 positions to other locations.<wbr> </div><div style="margin-bottom: 10px;">The company expects to cut 500 jobs in Geneva as well as 80 positions across 3 manufacturing sites in Switzerland.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Rebif faces increased competition from newer therapies.<wbr> </div><div style="margin-bottom: 10px;">In June, the company dropped development of the multiple sclerosis pill cladribine, which had been its most promising experimental medicine.<wbr> </div><div>European regulators in 2009 rejected Erbitux for use in lung tumors.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9857">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-24T17:56:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-24T17:56:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Expanded Access Trial of Pasireotide for Cushing</title>
	<pubDate>2012-04-24T15:54:11+02:00</pubDate>
	<wp:post_id>3013</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing the "Seascape" expanded access study of pasireotide.<wbr> Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/study/NCT01582061?recr=Open&amp;fund=2&amp;rcv_s=04%2F10%2F2012&amp;rank=57&amp;show_locs=Y#locn"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Intervention: Pasireotide will be administered twice a day for a maximum of 1 year.<wbr> </div><div>Location: 67 sites (US).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6913">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-24T15:54:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-24T15:54:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence from ESOU 2012 - Part 1 - Challenging the Guidelines on Whether Intermittent Therapy is a Standard or Not</title>
	<pubDate>2012-04-24T15:18:16+02:00</pubDate>
	<wp:post_id>3014</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Two renowned Professors were asked to debate on the 2012 EAU Guidelines regarding intermmitent hormonal therapy (IAD).<wbr> With new recent data confirming the postulated advantages of IAD, Pr Wirth from Dresden believes IAD should no longer be regarded as investigational but as new standard.<wbr> On the other hand, Pr Mendoza-Valdes from Mexico concluded that IAD is not a standard, but another option for advanced prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN><SPAN lang="EN-GB" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;">Another trial was presented which also shows no significant difference between IAD and CAD (Mottel et al.<wbr>, BJU <STRONG>2012</STRONG>) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">A systemic review of the literature on the potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer highlights the following: </div><div style="margin-bottom: 10px;">(Abrahamsson, Eur Urol 2010) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">He finally concluded his talk with a table showing the outcomes of selected trials: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Pr Mendoza-Valdes started with unanswered questions: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">According to the 2012 EAU Guidelines, “the best candidates for IAD have still not been completely defined, but are probably patients with locally advanced or relapsing disease, provided a perfect response is provided”.<wbr> </div><div style="margin-bottom: 10px;">He also pointed out that there is no consensus on when to re-start the treatment : </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">When it comes to determine the best/<wbr>optimal combination, he presented a list of different options (LHRH agonists with AA in most combinations, but still heterogeneous): </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">Regarding survival, more uniform studies are needed: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">However, an update from the Vancouver experience shows a trend toward extended times to progression and death compared to continuous therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">Pr Mendoza-Valdez highlighted that even if continuous treatment provides a specific survival difference compared to IAD, the survival difference is completely counterbalanced by the increased specific toxicity of continuous ADT, which therefore results in a lack of difference in OS survival, the increasing of which remains the main objective.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_10_ScreenCapture10.jpg"> </div><!-- Comment details --><a name="oncology8227attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(37,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(35,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(30,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(24,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(31,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(36,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(30 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(38,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(33,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(48,6 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(38,9 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8227_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(43,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8227">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-24T15:18:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-24T15:18:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Pfizer R&D Center Inaugurated in China</title>
	<pubDate>2012-04-24T10:14:19+02:00</pubDate>
	<wp:post_id>3015</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Situated in the Wuhan Optical Valley, the new 12-floor hub will focus on gastric cancer and diabetes on Asian patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>The center will be responsible for managing and analyzing new drug clinical data.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9854">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-24T10:14:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-24T10:14:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Buys Ardea Including Gout Drug and MEK Program for $1.26 Billion</title>
	<pubDate>2012-04-23T15:55:04+02:00</pubDate>
	<wp:post_id>3016</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ardea's clinically most advanced product candidate, lesinurad is currently in Ph3 development for the chronic management of hyperuricaemia in patients with gout.<wbr> The company's pipeline includes inhibitors of mitogen-activated ERK kinase (MEK) for the treatment of cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">$32 a share - a 54% premium to Ardea’s closing price on Friday April 20th.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">to bolster pipeline </div><div style="margin-bottom: 10px;">to counter competition arising from cheap generic of Seroquel (antipsychotic) </div><div style="margin-bottom: 10px;">to replenish its portfolio </div><div>AstraZeneca targets completion and filing of Ph3 clinical trials in 2014, and expects to 'absorb' Ardea's spend within its existing R&amp;D program.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9851">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-23T15:55:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-23T15:55:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Swiss Factory for Novartis</title>
	<pubDate>2012-04-23T15:12:42+02:00</pubDate>
	<wp:post_id>3017</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new facility, based in Stein, will make solid forms dosages such as pills and capsules, and allow Novartis to adapt production to meet demand more quickly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">by the end of 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">to replace the plant based in Nyon.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>&gt; CHF 500M ($ 550M).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9850">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-23T15:12:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-23T15:12:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Rejects Victoza Complaint</title>
	<pubDate>2012-04-20T20:00:20+02:00</pubDate>
	<wp:post_id>3018</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Public Citizen said on Thursday that Victoza increases the risk of serious health problems such as thyroid cancer and kidney failure.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Novo's Chief Science Officer Mads Krogsgaard Thomsen told Reuters on Friday that Public Citizen had referred to old data from studies on mice and rats which had no relevance to the use of Victoza in humans.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6910">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-20T20:00:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-20T20:00:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A New Targeted Experimental Approach To Treating pNET</title>
	<pubDate>2012-04-19T18:18:36+02:00</pubDate>
	<wp:post_id>3019</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV id="leftbar">
<DIV class="block block-block" id="block-block-9">
<DIV class="content">
<P>Comment: The Caring for Carcinoid Foundation  has announced a reearch award through its partnership with the AACR.<wbr> This two-year grant of $250,000 will support a research team headed by Renata Pasqualini, Ph.<wbr>D.<wbr>, of the University of Texas MD Anderson Cancer Center who will work on a new targeted strategy for treating patients with pNET</P></DIV></DIV></DIV> </div><div><DIV id="maincontent">
<DIV class="node">
<DIV class="content">
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">Specifically, Dr.<wbr> Pasqualini and her team will develop components of a virus that will be designed to kill neuroendocrine cancer cells.<wbr> The virus will be modified to attach to somatostatin receptors on pancreatic neuroendocrine tumor cells, limiting negative effects on healthy tissues.<wbr> The researchers will then test the effectiveness of the virus in the lab and in mouse models.<wbr></P>

<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">In 2011, CFCF and the AACR awarded a grant to Charles Rudin, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr> to examine how the Seneca Valley Virus targets neuroendocrine tumor cells.<wbr></P>

<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">From <A href="http://www.caringforcarcinoid.org/">http:/<wbr>/<wbr>www.<wbr>caringforcarcinoid.<wbr>org</A>, see <A href="http://www.caringforcarcinoid.org/news/announcing-2012-cfcf-aacr-grant-recipient">original source</A>.<wbr></P>
</DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6909">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-19T18:18:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-19T18:18:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Xeomin - Insights Into Merz's Promotional Messaging</title>
	<pubDate>2012-04-19T17:34:03+02:00</pubDate>
	<wp:post_id>3020</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Attached is the final outcome of a project jointly commissioned by the CI Dept and Neurology Franchise, to evaluate Merz's presence infrastructure and Xeomin messaging directed at KOLs and payers in 11 markets.<wbr> The final results were presented at a Competitors Detailing Workshop at the Global Brand Plan Meeting in Chantilly.<wbr> </div><div style="margin-bottom: 10px;">Highlights of the final report as presented are shown below with the full report attached for your review.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">77% of the KOL respondents had a favourable impression of Xeomin.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">The concept of purity, low level of neutralising antibodies plus discounts on volume purchases appears to resonate in particular with the payors (see quotes below) </div><div style="margin-bottom: 10px;">"“In principle, they present it as a more cost effective option, especially for blepharoplasty and cervical dystonia indications.<wbr> They even present money-saving data, for a calculation of a population of 500 patients.<wbr> And most of all they associate these savings to a lower presence of neutralising antibodies.<wbr>” (Spanish payer) </div><div style="margin-bottom: 10px;">"“It has a lower content of the protein of available botulinum toxins, and therefore it can reduce the formation of neutralising antibodies, which is one of the reasons for products not working, so therefore the company was promoting that it would give similar results to other products without the risk of antibody formation, therefore providing longer lasting effect.<wbr>” UK payer </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_10_ScreenCapture10.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_11_ScreenCapture11.jpg"> </div><!-- Comment details --><a name="neurology6362attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(250,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(195,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(214,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(181,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(113,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(127,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(162,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(173,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(227,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(206,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(146 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6362_12_Lifescience%20Dynamics%20Woodford%20Final%20Report%20April%202012%20.pdf">Lifescience Dynamics Woodford Final Report April 2012 .pdf</a>&nbsp;&nbsp;(3,7 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6362">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-19T17:34:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-19T17:34:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Preliminary Ph4 Results Evaluating Xeomin for CD and Blepharospasm in the US</title>
	<pubDate>2012-04-19T15:08:50+02:00</pubDate>
	<wp:post_id>3021</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Findings of the XCiDaBLE trial, designed to assess Xeomin in a "real world", will be presented on April 23rd @ AAN.<wbr> The preliminary results show that a significant proportion of CD and BEB patients find that theses disorders have negative consequences on their employment status, and significant adverse impact on their QoL.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Study Design <A href="http://clinicaltrials.gov/ct2/show/NCT01287247">NCT01287247</A></LI>
</UL> </div><div style="margin-bottom: 10px;">Recruitment: 130 CD and 184 BEB subjects were enrolled (76% female).<wbr> The mean age at enrollment was 62 years and the mean estimated duration of disease was 12.<wbr>2 years.<wbr> 91.<wbr>7% had been previously treated with a botulinum toxin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG> - XCiDaBLE: A Phase 4, Observational, Prospective Trial Evaluating Xeomin (IncobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States – Preliminary Baseline Employment History Data<BR></STRONG><BR><EM>Hubert Fernandez, Cleveland, OH, Fabio Danisi, Kingston, NY, Daniel Truong, Fountain Valley, CA, Eric Pappert, San Antonio, TX, Amit Verma, Greensboro, NC, Kapil Sethi, Augusta, GA, Cindy Zadikoff, Chicago, IL</EM> </div><div style="margin-bottom: 10px;">For CD subjects, the mean baseline CDIP score was 159.<wbr> For the BEB subjects the mean baseline JRS score was 5.<wbr>0.<wbr> At the onset of symptoms, 92 CD and 105 BEB subjects were employed.<wbr> </div><div style="margin-bottom: 10px;">The symptoms associated with CD or BEB affected employment status in 31 of CD and 19 of BEB subjects.<wbr> Of the subjects currently employed, 31 CD and 33 BEB subjects felt that their symptoms affected their productivity.<wbr> For those who felt productivity was affected, estimated productivity was 77.<wbr>6% for CD and 82.<wbr>8% for BEB (100%=normal and 0%=no work gets done).<wbr> 25 CD and 17 BEB subjects received or were seeking employee disability benefits related to symptoms.<wbr> </div><div style="margin-bottom: 10px;"><U>Conclusions</U> </div><div style="margin-bottom: 10px;">A significant proportion of CD and BEB patients find that theses disorders have negative consequences on their employment status.<wbr> XCiDaBLE is providing valuable insight into employment history for patients with the disabling conditions of CD and BEB.<wbr> </div><div style="margin-bottom: 10px;"><STRONG> - XCiDaBLE: A Phase 4, Observational, Prospective Trial Evaluating Xeomin (IncobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States – Preliminary Baseline Disease Severity and Quality of Life Data</STRONG> </div><div style="margin-bottom: 10px;"><EM>Mark LeDoux, Memphis, TN, Daniel J.<wbr> Lin, Warren, MI, Joseph Jankovic, Houston, TX, Eric Pappert, San Antonio, TX, Amit Verma, Greensboro, NC, Kapil Sethi, Augusta, GA, Hubert Fernandez, Cleveland, OH.<wbr></EM> </div><div style="margin-bottom: 10px;">For CD CGI-Severity at baseline was: 20.<wbr>2% normal-to-mild, 48.<wbr>1% moderate, 20.<wbr>9% marked, 9.<wbr>3% severe and 1.<wbr>6% extreme.<wbr> For CD subjects, the mean baseline CDIP score was 159 and subscale scores were: 47.<wbr>7-Symptom Scale Total; 45.<wbr>9-Daily Activities Total; and 66.<wbr>0-Psychosocial Functioning.<wbr> The SF-12v2 mean scores for CD were 44.<wbr>0-Mental QoL and 38.<wbr>1-Physical QoL.<wbr> The CGI-Severity at baseline for BEB subjects was 32.<wbr>8% normal-to-mild, 35.<wbr>5% moderate, 22.<wbr>4% marked and 9.<wbr>3% severe.<wbr> For BEB subjects, the mean baseline JRS score was 5.<wbr>0.<wbr> The SF-12v2 mean scores for BEB were 49.<wbr>1-Mental QoL and 43.<wbr>1-Physical QoL.<wbr> </div><div style="margin-bottom: 10px;"><U>Conclusions</U> </div><div>CD and BEB can have a significant adverse impact on QoL.<wbr> This observational study promises to provide valuable information about disease severity and QoL for patients with the often disabling conditions of CD and BEB treated with botulinum toxins.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6359">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-19T15:08:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-19T15:08:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Results of a Small Pilot Trial of Botox(R) for Nocturnal Bruxism to be Presented @ AAN</title>
	<pubDate>2012-04-19T14:35:37+02:00</pubDate>
	<wp:post_id>3022</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Supported by Allergan, the results show that Botox(R) effectively and safely improved nocturnal bruxism.<wbr> Primary efficacy points were CGI and VAS of change at 4 weeks post injection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><B>Design</B> </div><div style="margin-bottom: 10px;">Double blind, placebo injection controlled (1:1) trial of onabotulinum-A (BoNT) for nocturnal bruxism.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regimen</STRONG> </div><div style="margin-bottom: 10px;">Patients underwent a baseline/<wbr>screening overnight polysomnogram (PSG).<wbr> They were then randomized to receive BoNT or placebo into the bilateral masseter (60u/<wbr>side) and temporalis muscles (40u/<wbr>side) using visual landmarks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Endpoints</STRONG> </div><div style="margin-bottom: 10px;">Primary efficacy points were CGI and VAS of change at 4 weeks post injection.<wbr> </div><div style="margin-bottom: 10px;">Secondary points including change in PSG data, including masseter placed electrodes, pain scales, sleep scales, adverse events, and need for follow-up open label injection.<wbr> </div><div style="margin-bottom: 10px;"><B>Results</B> </div><div style="margin-bottom: 10px;">8 subjects were excluding after the initial PSG prior to randomization (six for lack of bruxism on PSG and two declined to continue).<wbr> 23 (19 female, age 47.<wbr>4(16.<wbr>9) were randomized.<wbr> </div><div style="margin-bottom: 10px;">Almost all reported temporal-mandibular pain.<wbr> All 13 randomized to drug and 9/<wbr>10 randomized to placebo completed the study.<wbr> </div><div style="margin-bottom: 10px;">CGI (p&lt;0.<wbr>05) and VAS of change (p&lt;0.<wbr>05) favored the BoNT group.<wbr> </div><div style="margin-bottom: 10px;">Secondary scales including the Headache Impact Test-6, total Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Self-Rated Anxiety Scale were not significantly changed.<wbr> A large percentage of subjects had moderate obstructive sleep apnea on PSG despite lack of typical risk factors.<wbr> The mean duration to open label f/<wbr>u injection was 107 days in those randomized drug vs.<wbr> 40 days in those randomized to placebo.<wbr> Adverse events were limited to 2 subjects with a cosmetic change in their smile.<wbr> No dysphagia was reported.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><STRONG>Onabotulinum Toxin-A Injections for Nocturnal Bruxism: A Parallel, Double Blind, Placebo Controlle Polysomnographic Study -</STRONG> William Ondo, Vera I.<wbr> Hashem, Christine Hunter, Jerry Simmons, Houston, TX </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6358">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-19T14:35:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-19T14:35:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Botox Cosmetic Celebrates 10-Yr Anniversary</title>
	<pubDate>2012-04-19T12:14:56+02:00</pubDate>
	<wp:post_id>3023</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px/16px Georgia, 'Times New Roman', Times, serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px/16px Georgia, 'Times New Roman', Times, serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px/16px Georgia, 'Times New Roman', Times, serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px/16px Georgia, 'Times New Roman', Times, serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><A href="http://www.paramuspost.com/"></A><A href="http://www.paramuspost.com/article.php/20120418181828336"></A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6357">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-19T12:14:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-19T12:14:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Xeomin Cosmetic Approval In Canada</title>
	<pubDate>2012-04-18T10:13:22+02:00</pubDate>
	<wp:post_id>3024</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday Health Canada announced the approval of Xeomin Cosmetic for the treatment of moderate to severe glabellar lines in adult patients.<wbr> </div><div style="margin-bottom: 10px;">The addition of Canada brings the total number of countries where Xeomin is approved for cosmetic use to 21.<wbr> </div><div style="margin-bottom: 10px;">Approval was based on the results of two pivotal clinical trials involving 547 healthy adult patients.<wbr> In both studies, XEOMIN Cosmetic significantly improved the appearance of glabellar lines 30 days following the first injection when compared to placebo.<wbr> </div><div style="margin-bottom: 10px;">Merz press release emphasises that XEOMIN and XEOMIN COSMETIC are the only botulinum toxin products currently approved in Canada that do not require refrigeration prior to reconstitution.<wbr> </div><div style="margin-bottom: 10px;">The product will be available nationwide by the summer.<wbr> </div><div>source: <A href="http://www.newswire.ca/fr/story/956233/merz-pharma-canada-ltd-announces-health-canada-approval-of-xeomin-cosmetic-clostridium-botulinum-neurotoxin-type-a-150kd-free-from-complexing-proteins">http:/<wbr>/<wbr>www.<wbr>newswire.<wbr>ca/<wbr>fr/<wbr>story/<wbr>956233/<wbr>merz-pharma-canada-ltd-announces-health-canada-approval-of-xeomin-cosmetic-clostridium-botulinum-neurotoxin-type-a-150kd-free-from-complexing-proteins</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6356">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-18T10:13:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-18T10:13:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Gene Therapy For Parkinson's Makes Continued Progress</title>
	<pubDate>2012-04-18T10:02:56+02:00</pubDate>
	<wp:post_id>3025</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div>Source: <A href="http://www.oxfordbiomedica.com">www.<wbr>oxfordbiomedica.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6355">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-18T10:02:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-18T10:02:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Reports Very Strong Uptake Of Zytiga (abiraterone)</title>
	<pubDate>2012-04-17T19:47:50+02:00</pubDate>
	<wp:post_id>3026</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Overall sales of J&amp;J's oncology products increased 38.<wbr>5% on an operational basis due to the very strong results for ZYTIGA and VELCADE, partially offset by lower sales of DOXIL/<wbr>CAELYX related to manufacturing issues at our third-party supplier.<wbr> J&amp;J was not in a position to clarify what level of sales has been in the off-label pre-chemo setting but noted that doctors are free to prescribe even if it is not being promoted.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">At the upcoming ASCO meeting in June it will unveil the results from its pre-chemo trial in terms of progression-free survival and then it will file for approval in the second-half of the year.<wbr></SPAN> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8226">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-17T19:47:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-17T19:47:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OncoGenex/Teva to Start New Ph3 of Custirsen for 2nde-Line mCRPC</title>
	<pubDate>2012-04-17T17:00:39+02:00</pubDate>
	<wp:post_id>3027</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As a result of the recent amendment of OncoGenex and Teva collaboration, the AFFINITY study has been designed to confirm that adding custirsen to cabazitaxel/<wbr>prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard cabazitaxel/<wbr>prednisone treatment in men with mCRPC.<wbr> Primary outcome measures will evaluate survival.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01578655?fund=2&amp;rcv_s=04%2F03%2F2012&amp;rank=8"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><STRONG>-</STRONG> Protocol </div><div style="margin-bottom: 10px;"><UL><LI>one arm/<wbr>Experimental - cabazitaxel, prednisone, custirsen</LI>
<LI>one arm/<wbr>Comparator - cabazitaxel and prednisone</LI>
</UL> </div><div style="margin-bottom: 10px;">
- Recruitment: approx.<wbr> 630 </div><div style="margin-bottom: 10px;">- Start date: Sept 2012 - Completion date: Dec 2015.<wbr> </div><div style="margin-bottom: 10px;">- Location: USA (in lieu of the  cancer SATURN study) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8156" class="defaultlink">Oncology8156: Teva and Oncogenex Update Custirsen Ph3 Program in CRPC</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8225">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-17T17:00:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-17T17:00:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FIM of Prolor's Long-acting GLP-1/Glucagon Dual Receptor Agonist to be Initiated in 2013</title>
	<pubDate>2012-04-17T16:33:36+02:00</pubDate>
	<wp:post_id>3028</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Positive PC results will be presented @ GTC's 5th Diabetes Drug Discovery and Development Conference (April 19 in Boston).<wbr> The drug is a once-weekly version of oxyntomodulin, a native peptide that acts as a natural satiety signal to reduce food intake.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">MOD-6030 administered to diet-induced obese (DIO) mice once weekly over a 30-day period demonstrated significant efficacy in reducing weight, lowering blood glucose levels, increasing insulin sensitivity and reducing cholesterol levels as compared to a group that received placebo.<wbr> </div><div>Animals in the placebo group showed minimal changes in the study parameters, while the animals receiving MOD-6030 achieved on average a <U>28% reduction in weight</U>, a 29% reduction in food intake, a 19% reduction in blood glucose levels and a <U>57% reduction in cholesterol levels</U>.<wbr>  Body composition analysis showed that the weight loss resulted specifically from reductions in body fat.<wbr> </div><!-- Comment details --><a name="endocrinology6908attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6908_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6908">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-17T16:33:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-17T16:33:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Ph3 Trial to Compare 177Lu-DOTA0-Tyr3-Octreotate and Octreotide LAR for Midgut Carcinoid Tumours</title>
	<pubDate>2012-04-16T16:59:29+02:00</pubDate>
	<wp:post_id>3029</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01578239?fund=2&amp;rcv_s=04%2F02%2F2012&amp;rank=5"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7088c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"> </div><div> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6907">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-16T16:59:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-16T16:59:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Russia's MoH Presents "Road Map" to Planned Healthcare Changes</title>
	<pubDate>2012-04-16T14:48:25+02:00</pubDate>
	<wp:post_id>3030</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The "road map" of planned changes presented by the health minister indicates a potential decentralisation and handing over of more power to the regions.<wbr> The success of the programmes outlined will be depend upon the MOH's ability to enforce and streamline these changes across regions, which has previously met with setbacks and the regions' inability to implement the regulatory changes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Russia's Minister of Health, Tatiana Golikova, presented a "road map" of legislative changes in healthcare and medical insurance, reports <I>Pharmvestnik.<wbr>ru.<wbr> </I>A meeting on improving the healthcare system in the framework of socio-economic development of Russia up to 2020—"Strategy 2020"—was held on 13 April and was attended by Russian president Dmitri Medvedev.<wbr> According to Golikova, the transfer of authority for the organisation of medical care to the level of the Russian Federation will continue in 2012.<wbr> In 2013, uniform standards and procedures for care will come into force.<wbr> Furthermore, the transfer of powers for the licensing of medical activities to the regional level will take place.<wbr> </div><div style="margin-bottom: 10px;">The Ministry of Health (MoH) plans to devolve power to ensure the supply of drugs for patients with certain diseases, as well as to launch a pilot project to reimburse the cost of drugs on an outpatient basis for the preferential categories of citizens by 2014.<wbr> In 2015, the MoH will implement an independent medical examination, and establish criteria for assessing the quality of care.<wbr> In 2016, the accreditation of health workers will be introduced.<wbr> In the same period, an evaluation of the pilot project to reimburse the cost of drugs on an outpatient basis for the preferential categories of citizens is planned, as well as making a decision on the transition to universal drug insurance, or a system of reimbursement of the cost of medicines for preferential categories of citizens.<wbr> </div><div>Frm Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9848">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-16T14:48:25+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-16T14:48:25+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Addex Announces Positive Preclinical Data for its Lead GABA-PR PAM in OAB</title>
	<pubDate>2012-04-16T10:21:27+02:00</pubDate>
	<wp:post_id>3031</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The data on ADX71441 will be presented at the AUA Annual Meeting in Atlanta (May 19-23, 2012).<wbr> The company has planned to initiate clinical studies by the end of 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Evaluation in female guinea pigs with bladder overactivity</LI>
</UL> </div><div style="margin-bottom: 10px;">
ADX71441 (1 and 3 mg/<wbr>kg, i.<wbr>v.<wbr>) induced a strong increase in inter contraction interval (ICI), a validated measure of bladder muscle control, in the first 15 min post-administration compared to vehicle.<wbr> The efficacy of ADX71441 was well correlated with its pharmacokinetic properties.<wbr> ADX71441 also significantly decreased micturition (urination) frequency compared to vehicle at the 1 mg/<wbr>kg dose.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Evaluation in an independent mouse diuretic stress-induced model of overactive bladder</LI>
</UL> </div><div style="margin-bottom: 10px;">
ADX71441 also dose-dependently reduced micturition frequency in furosemide- treated animals.<wbr> The magnitude of the effect in response to 10 mg/<wbr>kg ADX71441 was similar to those observed in oxybutynin (a commonly prescribed anti- cholinergic medication for OAB) - treated animals.<wbr> At this dose, however, unlike oxybutynin-treated animals, ADX71441 was well tolerated and had no marked effects on body temperature, locomotor activity or motor coordination.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8224_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8224attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8224_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8224">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-16T10:21:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-16T10:21:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Single Sign On Implemented in Traction</title>
	<pubDate>2012-04-13T15:44:53+02:00</pubDate>
	<wp:post_id>3032</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div>Dear Traction Readers,<BR>To simplify your access, "Single Sign On" has been implemented in Traction for authorised members.<wbr>  You are now automatically logged in when accessing Traction via Ipsen Planet or the daily CI-Digest.<wbr><BR>The CI &amp; IT Teams </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9843">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-13T15:44:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-13T15:44:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights of Leerink Swann's 1Q Cosmetic Survey Results</title>
	<pubDate>2012-04-13T14:01:02+02:00</pubDate>
	<wp:post_id>3033</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The survey polled 80 U.<wbr>S based dermatologists (42) and plastic surgeons (38).<wbr> The results suggest that Botox captured ~80% of the overall market and 77% of new patients.<wbr> Physicians continued to cite interest in Xeomin &amp; Belotero in the next 6-12 months despite the recent injunction.<wbr> A selection of key slides is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6354_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6354_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6354_3_ScreenCapture3.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="neurology6354attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6354_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6354_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(48,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6354_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(72,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6354">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-13T14:01:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-13T14:01:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alpharadin Submission Timelines For CPRC</title>
	<pubDate>2012-04-13T10:49:25+02:00</pubDate>
	<wp:post_id>3034</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment Algeta has exercised an option under a 2009 deal with </SPAN>Bayer AG<SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">  to co-promote  prostate cancer compound </SPAN>Alpharadin<SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> in the U.<wbr>S.<wbr> Bayer plans to submit an NDA and MAA for the compound to treat bone metastases in patients with CRPC by mid-year.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">There was no payment associated with exercising the option.<wbr> Algeta is now eligible for 50% of profits from Alpharadin sales and is responsible for 50% of commercialization costs.<wbr>  Algeta is also eligible for a EUR 50 million ($65.<wbr>4 million) milestone from Bayer on regulatory filing, and another EUR 50 million milestone on the first sale of the radiopharmaceutical.<wbr></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: Biocentury</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8223">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-13T10:49:25+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-13T10:49:25+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Personalizing Prostate Cancer Treatment</title>
	<pubDate>2012-04-12T18:01:40+02:00</pubDate>
	<wp:post_id>3035</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Prostate Cancer Foundation and the American Association for Cancer Research have just announced a prostate cancer "Dream Team", in which Professor Johann de Bono from The Royal Marsden and The Institute of Cancer Research (ICR) will be collaborating with other prostate cancer researchers in a $10 million global effort to drive the development of personalized treatment for this disease.<wbr> </div><div style="margin-bottom: 10px;">A number of leading prostate cancer clinical research centers in the US and London will be involed including:- </div><div style="margin-bottom: 10px;"><UL><LI>The University of Michigan at Ann Arbor
</LI>
<LI>The Memorial Sloan-Kettering Cancer Center
</LI>
<LI>The Weill Medical College of Cornell University in New York
</LI>
<LI>The Dana-Farber Cancer Institute
</LI>
<LI>The Broad Institute at Harvard in Bostons
</LI>
<LI>The Fred Hutchinson Cancer Research Center at The University of Washington in Seattle.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">The team also includes another doctor from the ICR and The Royal Marsden, Dr Gerhardt Attard.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Timelines<BR></U></STRONG>It is estimated that the project will commence in the middle of 2012, with the first clinical trials scheduled to open in early 2013.<wbr>   </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Background To This Venture</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Professor de Bono, Professor in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology at the ICR and The Royal Marsden, who is the Dream Team's principal member, declared: </div><div style="margin-bottom: 10px;">"We have made great strides forward in developing new drugs to treat men with prostate cancer, along with the technology needed to examine the DNA faults causing these cancers.<wbr> This project represents the next step - a global effort to combine these two advances to create a truly personalized approach to treating prostate cancers.<wbr> I am thrilled and proud to be part of this collaboration, which should make a real and lasting difference to the way we care for men with advanced prostate cancer.<wbr>" </div><div style="margin-bottom: 10px;">Over the last few years, several new drugs have demonstrated their ability to extend life for men with advanced prostate cancer.<wbr> Professor de Bono, and his team at the ICR and The Royal Marsden helped to develop several of these drugs.<wbr> </div><div style="margin-bottom: 10px;">The target of the Dream Team is to design tests that can assist doctors in determining which of these new options, as well as future experimental drugs, can provide the ultimate benefit for their patients.<wbr> </div><div style="margin-bottom: 10px;">Over their three-year project duration, they will systematically scan genomes of patients with advanced metastatic cancer, in order to search for gene alterations that are more frequent in patients who are responsive to therapies, as well as alterations in those, who develop resistance to the drugs.<wbr> </div><div style="margin-bottom: 10px;">The aim is to ultimately identify a range of biological markers, which can be used by doctors to ensure that treatments are personalized to their patient's cancer in addition to successfully develop further therapies for the most common type of male cancer.<wbr> </div><div>From <A href="http://www.medicalnewstoday.com/">http:/<wbr>/<wbr>www.<wbr>medicalnewstoday.<wbr>com</A>, see <A href="http://www.medicalnewstoday.com/articles/244017.php">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8218">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-12T18:01:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-12T18:01:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Trials of Botox in Adults with PSLL Spasticity</title>
	<pubDate>2012-04-12T16:35:42+02:00</pubDate>
	<wp:post_id>3036</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to clinicaltrials.<wbr>gov, Allergan is sponsoring a new Ph3  in Hungary in adults with post-stroke lower limb spasticity.<wbr> Two other trials will follow in Germany and the UK.<wbr> Primary endpoint will assess change from baseline in Modified Ashworth Scale-Bohannon Score using a 6-point scale.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01575054?cond=prostate+OR+hemophilia+OR+spasticity+OR+neuroendocrine+OR+botulinum&amp;fund=2&amp;rcv_s=02%2F12%2F2012&amp;rank=18"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: 274 (18 to 85 years).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI style="margin-top: 0.7ex;">Diagnosis of post-stroke lower limb spasticity for at least 3 months.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI style="margin-top: 0.7ex;">Minimum body weight of 50 kg.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI style="margin-top: 0.7ex;">Never treated with botulinum toxin of any serotype for any reason, or if previously treated with botulinum toxin of any serotype, if previously treated for spasticity in the affected lower limb, must have been administered.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="margin-right: 0px;">
<P style="margin-top: 0.7ex;">* 20 weeks before Day 1, or if previously treated for any other indication must have been administered &ge;12 weeks prior to Day 1.<wbr></P>
</BLOCKQUOTE> </div><div>Start date: April 2012 - Completion dates: Dec.<wbr> 2013 /<wbr> Nov.<wbr> 2014 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6350">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-12T16:35:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-12T16:35:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi to Start the "Switch" Trial</title>
	<pubDate>2012-04-12T16:22:21+02:00</pubDate>
	<wp:post_id>3037</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph2 trial will compare the continuation of treatment with docetaxel vs switching to cabazitaxel regarding the time to PSA progression in patients with CRPC that, after four cycles of docetaxel, have minor PSA response (primary endpoint).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01576029?cond=prostate+OR+hemophilia+OR+spasticity+OR+neuroendocrine+OR+botulinum&amp;fund=2&amp;rcv_s=02%2F12%2F2012&amp;rank=15"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Secondary endoints will assess PSA response rate; OS and AEs.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 78 </div><div>Start date: May 2012 - Completion date: June 2014 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8217">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-12T16:22:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-12T16:22:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Watson on Track to Buy European-Based Actavis for Around $6bn</title>
	<pubDate>2012-04-12T10:15:48+02:00</pubDate>
	<wp:post_id>3038</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The deal would further diversify Watson's generic footprint in the EU, and help the company to compete more effectively against Teva and Sandoz.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9837_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9837_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9837_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9837_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Founded in 1956, private company Actavis has &gt;10,000 employees operating in over 40 countries around the world.<wbr> </div><div>The Group’s biggest markets are the US, Turkey, Bulgaria (Actavis is the biggest pharmaceutical company in Bulgaria.<wbr> It has the broadest product portfolio within the Bulgarian market, with almost 280 products covering all the main therapeutic groups), Russia and the CIS, Germany, UK, the Nordic countries and Serbia.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10298c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Watson Pharmaceuticals has announced that the company has adopted Actavis, Inc.<wbr> as its new global name and will today begin trading under the symbol — ACT — on the New York Stock Exchange.<wbr> The combination created the world's 3rd largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">On Jan 23rd, Watson completed the acquisition of <LOCATION value="LC/be;LB/weur">Belgium</LOCATION>-based <ORG>Uteron Pharma SA</ORG> for <MONEY>$150M</MONEY> in cash up front, and up to <MONEY>$155 million</MONEY> in potential future milestone payments.<wbr> </div><div style="margin-bottom: 10px;"><U>Rationale</U> </div><div style="margin-bottom: 10px;">The acquisition of Uteron expands Watson's <ORG>Global Brands</ORG> pipeline of Women's Health products including two potential near term global commercial opportunities in contraception and infertility, and one novel oral contraceptive, projected to launch globally in 2018.<wbr>  Several additional products in earlier stages of development are also included in the acquisition.<wbr> </div><div>Source: Actavis; Watson </div></div><a name="pharmaworld9837attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9837_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9837_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9837_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(52,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9837_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(57,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9837">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-12T10:15:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-12T10:15:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Threshold Recieves $20m Milestone From Merck Serono Based On Positive Pancreatic Cancer Data</title>
	<pubDate>2012-04-11T18:38:43+02:00</pubDate>
	<wp:post_id>3039</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Threshold has received the milestone after reporting positive phase II data at the recent AACR meeting demonstrating that a combination of gemcitabine and TH-302 ( a hpoxia targeted drug) resulted in a median increase in progression-free survival from 3.<wbr>6 months to 5.<wbr>6 months compared to gemcitabine alone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Study Design</U></STRONG> </div><div style="margin-bottom: 10px;">The phase 2b study was a multi-center, randomized, controlled, dose-ranging,crossover clinical trial of TH-302 in combination with a standard gemcitabine regimen in patients with first-line advanced pancreatic cancer.<wbr> The primary endpoint of the trial was PFS.<wbr> The secondary endpoints were overall response rate, overall survival, and change in CA19-9 as well as various other efficacy and safety parameters.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Key Findings</U></STRONG> </div><div style="margin-bottom: 10px;">The combination regimen was associated with an increase in tumor response rate from 12% to 22% and a greater decrease in serum CA19-9.<wbr> In addition, a dose response was identified with the greatest efficacy in the higher 340 mg/<wbr>m2 group with a median PFS of 6.<wbr>0 months, response rate of 27% and larger CA19-9 decreases.<wbr> </div><div style="margin-bottom: 10px;">TH-302-related toxicities were also dose dependent.<wbr> TH-302 related toxicities including skin and mucosal toxicities and myelosuppression were dose dependent and consistent with previous trials and did not result in an increase in discontinuations due to adverse events.<wbr> </div><div style="margin-bottom: 10px;">"The detailed results from this first randomized study of TH-302 (see below) confirm the earlier results from our previous non-randomized 402 study for patients with pancreatic cancer.<wbr> In that study, patients in a number of indications including pancreatic cancer appeared to benefit from the addition of TH-302 to standard chemotherapy based on comparisons to historical control data," said <PERSON value="APIN:3770958185">Barry Selick</PERSON>, Ph.<wbr>D.<wbr>, Chief Executive Officer of Threshold.<wbr> </div><div style="margin-bottom: 10px;">From <A href="http://investor.thresholdpharm.com/">http:/<wbr>/<wbr>investor.<wbr>thresholdpharm.<wbr>com</A>, see <A href="http://investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=660857">original source</A>.<wbr> </div><div style="margin-bottom: 10px;">Detailed Study Abstract (see below) </div><div><A href="http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=21a1ec6b-0397-4425-b223-31844c6077c3&amp;cKey=edf55bb0-41e9-4d4e-8f01-368a2ebeee69&amp;mKey=%7b2D8C569E-B72C-4E7D-AB3B-070BEC7EB280%7d">http:/<wbr>/<wbr>www.<wbr>abstractsonline.<wbr>com/<wbr>Plan/<wbr>ViewAbstract.<wbr>aspx?sKey=21a1ec6b-0397-4425-b223-31844c6077c3&amp;cKey=edf55bb0-41e9-4d4e-8f01-368a2ebeee69&amp;mKey=%7b2D8C569E-B72C-4E7D-AB3B-070BEC7EB280%7d</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8216">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-11T18:38:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-11T18:38:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma</title>
	<pubDate>2012-04-11T17:23:37+02:00</pubDate>
	<wp:post_id>3040</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment Acceleron Pharma, presented preclinical data at the recent AACR meeting demonstrating that ACE-041, an activin-receptor like kinase 1 (ALK1) receptor ligand trap, when used in combination with sunitinib, inhibits tumor growth in a model of VEGF-inhibitor-resistant renal cell carcinoma (RCC).<wbr> ALK Translocations have been demonstrated in neuroendocrine tumours and activity was recently shown in one patient with a carcinoid tumour.<wbr> </div><div style="margin-bottom: 10px;">Whilst angiogenic treatments cause tumor shrinkage and extend progression-free survival in many patients, responses can typically short-lived due to the development of drug resistance.<wbr> Mice bearing A498 and 786-0 human RCC xenografts that receive anti-VEGF treatment mirror this clinical experience with a period of tumor stabilization that is followed by the restoration of angiogenesis and resumption of growth despite continued drug administration.<wbr> </div><div style="margin-bottom: 10px;">Preclinical data, presented by Rupal Bhatt, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>, Assistant Professor, Hematology-Oncology, Beth Israel Deaconess Medical Center provide evidence that combining two distinct anti-angiogenic drugs, a VEGF inhibitor and ACE-041, may produce an enhanced therapeutic effect in the treatment of metastatic RCC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Preclinical Study Description and Results</U></STRONG> </div><div style="margin-bottom: 10px;">Two renal cell carcinoma cell lines (A498 and 786-O) were used in a mouse xenograft model.<wbr> In each tumor cell line, mice treated with the combination of ACE-041 and sunitinib slowed tumor growth to a greater extent than either agent alone.<wbr> Additionally, the combination of ACE-041 and sunitinib prevented the restoration of tumor perfusion during the resistant phase of sunitinib-alone treatment and lowered tumor perfusion to a greater extent than sunitinib-alone.<wbr> </div><div style="margin-bottom: 10px;">These data demonstrate that blocking ALK1 ligand signaling, either alone or in combination with other anti-angiogenesis therapies, may be an attractive treatment strategy.<wbr> </div><div style="margin-bottom: 10px;">&ldquo;There is increasing evidence that combining anti-angiogenesis inhibitors with distinct mechanisms of action, such as a VEGF inhibitor with an ALK1 ligand trap, like ACE-041, can more effectively inhibit tumor angiogenesis,&rdquo; said Matthew Sherman, M.<wbr>D.<wbr>, Chief Medical Officer at Acceleron.<wbr> &ldquo;We believe this approach holds great promise and we&rsquo;re excited to pursue Phase 2 studies of ACE-041 in combination with VEGF inhibitors later this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ACE-041's Profile</STRONG> </div><div style="margin-bottom: 10px;">ACE-041 is an ALK1 ligand trap that inhibits angiogenesis by preventing BMP9 and BMP10, members of the TGF&beta; protein superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a receptor found on proliferating endothelial cells.<wbr> ACE-041 inhibits ALK1 signaling, which is required for the development of mature, functional capillary networks.<wbr> </div><div style="margin-bottom: 10px;">In a clinical study of patients with advanced, refractory solid tumors, treatment with ACE-041 was generally well-tolerated and antitumor activity was observed, resulting in tumor shrinkage and stabilization of disease including in one patient with carcinoid disease (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6443" class="defaultlink">Endocrinology6443: Intelligence From ASCO & ENDO 2011 - Key Data on New NET Drugs</a>).<wbr> </div><div style="margin-bottom: 10px;">As Anplastic lymphoma kinase translocation is a potent predictor of benefit of treatment with ALK inhibitors two research groups from Barcelona set out to examine ALK translocations in a number of neuroendocrine tumour samples.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology6443.045i">
<DIV class="ii" id="endocrinology6443.045ii">111 samples were included in the study and 68 proved valuable for analysis.<wbr></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology6443.046i">
<DIV class="ii" id="endocrinology6443.046ii">The clinicopathological features of the patients involved and the gene translocations identified were highligted (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6443" class="defaultlink">Endocrinology6443: Intelligence From ASCO & ENDO 2011 - Key Data on New NET Drugs</a>).<wbr> The authors concluded that although rare ALK translocations do exist in neuroendocrine tumours revealing a potential new indication for ALK inhibitors that merits further investigation.<wbr></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><STRONG>About Acceleron</STRONG> </div><div style="margin-bottom: 10px;">Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer.<wbr> Acceleron&rsquo;s scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF-&beta; protein superfamily.<wbr> </div><div style="margin-bottom: 10px;">The investors in Acceleron include Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.<wbr> </div><div>Source: <A>www.<wbr>acceleronpharma.<wbr>com</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6905">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-11T17:23:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-11T17:23:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Victoza's Gains Label Expansion</title>
	<pubDate>2012-04-11T16:34:28+02:00</pubDate>
	<wp:post_id>3041</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="endocrinology6904attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6904_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(15 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6904_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(14,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6904">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-11T16:34:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-11T16:34:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GTx Strives To Move Forward With Capesaris Development</title>
	<pubDate>2012-04-10T09:30:43+02:00</pubDate>
	<wp:post_id>3042</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment GTx has submitted a complete response to FDA&rsquo;s requests following a February clinical hold on its oral selective estrogen receptor alpha agonist Capesaris to treat prostate cancer.<wbr> According to GTx, the FDA has said it will provide a decision on whether to lift the hold within 30 days.<wbr> </div><div style="margin-bottom: 10px;">The company suspended 3 open-label Phase II trials of the product following reports of an increased risk of venous thromboembolic events (VTE) in patients receiving the prostate cancer therapy (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8109" class="defaultlink">Oncology8109: FDA Has Placed a Clinical Hold on GTx' Capesaris for Advanced Prostate Cancer</a>).<wbr> </div><div style="margin-bottom: 10px;">GTx claims to have submitted information requested by FDA required to resolve the clinical hold, as well as the company&rsquo;s plans to develop Capesaris as a second-line therapy for advanced prostate cancer at doses lower than the 1,000 mg doses previously tested.<wbr> </div><div>Source: <a href="http://www.gtxinc.com" class="defaultlink" title="http://www.gtxinc.com">gtxinc.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8214">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-10T09:30:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-10T09:30:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recent Developments In Parkinson's Disease</title>
	<pubDate>2012-04-10T09:18:07+02:00</pubDate>
	<wp:post_id>3043</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last week the FDA approved a room-temperature stable formulation of transdermal Parkinson’s disease (PD) drug Neupro rotigotine from UCB along with 2 new indications.<wbr> FDA approved the original formulation of Neupro in 2007 for early PD but the product was recalled in 2008 due to crystallization on the patches.<wbr> </div><div style="margin-bottom: 10px;">The agency approved the reformulated product for signs and symptoms of advanced stage idiopathic PD and moderate to severe primary restless legs syndrome (RLS).<wbr> UCB plans to reintroduce the new formulation in the U.<wbr>S.<wbr> in July.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Developments in Japan</U></STRONG> </div><div style="margin-bottom: 10px;">Meanwhile, in Japan Kyowa submitted an NDA to Japan’s Ministry of Health, Labor and Welfare for istradefylline (KW-6002) to treat Parkinson’s disease.<wbr> Istradenfylline is an adenosine A2A receptor antagonist </div><div>Japan’s Ministry of Health, Labor and Welfare also approved an NDA from Kyowa for 30 mg subcutaneous Apokyn apomorphine to treat Parkinson’s disease.<wbr> Apokyn has Orphan Drug designation in Japan.<wbr> Kyowa has rights to the apomorphine hydrochloride injection in Japan and part of Asia from Stada’s Britannia Pharmaceutical Ltd.<wbr> subsidiary under a 2006 deal.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6349">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-10T09:18:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-10T09:18:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Troubled Times For AstraZeneca</title>
	<pubDate>2012-04-10T08:52:01+02:00</pubDate>
	<wp:post_id>3044</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Financial Times reported on Monday that some of the largest shareholders in AstraZeneca are lobbying for change including a totally new management structure plus a coherent and credible strategy for the group.<wbr> </div><div style="margin-bottom: 10px;">There is talk of the company being in a downward spiral failing to deliver any return on inevestments in acquisitions, in-licensing and internal research and development in more than a decade.<wbr> </div><div style="margin-bottom: 10px;">Some investors want the CEO David Brennan to step down and a new appointee to either totally restructure the group for sale or for a succesful scientist to take charge and really make something of the research team.<wbr> </div><div style="margin-bottom: 10px;">The call for action comes as Leif Johansson seeks formal election as the new Chairman of the board at next month's AGM.<wbr> </div><div>Source: Financial Times Monday 9th </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9834">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-10T08:52:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-10T08:52:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Joint Baltic Drug Procurement Agreement to Be Signed in May</title>
	<pubDate>2012-04-06T15:25:49+02:00</pubDate>
	<wp:post_id>3045</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Remigijus Bielinskas, an advisor in Lithuania's Ministry of Health, announced that the agreement between Lithuania, Latvia, and Estonia to engage in joint procurement of medicines is due to be signed on 2 May, reports the Baltic News Service.<wbr> The agreement will be signed in Riga and, according to his statement, would definitely go ahead unless there are serious concerns raised by the ministries of finance of the respective countries at the last minute.<wbr> </div><div style="margin-bottom: 10px;">Last minute objections, however, seem unlikely considering that earlier statements from Estonian radio ERR, as reported by the Baltic News Service, indicate that Estonia and Lithuania have already completed the administrative requirements and only approval by Latvia's parliament is still pending before the agreement could be signed.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">The idea for joint procurement of medicines in not new, but it seems that only now bureaucratic hurdles are finally about to be resolved.<wbr> </div><div style="margin-bottom: 10px;">The agreement makes sense from a payer standpoint: purchasing jointly would allow payers to negotiate higher discounts on larger pharmaceutical orders.<wbr> The pharmaceutical markets of Lithuania, Latvia, and Estonia individually are relatively small, but theoretically together they should be able to achieve a scale that makes them attractive to pharmaceutical companies.<wbr> </div><div style="margin-bottom: 10px;">The downside for the pharmaceutical industry, of course, is that the negotiating power of the Baltics as a whole will be greater and the pressure to offer discounts on pharmaceutical prices will be higher than is currently the case.<wbr> </div><div style="margin-bottom: 10px;">Another issue to ponder is that the three countries have separate, nationally set reimbursement lists for medicines.<wbr> If the three are going to be purchasing publicly funded medicines jointly, there would be growing pressure for conformity among the three separate reimbursement lists.<wbr> It is yet uncertain how the move for conformity will play out.<wbr> In principle, it could be a positive development for pharma if they manage to secure reimbursement in one of the three countries and that then translates into positive reimbursement listings in the other two.<wbr> </div><div style="margin-bottom: 10px;">The joint procurement agreement—if it works successfully as a cost containment tool—could be expanded into medical devices as well and even expanded to encompass additional countries in the regions, based on earlier announcements.<wbr> If this happens, downward pressure on pharmaceutical companies will intensify further and medical device manufacturers will be also adversely affected.<wbr> </div><div>From Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9832">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-06T15:25:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-06T15:25:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Safety and Efficacy of a Urine DEK ELISA in Diagnosis of Bladder Cancer</title>
	<pubDate>2012-04-05T17:30:10+02:00</pubDate>
	<wp:post_id>3046</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sponsored by Medical Diagnostic Laboratories, the multi-center study will use a DEK ELISA to quantitavely measure DEK protein in the urine of patients suspected having bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01563796?recr=Open&amp;fund=2&amp;rcv_s=03%2F22%2F2012&amp;rank=112"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 1000 patients who are at least 25 years of age with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones.<wbr> </div><div style="margin-bottom: 10px;">Start date: March 2012 - Completion Date: June 2013 /<wbr> Dec.<wbr> 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Founded in 1997, serves primarily as a reference laboratory for Polymerase Chain Reaction (PCR) based testing to physicians, laboratories and hospitals worldwide.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8212">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-05T17:30:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-05T17:30:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Study to Assess Sanofi's Jevtana and ADT Before Surgery</title>
	<pubDate>2012-04-05T16:13:44+02:00</pubDate>
	<wp:post_id>3047</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The aim of the Ph2 trial, sponsored by H.<wbr> Lee Moffitt Cancer Center and Research Insitute, is to test whether adding cabazitaxel and ADT (leuprolide or goserelin)before surgical removal of the prostate would improve the outcome of salvage surgery for patients with high risk PSA.<wbr> Surgical Margin Negative Rate (SM Rate) has been selected as primary outcome measures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01531205?recr=Open&amp;cond=prostate+OR+hemophilia+OR+spasticity+OR+neuroendocrine+OR+botulinum&amp;fund=2&amp;rcv_s=02%2F05%2F2012&amp;rank=18"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: 25 </div><div style="margin-bottom: 10px;">Start Date: April 2012 - Completion date: April 2022 </div><div style="margin-bottom: 10px;">Lead Investigator: Julio Pow-Sang, M.<wbr>D </div><div>Location: U.<wbr>S </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8211">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-05T16:13:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-05T16:13:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spectrum Buys Allos for $206M and Announces its Bladder Cancer Drug Fails</title>
	<pubDate>2012-04-05T15:38:43+02:00</pubDate>
	<wp:post_id>3048</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="oncology8208attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8208_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8208_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(26,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8208">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-05T15:38:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-05T15:38:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Analysts @ Deutsche Bank Report on Medicis</title>
	<pubDate>2012-04-05T12:09:49+02:00</pubDate>
	<wp:post_id>3049</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Post meeting with Medicis' management, analysts issued a detailed look at the company's key marketed products, development pipeline, business development activities as well as its growth outlook.<wbr> Of note, no reference was made to Revance.<wbr> Key messages on the aesthetic franchise are outlined below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management believe Dysport is still gaining share from Allergan's Botox.<wbr> They reported that Dysport may now have close to 40% MS.<wbr> </div><div>Management noted that on the Q4 call, Restylane achieved its strongest quarter since 2007, while Dysport posted the most units solid in any quarter since launch 2 years ago.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6347">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-05T12:09:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-05T12:09:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ZALTRAP Ph3 Trial in Prostate Cancer Did Not Meet Primary Endpoint</title>
	<pubDate>2012-04-05T11:37:03+02:00</pubDate>
	<wp:post_id>3050</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The results from the <A href="http://clinicaltrials.gov/ct2/show/NCT00519285?term=venice&amp;rank=2">VENICE</A> trial, evaluating the addition of ZALTRAP (aflibercept) to a regimen of docetaxel and prednisone for the 1st-line treatment of mCRPC, did not meet the pre-specified criterion of improvement in overall survival (OS).<wbr> The drug is an anti-angiogenic agent similar to Roche's <CLASSIFIER class="RIC" value="ROG.VX">Avastin, which failed to extend OS compared to chemotherapy and prednisone alone in patients with HRPC.<wbr></CLASSIFIER> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=6126" class="defaultlink">Oncology6126: Primary Objective Not Meet with Avastin for Prostate Cancer</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sanofi and Regeneron are conducting a detailed analysis of the VENICE data, and full results will be presented at an upcoming medical meeting (ASCO ?).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>The FDA has granted a priority review to the companies to examine Zaltrap in the treatment of colon cancer.<wbr> The FDA is due to give a decision by Aug.<wbr> 4 2012.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8206">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-05T11:37:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-05T11:37:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Clinical Study of MDV3100 + Docetaxel in Advanced Prostate Cancer</title>
	<pubDate>2012-04-04T16:48:05+02:00</pubDate>
	<wp:post_id>3051</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph1b is designed to assess the safety and tolerability of the combination as primary endpoint.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01565928?recr=Open&amp;cond=prostate+OR+hemophilia+OR+spasticity+OR+neuroendocrine+OR+botulinum&amp;fund=2&amp;rcv_s=02%2F04%2F2012&amp;rank=3"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 18 men &gt;18 years of age, ongoing ADT </div><div style="margin-bottom: 10px;">Start Date: Feb 2012 - Completion dates: March/<wbr>April 2014 </div><div>Locations: U.<wbr>S.<wbr>A.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8204">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-04T16:48:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-04T16:48:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Preclinical Data of Peregrine's Bavituximab in TRAMP Mice Presented @ AACR</title>
	<pubDate>2012-04-04T16:25:53+02:00</pubDate>
	<wp:post_id>3052</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a poster presentation, researchers presented data showing robust anti-tumour responses in a challenging preclinical prostate cancer model when an animal version of bavituximab was combined with androgen deprivation therapy (ADT).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to Philip Thorpe, Ph.<wbr>D.<wbr>, senior author of the study and scientific advisor to Peregrine, "Using the TRAMP model of prostate cancer in which mice are genetically engineered to continually generate prostate cancer, the combination regimen of bavituximab with ADT remarkably resulted in complete inhibition of cancer in roughly 40% of the animals, preventing tumor growth until the animals died of old age".<wbr> </div><div style="margin-bottom: 10px;"><U>Title</U>: Cure of castration-resistant prostate cancer in TRAMP mice by reactivating tumor immunity with a phosphatidylserine-targeting antibody.<wbr> </div><div><U>Authors</U>: <PERSON>Yi Yin</PERSON>, <PERSON>Xianming Huang</PERSON>, <PERSON>Gustavo Barbero</PERSON>, <PERSON>Dan Ye</PERSON>, <PERSON>Philip E.<wbr> Thorpe</PERSON>.<wbr> UT Southwestern Medical Ctr.<wbr>, <LOCATION value="LU/us.tx.dallas">Dallas, TX.<wbr></LOCATION> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8203">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-04T16:25:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-04T16:25:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Contributed $50M to Share the Risks of Early-Stage Research</title>
	<pubDate>2012-04-04T10:24:33+02:00</pubDate>
	<wp:post_id>3053</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda has joined the Structural Genomics Consortium (SGC), a not-for-profit, public-private partnership that supports the discovery of new medicines through open access research.<wbr> Among the funders, GSK, Novartis, Pfizer and Lilly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">To promote Takeda's drug discovery efforts by accessing new research first hand.<wbr> </div><div style="margin-bottom: 10px;">The company also can influence the research direction of the SGC network by participating on the SGC Scientific Committee and its Board of Directors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://www.thesgc.org/"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">The Structural Genomics Consortium was established in part to overcome the conservatism of much research.<wbr> Its goal is to produce 1,000 three-dimensional structures of therapeutically relevant biological targets, along with 100 structures of parasite drug targets.<wbr> </div><div>It is funded by the Canadian government, has a board of directors and a scientific committee, and oversees work in laboratories in Toronto, Oxford, and Stockholm.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9831">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-04T10:24:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-04T10:24:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Concerned with Astellas' Mirabegron Safety Issues</title>
	<pubDate>2012-04-03T16:14:31+02:00</pubDate>
	<wp:post_id>3054</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The U.<wbr>S.<wbr> agency said the once-daily tablet worked to reduce frequent urination and the inability to control it.<wbr> The beta-3 adrenoceptor was also tied to a higher rate of neoplasms, urinary tract problems, and hypersensitivity reactions.<wbr> Mirabegron is approved in Japan under the trade name Betanis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The FDA will make a final decision by June 29, taking into account the panel's recommendation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The FDA staff said most of the safety data for mirabegron appeared "reasonable," except for the heart and liver issues.<wbr> However, there were some discrepancies in how much the drug increased blood pressure and heart rate in different clinical trials.<wbr> </div><div>The FDA reviewers also said people taking the drug during clinical trials had a higher rate of tumors compared to people on a placebo, but it was unclear why this happened.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8202">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-03T16:14:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-03T16:14:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph3 Results of GSK's Albiglutide (Once-Weekly GLP-1) Support Progression to Regulatory Filing</title>
	<pubDate>2012-04-03T12:35:56+02:00</pubDate>
	<wp:post_id>3055</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GSK expects to have all the Ph3 data required to support regulatory filing in the U.<wbr>S.<wbr> (H2:12) and approval in H2:13.<wbr> Albiglutide comes in a pen, which does the reconstitution.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Comprises 8 individual studies, known as Harmony 1 to Harmony 8.<wbr> </div><div style="margin-bottom: 10px;">The primary efficacy endpoint for all studies is the change from baseline in HbA1c compared to placebo and/<wbr>or active comparators.<wbr> </div><div style="margin-bottom: 10px;">A majority of the studies will include active comparators, including sulphonylurea, thiazolidinedione (TZD), insulin and a dipeptidyl peptidase four inhibitor (DPP IV).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Harmony 6 and Harmony 7 have completed.<wbr> </div><div style="margin-bottom: 10px;">Harmony 8 will complete in mid-2012.<wbr> </div><div>The remaining 5 studies are expected to complete by early 2013; these ongoing studies have a primary efficacy endpoint set at between one and two years, and this timepoint has now been reached for each of these studies.<wbr> As per the study protocols, these studies will remain blinded past the primary efficacy endpoint until completion, which for most studies is 3 years.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6902">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-03T12:35:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-03T12:35:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>German's IQWiG Assigns Sativex 'No Additional Benefit' Rating for Spasticity in MS Patients</title>
	<pubDate>2012-04-03T10:21:55+02:00</pubDate>
	<wp:post_id>3056</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The agency outlined the data provided by GW were not suited for comparison with its comparator of "optimized standard therapy" baclofen, tizanidib or other anti-spasticity drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>GW' deadline to respond to the assessment is April 23.<wbr></LI>
<LI>The G-BA will then review IQWiG's recommendation and issue a final decision (which is expected mid-June 2012).<wbr></LI>
<LI>Pricing negociations would start after G-BA's final assessment.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6344">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-03T10:21:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-03T10:21:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tokai's Galeterone Completes Ph1 for Patients with CRPC</title>
	<pubDate>2012-04-03T09:45:11+02:00</pubDate>
	<wp:post_id>3057</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Early Ph1 results were presented during a "late-breaking clinical trials" session @ the AACR Annual Meeting 2012.<wbr> A Ph2 study is planned for H2 2012.<wbr> Galeterone, a small molecule, combines 3 distinct mechanisms of action in one compound, and acts as an androgen receptor antagonist, as a CYP17 lyase inhibitor and decreases androgen receptor levels in prostate tumors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT00959959?term=tokai&amp;cond=prostate&amp;rank=1"><STRONG></STRONG></A><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Lead by co-principal investigators Dr.<wbr> Taplin and Bruce Montgomery, M.<wbr>D.<wbr>, associate professor of medical oncology at the U.<wbr> of Washington School of Medicine, and their colleagues at leading prostate cancer research centers in the U.<wbr>S.<wbr> </div><div style="margin-bottom: 10px;">- Primary Endpoint: Incidence of AEs.<wbr> </div><div style="margin-bottom: 10px;">- Secondary Endpoints: Efficacy assessed by evaluation of change in PSA level, changes from baseline in CT/<wbr>MRI and bone scans, response rate RECIST criteria and additional special laboratories.<wbr> </div><div style="margin-bottom: 10px;">- Recruitment: 49 </div><div style="margin-bottom: 10px;">- Protocol: single or split oral escalation doses of 650 mg, 975 mg, 1,300 mg, 1,950 mg or 2,600 mg every day for 12 weeks.<wbr> None of the patients had received chemotherapy for their prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- <U>Safety</U>: Most side effects were minor and included fatigue, nausea and diarrhea.<wbr> </div><div style="margin-bottom: 10px;">- <U>Efficacy</U>: Early efficacy tests demonstrated that 49% of patients had PSA reductions of 30% or more; 11 of these patients had reductions of 50% or more.<wbr> In addition, CT scans revealed a significant reduction in tumor size for some patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>Privately held U.<wbr>S.<wbr> biopharmaceutical company based in Cambridge, MA.<wbr></LI>
<LI>Focused on developing new treatments for prostate cancer.<wbr></LI>
<LI>Founded by Apple Tree Partners.<wbr> </LI>
<LI>Recent Information - In September 2011, Tokai announced that the company closed $23M in additional funding from both existing investors, Apple Tree Partners and Novartis Venture Fund (NVF).<wbr> (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7772" class="defaultlink">Oncology7772: Tokai Secures $23m in Financing & A New CEO</a>).<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8198">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-03T09:45:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-03T09:45:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Vantas Granted 100% Reimbursement in France</title>
	<pubDate>2012-04-02T14:00:19+02:00</pubDate>
	<wp:post_id>3058</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Vantas Granted 100% Reimbursement in France</span>&nbsp;<br><span style="font-size: 12px;">Comment: France's Transparency Commission (TC) recommended Recordati (Italy)'s Vantas (histrelin implant) for reimbursement in the palliative treatment of patients with advanced prostate cancer.<wbr> The Transparency Commission has estimated that approx.<wbr> 21,500 patients could potentially be treated with Vantas each year in France.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8190">...</a><br></div><div style="margin-bottom: 10px;">Just to highlight  that VANTAS is a long acting implant 1 year  (reservoir type)  of 50 mg of Histrelin acetate , size <STRONG>3.<wbr>5 cm</STRONG> (length) X <STRONG>3 millimeters</STRONG> (Diameter) to be injected SC with a specific disposable device ( trocar size ? around 3.<wbr>6 mm diameter) .<wbr> More info on <a href="http://www.vantasimplant.com" class="defaultlink" title="www.vantasimplant.com">vantasimplant.com</a> </div><div>Bruno Tissier </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8196">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8190">View thread  Oncology8190: Vantas Granted 100% Reimbursement in France</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-02T14:00:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-02T14:00:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen's Success With UK NICE</title>
	<pubDate>2012-04-02T12:18:03+02:00</pubDate>
	<wp:post_id>3059</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Comment: Despite its rejection of abiraterone, NICE has recommended the use of Amgen's Xgeva for the prevention of skeletal-related events in people with bone metastasis derived from breast cancer, hormone-refractory prostate cancer (where other treatments have failed) and other solid tumours (where treatment with zoledronic acid is indicated).<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">A full recommendation from NICE is expected to reduce Amgen's exposure to at least one downward-pressure pricing point in the region and  with the UK acting as a key reference price state in both the EU and further afield, this route has 'domino effect' implications on an international basis.<wbr> That said, NICE has noted that the company will only gain a recommendation if it agrees a discounted rate with the NHS via a patient access scheme.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Xgeva has performed robustly for Amgen in the US market since its launch in December 2010.<wbr> Sales in that market are now almost on par with Novartis' Zometa (zoledronic acid) an impressive post-launch commercial performance over just a 15-month period,</P> </div><div><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Reportedly, the entrance of Xgeva has grown the skeletal-related events market by between 40 percent and 60 percent.<wbr> Building momentum remains a continued goal for Amgen, particularly as Zometa loses US patent exclusivity next year.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8195">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-02T12:18:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-02T12:18:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medy-Tox Launches Training Website</title>
	<pubDate>2012-04-02T10:40:03+02:00</pubDate>
	<wp:post_id>3060</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-bidi-font-size: 14.0pt; mso-fareast-font-family: 굴림; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-bidi-font-size: 14.0pt; mso-fareast-font-family: 굴림; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-bidi-font-size: 14.0pt; mso-fareast-font-family: 굴림; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA"></SPAN> </div><div><UL><LI><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-bidi-font-size: 14.0pt; mso-fareast-font-family: 굴림; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA"></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-bidi-font-size: 14.0pt; mso-fareast-font-family: 굴림; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA"></SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-bidi-font-size: 14.0pt; mso-fareast-font-family: 굴림; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA"></SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-bidi-font-size: 14.0pt; mso-fareast-font-family: 굴림; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA"></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-bidi-font-size: 14.0pt; mso-fareast-font-family: 굴림; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA"></SPAN></LI>
</UL> </div><!-- Comment details --><a name="neurology6342attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6342_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(18 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6342">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-04-02T10:40:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-04-02T10:40:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: MAP Submits NDA for LEVADEX (Migraine)</title>
	<pubDate>2012-03-30T17:24:15+02:00</pubDate>
	<wp:post_id>3061</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">MAP Submits NDA for LEVADEX (Migraine)</span>&nbsp;<br><span style="font-size: 12px;">Comment: At the beginning of the year, Allergan acquired US co-promotion rights to LEVADEX for $60M.<wbr> If approved by the FDA, Allergan will terminate the year with a strong position, having the strategic combination of products for prophylaxis of chronic migraine.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=5742">...</a><br></div><div style="margin-bottom: 10px;">The FDA, which raised issues related to the chemistry, manufacturing and controls (CMC) of the treatment, has rejected MAP's Levadex treatment for migraine.<wbr> The agency did not ask for additional trials and did not cite any safety or efficacy issues.<wbr> </div><div>MAP plans to request a meeting with the FDA to discuss the issues raised in the Complete Response letter.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6340">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology5742">View thread  Neurology5742: MAP Submits NDA for LEVADEX (Migraine)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-30T17:24:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-30T17:24:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Report From Leerink Swann Highlights AAD 2012 Main Trends</title>
	<pubDate>2012-03-30T16:51:48+02:00</pubDate>
	<wp:post_id>3062</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Report From Leerink Swann Highlights AAD 2012 Main Trends</span>&nbsp;<br><span style="font-size: 12px;">Comment: According to the report, a low interest in Merz' Xeomin and JNJ's PurTox as well as Merz's new filler, Belotero, was perceived.<wbr> Interest was high for products to treat acne and rosacea.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6309">...</a><br></div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 15px Calibri, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(64,49,82); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 15px Calibri, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(64,49,82); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6338">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6309">View thread  Neurology6309: Report From Leerink Swann Highlights AAD 2012 Main Trends</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-30T16:51:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-30T16:51:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>G-BA Assessment on Jevtana and Zytiga</title>
	<pubDate>2012-03-30T16:12:11+02:00</pubDate>
	<wp:post_id>3063</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8194">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-30T16:12:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-30T16:12:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Analysts @ Shinhan Investment Report on Medy-Tox</title>
	<pubDate>2012-03-30T14:50:53+02:00</pubDate>
	<wp:post_id>3064</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to the report, Medy-Tox has planned to roll out its filler, Neuramis Deep, in 2013, to diversify its product lineup and create synergy with Meditoxin.<wbr> The next generation Meditoxin, currently undergoing Ph2 clinical testing in Australia, is expected to receive approval in 2015 and start in the U.<wbr>S.<wbr> and E.<wbr>U.<wbr> in 2016.<wbr> The report outlines that Medytox aims to offer botulinum toxin products and fillers that are competitive with Allergan’s products at cheaper prices and strengthen its global presence starting with emerging markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><IMG height="252" name="C:\Data\Traction Instant Publisher\Autosaved\3-30-2012\ScreenCapture4.jpg" src="file:///C:/Data/Traction%20Instant%20Publisher/Autosaved/3-30-2012/ScreenCapture4.jpg" width="557"> </div><div style="margin-bottom: 10px;">The product is sold directly through the company’s sales personnel, which allows better margins than the aesthetic version which is sold through Pacific Pharmaceutical.<wbr> </div><div style="margin-bottom: 10px;">The therapeutic version is covered by insurance.<wbr> In addition, it is undergoing clinical testing for new indications.<wbr> As a result, sales are expected to continue growing.<wbr> </div><div style="margin-bottom: 10px;"><IMG height="175" name="C:\Data\Traction Instant Publisher\Autosaved\3-30-2012\ScreenCapture2.jpg" src="file:///C:/Data/Traction%20Instant%20Publisher/Autosaved/3-30-2012/ScreenCapture2.jpg" width="707"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Analysts reported that Medytox is currently engaged in clinical testing for its hyaluronic acid filler Neuramis Deep, which is slated for release in 2013.<wbr> Neuramis Deep is expected to be sold at 70% of the price of market leaders Juvederm and Restylane.<wbr> Unlike Botox, which is categorized as a drug, fillers are considered medical devices, which will allow easier penetration into the U.<wbr>S.<wbr>, Europe and other advanced markets.<wbr> The product received CE (Comformite Europeenne) in December 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><IMG height="180" name="C:\Data\Traction Instant Publisher\Autosaved\3-30-2012\ScreenCapture5.jpg" src="file:///C:/Data/Traction%20Instant%20Publisher/Autosaved/3-30-2012/ScreenCapture5.jpg" width="565"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><IMG height="351" name="C:\Data\Traction Instant Publisher\Autosaved\3-30-2012\ScreenCapture1.jpg" src="file:///C:/Data/Traction%20Instant%20Publisher/Autosaved/3-30-2012/ScreenCapture1.jpg" width="704"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The sales of the therapeutic product are expected to grow 293.<wbr>3% YoY to W5.<wbr>9bn in 2012.<wbr> By 2016, it should generate 21% (W9.<wbr>2bn) of total Meditoxin sales.<wbr> </div><div style="margin-bottom: 10px;"><IMG height="220" name="C:\Data\Traction Instant Publisher\Autosaved\3-30-2012\ScreenCapture3.jpg" src="file:///C:/Data/Traction%20Instant%20Publisher/Autosaved/3-30-2012/ScreenCapture3.jpg" width="762"> </div><div><STRONG></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6337">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-30T14:50:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-30T14:50:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Vantas Granted 100% Reimbursement in France</title>
	<pubDate>2012-03-30T14:09:00+02:00</pubDate>
	<wp:post_id>3065</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: France's Transparency Commission (TC) recommended Recordati (Italy)'s Vantas (histrelin implant) for reimbursement in the palliative treatment of patients with advanced prostate cancer.<wbr> The Transparency Commission has estimated that approx.<wbr> 21,500 patients could potentially be treated with Vantas each year in France.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The TC recommended a reimbursement at 100% despite the granting of a moderate clinical value (SMR) rating owing to a lack of comparative study versus alternatives available on the market and to a lack of data.<wbr> In its approved indication, Vantas was found to bring no added benefit (ASMR rating of V) in the treatment of metastatic prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Recordati provided efficacy data from two Phase III clinical trials (Study 301 and 302).<wbr> In the open-label, multi-centre, Phase III study 301, patients with advanced or metastatic prostate cancer who required an androgen-deprivation therapy were treated with a single Vantas implant every 12 months.<wbr> In the study, serum testosterone levels were monitored to evaluate both achievement (at week 4) and maintenance (at week 52) of a level ≤ 50 ng/<wbr>dL (primary endpoint of the study).<wbr> Of 138 patients who received an implant, serum testosterone was suppressed to below the castrate level (≤50ng/<wbr>dL) in 80% of patients at week 4 and maintained below the 50ng/<wbr>dL castrate threshold until week 52.<wbr> Meanwhile, in the supportive study 302, the primary endpoint was met in 31 of the 33 patients included in the trial.<wbr> The initial study design of study 301 and study 302 included a direct comparison versus a single goserelin acetate (Zoladex) 10.<wbr>8mg implant every three months and versus a single injection of leuprorelin acetate (Eligard) 22.<wbr>5mg every three months, respectively.<wbr> The Commission noted that the respective recruiting for the Zoladex arm and the Eligard arm were stopped during the studies.<wbr> </div><div style="margin-bottom: 10px;">The Commission noted that efficacy and safety data provided for Vantas comes from two studies of small size.<wbr> At week 60, 87 patients achieved a complete response and 12 experienced progression in the study 301.<wbr> However, Recordati does not provide data on the 39 remaining patients (28%) on these criteria.<wbr> Besides, the TC notes that the quantification of the therapeutic effect of Vantas in prostate cancer is difficult to estimate due to the lack of comparative data with luteinizing hormone releasing hormone (LHRH) agonists.<wbr> In the TC's view, the low level of proof of a therapeutic benefit with Vantas as well as its complex handling pose the question of its interest in the treatment of prostate cancer.<wbr> </div><div>From Global Insight </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8196c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Just to highlight  that VANTAS is a long acting implant 1 year  (reservoir type)  of 50 mg of Histrelin acetate , size <STRONG>3.<wbr>5 cm</STRONG> (length) X <STRONG>3 millimeters</STRONG> (Diameter) to be injected SC with a specific disposable device ( trocar size ? around 3.<wbr>6 mm diameter) .<wbr> More info on <a href="http://www.vantasimplant.com" class="defaultlink" title="www.vantasimplant.com">vantasimplant.com</a> </div><div>Bruno Tissier </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8190">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-30T14:09:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-30T14:09:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cynapsus Therapeutics's New Sublingual Apomorphine</title>
	<pubDate>2012-03-29T17:19:28+02:00</pubDate>
	<wp:post_id>3066</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside its Q4 results Cynapsus noted that it has successfully completed its first human volunteer pilot POC trial with its buccal apomorphine formulation APL-130277 and a large survey which serves to underpin the unmet need for such a therapy.<wbr> </div><div style="margin-bottom: 10px;">The study showed a pharmacokinetic (PK) profile that compared favorably to injected apomorphine with a mean T-max of 25 minutes and good tolerability.<wbr> The company claims that this was a significant milestone and de-risking event for the project.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>It has also completed a significant neurologist survey confirming the need for improved administration of acute rescue therapy for PD.<wbr> The</STRONG> survey was undertaken amongst neurologists and movement disorder specialists in the United States, Europe, Japan, China and select countries in the Rest of the World.<wbr> In total, 500 neurologists and movement disorder specialists were surveyed on their treatment of patients with Parkinson’s disease.<wbr> Collectively, these professionals treat approximately 62,000 Parkinson’s patients per year with approximately 41.<wbr>4% classified as mild-moderate in severity, 42.<wbr>2% as moderate-severe, and 16.<wbr>4% as severe.<wbr> </div><div style="margin-bottom: 10px;">Cynapsus also claims that a survey of US HMO’s and insurers showed that they would be willing to place APL-130277 on their formularies and that they would be willing to reimburse at a price similar to that of the injectable form.<wbr> </div><div>From <A href="http://www.cynapsus.ca/">http:/<wbr>/<wbr>www.<wbr>cynapsus.<wbr>ca</A>, see <A href="http://www.cynapsus.ca/news.php?article=248">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6336">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-29T17:19:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-29T17:19:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer to Present New Data on Oncology Pipeline</title>
	<pubDate>2012-03-29T17:01:04+02:00</pubDate>
	<wp:post_id>3067</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer has announced its intention to disclose more about its early development pipeline in oncology at the upcoming AACR meeting in Chicago (March 31st to April 4th).<wbr> 15 posters will be presented highlighting the group's growing interest in the oncology area.<wbr> Key posters will focus on the group's new PI3K inhibitor, MEK inhibitor and its prostate cancer drug PSMA/<wbr>CD3-bispecific BiTE antibody.<wbr> </div><div style="margin-bottom: 10px;"><EM>Tumor specific imaging by L-5-F-18-ethoxy-Tryptophan mediated by LAT1 and IDO1</EM><BR>o Presentation #360, Session: Imaging of Molecular and Cellular Events in Tumors and Tumor Cells<BR>o Sunday, April 1, 2012, 1:00 p.<wbr>m.<wbr>-5:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 13 </div><div style="margin-bottom: 10px;"><EM>• Comparison of commercially available phosphorylated ERK antibodies for immunohistochemical biomarker analysis</EM><BR>o Presentation #742, Session: Clinical Trials in Radiation Oncology /<wbr> Regulatory Science<BR>o Sunday, April 1, 2012, 1:00 p.<wbr>m.<wbr>-5:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 27 </div><div style="margin-bottom: 10px;"><EM>• Potent in vitro and in vivo anti-tumor activity of PI3K inhibitor BAY 80-6946 and MEK inhibitor BAY 86-9766 in preclinical biliary tract cancer models.<wbr></EM><BR>o Presentation #869, Session: Kinase and Phosphatase Inhibitors 1<BR>o Sunday, April 1, 2012, 1:00 p.<wbr>m.<wbr>-5:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 32 </div><div style="margin-bottom: 10px;"><EM>• Antiproliferative effects of DNA methyltransferase 3B depletion are not associated with DNA demethylation.<wbr></EM><BR>o Presentation #1036, Session: Chromatin Regulators<BR>o Monday, April 2, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 1 </div><div style="margin-bottom: 10px;"><EM>• Regorafenib (BAY 73-4506): Anti-metastatic activity in a mouse model of colorectal cancer.<wbr></EM><BR>o Presentation #2337, Session: Angiogenesis Inhibitors<BR>o Monday, April 2, 2012, 1:00 p.<wbr>m.<wbr>-5:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 12<BR> <BR><EM>• Efficacy and Candidate Biomarker Evaluation for the anti-Mesothelin antibody drug conjugate BAY 94-9343, Mesothelin-ADC in Mesothelin positive preclinical xenograft models.<wbr></EM><BR>o Presentation #2726, Session: Biological Therapy Based on Viruses, Antibodies, or Metformin<BR>o Monday, April 2, 2012, 1:00 p.<wbr>m.<wbr>-5:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 28 </div><div style="margin-bottom: 10px;"><EM>• BAY 1082439, a highly selective and balanced PI3Kα/<wbr>β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN.<wbr></EM><BR>o Presentation #2799, Session: Kinases as Targets for Therapy<BR>o Monday, April 2, 2012, 1:00 p.<wbr>m.<wbr>-5:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 31 </div><div style="margin-bottom: 10px;"><EM>• CD24 regulates tumor cell behaviour in a c-Src dependent fashion.<wbr></EM><BR>o Presentation #3087, Session: Cross-Talk between Signaling Pathways and Transcription Factors<BR>o Tuesday, April 3, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 4 </div><div style="margin-bottom: 10px;"><EM>• Development of a novel Wnt pathway antagonist antibody, OMP-18R5 that reduces tumor initiating cell frequency in breast cancer.<wbr></EM><BR>o Presentation #3356, Session: Identification and Targeting of Cancer Stem Cells<BR>o Tuesday, April 3, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 14 </div><div style="margin-bottom: 10px;"><EM>• Subcutaneous administration of PSMA/<wbr>CD3-bispecific BiTE antibody MT112/<wbr>BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice.<wbr></EM><BR>o Presentation #3526, Session: Mobilizing Immune Effector Cells for Cancer Therapy<BR>o Tuesday, April 3, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 19 </div><div style="margin-bottom: 10px;"><EM>• In vitro and in vivo pharmacological profile of BAY 1001931, a novel highly potent allosteric AKT1/<wbr>2 inhibitor.<wbr></EM><BR>o Presentation #3751, Session: Kinase Inhibitors<BR>o Tuesday, April 3, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 29 </div><div style="margin-bottom: 10px;"><EM>• BAY 87-2243, an inhibitor of HIF1α-induced gene activation, showed promising anti-tumor efficacy in combination with anti-angiogenic therapy and irradiation in preclinical tumor models.<wbr></EM><BR>o Presentation , Session: Late-Breaking Research: Experimental and Molecular Therapeutics 1<BR>o Tuesday, April 3, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 39 </div><div style="margin-bottom: 10px;"><EM>• Pilot clinical trials of FSPG (BAY 94-9392): An 18F-labeled glutamate derivative for PET imaging of system xC-activity in tumors.<wbr></EM><BR>o Presentation , Session: Late-Breaking Research: Clinical Trials<BR>o Tuesday, April 3, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 40 </div><div style="margin-bottom: 10px;"><EM>• LKB1 and KRAS mutations predict resistance to PI3K/<wbr>Akt inhibitors in non-small cell lung cancer</EM><BR>o Presentation #5605, Session: Cytoplasmic Kinases and Drug Resistance<BR>o Wednesday, April 4, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 29 </div><div style="margin-bottom: 10px;"><EM>• Alpharadin (Radium-223 chloride) completely prevents tumor growth in bone and increases survival in a mouse model of breast cancer bone metastases in preventive and micro-metastatic settings</EM><BR>o Presentation #5712, Session: Preclinical Radiotherapeutics<BR>o Wednesday, April 4, 2012, 8:00 a.<wbr>m.<wbr>-12:00 p.<wbr>m.<wbr>, McCormick Place West (Hall F), Poster Section 34 </div><div>From <A href="http://press.bayerhealthcare.com/">http:/<wbr>/<wbr>press.<wbr>bayerhealthcare.<wbr>com</A>, see <A href="http://press.bayerhealthcare.com/en/press/news-details-page.php/14531/2012-0136">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8189">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-29T17:01:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-29T17:01:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sorafenib As A Potential Agent For The Treatment of CRPC</title>
	<pubDate>2012-03-29T15:30:01+02:00</pubDate>
	<wp:post_id>3068</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; LINE-HEIGHT: 17px; FONT-FAMILY: arial, helvetica, clean, sans-serif; TEXT-ALIGN: left"></SPAN></SPAN> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8188">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-29T15:30:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-29T15:30:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's R&D Day Highlights New Therapeutic Opportunities For Botox & Its Novel TEM Programme</title>
	<pubDate>2012-03-28T22:31:48+02:00</pubDate>
	<wp:post_id>3069</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan's R&amp;D day highlighted the significant results it has obtained in iOAB, (approval now anticipated Q113), an efficacious dose identified for BPH (phII POC ongoing), a new opportunity for Botox in osteoarthritis and initial efficacy data with senrebotase its new targeted toxin in post herpetic neuralgia.<wbr> It is also excited by its opthalmology and medical aesthetics pipeline and investing significantly in these areas envisioning the use of Latisse for treating alopecia as a huge opportunity.<wbr> The first aesthetic filing will be for crows feet in 2H12.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Idiopathic OAB Data</STRONG> </div><div style="margin-bottom: 10px;">Allergan has conducted two major international phIII studies in iOAB which have produced reproducible and statistically significant results resulting in a global filing this month.<wbr> </div><div style="margin-bottom: 10px;">Baseline data, results and safety profile are shown below but more data on patients who were episode free will be presented at the upcoming AUA meeting in Atlanta on May 22nd.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Points Emerging From Q/<wbr>A</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>iOAB uniquely different to migraine.<wbr> Botox effect lasts longer, the effect on smooth muscle is longer, months longer than chronic migraine.<wbr> </LI>
<LI>A long-term study is ongoing to look at long-term effects.<wbr> Already know that the median response in nOAB is 9 months.<wbr> </LI>
<LI>Injection paradigm is similar to nOAB although fewer injections are needed 20 vs.<wbr> 30 for nOAB.<wbr> </LI>
<LI>Allergan believes the training component should be easier and may see slightly faster uptake because of experience already gained in nOAB setting.<wbr> </LI>
<LI>Allergan spent days debating the perfect dose and in the end it appears that 100U was right because of the lower rate of catheritisation seen than in previous studies.<wbr> </LI>
<LI>Following the sBLA filing Allergan expects a 10-month PDUFA date.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Points Emerging On BPH Programme</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Route of administration is transrectal.<wbr> </LI>
<LI>MOA still under investigation.<wbr> Definitely more than just an effect on smooth muscle.<wbr> </LI>
<LI>Longer acting toxin could be preferable given route of injection therefore TEN programme could generate a follow-on product for this indication.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Botox Growth Strategy</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;">Why Botox for osteoarthritis? </div><div style="margin-bottom: 10px;"><UL><LI>Efficacy in pain both in chronic migraine and cervical dystonia </LI>
<LI>Local therapy </LI>
<LI>Office administered </LI>
<LI>Ultrasound guidance possible </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>TEM Programme</STRONG> </div><div style="margin-bottom: 10px;">This is seen as capitalising on the high efficacy and specificity of Botox.<wbr> The re-engineered toxin effectively has a different and undisclosed binding domain to Botox which targets pain fibres specifically.<wbr> To date it appears that it can has no motor effects, greater efficacy on pain and an ability to be used at much higher doses.<wbr> After generating "very encouraging" phI data, Allergan has started a phase II and has data so far on the first two doses evaluated.<wbr> A slight seperation in effect between senrebotase and placebo was seen in the allcomers group but in patient taking no concomitant pain medication a much better response (separation) has been seen.<wbr> If the data from the two follow-on doses looks positive then Allergan plans to move in full development for post herpetic neuralgia or another neuropathic pain indication.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_23_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_24_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_25_ScreenCapture25.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_26_ScreenCapture26.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_27_ScreenCapture27.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Points to Emerge From Q/<wbr>A on TEM Programme</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Manufacturing is differnt and for proprietary reasons Allergan was not prepared to disclose what is required or the level of investment.<wbr> </LI>
<LI>Recombinant technology and as a brand new technology multiple patents have been filed.<wbr> Not prepared to comment on these.<wbr> </LI>
<LI>In terms of area of diffusion it is early days to assess but potentially is likely to be less of an issue than with Botox.<wbr> </LI>
<LI>Biology is the same as Botox and the duration of effect similar.<wbr> </LI>
<LI>Data on the two higher doses should be available by end 2013.<wbr> Should obtain clarity at this point in terms of moving into phIII.<wbr> Decision which way to go will be data driven.<wbr> If the data is good a move in phIII for PHN could occur quite quickly.<wbr> If another pain indication is sought a further phIIb study may be required.<wbr> </LI>
<LI>No evidence of muscle laxity seen so far but studies fairly smalll but an interesting point to watch for.<wbr> An interesting point is you do not see muscle atrophy.<wbr> </LI>
<LI>Allergan was challenged to find any evidence of dose limiting toxicity in preclinical studies.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Aesthetics &amp; Dermatology</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_28_ScreenCapture28.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_29_ScreenCapture29.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_30_ScreenCapture30.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_31_ScreenCapture31.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_32_ScreenCapture32.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_33_ScreenCapture33.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_34_ScreenCapture34.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_35_ScreenCapture35.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_36_ScreenCapture36.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_37_ScreenCapture37.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_38_ScreenCapture38.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_39_ScreenCapture39.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_40_ScreenCapture40.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_41_ScreenCapture41.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_42_ScreenCapture42.jpg"> </div><!-- Comment details --><a name="neurology6332attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(69 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(43,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(84,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(20 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(90,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(91,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(64,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(75,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(84,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(94,8 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(73,9 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(86,4 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(49,1 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(94,9 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(100,3 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(112,9 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(88,4 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(87,9 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(77,4 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(100,3 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(54,1 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(98,5 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(79,2 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(88,4 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(103,8 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(77,3 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_29_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(76,7 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_30_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_31_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(99,1 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_32_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(91,5 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_33_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(86,6 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_34_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(96,2 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_35_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(106,4 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_36_ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(101,2 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_37_ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(87,2 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_38_ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(71,3 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_39_ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(61,3 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_40_ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(78,9 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_41_ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(89,3 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6332_42_ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(87,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6332">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-28T22:31:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-28T22:31:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Files For Approval Of iOAB</title>
	<pubDate>2012-03-28T18:28:24+02:00</pubDate>
	<wp:post_id>3070</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has today announced positive top-line results from two Phase III clinical trials of BOTOX<SUP>®</SUP> (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder and earlier than anticipated submitted a sBLA to the FDA and an application to the European regulators.<wbr> </div><div style="margin-bottom: 10px;">Top -line data will be revealed today at the company's Research and Development Technology Review, whilst the full study results of the North American Phase III study are expected to be presented at an upcoming medical meeting (most likely the AUA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Label Indication Sought</STRONG> </div><div style="margin-bottom: 10px;">Its regulatory filing is seeking approval for the use of BOTOX<SUP>®</SUP> as treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Current Urological Indication </STRONG> </div><div style="margin-bottom: 10px;">BOTOX<SUP>®</SUP> is currently approved in <LOCATION value="LC/us">the United States</LOCATION> and in several European countries for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.<wbr>g.<wbr>, spinal cord injury (SCI), multiple sclerosis (MS)) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design and Key Findings</STRONG> </div><div style="margin-bottom: 10px;">Patients included in the phIII trials were those who were suffering with urinary incontinence for at least six months and who were inadequately treated with an anticholinergic therapy.<wbr> Patients were randomly assigned to treatment with BOTOX<SUP>® </SUP>or placebo injections into the detrusor (bladder) muscle, followed by an injection with BOTOX<SUP>®</SUP> after a minimum of 12 weeks if desired.<wbr> In both studies, there was a highly statistically significant decrease in the number of daily incontinence episodes in patients treated with BOTOX<SUP>®</SUP> vs.<wbr> placebo (p &lt; 0.<wbr>001).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety Profile in iOAB</STRONG> </div><div style="margin-bottom: 10px;">In both Phase III clinical trials, BOTOX<SUP>®</SUP> treatments were well tolerated.<wbr> Adverse events were primarily limited to the urinary tract, with urinary tract infection rates between 15-20 percent and urinary retention rates between 5-6 percent for patients treated with BOTOX<SUP>®</SUP> in both studies.<wbr> However, patients receiving BOTOX<SUP>®</SUP> treatments in both studies also reported an improvement in quality of life.<wbr> </div><div>Source: <a href="http://www.allergan.com" class="defaultlink" title="www.allergan.com">allergan.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6331">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-28T18:28:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-28T18:28:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis to Assess POC with Pasireotide LAR or Everolimus Alone or in Combination</title>
	<pubDate>2012-03-27T15:35:12+02:00</pubDate>
	<wp:post_id>3071</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The LUNA trial, a new multicenter 3-arm Ph2 study which primary endpoint will evaluate proportion of patients progression-free at 12 months in approx.<wbr> 112 participants with well differentiated neuroendocrine carcinoma of the lung and thymus (primary endpoint).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01563354?fund=2&amp;rcv_s=03%2F13%2F2012&amp;rank=105"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 112 </div><div style="margin-bottom: 10px;">Start date: June 2012 - Completion date: March 2016 </div><div style="margin-bottom: 10px;"><UL><LI>arm1 : Pasireotide LAR (60mg i.<wbr>m inj once ev 28 days)</LI>
<LI>arm2: Everolimus (10 mg p.<wbr>o daily)</LI>
<LI>arm3: Pasireotide LAR + Everolimus (Pasireotide LAR 60 mg i.<wbr>m.<wbr> injected once every 28 days + Everolimus 10 mg p.<wbr>o.<wbr> daily)</LI>
</UL> </div><div>Location: US </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6899">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-27T15:35:12+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-27T15:35:12+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Elagolix Ph3 Program on Track to Start Q2 12 for Endometriosis</title>
	<pubDate>2012-03-27T14:54:00+02:00</pubDate>
	<wp:post_id>3072</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA has responded to the SPA filed on the design of the Ph3 program.<wbr> The agency's comments will be incorporated into the final pivotal trial designs.<wbr> Analysts @ Leerink Swann project a US launch in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Elagolix offers the convenience of an oral pill, strong efficacy, but without the profound estrogen suppression that causes clinical side effects.<wbr> </div><div style="margin-bottom: 10px;">- Oral contraceptives offer only modest improvement.<wbr> </div><div>- GNRH agonists or progesterone analogues result in excessive estrogen suppression and can cause bone mineral density loss and also require subcutaneous injections.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8187">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-27T14:54:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-27T14:54:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Neurocrine to Move Forward with Larger Ph2b Trial for Tardive Dyskinesia</title>
	<pubDate>2012-03-27T14:27:59+02:00</pubDate>
	<wp:post_id>3073</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: For the final Ph2 analysis, data from one site was removed due to the inconsistent and incorrect application of the efficacy assessment protocol.<wbr> With this site removed, the results showed a significant reduction in tardive dyskinesia symptoms at end of two weeks of active treatment with 50mg once-daily doses of NBI-98854 (a VMAT2 Inhibitor).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6328_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6328_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Design: randomized, double-blind, placebo controlled, cross-over, Phase II clinical trial</LI>
<LI>Recruitment: 37 subject study assessed once-daily NBI-98854 (12.<wbr>5mg and 50mg) over a 2 week dosing period.<wbr> </LI>
<LI>The primary endpoint of the study was a comparison of placebo vs.<wbr> active scores utilizing the Abnormal Involuntary Movement Scale (AIMS).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6328_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology6328attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6328_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6328_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(27,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6328_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(64 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6328_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(76,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6328_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(69,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6328">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-27T14:27:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-27T14:27:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bariatric Surgey Outstrips Medical Therapy In New Diabetic Therapy Study</title>
	<pubDate>2012-03-27T12:53:37+02:00</pubDate>
	<wp:post_id>3074</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Data presented yesterday at the American College Of Cardiology meeting showed that bariatric surgery was better at controlling diabetes in moderately obese patients than therapy with the GLP-1 analogue Liraglutide (Novo Nordisk's Victoza).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Treatment Paradigm Changing Data?</STRONG> </div><div style="margin-bottom: 10px;">Dr Philip Schauer Director of the Bariatirc Metabolic Institute at the Cleveland Clinic, the studies prinnicipal investigator suggested that the results of the study could represent a "potential paradigm change" in the way some patients should be treated for diabetes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The STAMPEDE study randomly assigned 150 patients with a BMI of between 27 and 43 to three different forms of intervention, laproscopic gastic bypass, sleeve gastrectomey or treatment with Victoza.<wbr> </div><div style="margin-bottom: 10px;">The main goal of the study was to reduce HbA1c from the average study entry point of 9 by 6% or lower within one year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">42% of the gastic bypass group achieved this goal,37% of the sleeve gastrectomy patients and only 12% of those taking Victoza.<wbr> </div><div style="margin-bottom: 10px;">Not surprisingly weight loss was five times higher in the surgery groups and many were able to lower the dose of their blood pressure and cholesterol lowering medications.<wbr> </div><div>Source: American College of Cardiology Congress </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6897">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-27T12:53:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-27T12:53:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Clinical Trials Register Available Via WHO’s International Clinical Trials Registry Platform</title>
	<pubDate>2012-03-27T12:45:01+02:00</pubDate>
	<wp:post_id>3075</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><SPAN style="font-size: x-small;">Comment:  Information contained in the<SPAN style="color: #333333;"> <A href="http://www.firstwordpharma.com/redirect/ext_link?url=https://www.clinicaltrialsregister.eu/&amp;tsid=17" style="margin: 0px; color: #d27728; text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; padding: 0px;" target="_blank"><SPAN style="color: #333333;">European Union (EU) Clinical Trials Register</SPAN></A> managed by the EMA is available from t26 March 2012 hrough the <A href="http://www.firstwordpharma.com/redirect/ext_link?url=http://www.who.int/ictrp/en/&amp;tsid=17" style="margin: 0px; color: #d27728; text-decoration: none; outline-style: none; outline-width: initial; outline-color: initial; padding: 0px;" target="_blank"><SPAN style="color: #333333;">WHO International Clinical Trial Registry Platform</SPAN></A> (ICTRP).<wbr></SPAN></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><SPAN style="font-size: x-small;">This follows recognition by the World Health Organization (WHO) in September 2011 of the EU Clinical Trials Register as one of the 'primary registries' for the ICTRP.<wbr> The WHO and the Agency have worked together in developing the technical processes to allow data transfer from the EU Clinical Trials Register to ICTRP.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: x-small 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px; font-family: Helvetica, Arial, sans-serif;">ICTRP is a web-based portal that allows access to a wide range of information from different clinical-trial registers from across the world, and the information is updated weekly.<wbr></SPAN></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: x-small 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px; font-family: Helvetica, Arial, sans-serif;"><A href="http://www.who.int/ictrp/en/">http:/<wbr>/<wbr>www.<wbr>who.<wbr>int/<wbr>ictrp/<wbr>en/<wbr></A></SPAN></SPAN></P> </div><div><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: x-small 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px; font-family: Helvetica, Arial, sans-serif;">Source: EMA 26 March 2012</SPAN></SPAN></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9825">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-27T12:45:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-27T12:45:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Antibody Conjugate Company Formed With $50m Of Funding</title>
	<pubDate>2012-03-27T12:27:02+02:00</pubDate>
	<wp:post_id>3076</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG><U></U></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG><U></U></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8186">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-27T12:27:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-27T12:27:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Migraine Survey Consistent with Allergan's Expectations</title>
	<pubDate>2012-03-26T15:37:07+02:00</pubDate>
	<wp:post_id>3077</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analysts @ Leerink Swann has commissioned a MEDACorp survey of 50 US-based neurologists to evaluate launch of Botox for chronic migraine.<wbr> Key outcomes are outlined below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>A &gt;$1 billion Market Opportunity</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6323_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Neurologists estimate that ~60% of their migraine patients are eligible for prophylaxis and, of those patients, 17% are eligible for Botox under the label.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6323_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Strong Physician Acceptance</STRONG> </div><div style="margin-bottom: 10px;">Respondents indicate a high degree of comfort with Botox with 52% currently administering, 4% awaiting training to begin administering the drug, and 44% referring their patients for Botox.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6323_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Early Physician Satisfaction</STRONG> </div><div style="margin-bottom: 10px;">Overall, neurologists estimate that 15% of patients eligible for Botox will be treated in 24 months.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6323_4_ScreenCapture4.jpg"> </div><div><STRONG>Patient-based Survey Estimates Suggest Sales of &gt;$200M in 2012</STRONG> </div><!-- Comment details --><a name="neurology6323attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6323_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6323_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(34,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6323_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(27,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6323_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(48 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6323">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-26T15:37:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-26T15:37:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Diabetes Afflicts Approx. 10% of Chinese Adults</title>
	<pubDate>2012-03-26T14:44:46+02:00</pubDate>
	<wp:post_id>3078</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to the Singapore's Saw See Hock School of Public Health and the Harvard School of Public Health, spending on diabetes reached $17 billion in China in 2011 (about 5% of total healthcare spending in the country).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">There are now approx.<wbr> 92 million diabetics in China.<wbr> It is expected to rise to 130 million by 2030.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6896_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Basic medicine to keep diabetes under control is relatively cheap in China, at approx.<wbr> 2,000 yuan ($320) a year.<wbr> </div><div style="margin-bottom: 10px;">But treatment for a patient who has developed advanced symptoms could easily reach 18,000 yuan a year, roughly equal to the average yearly income of urban Chinese.<wbr> </div><div style="margin-bottom: 10px;">Common drugs for diabetes are covered by insurance, but equipment for at-home testing and monitoring of blood sugar levels - which can reach 400 yuan a month - is not.<wbr> </div><div style="margin-bottom: 10px;">Adding to the burden, Asians in their prime earning years of 30-50 are more likely to develop diabetes than Caucasians, according to the Saw Swee Hock white paper on diabetes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Novo Nordisk, the top seller of insulin in China, and Bayer, which markets a drug that helps reduce glucose absorption after meals help educate on diabetes in China.<wbr> </div><!-- Comment details --><a name="endocrinology6896attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6896_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6896">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-26T14:44:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-26T14:44:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis CEO's Blog Illustrates Collaborative Efforts Underway With Walgreens</title>
	<pubDate>2012-03-26T11:19:41+02:00</pubDate>
	<wp:post_id>3079</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis is in discussions with the pharmacy and drugstore chain Walgreens to try and secure a collaboration regarding its "Clinical Trials Of The Future Program".<wbr> </div><div style="margin-bottom: 10px;">Essentially clinical trial patients would be able to visit a local Walgreen store for routine checks for vital signs and blood pressure rather than having to necessarily travel some distance to a clinical trial centre.<wbr> </div><div style="margin-bottom: 10px;">Novartis is already working with Walgreens to educate patients about products and services across the entire Novartis portfolio.<wbr> For example:- </div><div style="margin-bottom: 10px;">i) It is developing a unique program to transition appropriate patients on certain cardiovascular products from 30-day prescriptions to 90-day prescriptions as a way to improve adherence.<wbr> </div><div style="margin-bottom: 10px;">ii) It is also collaborating to establish Walgreens as a key location for Novartis flu vaccines.<wbr> </div><div style="margin-bottom: 10px;">Joe Jiminez notes that as Walgreen accounts for approx.<wbr> 20% of the retail pharmacy volume in the U.<wbr>S.<wbr> market, "such developments can have a significant impact on healthcare overall.<wbr>" </div><div style="margin-bottom: 10px;">Novartis is citing this collaboration as an example of the way it is working with key stakeholders to try and improve outcome and deliver more services for patients.<wbr> </div><div>Source Joe Jiminez's Blog <A href="http://freepdfhosting.com/c18a2aa279.pdf">http:/<wbr>/<wbr>freepdfhosting.<wbr>com/<wbr>c18a2aa279.<wbr>pdf</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9824">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-26T11:19:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-26T11:19:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Corcept To Launch Korlym Earlier Than Anticipated</title>
	<pubDate>2012-03-26T11:01:51+02:00</pubDate>
	<wp:post_id>3080</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Corcept intends to launch its 300mg oral Korlym mifepristone in the US for the treatment of Cushing's Syndrome on April 11th at a daily price of $186 (WAP).<wbr> </div><div style="margin-bottom: 10px;">The launch was originally planned for May 1st.<wbr> </div><div style="margin-bottom: 10px;">Korlym was approved by the US FDA back in February (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6871" class="defaultlink">Endocrinology6871: Corcept's Korlym™ Gains FDA Approval For Cushing's</a>) </div><div style="margin-bottom: 10px;">The progesterone and cortisol antagonist is indicated to control hyperglycaemia in adults with endogenous Cushing's syndrome who have type II diabetes or glucose intolerance.<wbr> </div><div>Source: <a href="http://www.corcept.com" class="defaultlink" title="http://www.corcept.com">corcept.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6892">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-26T11:01:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-26T11:01:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Outcome Research Goes A Step Further By Harnessing The Power Of IBM Watson</title>
	<pubDate>2012-03-26T10:57:37+02:00</pubDate>
	<wp:post_id>3081</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment IBM and the Memorial Sloane Kettering cancer center are to collaborate on an outcome and evidence-based decision support system for oncologists that uses the computational power and language processing ability of IBM’s computer IBM Watson.<wbr> The first therapy area targets are lung, breast and prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">The center’s oncologists will work with IBM to create the tool using a patient’s medical information, clinical knowledge, molecular and genomic data, and cancer case histories, along with treatment guidelines and published research.<wbr> </div><div style="margin-bottom: 10px;">The tool will also provide users with a detailed record of the data and evidence used to reach the recommendations.<wbr> </div><div style="margin-bottom: 10px;">The goal of the collaboration is to improve access to “current and comprehensive cancer data and practices” to help physicians create individualized cancer diagnostic and treatmentrecommendations based on current evidence.<wbr> </div><div style="margin-bottom: 10px;">The parties are initially aiming to pilot the system to a select group of oncologists in late 2012, with wider distribution planned for late 2013.<wbr> </div><div>Financial terms of the collaboration have not been disclosed </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8185">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-26T10:57:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-26T10:57:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon's LX-1032 Granted ODD by the FDA</title>
	<pubDate>2012-03-26T10:23:05+02:00</pubDate>
	<wp:post_id>3082</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On March 20th, the US FDA granted Orphan Drug Designation to Telotristat Etiprate (LX-1032) for the treatment of carcinoid syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Lexicon has previously received Orphan Drug designation from the European Medicines Agency and Fast Track status from the FDA for telotristat etiprate.<wbr> </div><div style="margin-bottom: 10px;">- Preparation for Ph3 is ongoing.<wbr> </div><div>- Lexicon is also currently planning a Ph2 trial in mild to moderate ulcerative colitis.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6891">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-26T10:23:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-26T10:23:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Clarity Regarding Merz Pricing of Xeomin In The UK</title>
	<pubDate>2012-03-23T18:12:55+01:00</pubDate>
	<wp:post_id>3083</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Soft intelligence in the UK has provided us with more granularity about the discount structure Merz is operating with in the regions.<wbr> Discounts based on volume are ranging from 24% down to close to 40% off-the NHS list price.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regardless Of Volume</STRONG> </div><div style="margin-bottom: 10px;">We understand the discount in this setting is around 24% at a price of GBP98 per 100U Xeomin vial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Volume Based Discounts At Individual Centres</STRONG> </div><div style="margin-bottom: 10px;">In this setting if a 100% switch to Xeomin is considered the price is reduced to 80GBP per100U Xeomin vial.<wbr> </div><div style="margin-bottom: 10px;">The NHS list price for Xeomin is GBP129 per 100U vial </div><div>If other countries are experiencing this level of discounting please do share experiences with the CI and market access teams.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6321">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-23T18:12:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-23T18:12:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENETS Intelligence Part 3- Key Developments With Imaging, Translational Science & Notable Posters</title>
	<pubDate>2012-03-23T16:40:26+01:00</pubDate>
	<wp:post_id>3084</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:This final report highlights i) the importance of imaging modalities in the context of a personalised medicine approach to NET; ii) genetic influences in pNET; iii) the growing interest in molecular pathways and combining targeted therapies; iv) epidemiological trends in China and some emerging markets; and, v) the efficacy of a new gastrin receptor antagonist in gastric carcinoids.<wbr> </div><div style="margin-bottom: 10px;">Professor Ruszniewski in the Chairman's introductory remarks, highlighted the growing number of attendees at the ENETS congress (1500 people in 2012) plus how neuroendocrine tumours account for the highest prevalence amongst GI cancers and an increasing incidence.<wbr> Another milestone in 2012, was that the society received the highest ever number of poster submission &gt; 200 +18% yr-on-yr.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The conference began with an interesting overview of imaging, tackling the issue of how much is needed and how much can we afford.<wbr> </div><div style="margin-bottom: 10px;">Key conclusions were that MR imaging has a limited role to play in the diagnosis of carcinoid disease, CT scanning being much better, whilst diffusion weighted imaging is a must for MR imaging of the pancreas.<wbr> Ultrasound imaging, by contrast, should be a first step as it is difficult to use for characterisation.<wbr> 18F Dopa has a higher sensitivity than octreoscan whilst GA Dota peptides are considered even better.<wbr> From a personalised medicine approach L Bodie (Milan) believes that new radiolabled scanning tools represent the future from both a treatment selection and prognostic biomarker perspective.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Summing up the session, Urlich Pape looked at use of imaging from a clinicians perspective, highlighting some of the limitations to usage and what are probably the most important modalities at the various stages.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Of interest are developments ongoing with SOMSCAN.<wbr> The developers of this product note that it will be the first PET tracer to be properly registered for use.<wbr> Preclinical studies are now complete and the product is ready to move into phase I development.<wbr> It was noted a proper development pathway is planned and that a file should be ready for submission in 2014 to coincide with what had been anticipated to be the registration of pasireotide for NET.<wbr> Of course, we now know that this registration is unlikely to occur due to the carcinoid NET study being terminated.<wbr> </div><div style="margin-bottom: 10px;">The morning progressed with a session on the &ldquo;HOT NEWS&rdquo; In NET presented by Robert Jensen from Bethseda.<wbr> Jensen highlighted the growing abundance of literature on NET presenting the key statistics for 2011.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">He chose to focus on several topics including key genetic abnormalities associated with pNETs, the importance of Menin in MEN-1 patients, the prognostic implications of incidental discovery of non-functional tumours and finally on some promising medical news </div><div style="margin-bottom: 10px;">Highlighted were some key genetic pathways altered in pNET patients.<wbr> including DAX/<wbr>ATRX, MEN1 and mTOR.<wbr> The pathways are distinctly different to those identified in pancreatic adenocarcinoma.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">Focusing specifically on the MEN1 patients, he noted some recent research which has shown that these patients experience abnormal localisation of cellular menin.<wbr> Importantly, the crystalline structure of menin has now been identified by two separate groups and such knowledge he suggests may lead to the development of inhibitors.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;">A number of papers have highlighted the growing number of non-functional tumours discovered on imaging which raises the question of what it their malignant potential and how should they be treated.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;">From a medical perspective, he chose to highlight some very promising results with temzolomide and capecitabine in progressive advanced pNETs and the recent results achieved with everolimus and sunitinib.<wbr> The temozolomide results look impressive when compared with other chemotherapy options but the trial was small and retrospective suggesting proper randomised trials should be undertaken.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;">The afternoon session included a track focused on new mocular pathways and targets.<wbr> Much has been reported already in the context of the Traction Novartis Symposium Report but the initial session on RAF signalling did provide and interesting perspective.<wbr> Fazio (Milan) acknowledged that RAF signalling has always been a controversial area in NET but that there have been some indications in the literature of efficacy.<wbr> </div><div style="margin-bottom: 10px;">Data on sorafenib was presented 2 years ago at ASCO demonstrating a level of efficacy but also how &ldquo;dirty&rdquo; this drug is.<wbr> Nonetheless, Fazio suggests that there is a strong rational to combine an mTOR inhibitor with a RAF inhibitor and that the concept of combining a RAF inhibitor with a PI3KmTOR inhibitor such as RAF-265 with NVP-BEZ235 (both Novartis drugs) is being explored.<wbr> Fazio claimed that dual inhibition with a PI3KmTOR and RAF inhibitor definitely produces superior efficacy in terms of tumour control compared to monotherapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;">Continuing the basic science theme, Scarpa and Papdopoulos co-chaired an interesting session on: - What&rsquo;s new? The focus being on genomics and new generation sequencing, SSTR mutants and the prognostic significance of circulating tumours cells.<wbr> </div><div style="margin-bottom: 10px;">The first session highlighted the data presented on the previous day by Robert Jenssen and treatment implications.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_23_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;">Whilst Justo Castano (Cordoba) presented an interesting data set on Somatostatin mutants and their prognostic significance.<wbr> He highlighted the still many unknowns in somatostatin receptor research.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_24_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;">He focused on new SSTR5 variants SSTMD4 &amp; 5 and their presence in tumours poorly responsive to somatostatin and how SSTMD4 is present in breast cancer tumours with a poor prognosis </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_25_ScreenCapture25.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_26_ScreenCapture26.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_27_ScreenCapture27.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_28_ScreenCapture28.jpg"> </div><div style="margin-bottom: 10px;">He raised the question as to whether there is a role for these variants in NET and suggested that it could be an emerging target.<wbr> He demonstrated that SSTMD4 is clearly expressed in some NETs and definitely in some phaeochromocytomas and concluded with a hypothesis generating statement (see below) He finished with a diagram illustrating how these mutants may represent a new scenario in terms of SST pathophysiology.<wbr> The team involved in this research is shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_29_ScreenCapture29.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_30_ScreenCapture30.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_31_ScreenCapture31.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_32_ScreenCapture32.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_33_ScreenCapture33.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_34_ScreenCapture34.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_35_ScreenCapture35.jpg"> </div><div style="margin-bottom: 10px;">M Khan (London) presented evidence of the prognostic significance of circulating tumour cells by drawing analogies with other cancers (notably breast cancer).<wbr> He then presented some data indicating how CTCs in G2 NETS do appear to be prognostic of a poor outcome.<wbr> He also presented a case history illustrating how they can predict response to therapy and eventually progression.<wbr> Finally he noted how that the results of a 138 patient prospective study has been submitted to ASCO 2012.<wbr> </div><div style="margin-bottom: 10px;">Moving on with the programme was an interesting session on the efficacy seen with a new gastrin receptor antagonist YF476 in gastric carcinoids.<wbr> Helge Waldum (Norway) highlighted the biological potential of gastric carcinomas and what is currently available to treat these tumours as of today.<wbr> He then presented the profile of YF476, noting that preclinical and phase I studies with the drug have not revealed any significant safety issues.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_36_ScreenCapture36.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_37_ScreenCapture37.jpg"> </div><div style="margin-bottom: 10px;">Trial results from a PhII study undertaken in 8 patients with gastric carcinoids were then highlighted showing reductions in chromogainin and photographic evidence of healing.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_38_ScreenCapture38.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_39_ScreenCapture39.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_40_ScreenCapture40.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_41_ScreenCapture41.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_42_ScreenCapture42.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_43_ScreenCapture43.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_44_ScreenCapture44.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Selection of The More Important Poster Presentations</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Epidemiology &amp; Treatment Management Trends</STRONG> </div><div style="margin-bottom: 10px;">The increasing incidence of GEP-NETS in Chengdu City (China) with a population of 14 million </div><div style="margin-bottom: 10px;">The authors acknowledge that the incidence of GEP-NETs in China is still unclear but refers to data obtained from databases of the Department of Pathology West China Hospital Sichuan University fitting the WHO 2010 criteria for GEP-NET tumours.<wbr> Their data is shown below:- </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_45_ScreenCapture45.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_46_ScreenCapture46.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Update on the observational GEPNET Registry: An International Collaboration</STRONG> </div><div style="margin-bottom: 10px;">The GEP-NET registry is sponsored by Novartis as a means of providing both epidemiological data, and trends in clinical management and outcomes.<wbr> 621 of 1000 patients have been enrolled as of 1<SUP>st</SUP> December 2011.<wbr> It was established in 2009 and at ENETS this year some interesting data was presented on participating countries from the Asia Pacific, Middle Ease, North Africa as well as Israel and South Africa.<wbr> Some of the key observations are highlighted below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Symptom Control </STRONG> </div><div style="margin-bottom: 10px;">Effectiveness of a combination of pasireotide and octreotide in a patient with a small intenstinal NET </div><div style="margin-bottom: 10px;">In this case a combination of pasireotide and octreotide proved to be an effective treatment which resulted in decreasing episodes of diarrhoea and the secretion of VIP in a a rare intestinal NET.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Symptomatic control of neuroendocrine tumours with everolimus</STRONG> </div><div style="margin-bottom: 10px;">The authors of this poster noted how all the RADIANT trials have focused on progression free survival but less on symptom control.<wbr> This retrospective study undertaken by researchers at the Royal Marsden Hospital in the UK looked at the symptomatic effect of everolimus in 15 patients with metastatic NET pre-treated with octreotide.<wbr> Reasons for initiation of everolimus was progressive disease.<wbr> 4/<wbr>5 pts without symptoms continued to progress on treatment, whilst 7/<wbr>/<wbr>10 syndromic patients had improvements in symptomatology with a current mean duration of 5.<wbr>1 months improvement in symptom control.<wbr> Of the 10 patients 6/<wbr>9 had reduced stool frequency, 3/<wbr>5 had reduced asthenia and 5/<wbr>7 had reduced frequency and severity of flushing.<wbr> The authors suggest that to their knowledge this represents the largest analysis of carcinoid symptom control with combined everolimus octreotide.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_47_ScreenCapture47.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Effectiveness of PRRT</STRONG> </div><div style="margin-bottom: 10px;">The outcomes of PRRT in an North American Cohort in patients with metastatic well differentiated neuroendocrine tumours </div><div style="margin-bottom: 10px;">A poster aimed at characterising outcomes from a University centre in IOWA.<wbr> The researchers conclude that PRRT represents a valuable treatment option especially for patients with tumours of mid-gut origin and that results warrant investigation of the role earlier in the course of the disease.<wbr> </div><div>Lastly attached for reference purposes are three posters presented by Pfizer on the cost-effectiveness of sunitinib in patients with advanced metastatic pancreatic neuroendocrine tumours in the Netherlands, Scotland and Wales and Portugal.<wbr> </div><!-- Comment details --><a name="endocrinology6889attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(95,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(103 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(115,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(102,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(100,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(63,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(76,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(74,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(90,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(113,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(101,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(109,8 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(97,4 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(78,5 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(89,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(123,7 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(123 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(122,7 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(660 B)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(115,3 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(113,6 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(127,8 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(60,9 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(95,4 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(91,3 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(65 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(91,6 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_29_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(114,1 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_30_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(103,6 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_31_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(132,4 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_32_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(135,3 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_33_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(128,7 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_34_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(150,2 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_35_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(187,6 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_36_ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(68,9 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_37_ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(68,3 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_38_ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(75,2 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_39_ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(75,3 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_40_ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(70,6 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_41_ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(78,5 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_42_ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(83,6 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_43_ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(82,1 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_44_ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(72,7 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_45_ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(91,2 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_46_ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(39,8 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_47_ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(64,6 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_48_Increasing%20Incidence%20of%20GEP%2dNETS%20in%20Chengdu%20City.pdf">Increasing Incidence of GEP-NETS in Chengdu City.pdf</a>&nbsp;&nbsp;(4,7 MB)<br>&nbsp;&nbsp;49.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_49_International%20GEP%2dNET%20registry.pdf">International GEP-NET registry.pdf</a>&nbsp;&nbsp;(203,9 KB)<br>&nbsp;&nbsp;50.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_50_Pasireotide%20octreotide%20combination%20in%20patient%20with%20small%20inestinal%20NET.pdf">Pasireotide octreotide combination in patient with small inestinal NET.pdf</a>&nbsp;&nbsp;(4,8 MB)<br>&nbsp;&nbsp;51.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_51_Symptomatic%20Control%20of%20Neuroendocrine%20Tumours%20with%20Everolimus.pdf">Symptomatic Control of Neuroendocrine Tumours with Everolimus.pdf</a>&nbsp;&nbsp;(4,5 MB)<br>&nbsp;&nbsp;52.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6889_52_Outcome%20of%20PRRT%20in%20North%20America%20Cohort%20of%20Patients%20with%20mNETS.pdf">Outcome of PRRT in North America Cohort of Patients with mNETS.pdf</a>&nbsp;&nbsp;(4,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6889">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-23T16:40:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-23T16:40:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Onocgenex - Key Takeaways From The Cowen H/C Conference</title>
	<pubDate>2012-03-22T17:49:48+01:00</pubDate>
	<wp:post_id>3085</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oncogenex was positioning itself at the Cowen Confernce as the emerging leader in next generation cancer therapeutics focused on novel mechanisms of action that address treatment resistance.<wbr> It has a unique array of candidates targeting the treatment of prostate and bladder cancer and a powerful partnership with its lead product Custirsen with Teva.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_7_ScreenCapture7.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_8_ScreenCapture8.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_9_ScreenCapture9.jpg"> </div><!-- Comment details --><a name="oncology8184attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(100,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(110,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(128,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(89,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(70,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(76,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(84,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8184_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(95,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8184">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-22T17:49:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-22T17:49:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK Confirms $800m Investment In New UK Manufacturing Plant</title>
	<pubDate>2012-03-22T12:21:08+01:00</pubDate>
	<wp:post_id>3086</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Confirmation in yesterday's UK budget to cut the corporation tax applied to income from patents prompted GSK to announce this morning that its investment in a new biopharmaceutical manufacturing facility in the UK will go ahead.<wbr> </div><div style="margin-bottom: 10px;">GSK will build its new plant in Ulverston, northern England at a cost of GBP350m with construction expected to start in 2014 or 2015.<wbr> It will create up to 1000 jobs.<wbr> </div><div style="margin-bottom: 10px;">At the same time it will invest more than GBP100 in its two manufacturing sites in Scotland.<wbr> </div><div style="margin-bottom: 10px;">In recent years the drug industry has tended to put manufacturing in low-tax countries like Ireland and Signapore but the new "patent box plan" has tipped the balance back in favour of the UK again.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9821">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-22T12:21:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-22T12:21:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Addex Demonstrates Robust POC In PD-LID</title>
	<pubDate>2012-03-22T12:05:12+01:00</pubDate>
	<wp:post_id>3087</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;">Comment: Addex has announced that its drug dipraglurant-IR plus levodopa met the primary safety endpoint with no reported changes in liver function tests in a Phase IIa trial to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID).<wbr> It also demonstrated significant efficacy based on the mAIMS scale.<wbr> The company is aiming to partner the product by the end of the year.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;"><STRONG>Trial Design</STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;">The double-blind trial enrolled 76 patients who received levodopa in combination with placebo or 50 mg dipraglurant on days 1-14 followed by 100 mg dipraglurant on days 14-28.<wbr> The trial was supported by a grant from the Michael J.<wbr> Fox Foundation for Parkinson's Research</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;"><STRONG>Key Efficacy Findings</STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;">On exploratory endpoints, dipraglurant significantly reduced peak modified Abnormal Involuntary Movement Scale (mAIMS) scores on day one and on day 14 vs.<wbr> placebo (p=0.<wbr>042 and p=0.<wbr>038, respectively).<wbr> On patient-reported diary outcomes, dipraglurant increased daily "on" time in which patients were symptom free without dyskinesia by as much as 70 minutes compared to placebo.<wbr> Furthermore, patients receiving dipraglurant reported a reduction of 50 minutes in daily "off" time in which patients experienced symptoms of their PD during week four of treatment.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;"><STRONG>Product Profile</STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;">The product is an oral immediate-release formulation of dipraglurant, a negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) a Class C G-Protein Coupled Receptor (GPCR).<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;"><STRONG>Investigator's Comments</STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;">The coordinating Investigator of the dipraglurant study, Olivier Rascol, MD, PhD, Professor of Clinical Pharmacology at the Toulouse University Hospital, a world leading experts on treating Parkinson's disease commented: "There is no drug approved for the treatment of PD-LID and dipraglurant is an exciting new approach.<wbr> The study was successful in achieving the primary objective of good safety and tolerability.<wbr> In addition, these proof of concept data are promising and warrant further investigation of dipraglurant in Parkinson's disease.<wbr>"</SPAN></SPAN> </div><div><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;">From <A href="http://www.addextherapeutics.com/">http:/<wbr>/<wbr>www.<wbr>addextherapeutics.<wbr>com</A>, see <A href="http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-positive-top-line-phase-iia-data-for-dipraglurant-in-parkinsons-disease-levodopa-indu/">original source</A>.<wbr></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6319">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-22T12:05:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-22T12:05:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Protox Q4 Results Update - Continued Progress With New BPH Drug</title>
	<pubDate>2012-03-21T16:36:38+01:00</pubDate>
	<wp:post_id>3088</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Having strengthened its management team and raised over $23m to continue the develompent of PRX302 for moderat to severe BPH, Protox is in a much stronger position than it was 12 months ago.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Lars Ekman, Executive Chairman and President of Protox noted the following operation and financial highlights during the previous year </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>The company received FDA approval for our Investigational New Drug (“IND”) Application to evaluate PRX302 in patients with moderate to severe benign prostatic hyperplasia.<wbr> 
</LI>
<LI>It commenced an ongoing Transrectal Study of PRX302 for the treatment of benign prostatic hyperplasia (“BPH”).<wbr> 
</LI>
<LI>Its IP position was strengthened by securing a key European patent covering method of use of PRX302 for the treatment of BPH.<wbr> 
</LI>
<LI>The company successfully transitioned operations from Vancouver, BC, to La Jolla, California, allowing the Company to benefit from the significant biotechnology presence in Southern California.<wbr> 
</LI>
<LI>It also recruited a strong and seasoned management team with the notable additions of Lars Ekman, MD Ph.<wbr>D.<wbr>, as Executive Chairman and President; Allison J.<wbr> Hulme, Ph.<wbr>D, as Chief Operating Officer and Head of Research &amp; Development; Alex Casdin as Chief Financial Officer; and Dr.<wbr> Richard Yocum as Chief Medical Officer.<wbr> 
</LI>
<LI>Secured a USD$15 million loan facility agreement in July with Oxford Finance LLC, strengthening the Company’s cash position.<wbr> 
</LI>
<LI>Received continued support from its largest shareholder, Warburg Pincus, in December with the additional investment of CND$8.<wbr>3 million under the original investment agreement.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">
At the recent Cowen H/<wbr>C Conference Protox gave a presentation on the clinical data it has observed so far with PRX302 and the expected next milestones.<wbr> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8183_1_ScreenCapture1.jpg"></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8183_2_ScreenCapture2.jpg">The </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8183_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8183_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Financial Position</STRONG> </div><div style="margin-bottom: 10px;">The Company reported net loss of $5.<wbr>7 million ($0.<wbr>05 per share) in the three months ended December 31, 2011, compared to a net loss of $2.<wbr>4 million ($0.<wbr>02 per share) for the three months ended December 31, 2010, representing an increase in net loss of $3.<wbr>3 million.<wbr> The increase in net loss in 2011 was a result of an increase in total expenses of $2.<wbr>7 million, as a result of a higher level of research and development activities associated with initiating the Transrectal Study, PRX302 drug manufacturing expenses as well as the costs of transitioning our operations to La Jolla, California.<wbr># </div><div>From <A href="http://www.protoxtherapeutics.com/">http:/<wbr>/<wbr>www.<wbr>protoxtherapeutics.<wbr>com</A>, see <A href="http://www.protoxtherapeutics.com/news/2012/032112.php">original source</A>.<wbr> </div><!-- Comment details --><a name="oncology8183attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8183_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8183_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(54,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8183_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(52,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8183_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(59,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8183">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-21T16:36:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-21T16:36:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva To Use Different Delivery Devices To Gain Share In Biosimilar Market</title>
	<pubDate>2012-03-21T16:05:48+01:00</pubDate>
	<wp:post_id>3089</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Teva' North America CEO at the recent Barclays Capial H/<wbr>C Conference noted how the FDA's plans to allow some variation in delivery devices used with biosimilars appears to create a chance for generic players to gain share by improving on the orginal.<wbr> </div><div>This is something that has been used to good effect in the generic injectable sector in which Teva competes.<wbr> Hence it is pleasantly surprised that similar thinking is now resident within the though process of biosimilars.<wbr> It does suggest that a true impression of what is required will only emerge as companies talk to the FDA about the pathway forward.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9820">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-21T16:05:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-21T16:05:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways From The Aesthetic Industry Forum</title>
	<pubDate>2012-03-21T14:13:00+01:00</pubDate>
	<wp:post_id>3090</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">C </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
<LI>
<PRE style="display: inline;"></PRE>

</LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><A href="http://www.revance.com"></A><A href="http://www.marketwatch.com/story/top-global-aesthetic-medicine-industry-executives-to-convene-at-the-aesthetic-industry-forum-hosted-by-medical-insight-inc-2012-02-23"></A> </div><div style="margin-bottom: 10px;"><PRE style="display: inline;"></PRE> </div><div>-- </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6317">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-21T14:13:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-21T14:13:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progress With New Bladder Cancerm Product</title>
	<pubDate>2012-03-21T10:36:51+01:00</pubDate>
	<wp:post_id>3091</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">, a second generation molecule in preclinical trials for the topical treatment of bladder cancer, skin cancer and other indications.<wbr> Additionally, the Company's third product, TMX-201, also is currently being developed for use as a vaccine adjuvant.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8182_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">From <A href="http://www.pipelinereview.com/">http:/<wbr>/<wbr>www.<wbr>pipelinereview.<wbr>com</A>, see <A href="http://www.pipelinereview.com/index.php/2012032047423/Small-Molecules/Telormedixs-TMX-101-Exhibits-High-Safety-in-Phase-I/II-for-Non-Muscle-Invasive-Bladder-Cancer.html">original source</A>.<wbr> </div><div><A href="http://www.telormedix.com">www.<wbr>telormedix.<wbr>com</A> </div><!-- Comment details --><a name="oncology8182attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8182_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8182">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-21T10:36:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-21T10:36:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Potential New Treatment Approach To Pancreatic Cancer</title>
	<pubDate>2012-03-20T18:33:14+01:00</pubDate>
	<wp:post_id>3092</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Scientists at Fred Hutchinson Cancer Research Center have found a way to break through the defense mechanisms that appears to make pancreatic cancer so resistant to treatment.<wbr> Their research represents a potential breakthrough in the treatment of pancreas cancer and potential triumph for the pharmaceutical company Halozyme Therapeutics which is undertaking a phase II trial with the new therapy.<wbr> </div><div style="margin-bottom: 10px;">In a paper to be published in the March 20 issue of <EM>Cancer Cell</EM>, senior author Sunil Hingorani, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>, an associate member of the Hutchinson Center's Clinical Research and Public Health Sciences divisions, and colleagues describe the biological mechanisms of how the tumor barrier is formed and detail a newly discovered way to break it down.<wbr> </div><div style="margin-bottom: 10px;">Their research significantly increased the length of survival in a genetically engineered mouse model of the disease.<wbr> Using a mouse model developed by Hingorani, the scientists combined gemcitabine, the current standard chemotherapy used to treat pancreatic ductal adenocarcinomas, with an enzyme called PEGPH20.<wbr> When they infused the combination into specially engineered mice whose pancreas tumors mimic those of human pancreas cancer, the combination broke down the matrix barrier within the tumors and allowed the chemotherapy to permeate freely and spread throughout the cancerous tissue.<wbr> The result was a 70 percent increase in survival time of the mice after the start of treatment, from 55 to 92 days.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Human Development Programme Ongoing &amp; Sponsored by Halozyme Therapeutics</STRONG> </div><div style="margin-bottom: 10px;">Early clinical trials in humans are under way at a few sites in the U.<wbr>S.<wbr> and Europe, including Seattle Cancer Care Alliance, the Hutchinson Center's patient treatment arm.<wbr> The study is being sponsored by Halozyme Therapeutics the manufacturer of the enzyme and is evaluating the combined effect of PEGPH20 with gemcitabine vs gemcitabine alone in in Stage IV previously untreated pancreatic cancer patients.<wbr> The study will be undertaken in 147 patients and should complete in November 2013.<wbr> </div><div style="margin-bottom: 10px;">Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, oncology, dermatology, and drug delivery markets.<wbr> The company's product portfolio is primarily based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8180_1_ScreenCapture1.jpg"> </div><div>From <A href="http://www.sciencedaily.com/">http:/<wbr>/<wbr>www.<wbr>sciencedaily.<wbr>com</A>, see <A href="http://www.sciencedaily.com/releases/2012/03/120319133904.htm">original source</A>.<wbr> </div><!-- Comment details --><a name="oncology8180attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8180_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(108 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8180">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-20T18:33:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-20T18:33:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Shire Has Exercised its Option to License Heptares' Adenosine A2A Antagonist for Up to $190M</title>
	<pubDate>2012-03-20T14:24:31+01:00</pubDate>
	<wp:post_id>3093</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain.<wbr> Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.<wbr> The drug, discovered by Heptares, is currently in preclinical development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Heptares grants Shire an exclusive licence to WW development and commercial rights to A2Aantagonists discovered by Heptares.<wbr> </div><div style="margin-bottom: 10px;">Heptares receives upfront option grant and exercise payments and is also eligible to receive future development and commercial milestone payments up to US$190 million plus royalties on product sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>In May 2011, Shire signed an exclusive option agreement for Heptares' A2A program.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6315">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-20T14:24:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-20T14:24:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PROLOR Starts Ph2 Pediatric Trial with its LA hGH</title>
	<pubDate>2012-03-20T13:23:51+01:00</pubDate>
	<wp:post_id>3094</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The pediatric trial follows successful completion of a Ph2 trial of hGH-CTP in growth hormone deficient adults, which demonstrated that hGH-CTP was safe and well tolerated with the potential to reduce the required dosing frequency of human growth hormone from the current standard of one injection per day to a single weekly injection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Objective</STRONG>: to provide information about the effectiveness and safety of a range of doses of hGH-CTP for a single week inj regimen in pediatric patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG>: randomized, open-label, dose-finding study </div><div style="margin-bottom: 10px;">The trial will compare the 12-month growth velocity of children receiving certain doses of hGH-CTP, injected once weekly, or commercial hGH injected daily, which is the current standard of care.<wbr> </div><div><STRONG>Locations</STRONG>: up to 35 sites in 12 countries.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6887">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-20T13:23:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-20T13:23:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Phylogica's Success in Targeting Intracellular Targets</title>
	<pubDate>2012-03-19T18:16:41+01:00</pubDate>
	<wp:post_id>3095</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Phylogica success in concluding four pharma deals in two years has led to it publishing an update this month on all of its activities centered around its phylomer peptide platform.<wbr> </div><div style="margin-bottom: 10px;">The publication covers the following points listed below and a link to it is shown below.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>First multi-product partnership </LI>
<LI>Four Pharma deals in two years </LI>
<LI>Contracts in late-stage negotiation </LI>
<LI>Strategic discussions on a number of fronts </LI>
<LI>Optimising the Phylomer libraries </LI>
<LI>Exploiting Phenomica with Cambridge University </LI>
<LI>Appointment of a new highly experienced biotech Director Jeremy Churnock Cook</LI>
</UL> </div><div><A href="http://www.phylogica.com/media/articles/News---Events---News/20120305-Phylogica-March-Shareholder-Update-963/PhylogicaMarch2012.pdf">http:/<wbr>/<wbr>www.<wbr>phylogica.<wbr>com/<wbr>media/<wbr>articles/<wbr>News---Events---News/<wbr>20120305-Phylogica-March-Shareholder-Update-963/<wbr>PhylogicaMarch2012.<wbr>pdf</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9816">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-19T18:16:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-19T18:16:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Neurologix Files For Bankruptcy</title>
	<pubDate>2012-03-19T17:33:46+01:00</pubDate>
	<wp:post_id>3096</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment Gene therapy company Neurologix Inc known for its research in the Parkinson's disease area has filed for protection under the liquidation provision of the U.<wbr>S.<wbr> Bankruptcy Code.<wbr> </div><div style="margin-bottom: 10px;">The Fort Lee, New Jersey-based company listed assets of $1.<wbr>2 million and debt of $12.<wbr>9 million as of March 6 in Chapter 7 documents filed today in U.<wbr>S.<wbr> </div><div style="margin-bottom: 10px;">Neurologix was continuing to make with the gene therapy product NLX-P101 in Parkinson's disease, but we believe ran out of money before identifying a partner for its phase 3 programme.<wbr> </div><div style="margin-bottom: 10px;">Its technology  was based on the targeted delivery of DNA encoding a therapeutic protein or peptide (a "gene") directly into the specific area of the brain associated with a particular neurological disorder.<wbr> Neurologix's gene transfer programs employed a viral vector known as the adeno-associated virus ("AAV"), based on a non-disease causing human virus, to delivery its gene-based therapies.<wbr> AAV is considered the vector of choice for human applications because of the efficiency of gene transfer coupled with its safety profile.<wbr> </div><div style="margin-bottom: 10px;">Neurologix was on track to submit a Phase 3 protocol to the U.<wbr>S.<wbr> FDA under a Special Protocol Assessment.<wbr> Several patients who participated in its Phase 2 trial for NLX-P101 and received sham surgery continued to be treated with NLX-P101 in an open-label arm of the Phase 2 trial.<wbr> The latter initiated based on the strong efficacy results demonstrated in the randomized Phase 2 trial of NLX-P101, which included one-year follow-up data demonstrating that NLX-P101 provided treated patients with sustained long-term clinical benefits.<wbr> </div><div>From <A href="http://www.neurologix.net">http:/<wbr>/<wbr>www.<wbr>neurologix.<wbr>net</A>, see <A href="http://www.biospace.com/News/neurologix-inc-files-to-liquidate-under-chapter-7/253493/Source=TopBreaking">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6314">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-19T17:33:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-19T17:33:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Report From Leerink Swann Highlights AAD 2012 Main Trends</title>
	<pubDate>2012-03-19T16:19:41+01:00</pubDate>
	<wp:post_id>3097</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to the report, a low interest in Merz' Xeomin and JNJ's PurTox as well as Merz's new filler, Belotero, was perceived.<wbr> Interest was high for products to treat acne and rosacea.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Analysts believe rosacea is an attractive $300M-$500M opportunity in the U.<wbr>S.<wbr> and Western Europe, and a product that proved to be safe and effective with reimbursement would be a “dermatology blockbuster”.<wbr> </div><div style="margin-bottom: 10px;">- The disorder affects over 45 million people worldwide and 15 million patients in the U.<wbr>S.<wbr>, and Type I or erythematotelenagietic rosacea (ETR), is the most common subtype of the disease (affecting almost 80% of rosacea patients).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Dermatologists noted that Merz was selling Xeomin in a fixed-dose vial, which did not appeal to them.<wbr> </div><div style="margin-bottom: 10px;">- Physicians do not like the idea of the pre-filled syringe because they like to be able to choose the number of units used for each patient.<wbr> Additionally, according to the physicians, Merz was not discounting Xeomin versus Dysport.<wbr> </div><div style="margin-bottom: 10px;">- Dermatologists forecast sustained 10-15% procedure growth in 2012.<wbr> At the meeting, the KOLs noted that consultations specifically for “smaller ticket” procedures costing under $3,000, in particular, are increasing, and they are not only seeing an uptick in demand for facial fillers (similar to last year) but also for botulinum toxins.<wbr> </div><div><STRONG>A copy of this report is available on demand to Brigitte Deschamps.<wbr></STRONG> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6338c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 15px Calibri, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(64,49,82); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 15px Calibri, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(64,49,82); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6309">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-19T16:19:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-19T16:19:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Raptor Close To Completing Enrolment In Ph2 Huntington's Disease Trial</title>
	<pubDate>2012-03-19T15:59:20+01:00</pubDate>
	<wp:post_id>3098</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During a recent presentation, Raptor highilghted the continued progress it is making with its ph2 development programme in Huntington's disease with its  long-acting cysteamine product RP-103.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6307_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6307_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6307_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6307_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="neurology6307attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6307_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(327,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6307_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(305,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6307_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(305,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6307_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(314,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6307">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-19T15:59:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-19T15:59:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Rhenovia Initiates Drug Research Program in Huntington's Disease (HD)</title>
	<pubDate>2012-03-19T15:00:20+01:00</pubDate>
	<wp:post_id>3099</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has started to develop the use of biostimulation as a novel approach for drug development in HD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Rhenovia is building a new biosimulation platform (RHENOMS(TM) STRI) aimed at modeling the complex interplay between biological mechanisms in striatum, the brain region that is most affected in HD.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6305_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>R&amp;D pharmaceutical and biotechnology company created in May 2007.<wbr></LI>
<LI>HQ: Mulhouse (France)</LI>
<LI>Core Activity: Biosimulation for brain diseases</LI>
</UL> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6792c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">After the 1st round of seed funding of &euro;350,000 in 2009, Rhenovia is preparing a second round of &euro;2.<wbr>5M to accelerate its development.<wbr> The company plans to recruit about 20 new employees in France over the next 5 years.<wbr> </div><div style="margin-bottom: 10px;">Rhenovi announced yesterday it has had its position confirmed as world leader in the field of biosimulation for research into drugs for the treatment of diseases of the CNS.<wbr> </div><div>Source: Company PR </div></div><a name="neurology6305attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6305_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(42,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6305_2_CHDI%20Posterv2%255f300dpi.pdf">CHDI Posterv2_300dpi.pdf</a>&nbsp;&nbsp;(20,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6305">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-19T15:00:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-19T15:00:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Belgian Government Introduces New Cost-Containment Measures for Medicines</title>
	<pubDate>2012-03-19T14:32:42+01:00</pubDate>
	<wp:post_id>3100</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The principal changes will happen during April and May 2012 and will consist of an increasing recourse to generic substitution, additional price cuts on reimbursable medicines, and the creation of a new reimbursement category.<wbr>
 </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Incentives for the prescription of drugs under the generic name prescription system have seen the number of international non-proprietary name (INN, called DCI in Belgium) prescriptions increase by 7% year-on-year (y/<wbr>y) during 2009 in Belgium.<wbr> The government now aims to use this successful growth to oblige pharmacists to deliver a medicine that belongs to the group of cheapest alternatives when physicians prescribe it under its DCI.<wbr> The dispensing of the cheapest medicines scheme began on 1 March 2012, and will become mandatory on 1 April 2012.<wbr> Pharmacists cannot substitute when it is mentioned on the prescription that substitution is contraindicated.<wbr> INN substitution will be mandatory for antibiotics and antimycotic agents covering acute care as of 1 May 2012.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Meanwhile, the reimbursement base of pharmaceuticals of category A (reimbursed at 100%) will decrease by 41% (instead of 31%).<wbr> After four years of reimbursement, a complementary cut of 7% (instead of 5.<wbr>5%) is applied.<wbr> This measure will come into effect on 1 April 2012.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">During 2012, the government will ask the industry to contribute to cost-containment efforts via new price cuts.<wbr> Pharmaceutical firms can opt for: </div><div style="margin-bottom: 10px;">A linear 1.<wbr>95% price cut on their whole portfolio; or an adjustable decrease in price on part of their products, as long as price cuts correspond to 1.<wbr>95% of their 2010 turnover.<wbr> The price cuts will be applied on 1 April 2012.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">The government has also decided to set up a new reimbursement category: Fa/<wbr>Fb as of 1 April 2012.<wbr> For medicines reimbursed under category F, the sum of the statutory health insurance's reimbursement and of the "ticket modérateur" (patient co-payments) can be inferior to the public price applied.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><EM></EM></STRONG></P> </div><div style="margin-bottom: 10px;">The Belgian government has also proposed to encourage the use of biosimilars by including the latter in physicians' prescription targets.<wbr> It is estimated that by 2015–16, about 10 new biosimilars will be launched in Belgium, according to the Belgian generics association, Febelgen.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Belgium is stepping up its cost-containment efforts in the pharmaceutical sector despite a drug spending growth reported at 2.<wbr>8% y/<wbr>y during 2010.<wbr> Medicines represent a significant share (17.<wbr>6%) of the public health insurance's spending and therefore represent a target of choice for the government in this period of austerity.<wbr> During 2012, Belgium aims to reduce its deficit to 2.<wbr>8% of GDP, down from 4.<wbr>2% last year.<wbr> As such, spending on pharmaceuticals does not escape the rule and will be subject to significant pressure during 2012.<wbr> Apart from reimbursement and price cuts, measures which have been common in Belgium since 2009, the government is aiming to encourage and develop generic and biosimilars substitution through mandatory INN prescription/<wbr>dispensing, and physician's targets.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9815">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-19T14:32:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-19T14:32:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Norgine Extends Collaboration with Medical Futures in Canada</title>
	<pubDate>2012-03-19T14:19:55+01:00</pubDate>
	<wp:post_id>3101</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left" dir="ltr" style="MARGIN-RIGHT: 0px">Comment: Norgine has appointed Medical Futures as its partner for Normacol(R) in Canada.<wbr> The drug is indicated for occasional constipation.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr" style="MARGIN-RIGHT: 0px"><STRONG></STRONG></P> </div><div><P align="left" dir="ltr" style="MARGIN-RIGHT: 0px">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120431&edate=20120101&rec=1780" class="defaultlink">GastroEnterology1780: Norgine Has Launched MoviPrep in Canada</a>.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120431&edate=20120101&rec=1836">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-19T14:19:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-19T14:19:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Origenis Receives Grant to Develop Biomarkers for Parkinson's Disease</title>
	<pubDate>2012-03-19T10:29:39+01:00</pubDate>
	<wp:post_id>3102</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Origenis, a privately owned company based in Germany, has started the development of biomarkers to complement the preclinical in-house development of its therapeutic small molecule inhibitors acting on LRRK2.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- development of fluorine labelled, LRRK2 specific, CNS penetrating compounds that will be used to visualize the disease progression in animal Parkinsons's models.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company receives a two-year grant from the Leading-Edge Cluster program "m4-Personalized Medicine and Targeted Companies".<wbr> </div><div>Source: Origenis - <A href="http://www.origenis.de/newsticker/">http:/<wbr>/<wbr>www.<wbr>origenis.<wbr>de/<wbr>newsticker/<wbr></A> - </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6302">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-19T10:29:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-19T10:29:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spanish Government Announces USD2.6 Bil. in Pharma Cuts</title>
	<pubDate>2012-03-16T08:09:11+01:00</pubDate>
	<wp:post_id>3103</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to <I>El Economista</I>, the cuts will affect pharmaceutical products most, given that austerity measures aimed at cutting drugs spending are expected to remain in place.<wbr> </div><div style="margin-bottom: 10px;">According to the source, the autonomous communities contracted a debt of EUR7.<wbr>738 million with pharmaceutical laboratories and of EUR1.<wbr>4 billion with pharmacies.<wbr> The government aims at reducing pharmaceutical prescription expenditure in order to make it 15% of the overall healthcare budget and therefore levelling to EU standards.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">The announcement of a further EUR2-billion cut in the pharmaceutical sector in order to save on the healthcare budget comes as unsurprising.<wbr> The government, through the Ministry of Health, plans to cut on prescription expenditure, in order to be able to level Spain with EU standards.<wbr> The average EU prescription expenditure for 2009 was 14.<wbr>1% of the national healthcare budget (source: Organization for Economic Cooperation and Development), whereas that of Spain's was 17.<wbr>43% (source: El Economista).<wbr> </div><div style="margin-bottom: 10px;">In order to bring back prescription expenditure to 15%, the government is considering a variety of economic solutions, such as that of continuing with the enforcement of Royal Decree 9/<wbr>11 on mandatory prescriptions by active pharmaceutical ingredients.<wbr> From an over-the-counter (OTC) drugs perspective, the government is looking into pharma association ANEFP's proposal to cut on the reimbursement of some OTC drug classes, such as artificial tears, mucolytic and anti-diarrhoea products, a measure that would not constitute a major financial strain on the consumers given the low cost of such drugs.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9813">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-16T08:09:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-16T08:09:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nursing Fraternity Impressed with Novartis's Sponsored NET Patient Education Booklet</title>
	<pubDate>2012-03-15T17:07:11+01:00</pubDate>
	<wp:post_id>3104</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The NET Nurses meeting at ENETS focused mainly on how to communicate to and treat patients side effects in light of the new targeted therapies.<wbr> The key message was for the nurses to be more immersed in new data, clinical trials and to raise awareness of a new online NET Nurse Forum and to distribute an educational booklet which was written by nurses and supported by Novartis.<wbr> </div><div style="margin-bottom: 10px;">The NET Nurses Meeting was full to capacity with many people being turned away at the door.<wbr> They are an enthusiastic and passionate bunch who truly have the patients care in mind.<wbr> Various NVS staff attended as they had previously set up a task force to help write an educational booklet on NETs which is extremely well put together and was distributed to each attendee of the session.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6885_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The goal of the session was to: </div><div style="margin-bottom: 10px;"><UL><LI>Provide the nurses with a solid overview of the treatments available in a language which was easily digested
</LI>
<LI>How to handle the many side effects of the new therapies
</LI>
<LI>Pull the EU NET nursing community together and use the online forum as a tool to do so
</LI>
<LI>A push to raise the nurses profiles in the hospital communities, with industry and patients
</LI>
<LI>How to speak to patients in a way that they can understand (used a tube map to describe the various pathways and how certain treatments block/<wbr>inhibit the pathways just like a the &lsquo;Piccadilly line&rsquo; shutting down)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6885_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">A new tool, the online NET NURSES FORUM was launched with support of the NPF to improve communication between the nurses and <EM>is a place to harness the wealth of expertise and energy amongst the nurses and to provide a tool so they can share, support and guide each other, for the ultimate benefit of the patients.<wbr></EM> In order to sign up, you had to provide your email to Phillipa Davies in the UK.<wbr> </div><div style="margin-bottom: 10px;">Other activities/<wbr>goals include the following: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6885_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">In order to maximise the session, the speakers asked if there were any other suggestions that the audience had in order to help make their jobs easier.<wbr> The suggestions included </div><div style="margin-bottom: 10px;"><UL><LI>EU Carcinoid Crisis FAQ sheet and procedures
</LI>
<LI>Travel Directory for when the patients go on holiday, they can be provided with the names of a NET nurse (who is a part of the NET nurse forum) in that location so they have a point of care and can enjoy their holiday
</LI>
<LI>Make education a priority, have more nurse sessions at congress and obtain more funding for nurses to come to the larger congresses
</LI>
</UL> </div><div>For those interested the CI Dept has a copy of the Patient Education Booklet thanks to the effort of Beth Elliot who covered this symposia.<wbr> </div><!-- Comment details --><a name="endocrinology6885attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6885_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6885_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(49,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6885_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(74,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6885">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-15T17:07:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-15T17:07:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Clarifies Its Position In The US Market Post Recent Court Ruling</title>
	<pubDate>2012-03-15T13:39:59+01:00</pubDate>
	<wp:post_id>3105</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz US has issued a press release confirming that <SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; border-collapse: collapse;">its two US subsidiaries Merz Aesthetics Inc.<wbr> and Merz Pharmaceuticals LLC will for now not be allowed to market Xeomin or its dermal fillers in the U.<wbr>S.<wbr> market without restrictions both in the aesthetic and therapeutic market</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 13px; color: #222222; font-family: arial, sans-serif; border-collapse: collapse;">The ruling was handed down by a U.<wbr>S.<wbr> federal court in the state of California last Friday and represents the end of the first phase of a two-year-long ongoing litigation between Merz and Allergan</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Implications For Merz in the US </STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
For the same timeframe, sales of Xeomin for therapeutic use are restricted from certain physicians in certain territories of the US unless these customers voluntarily request to purchase the product without solicitation from the Company.<wbr>

</LI>
<LI>
The dermal fillers Radiesse and Belotero can be distributed to certain pre-existing customers of Merz Aesthetics and to customers that voluntarily request to purchase these products without solicitation by the company.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;">Commenting on this development Merz's CEO Dr Marting Zugel has stated &rdquo;We deeply regret that this ruling will affect primarily physicians, patients and our customers in the US.<wbr> Every physician in the US should be able to offer the best available alternatives for treatment at all times.<wbr> As a globally successful pharmaceutical company, which has been under ownership by the founding family for over 100 years, Merz stands for clear worldwide rules and high ethical standards.<wbr> We thus regret that individual employees have violated existing guidelines and standards&ldquo; Z&uuml;gel added.<wbr> </div><div style="margin-bottom: 10px;">Merz has committed to follow the order of the court to conduct a systematic search of all electronically-stored data at both U.<wbr>S.<wbr> companies.<wbr> This investigation will enable the companies to ask the court to remediate and move the court to modify the injunction to remove the ban and/<wbr>or restrictions against sales of Xeomin and dermal fillers.<wbr> </div><div style="margin-bottom: 10px;">Merz has stated that its strategy remains unchanged.<wbr> Despite this setback it will continue to develop the U.<wbr>S.<wbr> market in order to be able to offer physicians, patients and customers an "intelligent range of products and advantageous therapeutic alternatives to established solutions".<wbr> </div><div>Source: <A href="http://www.merz.com">www.<wbr>merz.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6298">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-15T13:39:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-15T13:39:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>China Wishes To Extend Price Cuts To Oncology Drugs</title>
	<pubDate>2012-03-15T10:04:52+01:00</pubDate>
	<wp:post_id>3106</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Source: <A href="http://www.businessweek.com/news/2012-03-13/china-cutting-costs-to-expand-health-care-threatens-drugmakers">www.<wbr>businessweek.<wbr>com/<wbr>news/<wbr>2012-03-13/<wbr>china-cutting-costs-to-expand-health-care-threatens-drugmakers</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8178">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-15T10:04:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-15T10:04:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SMC Rejects Zytiga Based On High Cost</title>
	<pubDate>2012-03-14T18:49:23+01:00</pubDate>
	<wp:post_id>3107</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><UL style="margin: 0px; list-style-type: none; padding: 0px;"><LI style="margin: 0px 0px 10px; line-height: 1.4em; list-style-type: disc; padding: 0px;">
</LI>
</UL> <a name="Oncology8278c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">According to the newspaper 'The Scotsman'  Janssen-Cilag Ltd  has resubmitted abiraterone to the SMC, the final decision is due in August 2012 </div><div><DIV class="left" id="1.2291862">Source: The Scotsman 12 May 2012</DIV> </div></div></div><div><UL><LI style="margin: 0px 0px 10px; line-height: 1.4em; list-style-type: disc; padding: 0px;">
</LI>
<LI style="margin: 0px 0px 10px; line-height: 1.4em; list-style-type: disc; padding: 0px;">
</LI>
<LI style="margin: 0px 0px 10px; line-height: 1.4em; list-style-type: disc; padding: 0px;">
</LI>
<LI style="margin: 0px 0px 10px; line-height: 1.4em; list-style-type: disc; padding: 0px;">
</LI>
<LI style="margin: 0px 0px 10px; line-height: 1.4em; list-style-type: disc; padding: 0px;">
</LI>
<LI style="margin: 0px 0px 10px; line-height: 1.4em; list-style-type: disc; padding: 0px;">
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8176">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-14T18:49:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-14T18:49:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENETS Intelligence Part 2 - Novartis & Pfizer Symposia Plus Key New Trials</title>
	<pubDate>2012-03-14T17:23:13+01:00</pubDate>
	<wp:post_id>3108</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  The Novartis Symposia focused on some sub-group data from the RADIANT studies and highlighted its new non-functioning everolimus study RADIANT-4 which will start enrolling patients by the end of this month.<wbr> Pfizer’s symposia, by contrast, focused on defining disease progression and ways to minimise the side-effects of therapy.<wbr> The design of some other key new trials is also highlighted.<wbr> </div><div style="margin-bottom: 10px;"><B>Highlights of the Novartis Symposia:  The Expanding Palate of Theraputic Options for the Treatment of Advanced NETs</B> </div><div style="margin-bottom: 10px;">The Novartis symposia commenced with Marianne Pavel walking through the evoluation of therapies for NETs, linking into the current therapies for G1/<wbr>G2 NETs, stating that as long are there are no superiority studies with single agents or combinations, the treatment approach remains a very individualised one.<wbr>  
Following this, she pondered on how to integreate the new antiproliferative therapies into the treatment paradigm and ending on the number of unaswered questions we are faced with, not least whether combination therapy should be used in an earlier treatment setting.<wbr> 
<img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-no-proof: yes">James Yao  followed with a focus on targeted therapy for pNETS.<wbr> He highlighted how 60% of pNETs are diagnosied with distant metastases at the point of diagnosis.<wbr> He provided the scientific rational for mTOR inhibition and compared the outcomes with everolimus and sunitinib.<wbr> He noted how survival has improved, with everolimus OS now greater than 36 months.<wbr> Finally he highlighted the positioning of the various agents in terms of treatment management .<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-no-proof: yes"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_3_ScreenCapture3.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-no-proof: yes"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_4_ScreenCapture4.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-no-proof: yes"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_5_ScreenCapture5.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-no-proof: yes"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_6_ScreenCapture6.jpg"></SPAN> </div><div style="margin-bottom: 10px;">Ashley Grossman took the stage to discuss data from completed trials (PROMID, RADIANT-2) and highlighted the planned RADIANT-4 study (see below).<wbr>  The key limitations of PROMID revolved around insufficient data in patients with high hepatic tumour burden with the limitations of RADIANT-2 centred on the lack of stratification of baseline factors, leading to imbalances plus central PFS analysis confounded by informative censoring.<wbr> </div><div style="margin-bottom: 10px;">The subgroup analysis of lung and colorectal plus multivariate analysis of different variables showed PFS was signifcantly improved with everolimus in these sub-groups.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">He concluded his talk by describing i) the RADIANT-4 study design which it is hoped will be a ‘cleaner study’ than RADIANT-2 because of patient stratification and the lack of any placebo crossover and ii) a schematic regarding the positioning of targeted therapy in the treatment paradigm for mid-gut carcinoids </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;">During a seperate session entitled Pathways and Molecular Targets: mTOR-AKT3,  James Yao spoke about the adverse events with mTOR inhibitors and how to manage the more unusual AEs seen with this class including aphthous ulcerations, pneumonitis and hyperglycemia.<wbr> </div><div style="margin-bottom: 10px;">Lower side effects with the RCC patients due to duration of treatment </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">Patient was taken off the drug and give a short course of steriods followed by dose reduction (5mg of everolimus) and the symptoms ceased </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">Yao moved onto outlining that the pivotal phase III studies of everolimus demonstrated the importance of the PI3K-Akt-mTOR pathway in NET which has provided a solid foundation to move on to more studies.<wbr> </div><div style="margin-bottom: 10px;">Four trials were then discussed:- </div><div style="margin-bottom: 10px;"><UL><LI>RADIANT-4 to confirm the activity in non- functional GI &amp; Lung NETs;</LI>
<LI>COOPERATE-2 to evaluate the addition of pasireotide to everolimus (side effect profile and cost might be an issue here);</LI>
<LI>CALGB 80701 to evaluate the addition of bevacizumab to everolimus: and, </LI>
<LI>A randomized phase II trial of  BEZ235 and everolimus to evaluate the dual inhibition of mTOR and PI3K.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
RADIANT-4,  is a phase III study of everolimus versus placebo in nonfunctional GI &amp; Lung NET patients.<wbr>  This study will start to enroll patients by end March (n= 279).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;">Cooperate-2 is a phase II multicenter study evaluating the efficacy of everolimus alone or in combination with pasireotide in patients with advanced pNETs, the study is open and has just enrolled its first patient (n=150).<wbr>  Chief Investigator in the UK is Dr.<wbr> Juan Valle.<wbr>  Estimated completion date is March 2015.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;">The combintion of  VGEF + mTOR appears to be quite tolerable when you add these two agents together.<wbr>  This  study is open and is its postively enrolling (non-industry sponsored).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Various combination studies are planned looking at inhibitors of PI3K, mTOR1/<wbr>2 with BYL719, BKM120 including a head-to-head study comparing </SPAN><ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">BEZ</SPAN></ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">2235 to everolimus</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_17_ScreenCapture17.jpg"></SPAN> </div><div style="margin-bottom: 10px;">Other trials Yao spoke of included a phase I cixutumumab, everolimus and octreotide trial in patients with advanced low to intermediate grade NET which is still enrolling and is run at his centre (MD Anderson).<wbr> </div><div style="margin-bottom: 10px;"><B>Highlights from the Pfizer Symposia: Pancreatic NETs - Understanding progression of the disease</B> </div><div style="margin-bottom: 10px;">The aim of the Pfizer Symposia revolved around a multiple disciplinary panel discussing how to define disease progression.<wbr>  The panel started by defining the advances in the detection of disease progression using pathological markers, then went on to discuss the imaging techniques that can aid in the identification of disease progression and response to treatment followed by highlighting the clinical methods to delay disease progression (through optimal therapy management) and finally concluding with learnings from a case study of sunitinib from other tumor types (RCC) </div><div style="margin-bottom: 10px;">Eric Raymond took to stage and described how in the phase III clinical trials of sunitinib and everolimus, disease progression was defined using RECIST criteria and increase in size of tumours.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;">Moving onto the pathology and reviewing a retrospective analysis of 202 patients with advanced pancreatic NETs, Aldo Scarpa detailed that tumor proliferative activity is a strong predictor of progression but the WHO Ki-67 grading cut off fails to distinguish between grade 1 and 2 tumours, rather Ki-67 <U>&lt;</U> 5% is a better cut off to effectively distinguish between these tumors.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;">He highlighted that sunitinib prolonged PFS regardless of baseline Ki-67 data </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Next, Valérie Vilgrain walked us through her talk on Imaging Techniques to Support Disease Management including </SPAN><ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">MRI</SPAN></ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">, </SPAN><ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">SRS</SPAN></ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"> and </SPAN><ST1:STREET><ST1:ADDRESS><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">PET CT</SPAN></ST1:ADDRESS></ST1:STREET><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"> and finally discussing the pros and cons of RECIST.<wbr> Despite the poor ability of RECIST to evaluate the efficacy of non-surgical therapies, it is still useful for tumor progression.<wbr>  She concluded the talk on the Choi criteria and its usefulness in objective response</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_23_ScreenCapture23.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_24_ScreenCapture24.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Barbo Eriksson began her talk with an overview of the characteristics of functional pNETs and the spectrum of disease followed by a discussion on biochemical tumour markers used to monitor disease progression - with CgA being the most effective.<wbr>  She stated it was imperative that we find some predictors of response for the targeted therapies and it was disappointing that we do not have better markers to detect disease earlier (using the same ones since the 1980s).<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_25_ScreenCapture25.jpg"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_26_ScreenCapture26.jpg"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">She concluded the talk by highlighting that in order to evaluate disease progression, you should use a multidisciplinary approach and finally provided the audience with suggestions for follow-up monitoring to detect disease progression</SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_27_ScreenCapture27.jpg"></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS ??'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_28_ScreenCapture28.jpg"></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;">Manuela Schmidimnger wrapped up the session with her experience of using sunitinib in RCC which demonstrated impressive results via a case study.<wbr> The main message being, you can keep your patients on targeted therapy if you manage them in an individualised way — duration of treatment, dosing and side effect management all need to be considered.<wbr> With regards to the side effect management, two grated apples daily or prophylactic lopermide will stop grade 3 diarrhea, a pedicure before treatment should help with HFS and Pfizer are running clinical trials with a gapapentin mouthwash to help treat stomatitis.<wbr> </div><div>The CI Department would like to acknowledge coverage of these symposia by Jacquie Cantle &amp; Beth Elliott.<wbr> </div><!-- Comment details --><a name="endocrinology6883attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(48 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(62,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(78,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(74,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(64,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(47,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(54,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(58,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(70,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(72,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(63,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(68,1 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(56,6 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(66,3 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(64,2 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(112,9 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(5,4 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(146 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(146,8 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(139,7 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(75 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(63,6 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(47,5 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(45,9 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(57,4 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6883_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(90,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6883">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-14T17:23:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-14T17:23:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Two New Studies With Takeda's TAK-700</title>
	<pubDate>2012-03-14T11:21:33+01:00</pubDate>
	<wp:post_id>3109</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Two New Studies With Takeda's TAK-700</span>&nbsp;<br><span style="font-size: 12px;">Comment: Two new trials with Takeda's TAK-700 are cited in ClinicalTrials.<wbr>gov.<wbr> One is evaluating the effect of the drug on QT/<wbr>QTc intervals and the other sponsored by the Radiation Oncology group and the NCI is evaluating the drug as an adjunct to ADT and radiotherapy in high risk patients.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8171">...</a><br></div><div>In the <A href="http://clinicaltrials.gov/ct2/show/NCT01546987?term=NCT01546987&amp;rank=1">NCT01546987</A> trial  TAK 700 is used without prednisone.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8175">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8171">View thread  Oncology8171: Two New Studies With Takeda's TAK-700</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-14T11:21:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-14T11:21:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Global Clinical Trial Center to be Established in Tianjin (China)</title>
	<pubDate>2012-03-14T09:29:21+01:00</pubDate>
	<wp:post_id>3110</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Chinese government committed $7.<wbr>9M to help establish the center, which will be located in the Tianjin Biotechnology Research Park.<wbr> The Center will be tasked with building an internet network for clinical trials in China as well as a network for global trials.<wbr> This initiative promises to bring much needed transparency to China's trials activity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9812">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-14T09:29:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-14T09:29:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Xenoport Highlights Spasticity Data At Cowen H/C Conference</title>
	<pubDate>2012-03-13T18:59:25+01:00</pubDate>
	<wp:post_id>3111</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the recent Cowen H/<wbr>C conference, Xenoport presented some very interesting data on prescription trends and physician preferences within the spasticity market, highlighting the place for its new drug arbaclofen placarbil a prodrug of the R-isomer of baclofen which has an improved safety profile relative to baclofen.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Commenting on the size of the oral market, Xenoport management noted that there's roughly 9.<wbr>4 million prescriptions for baclofen and tizanadine annually in the U.<wbr>S which in 2011 grew at a rate greater than 10%.<wbr> Specific to spasticity about 60% of baclofen usage was for spasticity whilst about 20% of tizanidine use was for this indication.<wbr> This equates to approximately 3.<wbr>5 million prescriptions specifically for this particular disease state.<wbr> </div><div style="margin-bottom: 10px;">Considering the price points of the recently branded agents in this market, e.<wbr>g.<wbr> $7.<wbr>50 a day to $15 a day this translates into a marketplace for these agents in particular of $750 million to $1.<wbr>5 billion.<wbr> Xenoport views this as an attractive opportunity where there is limited competition but some specific unmet medical needs.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_7_ScreenCapture7.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Commercialisation Plans</STRONG> </div><div style="margin-bottom: 10px;">In the U.<wbr>S.<wbr> Xenoport feels it can efficiently cover the market with a sales team of between 50 and 100, sales representative.<wbr> Its current arrangements with GSK regarding its RLS product, affords Xenoport the ability to put up between 50 and 100 sales reps with a high concentration in neurology.<wbr> So it believes that there is significant overlap in this particular space and particular with the neurology segment such that it could have potentially two commercial products in the bag over commercial infrastructure moving forward.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_10_ScreenCapture10.jpg"> </div><!-- Comment details --><a name="neurology6295attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(147,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(80,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(83,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(78,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(86,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(81,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(90,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(82,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(84,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6295_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(70,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6295">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-13T18:59:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-13T18:59:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Results from a NICE International Health Audit in Romania</title>
	<pubDate>2012-03-13T17:28:39+01:00</pubDate>
	<wp:post_id>3112</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The audit, which was requested by the Romanian Health Authorities last year, suggests 30 drugs should be taken out of the reimbursement list.<wbr> Other topics are outlined below.<wbr> </div><div style="margin-bottom: 10px;"><UL style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><LI style="MARGIN-LEFT: 15px"> </LI>
<LI style="MARGIN-LEFT: 15px"><SPAN style="FONT-FAMILY: sans-serif">NICE report found </SPAN><SPAN style="LINE-HEIGHT: 18px; FONT-FAMILY: Arial, sans-serif">somatropin </SPAN><SPAN style="LINE-HEIGHT: 18px; FONT-FAMILY: Arial, sans-serif"> more expensive than in the UK</SPAN></LI>
<LI style="MARGIN-LEFT: 15px"><SPAN style="LINE-HEIGHT: 18px; FONT-FAMILY: Arial, sans-serif"><SPAN lang="EN" style="LINE-HEIGHT: 14px">NICE representatives recommended Ginkgo Biloba removal from the list to save nearly 20 million Euro from NIHI budget</SPAN></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;">
Contribution of Petruta Panait (MAM) is gratefuly acknowledged.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>NICE International - working with Dr Ruth Lopert, Visiting Professor at George Washington University - has been assisting the Romanian Ministry of Health in its desire to revise the content of the basic health care service package, through a technical assistance project financed by the World Bank.<wbr> NICE International was contracted by the Romanian authorities to deliver on a focused set of objectives, including the development of a non-exhaustive ‘negative list' (or rather, a framework that will capture recommendations for the exclusion from and/<wbr>or restriction of coverage of certain products and services) based on an explicit rationale and with reference to practice in other countries including the UK.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9810">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-13T17:28:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-13T17:28:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Analysts @ Woori Issue New Report on Medy-Tox</title>
	<pubDate>2012-03-13T12:32:03+01:00</pubDate>
	<wp:post_id>3113</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to the report, the breakdown in usage of botulinum toxin in Korea in 2013 is expected to be 80% aesthetic 20% therapeutic sector.<wbr> The Korean's botulinum toxin market size is estimated to reach 79.<wbr>1 Wbn in 2012 (vs 71 Wbn in 2011).<wbr> Details of the company's global growth strategy is highlighted, as well as mid/<wbr>long-term plans.<wbr> Interestingly, an analysis of Allergan is included in the report.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6289_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6289_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>In the domestic market</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Steady growth of cosmetic sector and mid/<wbr>long-term growth of therapeutic sector (increase indications) </LI>
<LI>Competition to heat up in cosmetic sector; to secure product competitiveness and increase indications </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Overseas</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Export growth on product registration </LI>
<LI>Product registration completed in 23 countries; application for registration completed in 28 countries → number of countries with product registration continues to increase </LI>
<LI>Sales network in 40 countries in 2012 → global entry </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6289_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Mid/<wbr>Long-term Plan</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Entry into US and Europe via next generation Meditoxin </LI>
<LI>Expand production facility meeting qualification of EU GMP and cGMP </LI>
<LI>Plans to build new plant in Life Science complex in Osong (construction to start in 1Q12) </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">With clinical testing of Meditoxin for the treatment of facial wrinkles in Brazil scheduled to be completed in 1Q12, exports to Brazil should rise by an additional W2.<wbr>0bn in 2012.<wbr> </div><div style="margin-bottom: 10px;">Upon completion of the clinical trials in Australia, the company plans to obtain a license to export the drug to the US and Europe.<wbr> As such, Medytox is seeking partnerships with US- and European-based multinational drug makers, with positive outcomes from these licensing out deals likely to materialize in 1H12.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Based on expectations for exports to the US and Europe, the company plans to build a new plant in Osong over 1Q12~1Q13.<wbr> </div><div style="margin-bottom: 10px;">While its current total capacity is equivalent to annual sales of around W60bn, its expanded capacity will be equivalent to annual sales of W300bn.<wbr> We estimate Medytox’s net cash at W23.<wbr>0bn in 2011.<wbr> Although the company is capable of internally funding the construction project, we expect it to apply for long-term borrowings (7- year loans at an interest rate of 3.<wbr>6%) from a government owned bank.<wbr> </div><div style="margin-bottom: 10px;">Source: March 13, 2012 Company Analysis - Woori </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="neurology6289attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6289_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(50,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6289_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(18,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6289_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(61,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6289">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-13T12:32:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-13T12:32:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Potentially Groundbreaking Therapeutic Results In DMD</title>
	<pubDate>2012-03-13T11:47:23+01:00</pubDate>
	<wp:post_id>3114</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6288">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-13T11:47:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-13T11:47:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Two New Studies With Takeda's TAK-700</title>
	<pubDate>2012-03-13T11:21:49+01:00</pubDate>
	<wp:post_id>3115</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Two new trials with Takeda's TAK-700 are cited in ClinicalTrials.<wbr>gov.<wbr> One is evaluating the effect of the drug on QT/<wbr>QTc intervals and the other sponsored by the Radiation Oncology group and the NCI is evaluating the drug as an adjunct to ADT and radiotherapy in high risk patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Radiation Oncology Group Trial</STRONG> </div><div style="margin-bottom: 10px;">Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs.<wbr> Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer </div><div style="margin-bottom: 10px;"><U>Primary Outcome is Overall Survival</U> </div><div style="margin-bottom: 10px;">The study plans to enroll 900 patients and is scheduled to start this April.<wbr> Completion in terms of primary endpoint is expected in October 2014.<wbr> </div><div style="margin-bottom: 10px;">High risk in terms of patient entry to the trial is defined as:- </div><div style="margin-bottom: 10px;">
<UL><LI style="MARGIN-TOP: 0.7ex">Histologically confirmed diagnosis of adenocarcinoma of the prostate within 180 days prior to registration at high risk for recurrence as determined by one of the following combinations (risk group):</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI style="MARGIN-TOP: 0.7ex">Gleason Score (GS) ≥ 9, PSA ≤ 150 ng/<wbr>mL, any T stage </LI>
<LI style="MARGIN-TOP: 0.7ex">GS ≥ 8, PSA &lt; 20 ng/<wbr>mL, T stage ≥ T2 </LI>
<LI style="MARGIN-TOP: 0.7ex">GS ≥ 8, PSA ≥ 20-150 ng/<wbr>mL, any T stage </LI>
<LI style="MARGIN-TOP: 0.7ex">GS ≥ 7, PSA ≥ 20-150 ng/<wbr>mL, any T stage</LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table indent2"><TBODY><TR><TD style="PADDING-RIGHT: 1em; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 1ex">Principal Investigator:</TD>
<TD style="PADDING-RIGHT: 1em; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 1ex">M.<wbr> Dror Michaelson, MD, PhD</TD>
<TD style="PADDING-RIGHT: 1em; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 1ex">Massachusetts General Hospital</TD>
</TR>
</TBODY>
</TABLE></DIV></DIV> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov identifier <A href="http://clinicaltrials.gov/ct2/show/NCT01546987?term=NCT01546987&amp;rank=1">NCT01546987<BR></A> </div><div style="margin-bottom: 10px;"><STRONG>Cardiac Study</STRONG> </div><div style="margin-bottom: 10px;">This phase II trial sponsored by Takeda will be an open-label single arm, multidose study which will investigate the effects of TAK-700 on QT/<wbr>QT internal in patients with metastatic castrate resistant prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">The 44 patient study will start in April and is expected to conclude in terms of primary endpoint (change from baseline in QTc) in December 2012.<wbr> </div><div style="margin-bottom: 10px;">Tak-700 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study </div><div>ClinicalTrials.<wbr>gov Identifier <A href="http://clinicaltrials.gov/ct2/show/NCT01549951?term=NCT01549951&amp;rank=1">NCT01549951</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8175c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>In the <A href="http://clinicaltrials.gov/ct2/show/NCT01546987?term=NCT01546987&amp;rank=1">NCT01546987</A> trial  TAK 700 is used without prednisone.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8171">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-13T11:21:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-13T11:21:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Zetiq Evaluates CellDetect® Device for the Detection of Bladder Cancer</title>
	<pubDate>2012-03-13T08:57:55+01:00</pubDate>
	<wp:post_id>3116</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The CellDetect® technology is a functional cell-based <EM>in v</EM>i<EM>tro</EM> assay that can ‎distinguish between normal and cancer cells.<wbr> The newly listed trial in clinicaltrials.<wbr>gov started in January 2012, and is planned to recruit approx 300 participants.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01551342?fund=2&amp;rcv_s=02%2F28%2F2012&amp;rank=40"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Inclusion Criteria: </div><div style="margin-bottom: 10px;"><UL><LI style="MARGIN-TOP: 0.7ex">Subjects diagnosed with bladder cancer undergoing routine cystoscopic surveillance</LI>
<LI style="MARGIN-TOP: 0.7ex">Subjects undergoig TURT or Cystectomy procedures</LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0.7ex"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0.7ex"><A href="http://www.zetiq.co.il/161586/Science"></A></P> </div><div><P style="MARGIN-TOP: 0.7ex"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8170_1_ScreenCapture1.jpg"></P> </div><!-- Comment details --><a name="oncology8170attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8170_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(39,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8170">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-13T08:57:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-13T08:57:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation Plans to Raise $175M</title>
	<pubDate>2012-03-13T08:39:16+01:00</pubDate>
	<wp:post_id>3117</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has announced its intention to offer approx $175M principal amount of convertible senior notes due April 1, 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9808">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-13T08:39:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-13T08:39:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tranzyme's Ghrelin Agonist Disappoints In PhIII Trial</title>
	<pubDate>2012-03-12T17:18:13+01:00</pubDate>
	<wp:post_id>3118</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tranzyme Pharma and its partner Norgine B.<wbr>V.<wbr> have announced negative top-line findings of the primary analysis of ULISES 007, the first of two Phase 3 pivotal trials evaluating Tranzyme's ghrelin agonist <I>ulimorelin.<wbr></I> </div><div style="margin-bottom: 10px;">The trial failed to meet both primary and secondary efficacy endpoints.<wbr> The company is still planning to analyze the data from the second phase 3 trial ULISES 008, data from which is expected by the end of the second quarter.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Meanwhile, it is stopping all other NDA activities for <I>ulimorelin and refocusing its efforts</I> on its oral drug TZP-102, currently in a phase 2b trial for the treatment of diabetic gastroparesis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings In The ULISES Trial</STRONG> </div><div style="margin-bottom: 10px;">The results of ULISES 007 showed that intravenous <I>ulimorelin</I>, at both 160 and 480 micrograms/<wbr>kg doses, was not statistically different from placebo for the primary endpoint, in terms of time to recovery of GI function as defined by the time from the end of surgery to GI2.<wbr> GI2 is defined as the later of first bowel movement and tolerance of solid food.<wbr> Key summary data include: </div><div style="margin-bottom: 10px;"><UL><LI><I>Median time to GI2 was approximately 80 hours in all arms.<wbr></I> 
</LI>
<LI><I>Median duration of therapy was approximately 3.<wbr>5 days in all arms.<wbr></I> 
</LI>
<LI><I>Both doses of ulimorelin were well tolerated.<wbr> </I></LI>
</UL> </div><div><STRONG>Source: </STRONG><A href="http://www.tranzyme.com"><STRONG>www.<wbr>tranzyme.<wbr>com</STRONG></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6882">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-12T17:18:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-12T17:18:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>U.S Federal Court Finds in Favor of Allergan vs Merz</title>
	<pubDate>2012-03-12T15:16:17+01:00</pubDate>
	<wp:post_id>3119</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Injunction prohibits Merz Pharmaceuticals and Merz Aesthetics from selling or soliciting purchases of Xeomin&reg; for facial aesthetics for 10 months.<wbr> What is unclear at this point is whether the injunction has application just in California where the court hearnig took place or nationwide.<wbr> In addition to the U.<wbr>S ruling, Allergan prevailed in 2 separate cases filed in EU (Spain and Germany).<wbr> </div><div style="margin-bottom: 10px;">The court concluded that Merz misappropriated important trade secrets belonging to Allergan, including "the specific identities and financial details (including sales targets, actual sales amounts, and product volumes over time) of Allergan's relationships with virtually all of its physician customers in the United States for BOTOX<SUP>&reg;</SUP> Cosmetic (onabotulinumtoxinA) and JUV&Eacute;DERM<SUP>&reg;</SUP> and a large segment of Allergan's physician customers in the United States for BOTOX<SUP>&reg;</SUP> (for therapeutic indications).<wbr>" The court also found that Merz misappropriated "Allergan's strategic marketing plans, including its plans to address competition from Merz Aesthetics and Merz Therapeutics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>In Germany</U>, the Hamburg Regional Court ruled that Merz is prohibited from claiming a 1:1 dose equivalent ratio between units of Allergan`s BOTOX&reg; (onabotulinumtoxinA) and Merz`s Xeomin&reg;, which is in line with a prior decision of that Court in December 2011.<wbr> </div><div><U>In Spain</U>, Merz was found to be in breach of the Spanish Pharmaceutical Code for referring to a conversion ratio without, at the same time, making an express warning about the fact that the unit doses are not interchangeable.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6283">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-12T15:16:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-12T15:16:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages From Leerink Swann Report on Neurocrines' Elagolix</title>
	<pubDate>2012-03-12T14:00:23+01:00</pubDate>
	<wp:post_id>3120</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The March issue of the report focused on the company's VMAT-2 inhibitor (for dyskinesia) as well as Elagolix (for endometriosis/<wbr>uterine fibroids), which Ph3 is expected to start soon.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Daisy PETAL endpoints are ones which will likely be used in Ph3.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology8169attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(71,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(83,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(34 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8169_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(125,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8169">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-12T14:00:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-12T14:00:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENETS Intelligence Part 1 - New Treatment Guidelines & Clinician Preferences</title>
	<pubDate>2012-03-12T12:35:21+01:00</pubDate>
	<wp:post_id>3121</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A focus of last week's ENETS congress was the newly published guidelines on the treatment of NET.<wbr> Some simplified schematics illustrating key recommendations and the results of key votes on product positioning highlight how in today's environment clinicians envisage utilisation of their expanding treatment options.<wbr> </div><div style="margin-bottom: 10px;">Marianne Pavel introduce the topic of the newly published guidelines as part of the Novartis symposium (to be reviewed separately).<wbr> Below are the slides which depict the consensus for both non-resectable intestinal NETs and pancreatic NETs.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">To try and reinforce the idea behind these new guidelines the conference concluded with an interactive session on NET management, key votes amongst which do illustrate  some key points with regards to market development at the present time.<wbr> </div><div style="margin-bottom: 10px;">Bertrand Widenmann Chaired the session and started by asking the following questions the responses to which are shown.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">The debate that followed examining the pros and cons of targeted therapy raised some interesting points.<wbr> </div><div style="margin-bottom: 10px;">Eric Baudin (France) presented the argument in favour of first line usage of targeted therapy in pNET, whilst R Jensen from Bethseda argued against.<wbr> Key slides from their presentations are shown below.<wbr> </div><div style="margin-bottom: 10px;">Pro </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">Against </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;">PRRT </div><div style="margin-bottom: 10px;">The other quesion raised was whether PRRT should be used as first line in metastatic G1/<wbr>G2 pNET.<wbr> The audience response was 23% in favour but 79% against.<wbr> </div><div style="margin-bottom: 10px;">D Keekkeboom Rotterdam presented in favour whilst T Meyer GBR was against.<wbr> </div><div style="margin-bottom: 10px;">PRO </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_23_ScreenCapture23.jpg"> </div><div>The argument against usage centred on the lack of proper evidence based trial data regarding usage of these therapies.<wbr> It appears that much of the work at Rotterdam has not been undertaken to GMP or GCP standards and as yet there is no radomised trial data.<wbr> The first such study is planned but unlikely to get underway until later this year.<wbr> PRRT is liked and ceratinly used by some of the key centres of excellence but it is not universally available as Illustrated by one of the votes highlighted above.<wbr> </div><!-- Comment details --><a name="endocrinology6881attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(86,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(91,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(68,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(72,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(38,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(40,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(74,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(97,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(83,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(66,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(75,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(77,8 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(58 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(137,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(106,1 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(107,2 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(797 B)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(107,4 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(129,9 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(127 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(122,4 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(54,7 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6881_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(102 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6881">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-12T12:35:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-12T12:35:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Ph3 Study Comparing Takeda's Leuprorelin 6M with Leuprorelin 3M</title>
	<pubDate>2012-03-09T17:27:36+01:00</pubDate>
	<wp:post_id>3122</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Hormone dynamics, pharmacokinetics, safety, and efficacy of the 11.<wbr>25 mg and 22.<wbr>5 mg formulations will be assessed in prostate cancer patients previously treated with hormonal therapy (HT).<wbr> Primary endpoint will measure the rate of suppression of serum testosterone to castrate level.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01546623?fund=2&amp;rcv_s=02%2F24%2F2012&amp;rank=27"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: 164 </div><div style="margin-bottom: 10px;">Start date: March 2012 </div><div>Location: Japan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8159">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-09T17:27:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-09T17:27:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bellicum Raised $10M to Fund POC Programs</title>
	<pubDate>2012-03-09T11:46:22+01:00</pubDate>
	<wp:post_id>3123</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bellicum, a privately held biotherapeutics company headquartered in Houston (Texas), plans to initiate a Ph2 DeCIDe vaccine study in 2012 for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC), and a Phase 1/<wbr>2 study of a T cell infusion product for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">BPX-101 is an autologous DeCIDe™ vaccine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Description</STRONG> </div><div style="margin-bottom: 10px;">BPX-101 is comprised of matured, prostate cancer antigen-expressing dendritic cells derived from monocytes collected from the patient in a leukapheresis procedure, and modified so that they can be activated by a proprietary drug, AP1903.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Administration</STRONG> </div><div style="margin-bottom: 10px;">BPX-101 is administered intradermally, followed 24 hours later by a two hour infusion of AP1903.<wbr> This one day delay gives the cells time to migrate to the patient’s lymph nodes, where they are activated by AP1903 – in the right place and at the right time to drive a maximal anti-cancer immune response.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9807_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld9807attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9807_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9807">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-09T11:46:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-09T11:46:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva and Oncogenex Update Custirsen Ph3 Program in CRPC</title>
	<pubDate>2012-03-09T11:20:36+01:00</pubDate>
	<wp:post_id>3124</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Teva and Oncogenex have amended their collaboration to enhance development plans for custirsen in advanced prostate cancer.<wbr> As a result, the clinical trial program will now include the initiation of a new Ph3 study to evaluate if custirsen has the potential to improve OS for prostate cancer patients when combined with Jevtana® (cabazitaxel).<wbr> Updates of the SATURN and SYNERGY trials are provided below.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI>Design: to show a survival benefit with 85% power based on hazard ratio of 0.<wbr>75, or approximate 25% increase in survival time when custirsen is combined with cabazitaxel for second line chemotherapy</LI>
<LI>Start date: H2 2012</LI>
<LI>Recruitment: approx.<wbr> 630</LI>
<LI>Location: in lieu of the  cancer SATURN study</LI>
</UL> </div><div style="margin-bottom: 10px;">
Analysts @ Blommburton expect this trial to take at least 4 years as survival times for the control group are expected to be 12-18 months, and it could take at least 2 years to recruit patients.<wbr> Thus, they would not expect data until end of 2016 or early 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> (NCT01188187) </div><div style="margin-bottom: 10px;">Primary endpoint: OS </div><div style="margin-bottom: 10px;">Timelines: The trial continues to accrue patients and is expected to complete enrollment later this year.<wbr> Results are expected Q4 2013.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: Teva/<wbr>Oncogenex are increasing the enrollment from 800 to 1000 patients to optimize the potential to be submitted to regulatory agencies independent of additional Phase 3 studies.<wbr> The increase in enrollment is not expected to alter timelines for completion of the study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> (NCT01083615) </div><div style="margin-bottom: 10px;">Primary endpoint: pain palliation </div><div style="margin-bottom: 10px;">Status: will be stopped </div><div style="margin-bottom: 10px;">The SATURN trial experiences difficulties recruiting a sufficient number of patients in a timely manner due to the eligibility criteria requiring stable baseline pain and analgesic use in men who have end stage cancer pain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>As announced at the ASCO GU conference, a Ph2 study of OGX-427 in combination with abiraterone is planned for later this year in men with CRPC (pre or post chemo ?) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8156">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-09T11:20:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-09T11:20:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MDV3100 to Enter POC Study as Neoadjuvant Prior to Prostatectomy</title>
	<pubDate>2012-03-09T09:38:25+01:00</pubDate>
	<wp:post_id>3125</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph2 study is planned to start this month, in approx.<wbr> 50 men with localized prostate cancer.<wbr> The primary outcome measure will assess the pathological complete response rate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01547299?intr=MDV3100&amp;rank=1"><STRONG></STRONG></A> (MDV3100-07) </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Completion dates: June 2013 /<wbr> Aug.<wbr> 2013 </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div style="margin-bottom: 10px;">One arm: MDV3100 160mg, orally, once daily </div><div>One arm: MDV3100 160mg, orally, once daily in combination with leuprolide 22.<wbr>5mg, IM Q 3 months + Dustasteride, 0.<wbr>5mg, PO, QD </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8155">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-09T09:38:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-09T09:38:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Acino's FY2011 Results</title>
	<pubDate>2012-03-09T08:59:44+01:00</pubDate>
	<wp:post_id>3126</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: FY2011 revenues grew by 6% to EUR 134.<wbr>9 million (2010: EUR 127.<wbr>5 million) supported by Mepha acquisition.<wbr> The Operating Segment Parenteral (transdermal systems and ER parenterals) achieved sales in 2011 of EUR 33.<wbr>5 million (vs EUR 36.<wbr>7 million in 2010).<wbr> Acino reported that the the short-fall was primarily related to lost German and UK sales of goserelin.<wbr> Of note the timelines for the launch of goserelin and leuprorelin are 2013/<wbr>EU and 2013 respectively.<wbr> Acino expects 2012 revenue of EUR 240-260 million.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">By early 2013, the company plans to move to own R&amp;D building in Aesch.<wbr> The purchased Mepha site in Aesch (Canton Basel- Landschaft, Switzerland) comprises: </div><div style="margin-bottom: 10px;"><UL><LI>
an FDA-compliant manufacturing facility, </LI>
<LI>
office space</LI>
<LI>
an R&amp;D unit focused on the development of oral formulations</LI>
</UL> </div><div style="margin-bottom: 10px;">Mepha is transferring a number of its existing generic R&amp;D development projects to Acino’s pipeline.<wbr> Going forward, Mepha will continue to source products from its former site in Aesch, adding B2B-sales for Acino.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">"<STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_8_ScreenCapture8.jpg"> </div><!-- Comment details --><a name="dkphybrids146attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(40,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(16,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(10,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(4,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(28,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(53,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_146_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(44,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=146">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-09T08:59:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-09T08:59:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Janssen Has Unblinded ZYTIGA® (abiraterone) Ph3 Pre-Chemo Study (COU-AA-302)</title>
	<pubDate>2012-03-08T16:48:05+01:00</pubDate>
	<wp:post_id>3127</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Based on unanimous recommendation of IDM Committee, the company has unblinded the international, randomized, double-blind, placebo controlled study for the treatment of asymptomatic or mildly symptomatic patients with mCRPC who have not received chemotherapy.<wbr> The company plans to submit for regulatory approval in the US and around the world beginning H2 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Differences in radiographic progression-free survival, overall survival, and secondary endpoints were observed and constitute evidence of clinical benefit as well as continued evidence of favorable safety in patients receiving abiraterone acetate plus prednisone as compared to those receiving placebo plus prednisone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The results will be presented at an upcoming medical meeting (probably ASCO 2012), and will also be submitted for publication in a peer-reviewed journal.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT00887198?term=abiraterone+302&amp;rank=1"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 1,088 patients </div><div style="margin-bottom: 10px;">Protocol: patients were randomized to receive ZYTIGA 1,000 milligrams (mg) administered once daily plus prednisone 5 mg administered twice daily or placebo plus prednisone 5 mg administered twice daily.<wbr> </div><div>The co-primary endpoints of the study are radiographic progression-free survival and overall survival.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8154">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-08T16:48:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-08T16:48:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Allergan's Management Meeting with Analysts</title>
	<pubDate>2012-03-08T10:00:24+01:00</pubDate>
	<wp:post_id>3128</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ahead of March 28 R&amp;D Meeting, analysts met with CEO Pyott and SVP Treasury Hindman.<wbr> Management believes the top 3 most promising pipeline candidates are Latisse (for hair loss), targeted Botox (for pain), and DARPin (for wet AMD).<wbr> Although Collins Stewart believe there are not likely to be any new pipeline products revealed on R&amp;D Day, Morgan Stanley expect possible unveiling of new candidates, coming from the Ph2 pipeline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Levadex for Migraine</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>The FDA action date for MAPP's Levadex for acute migraine is on Monday, Mar.<wbr> 26.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Botox in OAB</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Botox Phase III data in OAB in 1H:12</LI>
</UL> </div><div style="margin-bottom: 10px;">Management believes a launch of Botox Therapeutic in the iOAB indication would have a marginal advantage because medical directors at many managed care organizations may already be familiar with Botox Therapeutic in urology given the ongoing launch of the product in neurogenic overactive bladder.<wbr> Additionally, the procedure is not completely new for most urologists, so a trained base of physicians will already exist if Botox is approved in iOAB.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Targeted Botox</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Targeted botox Phase II data in post-herpetic neuralgia in 1H:12</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Botox Cosmetic and Juvederm/<wbr>XC</STRONG> </div><div style="margin-bottom: 10px;">According to Management, Merz' Belotero has still not launched despite U.<wbr>S.<wbr> approval ~3 months ago, and Belotero was not developed with lidocaine, a major disadvantage to fillers such as Juvederm XC which are used with lidocaine to lessen the pain of injections.<wbr> </div><div style="margin-bottom: 10px;">Additionally, Allergan now sells a 1mL syringe of Juvederm for the same price as the 0.<wbr>8mL syringe, so essentially physicians are getting more for their money.<wbr> The company believes that it can maintain and grow its share of the dermal filler market in the U.<wbr>S.<wbr> as well as globally with the addition of Juvederm Voluma (filed at the end of 2011 in the U.<wbr>S.<wbr>, already on the market in Europe/<wbr>Canada).<wbr> Management noted that Voluma addresses a different area of the face than Juvederm XC (the cheek area versus deep lines around the mouth) and physicians have stated that they have not seen another facial filler product like it.<wbr> For example, in Canada, one of AGN‟s largest overall markets in terms of sales, management noted that Juvederm Voluma added 40% to the complete Canadian filler market over the 18 months that it has been available.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Pyott emphasized that the company expects 2012 R&amp;D spending to be higher than expected.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6275_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology6275attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6275_2_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(6,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6275">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-08T10:00:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-08T10:00:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>API Prescriptions Reach 60% Within Three Months of Royal Decree 9/11 Enforcement in Spain</title>
	<pubDate>2012-03-07T17:50:13+01:00</pubDate>
	<wp:post_id>3129</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Although prescription by API reached an average of 60% in the first three months of Royal Decree 9/<wbr>11 enforcement (October–December 2011), inconsistent applications in different autonomous communities will continue to lead to uneven results in the short-to-medium term unless the new government reassesses the Decree's rules on prescriptions and drafts specific guidelines for the communities to follow.<wbr> A series of very inconsistent results has been recorded during the first three months since the Royal Decree 9/<wbr>11 on mandatory prescriptions by active pharmaceutical ingredient (API) came into force in Spain in October 2011.<wbr> </div><div style="margin-bottom: 10px;">According to Diario Medico, although the national average for API prescriptions is 60%, some regions such as Andalucia, Navarra, Canarias and Madrid are hitting 80% prescription by API, and others such as Galicia, Catalonia and Asturias are below average, with 30%.<wbr> According to the source, Andalucia is top of the list with 88,8% of prescriptions by API, followed by Navarra (86.<wbr>9%), Canarias (85%), Madrid (80%), Cantabria (78.<wbr>3%) and Castilla y Leon (75.<wbr>6%).<wbr> Bottom of the list are Asturias with 24.<wbr>3% of prescriptions by API, Catalonia (26.<wbr>3%), Galicia (28.<wbr>8%), La Rioja (32.<wbr>5%), and Baleares (44.<wbr>5%).<wbr> Mid-table positions were achieved by Aragon (53.<wbr>3%), Murcia (54.<wbr>4%), Castilla-La Mancha (61.<wbr>1%), Valencia (63%), Pais Vasco (65%), and Extremadura (60%).<wbr> </div><div style="margin-bottom: 10px;">According to the Spanish GP association SEMG's secretary Moises Robledo, cited by the source, these variations are due to the degree of flexibility that autonomous communities have granted to regional doctors and pharmacist for the prescription of generic drugs as opposed to branded products of equivalent price or cheaper.<wbr> According to the source, although savings made by the antonomous communities and the central government are equivalent if a prescription is a generic or a branded version of the same price or cheaper, the size of the pharmaceutical market changes.<wbr> In fact, since the enforcement of Royal Decree 9/<wbr>11 and the consequent need for brands to lower the prices of their products to keep competitive on the market, the size and revenues of the Spanish pharmaceutical market was reduced from EUR4 billion (USD5.<wbr>2 billion) to EUR2.<wbr>5 billion in 2011.<wbr> </div><div style="margin-bottom: 10px;">As a consequence of cheaper branded drugs competition, generic sales also dropped by an average of 7%, with great differences among different autonomous communities.<wbr> According to the source, all major generic molecules reduced their sales apart from escitalopram, as the company selling its branded version Lexapro, Forest laboratories, decided not to lower the price of their product, therefore generics sales of escitalopram are still 100% among all communities.<wbr> In some cases, branded prescription is still necessary as in the case of Zyprexa (olanzapine), where substitution with an equivalent generic product is still considered controversial.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">The inconsistent results on the percentage of mandatory prescriptions by API produced by different autonomous communities in Spain are a result of a flexibility in the decree application.<wbr> Although some communities such as Navarra were forced to stick to prescribing the cheapest generic, others such as Asturias allowed pharmacists and doctors more freedom to prescribe either a generic or a branded version of a certain drug as long as it represented the cheapest on the market.<wbr> </div><div style="margin-bottom: 10px;">This forced most brands active in Spain, such as Merck and Bayer, to lower the price of their over-the-counter (OTC) drugs in order to be competitive on the market, leading to a EUR1.<wbr>5 billion decrease in pharmaceutical revenues since 2010.<wbr> Although varying between different autonomous communities, generic sales also dropped by an average of 7% (source: Diario Medico) due to brand price competition.<wbr> Of all the government's austerity measures, Royal Decree 9/<wbr>11 has managed to prove the most effective in reducing the country's pharmaceutical debt while also creating an unfavourable climate for pharmacies and pharmaceutical associations which have been hit by a drop in sales and lower revenues.<wbr> As a consequence of the decree, Spain managed to save EUR1.<wbr>4 billion in 2011 on prescriptions.<wbr> </div><div style="margin-bottom: 10px;">Nevertheless, according to the Spanish Pharmaceutical Association (FEFE)'s forecast, this decree will lead to substantial losses for small-to-medium sized pharmacies, which are forecast to reduce their sales by EUR68,180 per pharmacy per year, with marginal losses of up to EUR15,000 per pharmacy per year.<wbr> By the end of 2012, pharmacies are expected to lose an average EUR100,000 per pharmacy per year as a consequence of the price cuts and imposed generic prescription laid out by the country's three Royal Decrees.<wbr> The hurdle for the new Spanish government will be in stablishing the sustainability of such austerity measures in the current economic climate and accommodating this to the needs of balancing governmental expenditure and those of the pharmaceutical associations.<wbr> </div><div style="margin-bottom: 10px;">Although prescription by API reached an average of 60% in the first three months of Royal Decree 9/<wbr>11 (October– December 2011), inconsistent applications in different autonomous communities will continue to lead to uneven results in the short-to-medium term unless the new government reassesses the Decree's norms on prescriptions and drafts specific guidelines for the communities to follow.<wbr> This mandatory generics pattern will only become consistent if the government sets equal guidelines to be followed by all communities.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9805">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-07T17:50:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-07T17:50:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Blocks Merz from Selling Xeomin</title>
	<pubDate>2012-03-07T13:06:56+01:00</pubDate>
	<wp:post_id>3130</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A J.<wbr> Guilford, a US district judge in Santa Ana (CA), issued an injunction preventing Merz from selling Xeomin after Allergan claimed its trade secrets were stolen.<wbr> Findings and conclusions are awaited on March 9th.<wbr> The commercial introduction of Xeomin for cosmetic use is scheduled for March 12 @ the annual meeting of the American Academy of Dermatology in San Diego.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Allergan alleges that Merz targeted Allergan sales reps who brought along confidential materials, including sales figures and customer lists.<wbr> </div><div>The case is Allergan v.<wbr> Merz, 11-00446, U.<wbr>S.<wbr> District Court, Central District of California (Santa Ana).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6270">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-07T13:06:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-07T13:06:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence From The Recent EAU Meeting - Bone Targeted Agents</title>
	<pubDate>2012-03-07T11:06:16+01:00</pubDate>
	<wp:post_id>3131</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The two symposia on these agents were sponsored by Amgen covering denosumab and Bayer its Radium-223 therapy.<wbr> Both speaker panels were multi-disciplinary, discussing phase III data with case studies presented during the Amgen symposia.<wbr> From the data shown, it seems Radium-223 is a cleaner drug with a demonstrated OS benefit which can even be used in patients unable to tolerate docetaxel.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Highlights from the Bayer Symposia</STRONG> Bayer&rsquo;s combi-presentation discussed the present and future directions of RCC and CRPC.<wbr> The CRPC talk commenced with Nicolas Mottet discussing the challenges in treating CRPC and then fast-forwarding to 2010, new agents became available: sipuleucel-T, cabazitaxel, abiraterone, cabozantinib and denosumab.<wbr> Overall, he mentioned that these new products are expensive and sequencing to optimize patient survival still needs to be defined, specifically with cabozantinib and denosumab.<wbr> Mottet focused on bone protection efficacy but stressed that there is no real effect on overall survival.<wbr> He then moved onto the future where TAK-700 was described as <EM>&lsquo;something like abiraterone but perhaps without a low dose steroid&rsquo;</EM> while MDV3100 was referred to as <EM>&lsquo;really a new class of anti-androgen receptor blocker &hellip;.<wbr> it has a totally different MOA&rsquo;</EM> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">He also spoke of the need for oncologists to be involved in treatment decisions, calling for a multidisciplinary approach</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_2_ScreenCapture2.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Next, Sten Nilsson discussed the advantages and limitations of surgery and radiotherapy in the management of bone metastatic CRPC and moved on to radionuclides, outlining Alpha vs.<wbr> Beta treatment &ndash; stating that Alpha has shown both pain relief and OS benefit</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_3_ScreenCapture3.jpg"></SPAN></SPAN> </div><div style="margin-bottom: 10px;">He followed by introducing Radium-223, showing the phase I and II study designs and results - well tolerated and bone marrow toxicity was low </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Dr.<wbr> Chris Parker spoke last with a presentation titled &lsquo;Rising Stars: Innovations in treatment bone metastases in CRPC&rsquo; where he discussed the interim data from the ALSYMPCA phase III study.<wbr> The data showed that Radium-223 is well tolerated and significantly prolonged OS, time to first SRE and time to spinal cord compression.<wbr> </div><div style="margin-bottom: 10px;">Bayer is aiming for Radium-223 to be a new standard of care for the treatment of CRPC patients with bone metastases.<wbr> During the Q&amp;A session, delegates spoke of the logistic and radioprotective hurdles to which the panel retorted are non-issues; &lsquo;<EM>there are no issues with this, it can be delivered to all centres&hellip;a simple pair of gloves is sufficient and the half life is 11 days&rsquo;.<wbr> </EM>The product will be ordered on demand and will not be stored on site.<wbr> It is also understood that the expanded access trial in the USA will open in the next few weeks while the EU expanded access trial will open mid year.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">An unusual aspect of this design is the inclusion of patients who are unfit for docetaxel.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_9_ScreenCapture9.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_10_ScreenCapture10.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 10pt; font-family: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_11_ScreenCapture11.jpg"></SPAN> </div><div style="margin-bottom: 10px;">The study is well balanced in terms of their age, ethnicity, performance status, extent of disease and baseline pain.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;">Treatment was more complete with radium-223 over placebo (more patients on placebo dropped out).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;">There were more overall adverse events seen with placebo group although there was more mild diarrhea and vomiting with the active drug </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Highlights from the Amgen Symposia</STRONG> </div><div style="margin-bottom: 10px;">The Amgen symposia was based around 3 case studies looking at denosumab and zoledronic acid usage, highlighting the advantages of denosumab (longer time without an SRE, less pain, no dose adjustments needed as there is no renal toxicity) and finally ending with their Phase III data on bone metastasis prevention in CRPC trial (superiority over zoledronic acid).<wbr> </div><div style="margin-bottom: 10px;">The below slide outlined the positioning of these agents, in that bone targeted therapy does not compete with the other treatments but is intended to be used in combination.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;">Despite this data, the ODAC recently recommended against approval of denosumab for this indication (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8094" class="defaultlink">Oncology8094: re: Amgen Not Guaranteed Success At Tomorrow's ODAC Meeting</a>) </div><div>The CI department gratefully acknowledges coverage of these symposia by Beth Elliott </div><!-- Comment details --><a name="oncology8151attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(56,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(45,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(53,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(70,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(75,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(56 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(54,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(53 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(64,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(61 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(57,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(56,2 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(90,1 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(35,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(39,4 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8151_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(39,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8151">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-07T11:06:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-07T11:06:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Regeneron to Report Interim Study Findings in 1st-line Hormone-Resistant mPCa</title>
	<pubDate>2012-03-07T10:19:29+01:00</pubDate>
	<wp:post_id>3132</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During its presentation @ Cowen Group H/<wbr>C conference, management confirmed that results from the VENICE  cancer Ph3 trial will be reported "early in this year in the first half of 2012".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT00519285?term=venice&amp;rank=2"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Title: Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer </div><div style="margin-bottom: 10px;">Primary Endpoint: OS </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 1200 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Aflibercept is a fusion protein designed by Regeneron scientists to bind two forms of Vascular Endothelial Growth Factor (called VEGF-A and VEGF-B).<wbr> </div><!-- Comment details --><a name="oncology8149attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8149_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(10,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8149">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-07T10:19:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-07T10:19:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence From The Recent EAU Meeting - Janssen & Astellas Symposia</title>
	<pubDate>2012-03-07T10:14:12+01:00</pubDate>
	<wp:post_id>3133</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:The Janssen Cilag and Astellas symposia were well balanced in terms of providing coverage of the new and pipeline agents within mCRPC.<wbr> J&amp;J's new trial with abiraterone in the hormone naive metastatic segment also featured.<wbr> Key discussions revolved around the need for sequencing data and how to best utilise the new and upcoming treatment arsenal.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><B></B><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA">He went on to explain Jansens extended Phase </SPAN><ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA">III</SPAN></ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"> programme and highlighted the imminent results announcement of COU-AA-302 (ASCO 2012) investigating the use of abiraterone as a first line therapy in asymptomatic or mildly symptomatic patients.<wbr> With PEACE-1 exploring the efficacy of abiraterone in newly diagnosed (hormone-naïve) prostate cancer patients.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_3_ScreenCapture3.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_5_ScreenCapture5.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA">At the end of his talk Dr Fizazi mention Takaeda’s Orteronel (TAK-700) dual Phase </SPAN><ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA">III</SPAN></ST1:STOCKTICKER><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"> programme also targeting the enzyme 17 α-hydroxylase/<wbr>C17, 20-lyase (CYP17).<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_6_ScreenCapture6.jpg"></SPAN></SPAN> </div><div style="margin-bottom: 10px;">The results of MDV3100 Phase III trial AFFIRM were described, demonstrating impressive results.<wbr> Emphasis during this section of the talk was placed on the balanced patient baseline characteristics, efficacy was observed across all subgroups and MDV3100’s performance as monotherapy verses placebo.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;">Algela/<wbr>Bayer’s ALSYMPCA Phase III programme was also presented.<wbr> When discussing the subgroup data, Dr Gschwand commented on lower efficacy with poor ECOG score patients </div><div style="margin-bottom: 10px;">The presentation ended with a multidisciplinary discussion on a few patient case studies </div><div style="margin-bottom: 10px;"><B>Highlights from the Astellas Symposium </B> </div><div style="margin-bottom: 10px;">Astellas appears to be already branding MDV3100 with strap-lines such as “back to the future” and the high tech train imagery.<wbr> The three trains could represent the three modes of action.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><B>Hormonal therapy in early CRPC: Established target, new approaches.<wbr></B> </div><div style="margin-bottom: 10px;"><B><I>A Heidenreich, </I></B><B><I>Germany</I></B> </div><div style="margin-bottom: 10px;">Definitions, diagnosis and epidemiology of CRPC were discussed as well as the lack of evidence to show that traditional hormone therapies (anti-androgen, corticosteroid and ketoconazole) improve overall survival.<wbr> </div><div style="margin-bottom: 10px;">With the improved understanding of the underlying biology of CRPC including AR signaling, a new generation of pre-chemotherapies are emerging of which abiraterone, TAK 700 and MDV3100 were heralded as examples.<wbr> With the emphasis being placed on MDV3100 and Astellas/<wbr>Medivation PREVAIL &amp; TERRAIN Phase II and III trials.<wbr> </div><div style="margin-bottom: 10px;"><B>Case study and panel discussion.<wbr></B> </div><div style="margin-bottom: 10px;"><B><I>N </I></B><B><I>James</I></B><B><I>, </I></B><B><I>UK</I></B> </div><div style="margin-bottom: 10px;">An unusual case was presented which illustrated the difficulty in defining hormonal non-response with the panel and the audience repeatedly arguing that the patient being discussed should be convinced to be maintained on an androgen deprivation therapy.<wbr> He has been treated intermittently with anti-androgen and oestrogens as monotherapy for the past 7 years.<wbr> Dr James raised the question of newer agents being tested on top of a traditional hormone therapy baseline and could it be time for a rethink and consider monotherapy? </div><div style="margin-bottom: 10px;"><B>Envisioning the future of hormonal treatment of late-stage CRPC</B> </div><div style="margin-bottom: 10px;"><B><I>C.<wbr>N.<wbr> </I></B><B><I>Sternberg</I></B><B><I>, </I></B><B><I>Italy</I></B> </div><div style="margin-bottom: 10px;">In her introductions Dr Sternberg highlighted the increasing collaboration between radiologists, oncologists and urologists in managing CRPC, which is helping to pushing treatment and outcomes into a new era.<wbr> The rapid expansion of current and likely future treatment options for CRPC was then highlighted </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;">Dr Sternberg participated in the pivotal COU-AA-302 abiraterone trial and focused on abiraterone’s impressive hazard ratios across a wide range of subgroups.<wbr> She did highlight the exception of patients with an ECOG status of 2.<wbr> The same pattern is being observed in the abiraterone Expanded Access trial in which Dr Sternberg is taking part.<wbr> A comparable adverse event profile to placebo was also highlighted.<wbr> </div><div style="margin-bottom: 10px;">Takaeda’s (Millennium) Orteronel TAK-700 Phase III was positioned as a similar molecular to abiraterone before going on to discuss MDV3100 post chemotherapy AFFIRM trial.<wbr> The trial was introduced as having the best results of any agent studied to date on overall survival (37% reduction in death) combined with impressive sub-group hazard ratios and virtually the same adverse event profile as placebo.<wbr> </div><div style="margin-bottom: 10px;">The talk concluded with the question of how will these new agents be integrated into a treatment when only a few years ago once post chemotherapy hormone treatment had failed there was nothing? Dr Sternberg then went onto challenge docetaxel as being the therapy against which newer agents are positioned.<wbr> Over the coming years answers will need to be found as to which agents to combine with chemotherapy, what is the optimal sequence of therapies and can a therapy be withdrawn? </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">Other data relating to MDV3100 includes Poster 235: Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model.<wbr> This study highlights the synergistic effect of Medivation’s MDV3100 and OncoGenex’s OGX-011 in combination.<wbr> OncoGenex phase III Custirsen is also in combination with first line docetaxel (fast track status with FDA).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_14_ScreenCapture14.jpg"> </div><div>The CI Dept gratefully acknowledges coverage of the above meetings by Beth Elliott.<wbr> </div><!-- Comment details --><a name="oncology8148attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(72,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(60,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(3,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(51,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(60,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(56,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(65,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(81,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(71,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(80,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(54,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(76,8 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(56,1 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8148_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(59,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8148">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-07T10:14:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-07T10:14:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aragon Raise Timely Financing</title>
	<pubDate>2012-03-07T09:30:40+01:00</pubDate>
	<wp:post_id>3134</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: San Diego-based Aragon Pharmaceuticals has secured $42m of Series C cash through the Topspin Fund to continue the development of its prostate drug ARN-509 to POC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature &amp; Rational For Fund Raising</STRONG> </div><div style="margin-bottom: 10px;">Based on some early indications of efficacy the biotech has married up with a nontraditional investor to raise financing for a POC study.<wbr> The Topspin Fund, headed by one-time hedge fund wiz Jim Simons, put up half of the cash </div><div style="margin-bottom: 10px;">ARN-509 has attracted a significant amount of buzz in the biotech field.<wbr> The treatment was discovered by a team of scientists led by Charles Sawyer, a Howard Hughes Medical Institute investigator who is credited with the development of MDV3100.<wbr> </div><div style="margin-bottom: 10px;">Aragon needed the capital on a short timeline, since investigators were able to transition from a successful Phase I into a Phase II, enrolling about 100 late-stage patients in half the time initially projected.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">The cash is expected to last about 2 years depends on whether a partnership is secured for phIII development.<wbr> If it is then Aragon plans to swiftly change gears and turn the spotlight on its follow-up program for breast cancer as the partner moves forward on the prostate cancer drug.<wbr> </div><div style="margin-bottom: 10px;">There's also potential for a tie-up with a PI3 kinase inhibitor, which helped inspire Aragon's decision to ask Carol Gallagher, who helmed Callistoga and its PI3 kinase inhibitor program ahead of its sale to Gilead to sit on the company's board.<wbr> </div><div>Source:www.<wbr>aragon.<wbr>com
<BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8147">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-07T09:30:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-07T09:30:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Entremed Plans to Establish in China</title>
	<pubDate>2012-03-06T15:53:56+01:00</pubDate>
	<wp:post_id>3135</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The clinical-stage pharma company expects to facilitate and accelerate drug development and clinical trials in this country, and certain of its territories.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Priority will be given to ENMD-2076, an orally-active, Aurora A/<wbr>angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8146_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8146attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8146_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(55,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8146">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-06T15:53:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-06T15:53:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph2 GVAX Prostate with Ipilimumab in Patients with mCRPC is Anticipated to Start this Year</title>
	<pubDate>2012-03-06T14:14:07+01:00</pubDate>
	<wp:post_id>3136</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BioSante has announced the publication of the Ph1 results of its cancer vaccine in combination with ipilimumab in the current issue of the <EM>Lancet Oncology</EM>.<wbr> A Ph2 is anticipated to begin this year at the Johns Hopkins Sidney Kimmel Comprehansive Cancer Center.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Protocol</U> </div><div style="margin-bottom: 10px;">Fixed doses of GVAX Prostate in combination with escalating 0.<wbr>1, 0.<wbr>3, 1.<wbr>0, 3.<wbr>0 and 5.<wbr>0 mg/<wbr>kg doses of ipilimumab.<wbr> </div><div style="margin-bottom: 10px;"><U>Recruitment</U> </div><div style="margin-bottom: 10px;"><UL><LI>12 patients in 3 dose escalation cohorts</LI>
<LI>16 patients in an expansion ipilimumab 3.<wbr>0 mg/<wbr>kg cohort</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">53% of patients achieving at least stable disease, with two patients showing clear regression of metastases.<wbr> </div><div style="margin-bottom: 10px;">In addition, 23% of patients in the higher dose cohorts had confirmed partial PSA responses of greater than 50% from baseline.<wbr> </div><div style="margin-bottom: 10px;">No serious AEs in tle lower dose ipilimumab cohorts and administration of immunotherpay was well tolerated in safe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Titla: "Combined Immunotherapy with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Allogeneic Prostate Cancer cells and Ipilimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.<wbr> A Phase 1 Dose Escalation Trial" - <EM>The Lancet Oncology</EM> (February 2012).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8144">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-06T14:14:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-06T14:14:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Combination of Cabazitaxel and Abiraterone Enters Ph1 for mCRPC</title>
	<pubDate>2012-03-05T16:52:52+01:00</pubDate>
	<wp:post_id>3137</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Investigator-Sponsored trial is being led by Dr Chris Sweeney at the Dana-Farber Cancer Institute, and will assess the maximum tolerated dose of the combination in men with mCRPC who have disease progression following treatment with up to two prior chemotherapy regimens.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Cabozantinib is a potent inhibitor of MET, and may therefore enhance the activity of abiraterone by blocking this putative resistance mechanism.<wbr> </div><div style="margin-bottom: 10px;">Additionally, the high level of activity that cabozantinib has demonstrated against both soft tissue and bone lesions in men with CRPC may complement the clinical activity of abiraterone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG> </div><div style="margin-bottom: 10px;"><U>Part A</U> is a dose-escalation study in which patients will receive cabozantinib (20 mg, 40 mg, or 60 mg) in combination with 1000 mg of abiraterone daily and 5 mg of prednisone twice daily.<wbr> This part of the study is a standard “3 plus 3” dose-escalation design in which 3 patients are initially accrued at each dose level.<wbr> If none of the patients experiences a dose-limiting toxicity (DLT) in the first 4 weeks of treatment, dose escalation will proceed to the next dose level.<wbr> If 1 patient experiences a DLT, 3 additional patients will be accrued at that dose.<wbr> If 2 or more patients experience a DLT, that dose will be considered as exceeding the MTD.<wbr> </div><div style="margin-bottom: 10px;"><U>Part B</U> of the study, the dose levels identified as safe and tolerable in Part A will be expanded to include up to 12 patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Primary Endpoint</STRONG> </div><div>Rate of dose limiting toxicity (DLT) in the first 4 weeks of therapy when abiraterone is combined with escalating doses of cabozantinib.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8142">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-05T16:52:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-05T16:52:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PWC's 15th Annual Global Pharma & Life Sciences CEO Survey</title>
	<pubDate>2012-03-05T10:47:56+01:00</pubDate>
	<wp:post_id>3138</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PWC has recently published the outcome of its annual survey of 82 pharma and life sciences CEOs in 29 countries to understand how businesses are preparing for growth in their priority markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Only 34% of all CEOs – and only 22% of those running pharma and life sciences companies – plan to make strategic alterations as a result of changes in risk tolerance over the next 12 months.<wbr></LI>
<LI>Only 12% believe the global economy will pick up this year.<wbr> But 45% are very confident of being able to generate higher revenues over the next 12 months, and 49% are very confident of being able to do so over the next three year</LI>
<LI>CEO's are refashioning their business models for a world where the opportunities and threats are increasingly interconnected but the sources of growth are often local.<wbr></LI>
<LI>66% of all pharma and life sciences CEOs plan to make other strategic alterations over the next 12 months.<wbr> And 21% of them anticipate making fundamental changes, in contrast with the overall average of just 13%</LI>
<LI>The ability to hire, develop, and retain talent in the developing economies has become a major point of competitive differentiationtalent constraints have restricted innovation in 33% of pharma and life sciences companies, and 45% have seen their labour costs climb more than expected.<wbr> </LI>
<LI>49% of pharma and life sciences CEOs are turning to technology to address the skill shortage.<wbr> Eli Lilly,  for example, has invested heavily in computational analysis and cloud computing to improve the productivity of its research team.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9804_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Thanks to Alison Attard (SIS) a link to a copy of the full report is shown below:- </div><div><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(17,85,204); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse; -webkit-text-decorations-in-effect: underline"><BR><a href="http://www.pwc.com/gx/en/ceo" class="defaultlink" title="http://www.pwc.com/gx/en/ceo">pwc.com/<wbr>gx/<wbr>en/<wbr>ceo</a>-<WBR>survey/<wbr>pdf/<wbr>15th-global-ceo-</WBR><WBR>survey-pharmaceuticals-life-</WBR><WBR>sciences.<wbr>pdf</WBR></SPAN></SPAN> </div><!-- Comment details --><a name="pharmaworld9804attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9804_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9804">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-05T10:47:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-05T10:47:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Eisai's Information Meeting</title>
	<pubDate>2012-03-05T10:15:41+01:00</pubDate>
	<wp:post_id>3139</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On 2 March, Eisai's President Haruo Naito hosted the company's annual information meeting to outline its long-term business vision.<wbr> Key messages are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In developing countries, the income level is different and also the healthcare or insurance system is different.<wbr> Management think about the pricing level which can be accepted in such countries.<wbr><BR> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9801_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Americas - Location: US</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9801_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>EMEA - HQs location: UK</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9801_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9801_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="pharmaworld9801attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9801_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(164,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9801_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(112,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9801_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(125,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9801_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(114,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9801">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-05T10:15:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-05T10:15:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Neurosearch Makes Progress Towards FDA Submission</title>
	<pubDate>2012-03-05T10:15:21+01:00</pubDate>
	<wp:post_id>3140</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NeuroSearch has completed enrollment of 118 patients in the open-label, North American Phase II Open-HART trial evaluating 45 mg twice-daily Huntexil.<wbr> Last year, the FDA indicated that additional clinical data would be needed to support an NDA submission following a meta-analysis which showed a significant improvement in UHDRS on therapy at 26 weeks.<wbr> </div><div style="margin-bottom: 10px;">The trial is an extension to the Phase IIb HART study.<wbr> In 2010, the company reported data from HART showing that Huntexil missed the primary endpoint of significantly improving voluntary motor function as measured by the change from baseline in the modified motor score subscale of the UHDRS vs.<wbr> placebo at week 12.<wbr> </div><div style="margin-bottom: 10px;">In December 2010, NeuroSearch reported data from a meta-analysis of HART and Phase III MermaiHD trial, showing that Huntexil non-significantly improved voluntary motor function by 0.<wbr>6 points as measured by the modified motor score (mMS) subscale of the UHDRS vs.<wbr> placebo at week 12 but significantly improved the endpoint by 1.<wbr>2 points at week 26.<wbr> </div><div>Scource: <a href="http://www.neurosearch.com" class="defaultlink" title="www.neurosearch.com">neurosearch.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6269">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-05T10:15:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-05T10:15:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MOVIPREP Filed in Japan</title>
	<pubDate>2012-03-02T18:02:51+01:00</pubDate>
	<wp:post_id>3141</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ajinomoto, Norgine's Japanese Partner, have filed an application in Japan for the manufacture and marketing authorisation of MOVIPREP, which will be used for bowel preparation prior to colonoscopy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Ajinomoto markets Niflec® which is used for cleaning the bowel prior to colonoscopy.<wbr> However it expects that MOVIPREP, with its reduced dosage volume will contribute to improving patient’s quality of life.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120431&edate=20120101&rec=1835">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-02T18:02:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-02T18:02:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Study with Degarelix Prior to Prostactectomy</title>
	<pubDate>2012-03-02T15:23:12+01:00</pubDate>
	<wp:post_id>3142</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The rationale of this study is for the investigator to learn how degarelix effects prostate cancer cells and use this information to develop better treatments in the future.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01542021?fund=2&amp;rcv_s=02%2F17%2F2012&amp;rank=78"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start Date: Feb 2012 - Completion date: Feb 2014 </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 30 </div><div style="margin-bottom: 10px;">Location : US </div><div style="margin-bottom: 10px;">PI: Dana Rathkopf, MD </div><div style="margin-bottom: 10px;">Primary Outcome Measures: </div><div><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI style="MARGIN-TOP: 0.7ex">To choose between two time intervals to determine the time of the maximal change in prostate cancer cell proliferation (Ki-67) and apoptosis rates (cleaved caspase-3) following treatment with degarelix</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8141">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-02T15:23:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-02T15:23:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Long-acting & Sub-type Toxin Developments</title>
	<pubDate>2012-03-02T14:16:32+01:00</pubDate>
	<wp:post_id>3143</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"><STRONG></STRONG></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><DIV>
<DIV><A href="http://www.ncbi.nlm.nih.gov/pubmed/22367089#" style="COLOR: rgb(17,85,204)" target="_blank" title="Applied and environmental microbiology."></A></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><A href="http://www.biochemj.org/bj/imps/pdf/BJ20120100.pdf" style="COLOR: rgb(17,85,204)" target="_blank"></A><BR> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6268">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-02T14:16:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-02T14:16:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Prostate Cancer Indication for Nymox' NX-1207 Enters Ph2</title>
	<pubDate>2012-03-02T13:07:47+01:00</pubDate>
	<wp:post_id>3144</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has initiated a U.<wbr>S.<wbr> trial to evaluate the NX-1207 for the treatment of low grade localized prostate cancer.<wbr> The drug is injected by a urologist in an office setting directly into the zone of the prostate where the enlargement occurs and involves little or no pain or discomfort.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 150 men </div><div style="margin-bottom: 10px;">Protocol: two dose 6 week Phase 2 study designed in accordance with specific direction and guidance provided by the FDA in Pre-IND meetings.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">On Feb 21, 2012 the company announced the start of activities aimed to the preparation of a EU Ph3 clinical trial, following the successful completion of a Scientific Advice meeting with the EMA.<wbr> </div><div>A Ph3 is currently in clinical development in the U.<wbr>S.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8140">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-02T13:07:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-02T13:07:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on ArQule's c-Met Inhibitor Trial in Prostate Cancer</title>
	<pubDate>2012-03-02T11:47:50+01:00</pubDate>
	<wp:post_id>3145</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During the company’s 4Q:11 earnings call, management provided updates on the broad array of ARQ-197 (tivantinib) programs.<wbr> Of note, the NCI randomized pre-chemo prostate trial, which Ph2 data will be reported in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Design: Phase II placebo controlled (NIH) trial</LI>
<LI>Start: Jan 2012</LI>
<LI>Recruitment: (n=78) pre-chemo patients</LI>
<LI>PE: PFS</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8139_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8139attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8139_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(71,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8139">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-02T11:47:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-02T11:47:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Public Results of Solabegron Ph2 for OAB Presented @EAU2012</title>
	<pubDate>2012-03-02T11:07:11+01:00</pubDate>
	<wp:post_id>3146</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The drug, a beta 3 adrenoceptor agonist, <SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
<LI><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">.<wbr></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8138">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-02T11:07:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-02T11:07:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>TAK-700 Data Suggests Side Effects Could Be An Issue</title>
	<pubDate>2012-03-01T19:03:12+01:00</pubDate>
	<wp:post_id>3147</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: TAK-700 PhII data suggests that its side effect profile is far from being benign, Whilst the company is claiming that it is feasible to use the drug without concomitant prednisone, the data suggests this may not be applicable to the majority of non-metastatic patients with a rising PSA (the study group evaluated).<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Study Design</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>Eligible men in the phII study had baseline PSA &ge;2ng/<wbr>mL  and surgical or ongoing medical castration, with testosterone &lt;50ng/<wbr>dL.<wbr>
</LI>
<LI>Prior chemotherapy, aminoglutethimide or ketoconazole, or concomitant corticosteroids were excluded.<wbr>
</LI>
<LI>Starting dose of TAK-700 was 300mg BID given continuously in 28-d cycles, optionally increasing to 400mg BID if &ge;50% decrease in PSA (PSA50) was not achieved after 3 mo.<wbr>
</LI>
<LI>TAK-700 was continued until PSA progression or metastases.<wbr>
</LI>
<LI>The study primary endpoint was the percentage of men with PSA &le;0.<wbr>2ng/<wbr>mL after 3 mo.<wbr>
</LI>
<LI>Secondary endpoints include safety, 3 and 6 mo PSA30, PSA50, PSA90 rates, progression-free survival, time to PSA progression, time to metastases, changes in endocrine markers and circulating tumor cell (CTCs).<wbr>
</LI>
<LI> 38 men with a median age 71 y (range 55-81), ECOG PS 0/<wbr>1 (84%/<wbr>16%), median PSA 12.<wbr>5ng/<wbr>mL (2.<wbr>6-67.<wbr>8), testosterone 0.<wbr>267nmol/<wbr>L (0.<wbr>05-0.<wbr>60), and ACTH 19.<wbr>5ng/<wbr>L (n=32; 0-47) were treated.<wbr>
</LI>
<LI>Median number of cycles was 5.<wbr>5 (1-13); 1 patient had dose reduction due to adverse events (AEs), 1 had dose increase to 400mg BID.<wbr> 99% of the total planned dose was taken
</LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV style="margin-top: 25px; margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Key Efficacy Results</STRONG></SPAN></DIV> </div><div style="margin-bottom: 10px;"><UL><LI>At 3 mo, 4 men (11%) achieved PSA &le;0.<wbr>2ng/<wbr>mL.<wbr> PSA50 and PSA90 rates were 69% and 28%, respectively.<wbr>
</LI>
<LI>At 3 mo, median PSA decline was 83% to 1.<wbr>96ng/<wbr>mL (n=28; 0.<wbr>12-50.<wbr>5); median testosterone declined by 89% to 0.<wbr>026nmol/<wbr>L (0-0.<wbr>28), and median ACTH increased by 228% to 55ng/<wbr>L (12-351).<wbr>
</LI>
<LI>Similar results were seen at 6 mo, with changes of &ndash;87% to 2.<wbr>05ng/<wbr>mL (0.<wbr>1-12.<wbr>3), &ndash;86% to 0.<wbr>033nmol/<wbr>L (0.<wbr>01-0.<wbr>41), and +312% to 83.<wbr>5ng/<wbr>L (21-173), respectively.<wbr> 6-mo PSA50 and PSA90 rates were 42% and 17%, respectively.<wbr> 14 men (37%) were on treatment &gt;6 mo.<wbr>
</LI>
<LI>Of 35 men with baseline CTC/<wbr>7.<wbr>5mL values, only 1 had CTC &ge;5 and 6 had 1-4 CTC.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Toxicity Issues</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Gr &ge;3 AEs occurred in 16 men (drug-related in 13); most common (&ge;5%) were dyspnea (11%), hypertension (8%), fatigue, hypokalemia, pneumonitis (5% ea).<wbr> </div><div style="margin-bottom: 10px;">Seven men (18%) had serious AEs; most common was pneumonitis (2=Gr3, 1=Gr2).<wbr> </div><div style="margin-bottom: 10px;">Eight men discontinued ortl due to AEs (dyspnea, pneumonitis, adrenal insufficiency, fatigue, hypertension, diarrhea, dysgeusia).<wbr> </div><div>EAU Abstract 124 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8137">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-01T19:03:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-01T19:03:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Leuprorelin Hybrid in Poland</title>
	<pubDate>2012-03-01T09:55:13+01:00</pubDate>
	<wp:post_id>3148</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to our colleagues Robert and Jurek (<SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">) </SPAN>we have learnt that Sandoz' Leuprostin did not get reimbursement status in Poland.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Medical reps have been working with the product for two months now.<wbr> </div><div style="margin-bottom: 10px;">Although intensive efforts deployed by Sandoz, the Polish authorities did not recognize sufficient evidence in the scientific papers.<wbr> </div><div>For that reason, Leuprostin did not obtain reimbursement status in the second update of the reimbursement list for 2012.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=142">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-01T09:55:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-01T09:55:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation Management Provides Insights on Ongoing Trials with MDV3100</title>
	<pubDate>2012-03-01T08:44:32+01:00</pubDate>
	<wp:post_id>3149</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results for Q4 2011, management reported S&amp;GA continued to grow to almost 30% in anticipation of a MDV3100 commercial launch.<wbr> If MDV3100 receives marketing approval, Medivation will provide 50% of the sales and medical affairs support for MDV3100 in the US.<wbr> Regarding a new breast cancer indication for MDV3100, the company announced it will "get into clinical as quickly as it can".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Enrolment completed (67 men with advanced cancer who have not yet undergone chemical castration with LHRH analogs.<wbr> The primary endpoint is PSA response).<wbr><BR>Data of the six month study to be presented at "an upcoming meeting".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment is about 370 advanced prostrate cancer patients who have progressed following medical castration with LHRH analog therapy or surgical castration.<wbr><BR>Management outliners that this trial "will be useful to gain market access both in the US and EU".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Enrolment of approx 1,670 patients will be larger than the Zytiga 302 study.<wbr> Regarding the interim analysis, management iindicated they "intend to sit tight and see what Zytiga is going to do, and make the very best plan for MDV3100".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">David Hung (President &amp; CEO) noted that the company is "trying to expand 3100 to upstream indications" and "have three other trials ongoing", and "are also interested in expanding MDV3100 to other indications, and breast cancer is certainly one possibility".<wbr> </div><div style="margin-bottom: 10px;">Other internal programs are being assessed, and not all in cancer.<wbr> </div><div style="margin-bottom: 10px;">Management noted that "For 3100, as you know we licensed MDV3100 from  That included a stable of about 170-plus compounds, all part of something called the RD series.<wbr> And so those are all potential -- those are similar structures based on the same scaffold and several of them are potential backups to 3100".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Medivation expects to to receive $45 million in development milestone payments in 2012 under the Astellas collaboration based on the assumption that marketing applications for MDV3100 in post chemotherapy patients will be filed in both the US and Europe and that the US NDA will be approved in 2012.<wbr> </div><div style="margin-bottom: 10px;">These 3 events would trigger milestone payments of $10 million, $5 million and $30 million, respectively.<wbr> </div><div>The company is required to share 10% of any such development milestone payments received with  </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8133">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-03-01T08:44:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-03-01T08:44:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dainippon Sumitomo Pharma Snags Leader In Stem Cell Therapy For $200M</title>
	<pubDate>2012-02-29T17:42:31+01:00</pubDate>
	<wp:post_id>3150</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dainippon Sumitomo has made a major move into the stem cell therapy arena acquiring Boston Biomedical for an upfront of $200m with a promise of another $2.<wbr>43bn in milestones if Boston's two cancer candidates BB1608 and BB1503 are commercialised.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Development Status &amp; Timelines</U></STRONG> </div><div style="margin-bottom: 10px;">DSP currently aims to commercialize BBI608 and BBI503 in 2015 or later.<wbr> </div><div style="margin-bottom: 10px;">Both drugs are oral small molecule inhibitors of cancer stem cells.<wbr> </div><div style="margin-bottom: 10px;">BBI608 is currently in the preparatory stage for a Phase III trial in colorectal cancer in North America and in Phase Ib and II trials for various solid tumors.<wbr> BBI503 is in a Phase I trial in North America involving patients with various advanced solid tumors.<wbr> It is competing in the stem cell therapy space with companies such as Versatem and OncoMed Pharma (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7677" class="defaultlink">Oncology7677: Verastem's Technology Overcomes Signficant Stem Cell Challenge</a>).<wbr> </div><div style="margin-bottom: 10px;">DSP previously signed an exclusive product option license agreement with BBI in March 2011 on the rights of development and commercialization of BBI608 in Japan for all cancer indications.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the acquisition Masayo Tada President and CEO of DSP stated:-The acquisition of BBI is not only an acquisition of an innovative pipeline in the oncology area, it also represents obtaining an excellent drug discovery and development platform with the capabilities of BBI, enabling us to continuously create candidate compounds likely to advance into later development stages".<wbr> </div><div style="margin-bottom: 10px;">&ldquo;Subsequently" he noted "we intend to establish our R&amp;D base in the U.<wbr>S.<wbr> to expand our presence in cancer treatment globally.<wbr> We are aiming to make the oncology area one of our future focus therapeutic areas next to the CNS area.<wbr>&rdquo; </div><div>Scource.<wbr> <a href="http://www.bosstonbiomedical.com" class="defaultlink" title="http://www.bosstonbiomedical.com">bosstonbiomedical&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8130">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-29T17:42:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-29T17:42:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Patients Enrollment Started with Leuplin ® 6M in Japan</title>
	<pubDate>2012-02-29T13:09:21+01:00</pubDate>
	<wp:post_id>3151</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Two Ph3 trials that have been started are multicenter, randomized, open-label, comparative studies, with patients with prostate cancer and those with premenopausal breast cancer.<wbr> The primary endpoints for prostate cancer is the suppression rate of serum testosterone to castrate level, and those for premenopausal breast cancer is the suppression rate of serum estradiol to menopausal level </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Each trial is planned to enroll approx.<wbr> 160 patients to evaluate safety, efficacy, pharmacokinetics, and hormone dynamics of the medicine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The 6M depot is currently available in United States and Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Takeda is looking to strengthen its Leuplin geographical roll-out.<wbr> </div><div style="margin-bottom: 10px;">The company is investing in the hormone dependent cancer portfolio with the development of : </div><div><UL><LI>TAK-700 Non-steroidal androgen synthesis inhibitor (Ph3 US/<wbr>EU/<wbr>Jpn)</LI>
<LI>TAK-385 LHRH antagonist (Ph1 Jpn)</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8128">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-29T13:09:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-29T13:09:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Update on Abbott's Procrin 6M in Spain</title>
	<pubDate>2012-02-29T10:32:04+01:00</pubDate>
	<wp:post_id>3152</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">We have been informed that Procrin 6M might be launched in January 2012 in Spain.<wbr> Price will be 491.<wbr>88&euro; (same as Decapeptyl).<wbr> Contribution from Ipsen Spain is greatefuly acknowledged.<wbr></span>&nbsp;<br></div><div style="margin-bottom: 10px;">It has been published new information in PM Pharma (IberoAmerican Pharmaceutical Marketing Portal).<wbr> </div><div style="margin-bottom: 10px;">&ldquo;Abbott has announced the commercialization in Spain of the new presentation of Procrin (leuprolide acetate) in the treatment of hormone-dependent advanced prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">The new formulation of Procrin, a 6 months presentation, contains 30 mg of leuprolide acetate.<wbr> In addition, it has also changed the method of administration <STRONG>replacing the current format (syringe and vial) by a pre-filled syringe</STRONG>, the first in the market in a biannual presentation.<wbr> </div><div style="margin-bottom: 10px;">The transition from intramuscular to subcutaneous allows their use in patients on anticoagulants.<wbr> This new delivery device, containing 1 ml injection volume, is easy to reconstitute and does not require special storage conditions.<wbr> </div><div>Not only there is a new commercialization of the semestral presentation of Procrin but also the <STRONG>harmonization of the other leuprolide acetate Procrin presentations in Spain</STRONG>, <STRONG>monthly and quarterly</STRONG>, with the new 3.<wbr>75 mg and 11.<wbr>25 mg, respectively.<wbr> The new syringe of subcutaneous administration is also applicable to these new doses.<wbr>&rdquo; </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8127">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology7356">View thread  Oncology7356: Update on Abbott's Procrin 6M in Spain</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-29T10:32:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-29T10:32:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tongyang Securities Reports on Medy-Tox Earnings</title>
	<pubDate>2012-02-28T20:07:47+01:00</pubDate>
	<wp:post_id>3153</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In the domestic market, average sale price of Meditoxin fell 20% in early 2011 due to the launch of Hugel's Botulax in Korea (3Q10).<wbr> Overseas sales decreased in 2011 as Medy-Tox stopped exportation in Brazil, where its partner Bergamo was sold to Amgen.<wbr> The company is seeking potential partner for its next-generation toxin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Medy-Tox plans to market existing product Meditoxin in Korea and developing countries, and sell the next-generation version of Meditoxin in advanced countries.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6267">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-28T20:07:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-28T20:07:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Selection of Urology Toxin Data Presented @ the EAU2012</title>
	<pubDate>2012-02-28T18:23:58+01:00</pubDate>
	<wp:post_id>3154</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Several posters and abstracts highlighted new urological toxin results.<wbr> During a poster presentation, it was reported that regardless of concomitant anticholinergics (AC) use, significant improvements in UI symptoms, urodynamics, and QOL were seen in OnabotA-treated patients with UI due to NDO, indicating that onabotA alone can be used in pts who do not respond to AC (Allergan sponsored study).<wbr> During the 'Souvenir session by the EAU Scientific Congress Office' Prof.<wbr> Francisco Cruz outlined 2 important studies.<wbr> One focused on the Zurich experience including 10 year results with 100 U injections of botulinum-A in the detrusor muscle for OAB, and another on the safety and efficacy of using a reduced dose of OnabotA (200 U) in 46 MS patients previously treated with higher doses (300 U).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Poster 461</STRONG> - Efficacy of OnabotulinumtoxinA in Neurogenic Detrusor Overactivity Is Independent of Concomitant Anticholinergic Use </div><div style="margin-bottom: 10px;">Results were pooled from 2 pivotal, double-blind, randomized, placebo-controlled phase 3 studies with identical entry criteria and treatments (Double-blind InvestiGation of purified Neurotoxin complex In neurogenic deTrusor overactivitY (DIGNITY) program: studies 191622-515 (NCT00311376) and 191622-516 (NCT00461292).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_6_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_7_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Abstract 692</STRONG> - Experiences including 10 year results of 253 Cases treated with low-dose (100 U) Botulinum-A Toxin Injections in the Detrusor Muscle for Overactive Bladder refractory to Anticholinergics </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Abstract 464 -</STRONG> Does dose reduction of Botulinum toxin-A affect quality of life in patients with multiple sclerosis? </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="neurology6262attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_6_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6262_7_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(50,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6262">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-28T18:23:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-28T18:23:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Esmya(R) Granted EMA for Uterine Fibroids</title>
	<pubDate>2012-02-28T15:41:49+01:00</pubDate>
	<wp:post_id>3155</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The EC has granted marketing authorization to Richter/<wbr>PregLem's Esmya(R) 5mg tablet for pre-operative treatment of moderate to severe symptoms of uterine fibroids.<wbr> </div><div>This decision follows positive opinion from the CHMP for the EMA on December 2011 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7967" class="defaultlink">Oncology7967: Richter/<wbr>PregLem's Esmya® Receives Positive Opinion from the EMA/<wbr>CHMP</a>).<wbr> <a name="Oncology8309c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Esmya is now commercially available in the UK from Preglem at a price of &pound;114.<wbr>13 for 28 5mg tablets.<wbr> </div></div></div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8359c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Clinicaltrials.<wbr>gov is listing a new Ph3 trial which is to evaluate the sustained efficacy and safety of long term on-off treatment with Esmya (5 or 10mg doses) on uterine bleeding, myoma size, pain and quality of life.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Start date: June 2012 - Completion date: April 2015/<wbr>June 2015</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Recruitment: Approx.<wbr> 600 pre-menopausal women with symptomatic uterine myoma(s) characterised by heavy bleeding</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Locations: 13 EU countries</SPAN> </div><div><SPAN style="background-color: #ffffff;">Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01629563?recr=Open&fund=2&rcv_s=06%2F13%2F2012&rank=71" class="defaultlink">NCT01629563</a></SPAN> </div></div><a name="Oncology8779c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The Scottish Medicines Consortium (SMC) backed the use of Esmya on the NHS as the 1st oral treatment for uterine fibroids.<wbr> The licence from the SMC means the drug ca now be prescribed generally in treatment.<wbr> </div></div><a name="Oncology10436c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The EMA has positively assessed Richter's application to extend the indication of its Esmya tablets to the long-term treatment of symptoms of uterine fibroids.<wbr> The Agency's positive opinion would be forwarded to the European Commission, which is expected to amend the marketing authorisation for Esmya for all countries of the European Union, within two months.<wbr><BR><BR>Esmya's initial EU marketing licence was for the pre-operative treatment of moderate-to-severe symptoms of uterine fibroids in adult women.<wbr><BR><BR>"The extension of indication to include the repeated intermittent treatment will give, should it be approved, the opportunity to many women suffering from this condition to be relieved from the symptoms of fibroids," Richter said in a statement on the Budapest bourse's website.<wbr> </div></div><a name="Oncology10517c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 23 April 2015 EC has granted approval for a label extension of Esmya 5mg, which now adds the intermittent treatment courses.<wbr>  This is applicable for all Member States in the European Economic Area.<wbr> </div><div>This will provide an opportunity to women to benefit from long term medical management of uterine fibroids and potentially avoid surgery.<wbr> This also means more choice for physicians.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8125">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-28T15:41:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-28T15:41:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Uptake of Provenge Begins to Taper Off</title>
	<pubDate>2012-02-28T13:40:55+01:00</pubDate>
	<wp:post_id>3156</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Comment: Dendreon's shares fell by nearly 19 percent yesterday after the company said it expects sales growth for Provenge to moderate in the first quarter to low single digits, based partly on fewer new patient enrollments.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Revenue from the product was $77 million for the fourth quarter, up from $25 million in the corresponding period a year ago and pulling slightly ahead of the $76 million anticipated by analysts.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Total fourth-quarter revenue was $202 million, boosted by a $125 million payment for Dendreon&rsquo;s sale of its royalty interest in Merck&rsquo;s Victrelis hepatitis C treatment.<wbr> The royalty helped Dendreon post a fourth-quarter profit of $38.<wbr>1 million, up from a loss of $91.<wbr>8 million in the year earlier period.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><STRONG>Uptake of Provenge</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Dendreon claims to be making progress with the insurance reimbursement issues that had hampered Provenge&rsquo;s financial performance following its introduction in 2010.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Looking ahead, management reiterated plans to expand sales of Provenge, reduce manufacturing costs and advance the company&rsquo;s pipeline of experimental drugs.<wbr></P> </div><div><P align="left">It noted that its  European application has now been validated  and that it needs to begin to enter that market and enrollment is also well underway for our study examining the sequencing of abiraterone and PROVENGE in androgen deprivation therapy in men with a rising PSA after primary therapy, especially important in the urology setting.<wbr> Urology has been our fastest growing segment of the business and is viewed as a very important segment of the business for Dendreon moving forward.<wbr> Currently urology  is about 20% of the business, oncology  80% .<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8124">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-28T13:40:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-28T13:40:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New iOAB Drug Demonstrates Better Efficacy Than Standard Of Care</title>
	<pubDate>2012-02-27T21:23:48+01:00</pubDate>
	<wp:post_id>3157</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 10px; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"></P></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 10px; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"><STRONG></STRONG></P></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 10px; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"></P></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 10px; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"><STRONG></STRONG></P></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 10px; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<UL><LI style="MARGIN-LEFT: 15px"></LI>
<LI style="MARGIN-LEFT: 15px"></LI>
<LI style="MARGIN-LEFT: 15px"></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 10px; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"></P></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-BOTTOM: 10px; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"><STRONG></STRONG></P></DIV> </div><div><DIV style="MARGIN-BOTTOM: 10px; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6261">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-27T21:23:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-27T21:23:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Astellas' Sympo on OAB @EAU2012</title>
	<pubDate>2012-02-27T21:12:56+01:00</pubDate>
	<wp:post_id>3158</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The sympo aimed to explore current and future trends in the management of OAB, identify the current needs of OAB patients, and look to the new prescribing agents on the horizon.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Non-Adherence to Medication</U> </div><div style="margin-bottom: 10px;">According to Astellas market research between 30 and 50% of patients do not adhere to their prescribed treatments irrespective of disease or prognosis.<wbr> </div><div style="margin-bottom: 10px;">Medication non-adherence results in increased clinical risk and therefore in increased morbidity and mortality.<wbr> </div><div style="margin-bottom: 10px;">Non-adherence along with suboptimal diagnosis, prescribing and medication administration costs £290 billion/<wbr>year in the U.<wbr>S </div><div style="margin-bottom: 10px;">To improve adherence with antimuscarinic drug therapy, it is necessary to improve patient information (about their condition and their treatment), to assess the individual wishes and concerns of patients, and understand more about the correct regimen for OAB drug therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Antimuscarinics remain the mainstay of OAB treatment but patient adherence levels demonstrate a need for alternative therapies.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">- beta3-adrenoreceptor agonists are currently in development, and have different mechanism of action compared to antimuscarinics.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Ph3 studies with mirabegron</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">- Therapies such as neuromodulation and botulinum toxin do not require patient motivation to be effective.<wbr> </div><div>Also See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6261" class="defaultlink">Neurology6261: New iOAB Drug Demonstrates Better Efficacy Than Standard Of Care</a> </div><!-- Comment details --><a name="oncology8121attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(57 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(58,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(31,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8121_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(57,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8121">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-27T21:12:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-27T21:12:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nature of Medy-Tox's MT10109 Formulation</title>
	<pubDate>2012-02-27T16:19:50+01:00</pubDate>
	<wp:post_id>3159</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: #222222; FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN> </div><div><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: #222222; FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6250">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-27T16:19:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-27T16:19:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Combined Inhibition of VEGF and c-MET Can Decrease Metastasis In pNET</title>
	<pubDate>2012-02-27T10:50:47+01:00</pubDate>
	<wp:post_id>3160</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"><STRONG></STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"> </div><div><A href="http://http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=2686"></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6880">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-27T10:50:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-27T10:50:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from the Ferring Sympo @ EAU2012</title>
	<pubDate>2012-02-27T10:04:50+01:00</pubDate>
	<wp:post_id>3161</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: New emerging therapies and more data becoming available represent a challenge for established practices.<wbr> Evidence to support neoadjuvant/<wbr>adjuvant/<wbr>intermittent ADT, optimal sequencing and drug combinations for the treatment of CRPC remain to be established.<wbr> A preview of the CS30 trial comparing degarelix to goserelin + bicalutamide in the neoadjuvant setting was presented by Prof.<wbr> Malcom Mason.<wbr> At the end of the symposium, the takehome messages from Pf Montorsi outlined that degarelix is an effective 1<SUP>st</SUP>-line ADT with tangible benefits for patients, and that results in first study in intermittent ADT are promising.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Malcom Mason</STRONG> (Professor of Clinical Oncology and Director of the Institute of Cancer &amp; Genetics art Cardiff University’s School of Medicine) introduced his session in outlining that neoadjuvant HT before RT can improve disease control and/<wbr>or survival versus RT alone (Payne &amp; Mason Br J Cancer 2011:105:1628-34).<wbr> </div><div style="margin-bottom: 10px;">Pf M Mason selected 2 trials demonstrating the importance of neoadjuvant HT (NADHT).<wbr> </div><div style="margin-bottom: 10px;">RTOG8610: Neoadjuvant HT (4 months) + RT Vs RT alone </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">10-year results show that neoadjuvant HT significantly improved disease-specific mortality and measures of disease control, <STRONG>but</STRONG> not OS or median survival time.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">TROG96.<wbr>01: Neoadjuvant HT (3 or 6 months) + RT Vs RT alone </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">10-year results show a high difference in OS in favor of 6-month NADT.<wbr> Other outcomes show that 3- and 6- month ADT significantly improved PSA, local progression and event-free survival.<wbr> 6-month ADT also significantly improved distant progression an PCa mortality (Denham et al.<wbr> Lancet Oncol 2011:12:451-9).<wbr> </div><div style="margin-bottom: 10px;">He indicated that robust data show that adjuvant HT + RT can significantly improve progression and/<wbr>or OS in high-risk PCa vs RT or ADT alone (Payne &amp; Mason Br J Cancer 2011 105:1628-34).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Optimum treatment duration with neoadjuvant HT remains a big question </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Optimum treatment duration with adjuvant HT </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Selecting the right patient is important </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">.<wbr> </div><div style="margin-bottom: 10px;">This was a randomised, parallel-arm, active-controlled, open-label, multi-centre trial on 182 patients treated with either monthly degarelix (240/<wbr>80 mg) or goserelin (3.<wbr>6 mg) for 12 weeks.<wbr> For effective flare protection, goserelin-treated patients also received daily bicalutamide (50 mg) during the initial 28 days.<wbr> </div><div style="margin-bottom: 10px;">Key trial parameters monitored monthly were TPV (primary endpoint), serum testosterone, prostate-specific antigen (PSA), the International Prostate Symptom Score (IPSS), IPSS QoL and the BPH Impact Index.<wbr> </div><div style="margin-bottom: 10px;">Non-inferiority for the primary endpoint was considered to be established, if the treatment difference in adjusted mean percentage reduction was significantly greater than Δ = ‑10 points in both the FAS and PP analyses sets (two-sided at α=0.<wbr>05 level).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">Degarelix is non inferior to goserelin + bicalutamide.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;">Secondary endpoint </div><div style="margin-bottom: 10px;">Decreases in IPSS were more pronounced in degarelix versus goserelin-treated patients, differences being statistically significant in patients with moderate/<wbr>severe LUTS.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">In conclusion, Pf Mason reported that ADT + RT is now the standard of care for patients with locally advanced PCa (Heidenreich et al.<wbr> 2011).<wbr> The combination of ADT plus RT prevents death from prostate cancer, and delays disease progression.<wbr> Significant improvement in symptom control with neoadjuvant degarelix vs GnRH agonist, without need for flare protection.<wbr> Last but not least, he highlighted that a multi-disciplinary approach involving urologist and oncologists is key (Valadagni et al.<wbr> Eur J Cancer 2011:47;1-7).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Peter Albers</STRONG> (Professor and Chairman of the Department of Urology at the U.<wbr> of Düsseldrof, Germany) focused his talk on IAD and CAD.<wbr> He selected 2 Ph3 trials in locally advanced or metastatic PCa: </div><div style="margin-bottom: 10px;"><UL><LI>SEUG9401 (Calais da Silva FM et al.<wbr> J Clin Oncol 2006 24 (185) 4513 Calais da Silva FEC et al.<wbr> Eur Urol 2009 55:1269-77) SWOG9346 (Hussain M et al.<wbr> J Clin Oncol 2006 24:3984-90) </LI>
</UL> </div><div style="margin-bottom: 10px;">Respective results are provided below : </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;">Can those results be transferred to patients with PSA relapse ? </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;">In summary, </div><div style="margin-bottom: 10px;"><UL><LI>IAD is non-inferior to CAD in patients with PSA relapse </LI>
<LI>All QoL parameters in patients with IAD are improved </LI>
<LI>Details o IAD are still unclear (PSA cut-off, re-start cut-off).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">In summary for clinical practice: </div><div style="margin-bottom: 10px;"><UL><LI>Similar efficacy outcomes with IAD and CAD </LI>
<LI>EAU prostate cancer guidelines 2011: IAD no longer experimental </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>Benefits regarding potency, QoL improvements possible </LI>
<LI>Recommended in patients with locally advanced disease and/<wbr>or PSA relapse after curative treatment (long life expectancy) </LI>
</UL> </div><div style="margin-bottom: 10px;">Regarding IAD with a GnRH antagonist, Pf Albers reported that: </div><div style="margin-bottom: 10px;"><UL><LI>no published studies as yet </LI>
<LI>it remains unclear whether LHRH agonist monotherapy may be used as IAD </LI>
<LI>a GnRH antagonist “might be a valid alternative, provided clear results are obtained from randomized trials”.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">Interim data available for 213 patients in the first study of degarelix as IAD (CS29) was presented: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_23_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;">PSA and testosterone recovery demonstrated </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_24_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;">Sexual function tends to improve in off-period </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_25_ScreenCapture25.jpg"> </div><div style="margin-bottom: 10px;">In summary, Pf Albers outlined that degarelix is suitable for IAD.<wbr> However, questions remain: </div><div style="margin-bottom: 10px;"><UL><LI>Induction phase — how long ? </LI>
<LI>Survival benefit over LHRH agonists ? </LI>
<LI>QoL benefit over LHRH agonists ? </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_26_ScreenCapture26.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Francesco Montorsi </STRONG>(Professor of Urology at U.<wbr> Vita-Salute San Raffaele, Milan) dedicated his session to the pharmacology of GnRH agonists and antagonists, the comparison of the efficacy and the safety of agonists vs antagonists.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_27_ScreenCapture27.jpg"> </div><div style="margin-bottom: 10px;">He highlighted that approx.<wbr> 2000 patients in total in the US, Canada, EU and South America were included in studies to compare degarelix vs GnRH agonists.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_28_ScreenCapture28.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_29_ScreenCapture29.jpg"> </div><div style="margin-bottom: 10px;">A review of the most significant results of the CS21 and CS21a trials was presented.<wbr> </div><div style="margin-bottom: 10px;">Of note,  for: </div><div style="margin-bottom: 10px;">PSA PFS for degarelix vs leuprolide in Baseline Gleason &gt; or equal to 8 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_30_ScreenCapture30.jpg"> </div><div style="margin-bottom: 10px;">Tme to first CV event in PCa patients with no manifest CV event disease at baseline </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_31_ScreenCapture31.jpg"> </div><div style="margin-bottom: 10px;">Lower risk of CV events for degarelix vs GnRH agonists in patients with established CV disease </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_32_ScreenCapture32.jpg">Implications for patients </div><div style="margin-bottom: 10px;">Compared with GnRH agonist therapy, degarelix offers: </div><div style="margin-bottom: 10px;"><UL><LI>No risk of clinical flare </LI>
<LI>Longer time to CRPC, and therefore initiation of second-line treatment </LI>
<LI>Better tumour control, and a delay in time to death or progression over 7 months </LI>
<LI>Improved control of skeletal mets and less bone pain </LI>
<LI>Potential for improved LUTS control in more symptomatic patients </LI>
<LI>Patients with a history of CVD are at lower risk of another CV event when treated with degarelix vs leuprolide </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Neal</STRONG><STRONG> </STRONG><STRONG>Shore</STRONG> (Medical Director for the Carolina Urologic Research Center, USA) focused on new approaches when castration is not enough.<wbr> Mechanism of action as well as the latest results of Cabazitaxel, abiraterone, and MDV3100 were presented.<wbr> </div><div style="margin-bottom: 10px;">Regarding immunotherapy for CRPC, Dr Shore noted the improved OS with sipuleucel-T, and PROSTVAC.<wbr> He also cited Ipilimumab and tremelimumab that potentiate T-cell responses.<wbr> Other agents such as denosumab and Radium-223 were part of the presentation.<wbr> A table with other investigational agents was presented.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The future of mCRPC</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_33_ScreenCapture33.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_34_ScreenCapture34.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Implications for patients</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_36_ScreenCapture36.jpg"> </div><!-- Comment details --><a name="oncology8114attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(727 B)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(633 B)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_35_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(48,3 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_37_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_38_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_39_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_40_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_41_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_42_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_43_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_44_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_45_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_46_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_47_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_48_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;49.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_49_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;50.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_50_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;51.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_51_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;52.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_52_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;53.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_53_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;54.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_54_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;55.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_55_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;56.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_56_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;57.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_57_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;58.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_58_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;59.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_59_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;60.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_60_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;61.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_61_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;62.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_62_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;63.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_63_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;64.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_64_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;65.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_65_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;66.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_66_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;67.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_67_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;68.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_68_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;69.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8114_69_ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(6,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8114">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-27T10:04:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-27T10:04:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>2011 A Good Year For The Venture Capital Community</title>
	<pubDate>2012-02-24T17:51:43+01:00</pubDate>
	<wp:post_id>3162</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At this week's CI In Pharma Summit in Zurich a very interesting overview of trade sales in pharma was presented by the private equity group HBM Partners.<wbr> The group has recently published an updated report detailing all completed trade sales of North American and European specialty pharma, generics, OTC and traditional pharma companies since 2005.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key 2011 Findings</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>2011 was a strong year for pharma/<wbr>biotech M&amp;A with transaction volume totalling $64.<wbr>9bn in value (excluding the Pharmasset purchase by Gilead).<wbr>
</LI>
<LI>The number of M&amp;A deals at 71 was on a par with previous years albeit those where the upfront consideration was at least $100m accounted for a record number (38).<wbr>
</LI>
<LI>Deal activity was most prominent during the first half of the year due to the purchase of Genzyme by Sanofi and Nycomed by Takeda.<wbr> The latter also resulted in a record volume for VC/<wbr>PE backed company trade sales.<wbr>
</LI>
<LI>Average multiples for VC-backed company sales jumped to 2.<wbr>8x so 2011 will be remembered as a good year for the venture capital community.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_1_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_4_ScreenCapture4.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_5_ScreenCapture5.jpg"> </div><div>A copy of the full report is attached for review.<wbr> </div><!-- Comment details --><a name="pharmaworld9799attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(665 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(90,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(57,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9799_6_HBM%20Partners%202011%20Trade%20Sale%20Report.pdf">HBM Partners 2011 Trade Sale Report.pdf</a>&nbsp;&nbsp;(942,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9799">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-24T17:51:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-24T17:51:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Panel Recommends US Approval Of Chelsea's Northera</title>
	<pubDate>2012-02-24T16:36:20+01:00</pubDate>
	<wp:post_id>3163</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chelsea Therapeutics received a positive FDA recommendation that its drug Northera (droxidopa) should be approved for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), a condition most frequently found amongst Parkinson disease patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Panel Vote</STRONG> </div><div style="margin-bottom: 10px;">The vote despite critical pre-meeting documentation was 7-4 in favour of approval.<wbr> FDA reviewer Melanie Blank was concerned about a possible link between the drug's usage and neuroleptic malignant syndrome.<wbr> However, panel members voted in favour saying that the drug's benefits outweigh its risks because there are so few treatments for NOH and the risks are not unpredictable.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commercialisation Plans</STRONG> </div><div style="margin-bottom: 10px;">During its November earnings call, Chelsea management noted that amongst the first things it would do in the New Year was to hire ten regional sales directors, and then it would look to recruit and secure approximately 85 specialty sales reps on a conditional basis.<wbr> It was working with a vendor at that time to provide logistical support in sales force operations, needed not only to transition into a commercial organization, but to do so successfully over a relatively short period of time.<wbr> It felt that this approach offered the company the ability to scale up rapidly while limiting internal infrastructure and head count costs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Current Market/<wbr> Treatment Opportunity In Parkinson's Disease</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">The market consists primarily of two drugs used to treat NOH: midodrine and fludrocortisone.<wbr> It is estimated that of the approximately 180,000 patients that suffer from symptomatic NOH in the U.<wbr>S.<wbr>, about 80,000 to 85,000 of them take midodrine while another 80,000 to 90,000 takes fludrocortisone, a sympathetic adrenal corticosteroid that works by increasing sodium retention enhancing plasma volume, and thereby raising blood pressure.<wbr></P> </div><div><P align="left">The Parkinson's market is perceived to offer the most significant growth opportunity because of the attention paid to the non-motor features of Parkinson's disease and the expanding no of 70 and 80-year olds with the disease.<wbr> While some of these patients do receive treatment, the efficacy and, in particular the side effects profile of current drug therapy, has limited both utilization and compliance.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6246">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-24T16:36:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-24T16:36:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Swiss and German Pharma Majors Face Up to Increasing Debts in Crisis-Hit Southern Europe</title>
	<pubDate>2012-02-23T16:39:02+01:00</pubDate>
	<wp:post_id>3164</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As the German edition of the <I>Financial Times </I>reports, Merck KGaA has implemented a policy of immediate payment on delivery, while Roche is reported to be planning to introduce a system whereby they only deliver products to hospitals within a specified credit limit.<wbr> The countries concerned are Greece, Spain, and Italy, with the first two in the worst situation.<wbr> </div><div style="margin-bottom: 10px;">As the source reports, Merck KGaA had taken Greek government bonds with a nominal value of EUR56 million (USD74.<wbr>1 million) to pay off hospital debts, but when the company sold these bonds, they received substantially less than this.<wbr> In the mean time, it is reported that although the situation in Spain has not yet led to stops in supplies, Roche is considering this, reporting that in some cases, hospitals have not paid bills for three years.<wbr> This is why Roche plans the introduction of a credit limit system in Spain and Portugal.<wbr> Swiss newspaper <I>Tagesanzeiger </I>reports that Roche and fellow Swiss major Novartis have billions of euro of outstanding payments from hospitals in southern European countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The debt situation in Greece, Spain, and Italy is deteriorating, and in the case of Greece, although the focus remains on the bond payments, which resulted in considerable losses for pharmaceutical companies, the debt situation appears to be worsening again.<wbr> </div><div style="margin-bottom: 10px;">In Spain, total debts owed to pharmaceutical and medical device producers have been estimated at EUR12 billion, while in Italy, although there are significant regional variations, the situation is approaching that of Spain.<wbr> </div><div style="margin-bottom: 10px;">Although Greece is a smaller market and therefore less of a danger in terms of potential inability to pay, the prospect of this in Spain, and particularly Italy, is not one pharma companies would like to contemplate.<wbr> Therefore, they will be hoping the austerity measures and measures to kick-start the economies of these countries will have the desired effects.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9798">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-23T16:39:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-23T16:39:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Leads the Way with its Cell-Based Assay for Botox(R) and Vistabel(R)</title>
	<pubDate>2012-02-23T13:10:25+01:00</pubDate>
	<wp:post_id>3165</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has received positive opinions from Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) and the Irish Medicines Board (IMB) regarding its fully <EM>in vitro</EM>, cell-based assay.<wbr> The European Coalition to End Animal Experiments (ECEAE) along with the British Union for the Abolition of Vivisection (BUAV) have welcomed these new milestones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The positive opinion from AFSSAPS</STRONG> relates to Vistabel(R), and paves the way for approval in 29 countries in the EU.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><U>France</U> serves as the Reference Member State covering 29 countries in the EU (Austria, Belgium, Bulgaria, Czec Rep.<wbr>, Cyprus, Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Iceland, Italy, Latvia, Lithuania, Luwxemburg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the U.<wbr>K)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>The positive opinion from IMB</STRONG> relates to Botox(R) and covers 14 EU countries involved in the Mutual Recognition Procedure (MRP).<wbr> </div><div><UL><LI><U>Ireland</U> serves as the Reference Member State in the MRP; other countries involved are: Austria, Belgium, Denmark, Finland, Germany, Greece, Iceland, Italy, Luxemburg, Norway, Portugal, Spain and Sweden).<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6243">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-23T13:10:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-23T13:10:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon's Pipeline Progress With LX1032 & LX4211</title>
	<pubDate>2012-02-23T12:48:14+01:00</pubDate>
	<wp:post_id>3166</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside its Q4 figures, Lexicon provided some detailed comment on the status of its pipeline, highlighting how in the coming 12 months it has a number of very important results coming from each of its five key development programs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>LX1032 (Carcinoid Programme)</STRONG> </div><div style="margin-bottom: 10px;">Lexicon is looking towards the end of the third quarter or early fourth quarter for initiation of the Phase 3 program providing regulatory interactions are supportive.<wbr> It has a meeting with the FDA scheduled for last week of March/<wbr>1st week of April and a meeting with the EMA this month.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the potential design of the phIII carcinoid study Pablo Lapuerta stated:- </div><div style="margin-bottom: 10px;">"we do have a protocol synopsis, and that envisions four months of therapy, which is consistent with some of the discussions we've had before with regulatory agencies.<wbr> And the total sample size, we think that for an orphan drug indication like this that we can get meaningful safety and efficacy data with – on a ballpark of 100 patients.<wbr> It could be slightly more or slightly less, but that's the type of area that we will be discussing with the FDA.<wbr> We also feel that a reduction in bowel movement frequency is a clinically relevant measure and objective measure that's easy to interpret.<wbr> And so that's what we are considering for our Phase 3 program, and we feel there is a precedent for that as well.<wbr>" </div><div style="margin-bottom: 10px;">Management comments regarding the ulcerative colitis indication noted that the goal for 2012 is to establish some basic proof-of-concept data with an appropriate safety profile that would allow us to go further into development.<wbr> </div><div style="margin-bottom: 10px;">A study called PARSEC has been initiated, a Phase 2 study of the relationship between serotonin and efficacy in ulcerative colitis.<wbr> 60 patients with mild-to-moderate ulcerative colitis have been randomised to placebo or two different doses of telotristat etiprate and the treatment period will be eight weeks.<wbr> </div><div style="margin-bottom: 10px;">LX1032 will be given on  top of mesalamine (standard of care for patients with ulcerative colitis).<wbr> There will be several efficacy measures including the Mayo score, which is primarily a clinical assessment, colonoscopy, histology.<wbr> Results are expected Q12013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Takeda's Positive Results In Pivotal Ulcerative Colitis Trial</STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12pt"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Status of the Diabetes Programme</STRONG> </div><div style="margin-bottom: 10px;">Preparations are also underway for the phIII development of the diabetic drug LX4211, with the ambition to start this as of 1H2013 ideally with a partner on board.<wbr> Phase 2b results are expected at the end of Q2.<wbr> And so that is coming up here.<wbr> That's a study of approximately 300 patients with type 2 diabetes and we are on track to have those results.<wbr> </div><div>Source; <A href="http://www.lexicon.com">www.<wbr>lexicon.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6877">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-23T12:48:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-23T12:48:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Combining Ipilimumab and PROSTVAC® Might Result in Prolonged OS</title>
	<pubDate>2012-02-23T10:55:56+01:00</pubDate>
	<wp:post_id>3167</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The scientific findings of the Ph1 dose escalation study, published in the <EM>Lancet Oncology</EM>, provide proof of concept that the combination of an immune checkpoint inhibitor with a therapeutic cancer vaccine is feasible, and might enhance the clinical efficacy of the combination treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Although the Ph1 trial was small and non-randomized, the median overall survival (OS) of 34.<wbr>4 months for the 30 patients treated raises the possibility that the combination ipilimumab and PROSTVAC® might result in prolonged OS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In a randomized placebo-controlled Phase 2 study, PROSTVAC® demonstrated an 8.<wbr>5-month improvement in median overall survival, in men with mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7885" class="defaultlink">Oncology7885: PROSTVAC® Ph3 trial Opened at First Site in the U.<wbr>S.<wbr></a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8112">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-23T10:55:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-23T10:55:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Questcor Receives Child Neurology Award As Allergan's Scott Whitcup Joins Its Board</title>
	<pubDate>2012-02-23T10:46:22+01:00</pubDate>
	<wp:post_id>3168</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Dr.<wbr> Whitcup currently is executive vice president of research and development and chief scientific officer at Allergan Inc.<wbr> In that position, he is responsible for leading the company&rsquo;s global research and development organization, including medical affairs, drug discovery, medical device research, and global development programs.<wbr>  </div><div style="margin-bottom: 10px;"><P style="font-weight: normal; font-size: 13px; margin: 0px 0px 1.5em; color: #000000; line-height: 1.5em; font-family: Arial, Helvetica, sans-serif! important; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="font-weight: normal; font-size: 13px; margin: 0px 0px 1.5em; color: #000000; line-height: 1.5em; font-family: Arial, Helvetica, sans-serif! important; padding: 0px;"></P> </div><div><A href="http://ir.questcor.com/"></A><A href="http://ir.questcor.com/releasedetail.cfm?ReleaseID=650676"></A> </div><!-- Comment details --><a name="neurology6240attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6240_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(103,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6240_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(80,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6240_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6240">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-23T10:46:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-23T10:46:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Updated DKPHybrids Database</title>
	<pubDate>2012-02-23T10:38:46+01:00</pubDate>
	<wp:post_id>3169</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Following the launch of a Leuprolide hybrid in Italy, the February version of the DKPHybrids database has been upgraded, in the Sandoz view, with an objection handling section.<wbr> It includes an overview of the leuprorelin implants in the EU, arguments differentiating Decapeptyl, a deep analysis of the Ph3 and Ph4 studies of the Sandoz' implant, and a focus on a leave behind from Sandoz Nordics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>From slide 61 to 68</STRONG> : overview of the leuprorelin implants in EU countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>From slide 69 to 77</STRONG> : <SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>From slide 78 to 90</STRONG> :  </div><div><STRONG>From slide 91 to 95</STRONG> : <SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><a name="dkphybrids138attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_138_1_DKPHybrids%20Dababase%255fFeb2012.ppt">DKPHybrids Dababase_Feb2012.ppt</a>&nbsp;&nbsp;(16 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=138">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-23T10:38:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-23T10:38:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Results with BioGaia's Lactobacillus Reuteri Protectis for the Treatment of Diarrhea</title>
	<pubDate>2012-02-22T10:10:46+01:00</pubDate>
	<wp:post_id>3170</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Outcomes of the study showed that supplementation of <EM>Lactobacillus reuteri</EM> Protectis significantly reduced episodes of diarrhoea.<wbr> <EM>Lactobacillus reuteri</EM> Protectis was particularly effective in children with lower nutritional status.<wbr> The study will be published in <EM>Journal of Pediatrics</EM>.<wbr> Dr Rina Agustina will also present the results at the International Symposium of Probiotics and Prebiotics in Pediatrics (IS3P) on 24 February 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Design: six month long double-blind, placebo-controlled study </div><div style="margin-bottom: 10px;">Recruitment: 494 healthy children aged one to six years </div><div style="margin-bottom: 10px;">Regimen: low-lactose milk with or without Lactobacillus casei 431 or Lactobacillus reuteri DSM17938 </div><div style="margin-bottom: 10px;">Country: Indonesia </div><div style="margin-bottom: 10px;">Primary endpoint: number and duration of acute diarrhoeal episodes </div><div style="margin-bottom: 10px;">Secondary endpoints: number and duration of acute respiratory infections </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- incidence of all diarrhoea episodes was significantly reduced by 32% in the group supplemented by <EM>Lactobacillus reuteri</EM> Protectis compared to placebo.<wbr> </div><div>- in children with lower nutritional status (below median height and weight for the age group) Lactobacillus reuteri Protectis had significant effect on both WHO defined and all episodes of diarrhoea.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120431&edate=20120101&rec=1834">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-22T10:10:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-22T10:10:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merz' CEO to leave the company</title>
	<pubDate>2012-02-22T08:51:30+01:00</pubDate>
	<wp:post_id>3171</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">According to Julia Hofer (German BU Director Neurology), German media sources are reporting that one of the reasons for Zugel's departure was that one of the major  owners of the company Jochen Huckmann has not been satisifed with Xeomin's performance and lack of profitability.<wbr></span>&nbsp;<br></div><div style="margin-bottom: 10px;">Background: Dr.<wbr> Martin Z&uuml;gel, CEO of Merz Pharmaceuticals, has decided to quit his job mid 2012 as soon as a successor has been found.<wbr> </div><div><A href="http://www.merz.com/press/pressreleases/company_2/detail_640.jsp?source=pmov" target="_blank">http:/<wbr>/<wbr>www.<wbr>merz.<wbr>com/<wbr>press/<wbr>pressreleases/<wbr>company_2/<wbr>detail_640.<wbr>jsp?source=pmov</A> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9797">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld5143">View thread  PharmaWorld5143: Merz' CEO to leave the company</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-22T08:51:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-22T08:51:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ongoing Medicine Evaluations In Europe To Become More Transparent</title>
	<pubDate>2012-02-21T19:02:30+01:00</pubDate>
	<wp:post_id>3172</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In an important move towards greater transparency, the EMA will from the 1st March 2012 s<SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: 16px 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 12px; LINE-HEIGHT: 16px; FONT-FAMILY: Verdana, Tahoma, sans-serif; TEXT-ALIGN: left">tart to publish information on applications for centralised marketing authorisation for human medicines that it has received for evaluation.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: 16px 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 12px; LINE-HEIGHT: 16px; FONT-FAMILY: Verdana, Tahoma, sans-serif; TEXT-ALIGN: left">This development follows the publication of recommendations on transparency of ongoing evaluations adopted by the European Medicines Agency and the Heads of Medicines Agencies in November 2010.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><P style="BORDER-TOP-WIDTH: 0px; CLEAR: none; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 12px; FLOAT: none; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; VERTICAL-ALIGN: baseline; WIDTH: auto; PADDING-TOP: 0px; BACKGROUND-COLOR: transparent; BORDER-RIGHT-WIDTH: 0px; background-origin: initial; background-clip: initial">Currently, the Agency does not publish information on other types of medicines until it has issued an opinion at the end of the assessment procedure.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-TOP-WIDTH: 0px; CLEAR: none; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 12px; FLOAT: none; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; VERTICAL-ALIGN: baseline; WIDTH: auto; PADDING-TOP: 0px; BACKGROUND-COLOR: transparent; BORDER-RIGHT-WIDTH: 0px; background-origin: initial; background-clip: initial"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: 16px 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 12px; LINE-HEIGHT: 16px; FONT-FAMILY: Verdana, Tahoma, sans-serif; TEXT-ALIGN: left"><STRONG>What Will Be Published</STRONG></SPAN></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-TOP-WIDTH: 0px; CLEAR: none; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 12px; FLOAT: none; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; VERTICAL-ALIGN: baseline; WIDTH: auto; PADDING-TOP: 0px; BACKGROUND-COLOR: transparent; BORDER-RIGHT-WIDTH: 0px; background-origin: initial; background-clip: initial">The Agency will publish the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the CHMP, along with information on the type of salt, ester or derivative of the active substance.<wbr> For generic and biosimilar medicines, it will publish the INN and therapeutic area.<wbr> It will only publish this information for medicines whose applications have been validated.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-TOP-WIDTH: 0px; CLEAR: none; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 12px; FLOAT: none; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; VERTICAL-ALIGN: baseline; WIDTH: auto; PADDING-TOP: 0px; BACKGROUND-COLOR: transparent; BORDER-RIGHT-WIDTH: 0px; background-origin: initial; background-clip: initial"><STRONG>Frequency of Updates</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-TOP-WIDTH: 0px; CLEAR: none; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 12px; FLOAT: none; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; VERTICAL-ALIGN: baseline; WIDTH: auto; PADDING-TOP: 0px; BACKGROUND-COLOR: transparent; BORDER-RIGHT-WIDTH: 0px; background-origin: initial; background-clip: initial">Every month following the plenary meeting of the CHMP.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-TOP-WIDTH: 0px; CLEAR: none; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 12px; FLOAT: none; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; VERTICAL-ALIGN: baseline; WIDTH: auto; PADDING-TOP: 0px; BACKGROUND-COLOR: transparent; BORDER-RIGHT-WIDTH: 0px; background-origin: initial; background-clip: initial"><STRONG>Next Steps</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-TOP-WIDTH: 0px; CLEAR: none; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 12px; FLOAT: none; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; VERTICAL-ALIGN: baseline; WIDTH: auto; PADDING-TOP: 0px; BACKGROUND-COLOR: transparent; BORDER-RIGHT-WIDTH: 0px; background-origin: initial; background-clip: initial">This initiative also prepares for the publication of agendas and minutes of the meetings of the Agency’s committees in the second half of this year.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-TOP-WIDTH: 0px; CLEAR: none; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 12px; FLOAT: none; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; VERTICAL-ALIGN: baseline; WIDTH: auto; PADDING-TOP: 0px; BACKGROUND-COLOR: transparent; BORDER-RIGHT-WIDTH: 0px; background-origin: initial; background-clip: initial">Thanks to Ros Eijgenhuijsen for forwarding the information for inclusion in Traction.<wbr></P> </div><div>source: <A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001437.jsp&amp;mid=WC0b01ac058004d5c1&amp;jsenabled=true">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>news_and_events/<wbr>news/<wbr>2012/<wbr>02/<wbr>news_detail_001437.<wbr>jsp&amp;mid=WC0b01ac058004d5c1&amp;jsenabled=true</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9796">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-21T19:02:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-21T19:02:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merz' CEO to leave the company</title>
	<pubDate>2012-02-21T18:48:43+01:00</pubDate>
	<wp:post_id>3173</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Source: Merz</span>&nbsp;<br></div><div style="margin-bottom: 10px;">According to Julia Hofer (German BU Director Neurology), German media sources are reporting that one of the reasons for Zugel's departure was that one of the major  owners of the company Jochen Huckmann has not been satisifed with Xeomin's performance and lack of profitability.<wbr> <a name="PharmaWorld9797c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Background: Dr.<wbr> Martin Z&uuml;gel, CEO of Merz Pharmaceuticals, has decided to quit his job mid 2012 as soon as a successor has been found.<wbr> </div><div><A href="http://www.merz.com/press/pressreleases/company_2/detail_640.jsp?source=pmov" target="_blank">http:/<wbr>/<wbr>www.<wbr>merz.<wbr>com/<wbr>press/<wbr>pressreleases/<wbr>company_2/<wbr>detail_640.<wbr>jsp?source=pmov</A> </div></div></div><div>According to the Manager Magazine "this decision comes at a very difficult point in time for the company, which currently needs to decide if it still sees a potential for future growth in pharma research as it is confronted with the expiry of memantine's patent in 2014.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9795">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld5143">View thread  PharmaWorld5143: Merz' CEO to leave the company</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-21T18:48:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-21T18:48:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>E. Kremer Has Joined Astellas' New Global Medical Affairs Organization</title>
	<pubDate>2012-02-21T16:58:54+01:00</pubDate>
	<wp:post_id>3174</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Charlotte M.<wbr> E.<wbr> Kremer, MD, MBA will provide global leadership for medical excellence and a unified medical perspective across regions for the company's portfolio of products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dr Kremer's Bio</STRONG> </div><div>Most recently, Dr.<wbr> Kremer held the position of Vice President, Therapeutic Area Head for Ophthalmology, PVD, Rare Diseases and Neuroscience at Pfizer.<wbr>  While at Pfizer, she successfully led and executed the clinical development and global medical strategy in these respective areas.<wbr>  Prior to joining Pfizer, Dr.<wbr> Kremer held positions of increasing responsibility providing medical support, developing Phase IIIB/<wbr>IV clinical trials, and initiating and directing a Medical Liaison program at Organon Pharmaceuticals, both in the Netherlands and in the United States </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9794">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-21T16:58:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-21T16:58:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>1st Indication of Pasireotide Results In Acromegaly & NET</title>
	<pubDate>2012-02-21T16:55:54+01:00</pubDate>
	<wp:post_id>3175</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Intelligence from two sources, CI department sponsored external primary intelligence gathering and a neuroendocrinology training course organised by the Mexican Endocrinology Society have confirmed that pasireotide performed better than octreotide LAR in Novartis's first phIII study undertaken in acromegaly patients CSOM230C2305, EudraCT number: 2007-001972-36.<wbr> NET data, by contrast, may not be as encouraging according to independent sources.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>PhIII Acromegaly Data</U></STRONG> </div><div style="margin-bottom: 10px;">Thanks to Harold Dumont (IC Product Manager for Somatuline) and information forwarded by Sarah Gerbaud in Mexico we have learnt that Professor Ashley Grossman presented some very preliminary data in Mexico showing to what extent pasireotide met its primary endpoint in the phIII trial.<wbr> </div><div style="margin-bottom: 10px;">The studies undertaken in 358 treatment naive patients evaluated response rate at 12 months both in terms of GH &lt;2.<wbr>5 ug/<wbr>l and normalisation of IGF-1.<wbr> </div><div style="margin-bottom: 10px;">The sample size for the trial was calculated to detect an increase in response rate of 15% from an expected 20% in the octreotide LAR group to 35% in the pasireotide LAR group based on the outcome of Novartis's historical phIII octreotide LAR studies CSMS995B2401 and B2402.<wbr> </div><div style="margin-bottom: 10px;">Professor Grossman's slide noted that "The first interpretable results indicate that the primary endpoint was met".<wbr> </div><div style="margin-bottom: 10px;">Primary intelligence gathering conducted by the CI Dept has established that Novartis is moving forward quickly now with pasireotide based on the Cushing's approval in Europe and the outcome of the acromegaly study, with data on the 2305 study expected to be presented at ENDO in Houston in June.<wbr> There may also be some biochemical control data presented at the ECE in May.<wbr> One US investigator described the data as "quite exciting".<wbr> There has been no mention so far as to the safety profile of the drug in acromegalics.<wbr> </div><div style="margin-bottom: 10px;">Apparently data is also available from the crossover study CSOM230C2402, EUDRACT 2009-016722-13, recruitment seemingly having been quicker in the non-responder than the naive patient population.<wbr> </div><div style="margin-bottom: 10px;">Submission for the acromegaly approval was initially planned for May but with data analysis still ongoing, intelligence suggests that the end of the year is more likely.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What about NET?</STRONG> </div><div>Whilst acromegaly may be moving forward, messages about the NET data set are a far more mixed, with the US study reportedly "kind of stuck" at the moment.<wbr> Some European data is expected soon according to one investigator and whilst showing good subjective responses in terms of flushing and diarrhoea effects on biomarkers and tumour growth are not significant.<wbr> Moroever, the side-effect profile vs octreotide LAR is significantly worse.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6875">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-21T16:55:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-21T16:55:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Has Placed a Clinical Hold on GTx' Capesaris for Advanced Prostate Cancer</title>
	<pubDate>2012-02-21T13:08:33+01:00</pubDate>
	<wp:post_id>3176</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The clinical hold follows the Company's reports to the FDA of an increased risk of venous thromboembolic events in subjects treated with Capesaris at the doses studied (1000 mg and higher).<wbr> The clinical hold affects the PhII loading dose finding clinical trial and its PhIIb maintenance dose finding clinical trial, as well as its PhII clinical trial in men with CRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">GTx believes there may be a path forward to develop Capesaris at lower doses to treat men with metastatic hormone sensitive prostate cancer or castration resistant prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">The Company will work with the FDA to determine the appropriate course of action to evaluate Capesaris in these patient populations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7929" class="defaultlink">Oncology7929: Data In Q112 Should Determine Whether GTx Has A Viable New 1st or 2nd Line Prostate Cancer Drug</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8109">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-21T13:08:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-21T13:08:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: J&J's Zytiga (abiraterone) Too Expensive for National Health Service (NHS)</title>
	<pubDate>2012-02-21T11:34:42+01:00</pubDate>
	<wp:post_id>3177</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">J&J's Zytiga (abiraterone) Too Expensive for National Health Service (NHS)</span>&nbsp;<br><span style="font-size: 12px;">Comment: <SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8065">...</a><br></div><div style="margin-bottom: 10px;">The All Wales Medicines Strategy Group has approved Zytiga (abiraterone acetate) for men with advanced castration resistant prostate cancer - s<SPAN style="letter-spacing: 0px;">pecifically, Zytiga is indicated for use alongside with prednisone or prednisolone in adult men whose disease has progressed after a docetaxel-based chemotherapy regimen.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="letter-spacing: 0px;">The AWMSG were able to approve abiraterone after assessing it as an end of life drug, meaning it will now be available on the NHS in Wales until NICE release their final guidance, which will override the AWMSG decision if abiraterone is rejected.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="letter-spacing: 0px;"><A href="http://www.wales.nhs.uk/sites3/Documents/371/Abiraterone%20%28Zytiga%29%20FAR.pdf">http:/<wbr>/<wbr>www.<wbr>wales.<wbr>nhs.<wbr>uk/<wbr>sites3/<wbr>Documents/<wbr>371/<wbr>Abiraterone%20%28Zytiga%29%20FAR.<wbr>pdf</A><BR></SPAN> </div><div><SPAN style="letter-spacing: 0px;">Source Pharmatimes 20 February 2012/<wbr>AWMSG</SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8108">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8065">View thread  Oncology8065: J&J's Zytiga (abiraterone) Too Expensive for National Health Service (NHS)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-21T11:34:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-21T11:34:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Asia Key Country for Allergan</title>
	<pubDate>2012-02-21T11:13:56+01:00</pubDate>
	<wp:post_id>3178</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Asia Key Country for Allergan</span>&nbsp;<br><span style="font-size: 12px;">Comment: In an interview with Reuters, Management has reported that Allergan will rely less on the U.<wbr>S for revenues in coming year, as its products gain wider acceptance in Asia, with China to be the main driver.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6217">...</a><br></div><div style="margin-bottom: 10px;">A<SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">llergan has currently authorised 180 Chinese hospitals nationwide to use Botox, including the major facilities of Shanghai Huamei Aesthetic in Shanghai and the Zhuhai Luda Plastic Surgery Hospital in Guangdong province.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">Ian Bell said that Allergan has d<SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">eliberately focused on physician training, working in partnership with select hospitals in key cities in China, instead of making it available everywhere in China.<wbr></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">He added that a local production plant in China is not planned because Allergan's existing facilities can meet global demand.<wbr></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN> </div><div><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">Source: Scrip 20 February 2012</SPAN></SPAN></SPAN></SPAN></SPAN></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6239">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6217">View thread  Neurology6217: Asia Key Country for Allergan</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-21T11:13:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-21T11:13:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer & Hisun Form Chinese Joint Venture</title>
	<pubDate>2012-02-20T13:08:24+01:00</pubDate>
	<wp:post_id>3179</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"> </P> </div><div><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9791">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-20T13:08:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-20T13:08:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Corcept's Korlym™ Gains FDA Approval For Cushing's</title>
	<pubDate>2012-02-20T11:02:36+01:00</pubDate>
	<wp:post_id>3180</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA on Friday Approved Corcept's Korlym&trade; (mifepristone) 300 mg tablets as a once-daily oral medicine to control hyperglycemia secondary to hypercortisolism in adult patients with Cushing&rsquo;s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.<wbr> Corcept is continuing to look for a European partner.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Approval was granted on the PDUFA date for the first and only approved medication for Cushing's syndrome in the US.<wbr> </STRONG><STRONG>This is an important milestone for the company and an achievement given Novartis's pasireotide has yet to be approved.<wbr> A resubmission for its approval will we understand be made within the coming weeks.<wbr></STRONG> </div><div style="margin-bottom: 10px;">Korlym will be launched commercially in the US by May 1 through what the company describes as "a distribution system designed to support both patients and prescribers.<wbr>" </div><div style="margin-bottom: 10px;">Corcept does not envisage that it will require a large sales force to reach out to the small number of endocrinologists who treat Cushing's patients The company has begun hiring Medical Science Liaisons to inform practitioners about the drug, which will be dispensed by the leading specialty pharmacy company CuraScript SP, a subsidiary of Express Scripts.<wbr> </div><div style="margin-bottom: 10px;">Korlym clinical trial investigator Amir Hamrahian, M.<wbr>D.<wbr>, Department of Endocrinology, Diabetes and Metabolism at the Cleveland Clinic said, &ldquo;There are not many effective treatment options for patients with Cushing&rsquo;s syndrome.<wbr> Although surgery is standard first line treatment for the disease, it is not always successful and not all patients are candidates.<wbr> As part of the clinical trial, I have used Korlym successfully and my patients continue to do well on the medicine.<wbr> I&rsquo;m excited to be able to continue using Korlym in these patients and others who need it.<wbr> This medicine&rsquo;s approval gives me a much needed tool to better treat patients.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><STRONG>Clinical Trial Results Supporting FDA Approval </STRONG> </div><div style="margin-bottom: 10px;">The clinical data supporting the FDA approval of Korlym resulted from an uncontrolled, open-label, multi-center, 24-week phase III study of 50 patients who had endogenous Cushing's syndrome and were either not eligible for or had relapsed from surgery and were either glucose intolerant (29 patients) or had hypertension (21 patients).<wbr> Within the glucose intolerant group, 60 percent of patients had a greater than 25 percent reduction from baseline in the area under the curve in the oral glucose tolerance test.<wbr> In this group, mean hemoglobin A1C (HbA1C) was reduced from 7.<wbr>4 percent to 6.<wbr>3 percent.<wbr> All 14 patients with above-normal HbA1C levels at baseline experienced reductions.<wbr> Eight of these 14 normalized their HbA1C.<wbr> Antidiabetic medications were reduced in seven of the 15 patients with diabetes mellitus type 2 and remained constant in the others.<wbr> </div><div style="margin-bottom: 10px;">Patients who responded to therapy were allowed enrollment in an extension trial.<wbr> Eighty-eight percent of the patients who completed the trial chose to do so.<wbr> </div><div style="margin-bottom: 10px;">A peer-reviewed analysis of the study results will soon be published in a leading journal.<wbr> </div><div style="margin-bottom: 10px;">The table below illlustrates how Corcept compares with pasireotide in terms of efficacy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6871_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The FDA has designated Korlym as an Orphan Drug for treatment of the clinical manifestations of endogenous Cushing&rsquo;s syndrome as a results Corcept will have marketing exclusivity consistent with the FDA&rsquo;s designation until February 2019.<wbr> </div><div style="margin-bottom: 10px;">As noted in its Q3 results Corcept is looking for a partner to commercialise the product in Europe (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6756" class="defaultlink">Endocrinology6756: Corcept PDUFA For Cushing's Disease Set For February 2012</a>) where the drug also has orphan drug status.<wbr> </div><div>Source: <A href="http://www.corcept.com">www.<wbr>corcept.<wbr>com</A> </div><!-- Comment details --><a name="endocrinology6871attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6871_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(209 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6871">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-20T11:02:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-20T11:02:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New US Draft Guidance on Biosimilar Product Development</title>
	<pubDate>2012-02-17T16:22:57+01:00</pubDate>
	<wp:post_id>3181</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;">Comment: The FDA has finally issued three draft guidance documents on biosimilar product development.<wbr> These documents provide FDA&rsquo;s current thinking on approaches to demonstrate that a proposed biological product is biosimilar to an FDA-approved biological product (the &ldquo;reference product&rdquo;) using the abbreviated pathway under section 351(k) of the Public Health Service Act (PHS Act).<wbr></P> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;"><STRONG>Thanks to GRA (Katie Ruffle &amp; Steve Scott) we have the summary below which provides a synopsis of the guidance issued</STRONG>.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;">Access to the relevant sections of the guidance can be obtained via the source link at the bottom of the article.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;">The abbreviated pathway was established by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), enacted on March 23, 2010, as part of the Patient Protection and Affordable Care Act.<wbr> FDA is accepting public comment on these draft guidance documents.<wbr> Instructions on how to submit comments will be announced in an upcoming Federal Register notice.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;"><STRONG>Guidance: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;">This draft guidance is intended to assist sponsors in demonstrating that a proposed therapeutic protein product is biosimilar to a reference product for the purpose of submitting an application under 351(k) of the PHS Act (a 351(k) application) to the FDA.<wbr></P> </div><div style="margin-bottom: 10px;"><UL style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_orangebullet.gif'); margin: 0px 0px 0px 15px; height: auto; text-align: left; border-style: none; padding: 0px;"><LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">Focuses on therapeutic protein products.<wbr> FDA will consider multiple factors as part of the biosimilarity assessment, including, but not limited to, the product&rsquo;s complexity, formulation, and stability; as well as usefulness of biochemical and functional characterizations.<wbr>
<UL style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_orangebullet.gif'); margin: 0px 0px 0px 15px; height: auto; text-align: left; border-style: none; padding: 0px;"><LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">The incorporation of these factors is risk-based and is affected by knowledge regarding various product characteristics including, for example, the mechanism of action, the product structure-function relationships, the clinical experience with the reference product, and the manufacturing process.<wbr>
</LI>
</UL>

</LI>
<LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">Describes the totality-of-the-evidence approach that FDA intends to use for review of biosimilar applications.<wbr>
<UL style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_orangebullet.gif'); margin: 0px 0px 0px 15px; height: auto; text-align: left; border-style: none; padding: 0px;"><LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">FDA intends to use a risk-based totality-of-the-evidence approach to evaluate all available data and information submitted in support of the biosimilarity of the proposed product.<wbr> The type and amount of analyses and testing that will be sufficient to demonstrate biosimilarity will be determined on a product-specific basis.<wbr>
</LI>
<LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">FDA recommends sponsors use a stepwise approach in developing evidence to support a demonstration of biosimilarity, ensuring that development at each step evaluate the extent to which there is residual uncertainty regarding a demonstration of biosimilarity between the proposed and reference product, and identify next steps to address that uncertainty.<wbr>
</LI>
<LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">FDA will be able to provide meaningful advice on the scope and extent of necessary animal and human testing after a thorough review of data from structural and functional analyses.<wbr> Additional animal and clinical studies should be tailored to address residual uncertainty regarding the biosimilarity between the two products to ensure such testing is appropriately targeted.<wbr>
</LI>
</UL>

</LI>
<LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">Recommends early consultation with the FDA.<wbr> FDA anticipates that early discussions with FDA about product development plans will facilitate biosimilar development.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;"><STRONG>Guidance: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;">This draft guidance provides an overview of analytical factors that may be relevant to assessing whether a proposed therapeutic protein product and a reference product are highly similar, as required for a determination of biosimilarity under the BPCI Act.<wbr></P> </div><div style="margin-bottom: 10px;"><UL style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_orangebullet.gif'); margin: 0px 0px 0px 15px; height: auto; text-align: left; border-style: none; padding: 0px;"><LI>
<UL style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_orangebullet.gif'); margin: 0px 0px 0px 15px; height: auto; text-align: left; border-style: none; padding: 0px;"><LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">Discusses general scientific principles, including the importance of extensive analytical, physicochemical and biological characterization.<wbr> Recommends that the type, nature, and extent of any differences between the proposed biosimilar product and the reference product, and the potential effect of any differences on the safety, purity, and potency of the proposed product should be clearly described and discussed by the sponsor in the 351(k) application.<wbr>
</LI>
<LI style="background-image: none; list-style-image: url('http://www.fda.gov/ucm/groups/fdagov-public/@system/documents/system/img_fdagov_bullet.png'); margin: 0px; height: auto; text-align: left; border-style: none; padding: 0px;">Recognizes that advances in analytical sciences and manufacturing technology, including integration of Quality by Design approaches, may facilitate a &ldquo;fingerprint&rdquo;-like analysis of therapeutic protein products, and thus may provide appropriate bases for a more selective and targeted approach to subsequent animal and/<wbr>or clinical studies to support a demonstration of biosimilarity.<wbr>
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;"><STRONG>Guidance: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="background-image: none; margin: 1% 0px; height: auto; text-align: left; border-style: none; padding: 0px;">This draft guidance provides answers to common questions from sponsors interested in developing proposed biosimilar products, biologics license application (BLA) holders, and other interested parties regarding FDA&rsquo;s interpretation of the BPCI Act.<wbr> The question and answer format is intended to promote transparency and facilitate development programs for proposed biosimilar products by addressing questions that may arise in the early stages of development.<wbr> The draft guidance will be posted on FDA&rsquo;s Web site and will be updated to include additional Q&amp;As as appropriate.<wbr></P> </div><div><A href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm">http:/<wbr>/<wbr>www.<wbr>fda.<wbr>gov/<wbr>Drugs/<wbr>DevelopmentApprovalProcess/<wbr>HowDrugsareDevelopedandApproved/<wbr>ApprovalApplications/<wbr>TherapeuticBiologicApplications/<wbr>Biosimilars/<wbr>default.<wbr>htm</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9787">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-17T16:22:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-17T16:22:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amylin's Comments on Bydureon Uptake At Leerink & Swann H/C Conference</title>
	<pubDate>2012-02-17T15:41:18+01:00</pubDate>
	<wp:post_id>3182</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Initial uptake of the weekly GLP-1 analogue Bydureon has been strong with data from Germany indicating that half of the patients are new to GLP-1 analogues.<wbr> Lilly is currently still marketing the product in Europe whilst Amylin looks for a new partner.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on this development Mark G.<wbr> Foletta Chief Financial Officer &amp; Senior Vice President, Amylin Pharmaceuticals, Inc.<wbr> noted</STRONG> </div><div style="margin-bottom: 10px;">"It's very early in any of the launches of BYDUREON to draw any conclusions.<wbr> But I think the metric that we really are going to continue to focus on is where are the patients coming from? We know that our competitor actually focuses on that as well and what we've seen is we think over half of the patients that are starting BYDUREON therapy in Germany are coming from a GLP-1 naive market.<wbr> That's our goal, that's our strategy with a weekly therapy to be able to continue to grow this market.<wbr>" </div><div style="margin-bottom: 10px;">"In our year-end call that showed the rate of growth as we were exiting 2011 being very rapid with the success of BYETTA and Victoza globally.<wbr> And we believe this market continued to have legs and it's a good sign that in -- albeit a very fast reimbursement market, Germany that that's what we're seeing is actually there is market growth.<wbr> </div><div style="margin-bottom: 10px;">When questioned on what marketing messages are being successful Mark Folleta noted:- </div><div style="margin-bottom: 10px;">"What we believe is working there and that we think will work in most markets is essentially our message with BYDUREON is it's continuous glucose control with one weekly dose.<wbr> And we've actually tried to help folks imagine what this is like, this is the first therapy for type 2 diabetes that is not a daily therapy, whether oral or injectable and so you can imagine sitting whatever day you choose, market research says many will choose Sundays and that they will in the privacy of their home can take this injection and then they know that their diabetes through the technology of the microspheres in BYDUREON will be -- their glucose will be controlled throughout the week.<wbr> That message resonates with physicians and that's a message that we're certainly going to carry into the U.<wbr>S.<wbr> market as well.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Regarding the development status of the suspension programme</STRONG> </div><div>This refers to either a weekly or a monthly exenatide formulation that wouldn't require reconstitution.<wbr> Amylin indicated that it has had an end of phase 2 discussions with the FDA and that it expects phase 3 trials for the weekly form to start in the middle of the year and for the monthly form the target is 2013.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6868">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-17T15:41:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-17T15:41:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J's Key Comments On Zytiga At The Leerink & Swann H/C Conference</title>
	<pubDate>2012-02-17T13:06:56+01:00</pubDate>
	<wp:post_id>3183</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Key data from the Zytiga chemonaive CRPC trial is expected this year with a filing for approval expected before the year end.<wbr> Comments on European growth and J&amp;J's reaction to the MDV3100 data were also aired.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on developments in Europe and the importance of Zytiga</STRONG> </div><div style="margin-bottom: 10px;">Sherilyn S.<wbr> McCoy Vice Chairman, Johnson &amp; Johnson stated </div><div style="margin-bottom: 10px;">"We continue to watch Europe very closely.<wbr> One of the things that we're seeing specifically in the Pharmaceutical group, while there are some challenges relative to the economic environment, we are seeing products like Incivo, Zytiga doing extremely well because they are truly differentiated.<wbr> And so I think the message for us is continue to look at how we make a difference in healthcare and bring new differentiated medicines, and that's a way to manage it.<wbr>" </div><div style="margin-bottom: 10px;">"Certainly I think there's going to continue to be pressure on environment and it's critically important that we show outcomes data, and show that we are in fact making a difference in public health if we want to get reimbursement support.<wbr> So I think that we've looked at from the standpoint of it is challenging, but we need to be focus on innovation and differentiation.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Focusing specifically on prostate cancer and Zytiga and when questioned about the chemotherapy naive study Sherilyn McCoy noted:- </STRONG> </div><div style="margin-bottom: 10px;">"So the pre-chemo data, what – it's dependent on events and we're waiting for overall survival.<wbr> So it's likely sometime later this year is what we estimate, but again it's dependent on events.<wbr>" </div><div style="margin-bottom: 10px;">When further pressed about the filing date, she confirmed that filing would take place post the results and hopefully this year.<wbr> </div><div style="margin-bottom: 10px;">When asked about the impact MDV3100 might have on Zytiga uptake McCoy commented:- </div><div>"Well, certainly Medivation has a study, it's very difficult to compare because the patient population is different.<wbr> It's not clear to us whether – all the usage components, so whether they're using prednisone or not, because they weren't clear on that, so we can't compare head to head.<wbr> We feel very good about Zytiga.<wbr> We have terrific data from patients and from physicians.<wbr> There's a comfort level with people using the product, very high market share, in post castrate resistant cancer amongst metastatic treatments.<wbr> So very, very high share and we feel very good about it.<wbr> Certainly we need to wait and see what the actual data says and understand a little bit more about their data information".<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8107">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-17T13:06:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-17T13:06:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Deutsche Bank Survey Evaluates Potential Impact of Merz' Xeomin in the U.S</title>
	<pubDate>2012-02-17T08:57:54+01:00</pubDate>
	<wp:post_id>3184</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The high-volume physicians surveyed (12 dermatologists and 13 plastic surgeons) have indicated that prior to Xeomin’s introduction, on average, Botox accounted for approx.<wbr> 74% of their procedures and Dysport for approx.<wbr> 26%.<wbr> After the initial major discounting period ends, the group, on average, indicated that they plan to use Botox in approx 64% of patients, Dysport in 22%, and Xeomin in 14%.<wbr> Key messages are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to learn how they viewed Xeomin relative to Botox and Dysport.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">12 dermatologists and 13 plastic surgeons with high-volume cosmetic neurotoxin practices and experience with Xeomin were surveyed.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Many doctors indicated that they liked the fact that Xeomin did not need to be refrigerated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Price, a key factor</STRONG> </div><div style="margin-bottom: 10px;">Two-thirds of the respondents said price was a major factor in their decision to use Xeomin.<wbr> </div><div style="margin-bottom: 10px;">Approx.<wbr> half indicated that the price was significantly lower relative to Botox and Dysport.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">With respect to efficacy and side effects, Xeomin is comparable to both Botox and Dysport.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_9_ScreenCapture9.jpg"> </div><div>Full report is attached </div><!-- Comment details --><a name="neurology6236attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(18,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(35,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(30,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(34,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(41,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(40,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(32,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(24,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(20 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6236_10_Deutsche%20Bank%255fPhysician%20Survey%255fFeb2012.pdf">Deutsche Bank_Physician Survey_Feb2012.pdf</a>&nbsp;&nbsp;(375,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6236">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-17T08:57:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-17T08:57:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Kissei Has Initiated a Second Ph2 Study with its In-House GnRH antagonist for Endometriosis</title>
	<pubDate>2012-02-16T17:13:43+01:00</pubDate>
	<wp:post_id>3185</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The multicenter, randomized, placebo-controlled, double-blind Ph2 trial is currently recruiting participants in Japan.<wbr> Primary outcome measure will assess the severity score of the pelvic pain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01533532?fund=2&amp;rcv_s=02%2F02%2F2012&amp;rank=43"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><UL><LI>Recruitment: Approx 100 women &gt;20 years old</LI>
<LI>Arms: low; medium and high dose</LI>
</UL> </div><div style="margin-bottom: 10px;">
The first Ph2 was initiated in July 2011 in approx 20 participants to assess low and high dose of KLH-2109 </div><div>(see <A href="http://clinicaltrials.gov/ct2/show/NCT01395940?term=KLH-2109&amp;rank=2">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01395940?term=KLH-2109&amp;rank=2</A>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8104">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-16T17:13:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-16T17:13:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis to Increase Investments in Taiwan</title>
	<pubDate>2012-02-16T14:10:14+01:00</pubDate>
	<wp:post_id>3186</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The <EM>Taiwan Economic News</EM> today reported that Novartis will invest &gt;NT$150M in Taiwan in 2012, with the objective of making the country its 10th clinical test center in the world.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Chang Chen-wu, President of the Novartis' Asian operation, outlined that the majority of the clinical tests will be conducted at National Taiwan University Hospital and 4 other domestic mmedical centres.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Novartis will undertake approx.<wbr> 100 clinical tests in Taiwan in 2012 (Vs.<wbr> 70 in 2011).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Most of the clinical tests in Taiwan are related to cancer drugs, with others including medicines in the fields of hematology, metabolism, and cardiology.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8101">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-16T14:10:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-16T14:10:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>DKPHybrids Competitors</title>
	<pubDate>2012-02-16T10:02:21+01:00</pubDate>
	<wp:post_id>3187</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Following is a list of key pharmaceutical companies that we are monitoring in Ipsen's DKPHybrid area, and links to CI material on each of them.<wbr> </div><div style="margin-bottom: 10px;">These links provide a lookup to DKPHybrid articles which have the specified competitor's label assigned to them.<wbr> </div><div><TABLE align="left" border="1" cellpadding="3" cellspacing="0" class="normaltable" frame="void" style="background-color: #f5f5f5; border-width: 1px; border-color: #ffffff; border-style: solid;"><TBODY><TR><TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aAcino&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aAcino%20All%20%27Acino%27&title=Acino" class="defaultlink">Acino</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aCamurus&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aCamurus%20all%20%27Camurus%27&title=Camurus" class="defaultlink">Camurus</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aCipla&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aCipla%20all%20%27Cipla%27&title=Cipla" class="defaultlink">Cipla</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle"><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aDaewong&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aDaewong%20all%20%27Daewong%27&title=Daewong" class="defaultlink">Daewong</a></STRONG></SPAN></TD>
</TR>
<TR><TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aDongKook&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aDongKook%20all%20%27Dongkook%27&title=Dongkook" class="defaultlink">Dongkook</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aGPPharm&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aGPPharm%20all%20%27GP%20Pharm%27&title=GP%20Pharm" class="defaultlink">GP Pharm</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aOakwood&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aOakwood%20all%20%27Oakwood%27&title=Oakwood" class="defaultlink">Oakwood</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P></P>
</TD>
</TR>
<TR><TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aSandoz&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aSandoz%20all%20%27Sandoz%27&title=Sandoz" class="defaultlink">Sandoz</a></STRONG></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120431&edate=All&cat=%3aDKPHybrids%3acomp%3aSunPharma&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aSunPharma%20all%20%27Sun%20Pharma%27&title=Sun%20Pharma" class="defaultlink">Sun Pharma</a></STRONG></SPAN></P>
</TD>
<TD align="left" colspan="2" scope="row" style="height: 50px; border-width: 1px; border-color: #ffffff; border-style: solid;" valign="middle">
<P><STRONG>Click here to access the <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20120431&edate=20120101&rs=/link%20DKPHybrids85%401" class="defaultlink">DKPHybrids Database</a></STRONG></P>
<P><STRONG>For more competitors use the search engine</STRONG></P>
</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=113">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-16T10:02:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-16T10:02:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NICE Needs Additional Evidence for the Use of Botox(R) for Chronic Migraine</title>
	<pubDate>2012-02-16T09:36:33+01:00</pubDate>
	<wp:post_id>3188</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: UK was the first country to approve Botox(R) in Q3 2010 for the prevention/<wbr><WBR>prophylaxis of headaches in adults who have chronic migraines.<wbr> NICE wants Allergan to provide better data before making a final guidance for the NHS in June.<wbr> This issue might be discussed by Management during its R&amp;D Technology review on March 28th.<wbr></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Discussion of the results &gt; see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=4935" class="defaultlink">Neurology4935: Allergan Presents Migraine Data at the AAN Meeting</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">NICE has estimated the cost would be £349.<wbr>40 for every 12-week cycle of treatment.<wbr> </div><div>Source: Nice PR <A href="http://www.nice.org.uk/newsroom/pressreleases/BotulinumToxinTypeAChronicMigraineACD.jsp">http:/<wbr>/<wbr>www.<wbr>nice.<wbr>org.<wbr>uk/<wbr>newsroom/<wbr>pressreleases/<wbr>BotulinumToxinTypeAChronicMigraineACD.<wbr>jsp</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6234">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-16T09:36:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-16T09:36:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>China : AZ Invests on a US$200Mn Manufacturing Center in JiangXu</title>
	<pubDate>2012-02-15T11:07:20+01:00</pubDate>
	<wp:post_id>3189</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : The British drug maker AZ has begun construction on a US$200 million manufacturing center in the eastern city of Taizhou (JiangXu).<wbr> </div><div style="margin-bottom: 10px;">The center, which is the largest investment that the company has made in a single facility worldwide, is expected to generate annual sales revenues of US$950 million after the facility opens in 2013.<wbr> </div><div style="margin-bottom: 10px;">Astra-Zeneca's substantial investment indicates that the company anticipates an increased demand for medical products in Jiangsu.<wbr> </div><div style="margin-bottom: 10px;">Since first establishing a presence in China in 1993, AstraZeneca has fast become one of the leading biopharmaceutical companies in the country, with a turnover of more than $1 billion in 2010.<wbr> The new manufacturing facility reinforces AZ's long term commitment to the country and its contribution to the Chinese economy.<wbr> </div><div style="margin-bottom: 10px;">AZ's direct investments in local capabilities to help deliver innovative medicines to Chinese patients and healthcare services to physicians include: </div><div style="margin-bottom: 10px;"><UL><LI>A state-of-the-art manufacturing and supply site in Wuxi New District, Jiangsu Province;
</LI>
<LI>The AstraZeneca Innovation Centre China (ICC) &mdash; a leading-edge translational science centre targeting, among others, biomarker research into cancer therapies specifically relevant for Chinese and Asian patients.<wbr> The ICC is one of AstraZeneca&rsquo;s most advanced scientific research hubs outside the UK, Sweden and US;
</LI>
<LI>An established sales and marketing operation; 
</LI>
<LI>Large scale clinical development capabilities and,
</LI>
<LI>An extensive network of collaborations with leading academic and medical institutions.<wbr>
</LI>
</UL> </div><div>Source : Frontier Strategy Group (Jan 2012) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8099">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-15T11:07:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-15T11:07:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Promising New Approach To The Treatment Of Huntington's Disease</title>
	<pubDate>2012-02-15T09:39:58+01:00</pubDate>
	<wp:post_id>3190</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medical researchers at the University of Alberta have discovered a promising new treatment approach for Huntington's disease that restores lost motor skills and may delay or stop the progression of the disease.<wbr> </div><div style="margin-bottom: 10px;">The new approach utilises a molecule already being used in clinical trials for other diseases and therefore it could move quickly into clinical development for Huntingotn's disease.<wbr> </div><div style="margin-bottom: 10px;">The experimental research undertaken by Simonetta Sipone produce dramatic changes with treatment leading to a complete restoration of motor skills </div><div style="margin-bottom: 10px;">Patients with HD appear to have slightly lower levels of a brain molecule known as GM1.<wbr> When U of A medical researchers restored GM1 to normal levels in lab models with the disease, motor skills in the lab models returned to normal within days </div><div style="margin-bottom: 10px;">Sipione, team's research has been published in this weeks Proc<I>eedings of the National Academy of Sciences</I>.<wbr> </div><div style="margin-bottom: 10px;">During the research stage, lab models at the U of A were given the GM1 molecule therapy for four weeks.<wbr> During the first two weeks after the treatment finished, the lab models still had normal motor function.<wbr> But after that, motor function started to decline and return to pre-treatment levels by the end of the fourth week.<wbr> So a potential treatment with this molecule would involve repeated treatments over the long-term, says Sipione.<wbr> </div><div>Source: Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice <CITE><ABBR class="site-title" title="Proceedings of the National Academy of Sciences">PNAS</ABBR> 2012 ; published ahead of print February 13, 2012, doi:10.<wbr>1073/<wbr>pnas.<wbr>1114502109 </CITE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6233">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-15T09:39:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-15T09:39:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Marina Biotech Closes Research Facility</title>
	<pubDate>2012-02-15T09:21:07+01:00</pubDate>
	<wp:post_id>3191</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Marina Biotech, Inc.<wbr> formerly known as MDRNA Inc, a leading nucleic acid-based drug discovery and development company has announced the closure of its Cambridge site and the consolidation of all R&amp;D efforts at its headquarters in Bothell, WA.<wbr> Meanwhile, dosing has been initiated in Cohort 2 of the START-FAP trial with CEQ508 (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis).<wbr> </div><div style="margin-bottom: 10px;">This consolidation will not impact the development of the tkRNAi platform which will continue in the labs in Bothell.<wbr> </div><div style="margin-bottom: 10px;">The closing of the Cambridge site was consistent with the group's continued efforts to reduce its cash utilization.<wbr> </div><div style="margin-bottom: 10px;"><B>About Marina Biotech</B> </div><div style="margin-bottom: 10px;">Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking.<wbr> </div><div style="margin-bottom: 10px;">The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs in bladder cancer and malignant ascites.<wbr> Marina Biotech entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7743" class="defaultlink">Oncology7743: Marina Biotech Highlights Bladder Cancer R&D Collaboration & Competitive Positioning</a>).<wbr> </div><div>In addition, Marina Biotech has recently entered into an agreement with Mirna Therapeutics to license Marina Biotech's SMARTICLES® technology for the delivery of Mirna Therapeutics' microRNA mimics.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8098">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-15T09:21:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-15T09:21:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SOFT Intelligence On Abiraterone, Firmagon, Jevtana & GnRH Market</title>
	<pubDate>2012-02-14T18:34:14+01:00</pubDate>
	<wp:post_id>3192</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><B>Jevtana</B> </div><div style="margin-bottom: 10px;">Tombal seems quite happy with the efficacy he sees with Jevtana (response in 4 out of 5 patients whereas abiraterone provides response in 3 out of 10 according to him), but that safety profile is not very good for fragile patients.<wbr> Indicated that price was also an issue, and Sanofi was reimbursing treatment cost to non responders.<wbr> Non response is seen after 3 "cures".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Overall Market Assessment</STRONG> </div><div>Tombal believes the <B>GnRH analog market</B> will decrease in size because of the new hormonal therapy, and in particular oral options.<wbr> He mentionned that bicalutamide 150mg was now given to 20% of patients in Belgium <I>(a little above what we have seen in the EU market research of 2010).<wbr> </I>He quoted his phase I/<wbr>II with MVD3100 and mentioned that the drug did not have the safety profile of the old anti-androgens, and that this was a problem, despite the fact that its affinity with the receptor was higher.<wbr> He believes that the dose for hormone-naive should be less than for CRPC patients but that dose escalation by patient type has never been done.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8096">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-14T18:34:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-14T18:34:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Gen-Probe's PROGENSA PCA3 Assay for Prostate Cancer on Track for Approval</title>
	<pubDate>2012-02-14T12:47:27+01:00</pubDate>
	<wp:post_id>3193</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Gen-Probe expects to receive an FDA approval for its urine-based molecular diagnosic assay in 1Q’12.<wbr> The company stated that the test has lower false positive rate by ~25% as compared to current standard.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Progensa PCA3 assay can : </div><div style="margin-bottom: 10px;"><UL><LI>help determine the need for repeat prostate biopsies</LI>
<LI>add value to clinicians in prostate cancer diagnostics</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>Marketed</LI>
<LI>CE-marked</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8095">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-14T12:47:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-14T12:47:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Development of a Novel In Vitro Alternative to the Mouse LD50 Test</title>
	<pubDate>2012-02-13T18:43:36+01:00</pubDate>
	<wp:post_id>3194</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Although the proof-of-concept aims to test for BoNT/<wbr>B, modification of the assay may provide the means of detecting additional relevant BoNT types, especially BoNT/<wbr>A .<wbr></span>&nbsp;<br></div><div style="margin-bottom: 10px;">The limitations of this type of assay are: </div><div style="margin-bottom: 10px;"><UL><LI>Will assess receptor binding only.<wbr> It would be useful in affinity studies and scatchard plot analyses.<wbr> </LI>
<LI>Assay will not assess internalization process.<wbr> </LI>
<LI>Assay will not assess enzymatic activity.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">It may be useful in research or screening of new toxins but will require assessment of the other functional attributes of toxin required for activity.<wbr> </div><div style="margin-bottom: 10px;">This will have little utility in the replacement of a regulatory method for potency assessment, at least in the United States.<wbr> </div><div>Steve Scott (VP Regulatory Affairs/<wbr>US) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6229">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6228">View thread  Neurology6228: Development of a Novel In Vitro Alternative to the Mouse LD50 Test</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-13T18:43:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-13T18:43:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Germany's MoH Confirms Price Freeze and Mandatory Rebate</title>
	<pubDate>2012-02-10T18:08:08+01:00</pubDate>
	<wp:post_id>3195</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Germany's Federal Ministry of Health (MoH) on 2 February reaffirmed the need to maintain the three-year price freeze and mandatory rebate in place since August 2010 in the country.<wbr> The two emergency measures introduced 18 months ago are still justified to ensure the financial stability of the statutory health insurance, said the MoH.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">Pharmaceutical prices will remain capped at their August 2009 level until at least 2013.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, manufacturers of non-reference-priced medicines remain obliged to pay a 16% mandatory rebate on the price of their medicine.<wbr> The confirmation is bad news for the pharma industry, which faces a tough time in this former market-access haven.<wbr> </div><div style="margin-bottom: 10px;">As part of the new Act for the Restructuring of the Pharmaceutical Market in Statutory Health Insurance (AMNOG) pricing reform, producers of innovative medicines now have the obligation to negotiate prices in addition to paying significant rebates.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9784">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-10T18:08:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-10T18:08:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Development of a Novel In Vitro Alternative to the Mouse LD50 Test</title>
	<pubDate>2012-02-10T14:21:09+01:00</pubDate>
	<wp:post_id>3196</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The 3R Research Foundation Switzerland, a cooperative institution set up in 1987, has announced that they will provide funding for a project on the development of a novel <EM>in vitro</EM> method for use in the potency testing of botulinum neurotoxin.<wbr> The new method is based on the use of liposomes with integrated nerve cell receptors to imitate the motoneuron membrane.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Although the proof-of-concept aims to test for BoNT/<wbr>B, modification of the assay may provide the means of detecting additional relevant BoNT types, especially BoNT/<wbr>A .<wbr> <a name="Neurology6229c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The limitations of this type of assay are: </div><div style="margin-bottom: 10px;"><UL><LI>Will assess receptor binding only.<wbr> It would be useful in affinity studies and scatchard plot analyses.<wbr> </LI>
<LI>Assay will not assess internalization process.<wbr> </LI>
<LI>Assay will not assess enzymatic activity.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">It may be useful in research or screening of new toxins but will require assessment of the other functional attributes of toxin required for activity.<wbr> </div><div style="margin-bottom: 10px;">This will have little utility in the replacement of a regulatory method for potency assessment, at least in the United States.<wbr> </div><div>Steve Scott (VP Regulatory Affairs/<wbr>US) </div></div></div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see @ <A href="http://www.forschung3r.ch/en/projects/pr_125_11.html">tp:/<wbr>/<wbr>www.<wbr>forschung3r.<wbr>ch/<wbr>en/<wbr>projects/<wbr>pr_125_11.<wbr>html</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Five research groups, from Switzerland and Germany, are involved in the collaborative project : </div><div style="margin-bottom: 10px;"><UL><LI>Laboratory of Food Microbiology, Institute for Food, Nutrition and Health (IFNH), ETH Zurich, Schmelzbergstrasse 7, 8092 Zurich, Switzerland</LI>
<LI>Toxinology Group, SPIEZ LABORATORY, 3700 Spiez, Switzerland</LI>
<LI>Institut für Toxikologie, OE 5340, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany</LI>
<LI>miprolab GmbH, Marie-Curie-Str.<wbr> 7, 37079 Göttingen, Germany</LI>
<LI>Federal Institute of Technology, Department of Materials, Wolfgang-Pauli-Strasse 10, 8093 Zürich, Switzerland</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Objectives</U> </div><div style="margin-bottom: 10px;"><UL><LI>to promote alternative research methods to animal experimentation through grants for research projects</LI>
<LI>to support projects aimed at developing new methods or refining accepted methods (validation) which offer practical improvements vis-à-vis standard animal experimentation in line with the 3R motto Reduce, Refine, Replace.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The 3R Foundation is set up by : </div><div><UL><LI>the Parliamentary Group for Animal Experimentation Questions (public organ), </LI>
<LI>Interpharma (Actelion Ltd, Merck Serono Ltd, Novartis Pharma Ltd, F.<wbr> Hoffmann-La Roche Ltd, and the associated members Bayer Schering Pharma Switzerland, Cilag Ltd and Vifor Ltd)</LI>
<LI>the Foundation for Animalfree Research (animal protection).<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6228">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-10T14:21:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-10T14:21:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Statistics From the American Society of Plastic Surgeons Report</title>
	<pubDate>2012-02-09T18:11:14+01:00</pubDate>
	<wp:post_id>3197</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The top-5 minimally-invasive procedures in the U.<wbr>S were botulinum toxins A (5.<wbr>7 million procedures, up to 5%), soft tissue fillers (+7%), chemical peel (-3%), laser hair removal (+15%), and microdermabrasion (+9%).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6226_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Hyaluronic acid (Restylane(R), Juvederm Ultra(R), etc.<wbr>), calcium hydroxylapatite (Radiesse(R)), and fat injections experienced some of the largest growth in the minimally-invasive market during 2011.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6226_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6226_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="neurology6226attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6226_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(43,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6226_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(15,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6226_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(53,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6226">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-09T18:11:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-09T18:11:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Amgen Not Guaranteed Success At Tomorrow's ODAC Meeting</title>
	<pubDate>2012-02-09T16:06:21+01:00</pubDate>
	<wp:post_id>3198</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Amgen Not Guaranteed Success At Tomorrow's ODAC Meeting</span>&nbsp;<br><span style="font-size: 12px;"><SPAN style="FONT-SIZE: small; FONT-FAMILY: arial,helvetica,sans-serif">Comment: Documents release ahead of tomorrow's ODAC meeting suggest that Amgen's denosumab (Xgeva) may well not receive approval to prevent the spread of bone metastases in prostate cancer patients.<wbr></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8077">...</a><br></div><div style="margin-bottom: 10px;">Much as anticipated Amgen did not get the go-ahead for approval of Xgeva to reduce the risk of developing bone metastases in CRPC patients.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">At the meeting, panelists considered the evidence that patients taking Xgeva experienced a four-month delay in the spread of cancer to the bones as statistically beneficial but not  a benefit that resulted in increased survival or higher quality of life for patients.<wbr> It the magnitude of the benefit had been more like one year then approval may have been forthcoming but at 4 months it was considered quite low.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Panel members also expressed concern about the drug&rsquo;s safety profile, including osteonecrosis of the jaw in about 5 percent of the 1432 patients studied.<wbr> In addition, staff questioned whether the drug may "shift the pattern of metastases to non-bony areas.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Overall the panel believed that  the drug&rsquo;s risk make it safer for patients to continue only taking Xgeva when tumours already have spread to their bones.<wbr> </P> </div><div><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Amgen said that it would continue discussions with the FDA regarding its filing.<wbr></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8094">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8077">View thread  Oncology8077: Amgen Not Guaranteed Success At Tomorrow's ODAC Meeting</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-09T16:06:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-09T16:06:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Shanghai Development Center Established to Drive Growth</title>
	<pubDate>2012-02-09T14:36:26+01:00</pubDate>
	<wp:post_id>3199</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Within Asia (outside Japan, including China), drug development is overseen by Takeda Global Research &amp; Development Center (Asia) Pte.<wbr> Ltd.<wbr> in Singapore (“TGRD (Asia)”) and Millennium Pharm.<wbr> in Cambridge (“Millennium”).<wbr> The Shanghai Development Center (TSDC) will work on extending and enhancing the company’s clinical development activities within the Asian region, with a focus on China for General Medicine working as an integrated regional team with TGRD (Asia), and across Asia for Oncology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Through the resources of TSDC, Takeda will continue to conduct high quality clinical trials which will lead to secure regulatory approval in Asia, with a growing emphasis on China, and continue to build deeper relationships with physicians and regulatory authorities.<wbr> </div><div style="margin-bottom: 10px;">- The acquisition of Nycomed has immediately established the company in high-growth emerging markets.<wbr> The establishment of TSDC will help the company leveraging its activities.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8093_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8093attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8093_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(50 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8093">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-09T14:36:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-09T14:36:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis Results Key Takeaways</title>
	<pubDate>2012-02-09T10:26:39+01:00</pubDate>
	<wp:post_id>3200</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: M.<wbr> Morrissey (President &amp; CEO) reported that 2 planned pivotal trial programs (COMET1 and COMET2) in mCRPC will drive cabozantinib differentiation in CRPC.<wbr> While Management focus is internal efforts in the CRPC space, it continues to implement its plans to maximize the drug's potential in additional tumour indications through external collaborations.<wbr> Nine abstracts on cabozantinib will be presented at the upcoming ASCO in June.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>COMET1 (307 study)</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Start date: H1 2012</LI>
<LI>
Location: Up to 200 on a WW basis</LI>
<LI>
Top line results expected H1 2014.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>COMET2 (306 study) - pain palliation study</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Start date: first site initiated in Dec.<wbr> 2011 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8049" class="defaultlink">Oncology8049: New Cabozantinib Study to Assess Pain Associated with Metastases in Men with CRPC</a>)</LI>
<LI>
Location: up to 40 sites</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Differentiated Thyroid Cancer (DTC)</U> - the company had a pre-NDA meeting in 2011 and obtained agreement from the FDA to initiate a rolling NDA.<wbr> Filling is on track to complete H1 2012.<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><U>Renal Cell Carcinoma</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><U>Hepatocellular Carcinoma (HCC)</U> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Metastatic Breast Cancer (MBC)</U> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>
Restructuring activities are complete</LI>
<LI>
All non-cabozantinib development activities discontinued.<wbr></LI>
<LI>
Of note, Exelixis started 2012 with over $300M in cash.<wbr></LI>
<LI>
Out-licensing of PI3K delta program to Merck (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7980" class="defaultlink">Oncology7980: Licensing of Exelixis' PI3K-delta Program to Provide Resources for Late-Stage Dev.<wbr> of Cabozantinib</a>).<wbr></LI>
</UL> </div><!-- Comment details --><a name="oncology8090attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(54,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(41,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(16,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(42,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(41,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8090_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(45,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8090">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-09T10:26:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-09T10:26:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Morgan Stanley Raises Allergan Price Target Post Management Visit</title>
	<pubDate>2012-02-08T18:11:15+01:00</pubDate>
	<wp:post_id>3201</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Morgan Stanley is expecting Allergan to communicate a strong pipeline poistion at its March 28th analyst day.<wbr> During his meeting with the analysts, Pyott stated his belief that the top three most exciting pipeline candidates are Latisse for hair loss, targeted Botox for pain and DARPinn for Wet AMD.<wbr> </div><div style="margin-bottom: 10px;">The analysts are suggesting that Allergan could initiate phIII trials with the targeted toxin for pain this year but may also be unveilling of some surprise new development candidates.<wbr> </div><div style="margin-bottom: 10px;">Key ongoing developments with the three most promising candidates potentially explains the higher than expected expansion in R&amp;D spending noted during the 2nd February call.<wbr> </div><div style="margin-bottom: 10px;">The analysts published their note with a raised price target of $98 based on an extension of their model to 2020.<wbr> Some of the key assumptions behind this price target are shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6224_1_ScreenCapture1.jpg"> </div><div>Source: Morgan Stanley Report 8th February </div><!-- Comment details --><a name="neurology6224attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6224_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(91,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6224_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(3,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6224">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-08T18:11:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-08T18:11:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK Results Key Takeaways</title>
	<pubDate>2012-02-08T11:12:06+01:00</pubDate>
	<wp:post_id>3202</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GSK reported an improving sales picture in underlying terms +4%, underpinned by strong growth of new products.<wbr> It also painted a picture of increasing returns on R&amp;D and pipeline progress.<wbr> Comprehensive phIII data on its GLP-1 analogue albiglutide is likely to be presented at a forthcoming R&amp;D day to be announced around the time of the Q1 results.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6866_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6866_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6866_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Drugs In Development - Key Comments </STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Albiglutide</STRONG> </div><div style="margin-bottom: 10px;">Patrick Vallance SVP-Medicines Discovery &amp; Development,  noted that some of the phIII data is available but that there's more coming in.<wbr>He stated "So where we are with this is it's a product that didn't meet the once-a-day efficacy in the first bit, but actually very well tolerated.<wbr> We expect that efficacy to continue.<wbr> We're very optimistic, actually, that this is a nice product with a very good tolerability profile that will have a good place in the market.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Votrient (multi-kinase inhibitor pazopanib)</STRONG> </div><div style="margin-bottom: 10px;">Votrient has achieved an 18% total prescription share in the US advanced renal cell carcinoma market.<wbr> Head-to-head data in 2012 from an event-driven study comparing Votrient to the current market leader, Sutent (which has a market share of approximately 50%) is expected in 2012.<wbr> Votrient is also under regulatory review in the USA and Europe for a new indication in soft-tissue sarcoma and in phIII development for renal cancer.<wbr> </div><div style="margin-bottom: 10px;">A number of phII ESS studies remain ongoing with pazopanib evaluating its use in the treatment of neuroendocrine tumours and pNET </div><div style="margin-bottom: 10px;">Two other notable products in phase III development are for Crohn's disease and GSK2402968 for Duchene's Musucular Dystrophy </div><div>Source: <A href="http://www.gsk.com">www.<wbr>gsk.<wbr>com</A> </div><!-- Comment details --><a name="endocrinology6866attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6866_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(99,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6866_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(65,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6866_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(110,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6866">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-08T11:12:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-08T11:12:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi Results Key Takeaways</title>
	<pubDate>2012-02-08T09:40:17+01:00</pubDate>
	<wp:post_id>3203</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Jevtana® sales reached €47 million in 4Q 2011.<wbr> Sales in the U.<wbr>S.<wbr> and Western Europe reached €24 million and €18 million, respectively.<wbr> FY2011 sales of the drug were €188 million compared to €82 million in 2010.<wbr> 2012 catalysts include the Ph3 results of Zaltrap  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Total sales grew 5.<wbr>3% (at CER) to €33,389 million.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8080_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>Total sales by Platform</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8080_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>Jevtana Sales by Quarter</LI>
</UL> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8080_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology8080attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8080_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(16,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8080_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(22,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8080_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(9,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8080">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-08T09:40:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-08T09:40:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Prostate Drug Target Identified</title>
	<pubDate>2012-02-07T14:58:16+01:00</pubDate>
	<wp:post_id>3204</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The February 6th publication of the Proceedings of the National Academy of Sciences highlights a new target for potential prostate cancer therapy intervention, a protein called ARD1.<wbr> </div><div style="margin-bottom: 10px;">Wango Lui Associated Professor of Genetics at LSU Health Sciences Centre New Orleans has identified what is claimed to be a new protein critical to the development of prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Dr Lui's team have been studying androgen receptor activators and discovered that this new protein ARD1 is overproduced in the majority of prostate cancer samples, that it activates the the androgen receptor and that it is an essential component of prostate cancer cell growth.<wbr> </div><div style="margin-bottom: 10px;">Moreoever, it seems that inactivation of ARD1 inhibits the function of the androgen receptor resulting in complete suppression of prostate cancer cell growth in tissue culture and prostate tumour growth in mice.<wbr> </div><div style="margin-bottom: 10px;">Dr Lui claims that his team's study provides a novel avenue for controlling AR-mediated prostate tumour development by directly inhibiting the function of the ARD1 or AR-ARD1 interaction.<wbr> </div><div><A href="http://www.pnas.org/content/early/2012/02/01/1113356109.abstract">http:/<wbr>/<wbr>www.<wbr>pnas.<wbr>org/<wbr>content/<wbr>early/<wbr>2012/<wbr>02/<wbr>01/<wbr>1113356109.<wbr>abstract</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8078">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-07T14:58:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-07T14:58:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen Not Guaranteed Success At Tomorrow's ODAC Meeting</title>
	<pubDate>2012-02-07T13:02:12+01:00</pubDate>
	<wp:post_id>3205</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small; FONT-FAMILY: arial,helvetica,sans-serif">Comment: Documents release ahead of tomorrow's ODAC meeting suggest that Amgen's denosumab (Xgeva) may well not receive approval to prevent the spread of bone metastases in prostate cancer patients.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="FONT-SIZE: small; FONT-FAMILY: arial,helvetica,sans-serif">What is the issue?</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: small arial,helvetica,sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="COLOR: #1a1a1a; LINE-HEIGHT: 22px">Whilst Amgen's study that examined how Xgeva might reduce the risk of developing bone metasteses in patients with CRPC and high risk factors met its pre-specified primary endpoint, it is unclear whether an improvement in median bone metastasis-free survival by 4.<wbr>2 months is an adequate measure of clinical benefit.<wbr></SPAN></SPAN> </div><div><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 14px; COLOR: #1a1a1a; LINE-HEIGHT: 22px; FONT-FAMILY: Helvetica, Arial, sans-serif"><SPAN style="FONT-SIZE: small; FONT-FAMILY: arial,helvetica,sans-serif">The FDA's pre-meeting report is critical of the use of this endpoint.<wbr> Moreove, analysts are suggesting that the oncology as opposed to urology profile of the committee members does not help Amgen's case as it is their preference to see new prostate cancer drugs demonstrating an improvement in overall survival</SPAN>.<wbr></SPAN></SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8094c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Much as anticipated Amgen did not get the go-ahead for approval of Xgeva to reduce the risk of developing bone metastases in CRPC patients.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">At the meeting, panelists considered the evidence that patients taking Xgeva experienced a four-month delay in the spread of cancer to the bones as statistically beneficial but not  a benefit that resulted in increased survival or higher quality of life for patients.<wbr> It the magnitude of the benefit had been more like one year then approval may have been forthcoming but at 4 months it was considered quite low.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Panel members also expressed concern about the drug&rsquo;s safety profile, including osteonecrosis of the jaw in about 5 percent of the 1432 patients studied.<wbr> In addition, staff questioned whether the drug may "shift the pattern of metastases to non-bony areas.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Overall the panel believed that  the drug&rsquo;s risk make it safer for patients to continue only taking Xgeva when tumours already have spread to their bones.<wbr> </P> </div><div><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;">Amgen said that it would continue discussions with the FDA regarding its filing.<wbr></P> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8077">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-07T13:02:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-07T13:02:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Europe: eTACT Anti-Counterfeit System</title>
	<pubDate>2012-02-07T12:52:39+01:00</pubDate>
	<wp:post_id>3206</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-size: x-small;">Comment: T<SPAN class="Apple-style-span" style="font-weight: normal; word-spacing: 0px; text-transform: none; color: #000000; text-indent: 0px; line-height: normal; font-style: normal; font-family: 'Times New Roman'; white-space: normal; letter-spacing: normal; border-collapse: separate; font-variant: normal; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">he eTACT traceability system for medicines has been officially launched by the European Directorate for the Quality of Medicines and Healthcare ( EDQM), part of the Council of Europe.<wbr></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><P style="width: auto;"><SPAN style="font-size: x-small;">eTACT will be a publicly governed service covering all medicines in the legal supply chain, and will be open to the 36 member states of the European Pharmacopoeia Commission and beyond.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="width: auto;"><SPAN style="font-size: x-small;">However, a mixed pharmaceutical industry/<wbr>distributor grouping has already tested another scheme, the European Stakeholder Model (ESM).<wbr> Its proponents also claim their system will be a "practical and cost-effective solution" to the growing problem of falsified medicines.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="width: auto;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: x-small 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">It is not clear which of the two systems will eventually predominate, or whether the end result will be some sort of combination of the two, as there may be collaboration between the two systems.<wbr></SPAN></SPAN></P> </div><div><P style="width: auto;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: x-small 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">Source: Scrip 6 February 2012</SPAN></SPAN></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9781">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-07T12:52:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-07T12:52:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Norgine Reports Ph2 Results of a New Orange Flavoured Formulation of MOVIPREP®</title>
	<pubDate>2012-02-07T10:34:03+01:00</pubDate>
	<wp:post_id>3207</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The results have shown that MOVIPREP® Orange was well tolerated.<wbr> In addition, a high rating of successful cleansing (96%) similar to rates shown by MOVIPREP® Lemon (the parent product) was observed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01251237?term=NRL0706&amp;rank=1"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Primary endpoint: Overall Acceptance on VAS (100mm) rating </div><div style="margin-bottom: 10px;">Recruitment: 121 subjects were enrolled, of which 118 were eligible to be randomised.<wbr> </div><div style="margin-bottom: 10px;">Location: 5 specialised gastroenterology units in private practice or ambulatory care centres in Germany.<wbr> </div><div>Dosage: 1 litre of MOVIPREP® Orange in the evening ahead of the colonoscopy and 1 litre early in the morning on the day of the colonoscopy.<wbr> Each dose of MOVIPREP® Orange was followed by at least 0.<wbr>5 litre of any additional clear fluid.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120431&edate=20120101&rec=1832">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-07T10:34:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-07T10:34:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivations's Review Of the AFFIRM Trial & The Future CRPC Treatment Paradigm</title>
	<pubDate>2012-02-06T17:25:47+01:00</pubDate>
	<wp:post_id>3208</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During last week's call on the MDV3100 results several interesting points emerged regarding the furture treatment paradigm in CRPC (usage ahead of abiraterone), potential ways to treat non-responders and potentially the use of AR modulators for the treatment of breast cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Invited speakers on the call were:-</STRONG> </div><div style="margin-bottom: 10px;">Howard I.<wbr> Scher, MD Chief, Genitourinary Oncology Service; D.<wbr> Wayne Calloway Chair in Urologic Oncology, Memorial-Sloan Kettering Cancer Center and Neal D.<wbr> Shore, M.<wbr>D.<wbr>, FACS Director, CPI, Carolina Urologic Research Center </div><div style="margin-bottom: 10px;">In the Q/<wbr>A session the following points were addressed:- </div><div style="margin-bottom: 10px;"><STRONG>How is MDV3100 likely to be positioned in oncology as well as urology and relative to PROVENGE by 2015.<wbr></STRONG> </div><div style="margin-bottom: 10px;">Howard Scher:- "So the way essentially that most of us practice now for the patient who requires hormonal treatment, we generally begin with a GnRH analogue or whether it's an agonist antagonist or pure antagonist.<wbr> Some will still use an antiandrogen for a short period of time, but that data I think has been beat to death over time and really does not change outcomes to a significant degree.<wbr> When the patient has progressed, we will typically – if they are progressing slowly than add an anti-androgen which has a very modest response rate, and then we will move on to – in the past we moved on to the steroid containing adrenal access, originally called adrenal access agents such as ketoconazole.<wbr> I think if we wind the clock ahead a few years that paradigm will have not changed except the anti-androgen will be replaced by a new generation compound of androgen receptor signaling inhibitor.<wbr> </div><div style="margin-bottom: 10px;">"I am not sure when PREVAIL will be out, but anticipating what we saw in the Phase 1, 2 study that will be positioned first, that will be based on safety and the fact that you don't need steroids, which is a way that communities have been practicing really for the past 20, 30 years.<wbr> If you want me to wind the clock even further forward, there is a potential role for this agent in the non-castrate population.<wbr> And those trials have actually been started in Europe, which really offers an enormous number of additional possibilities.<wbr>" </div><div style="margin-bottom: 10px;">"The issue with Provenge is very simple and it does have a Phase 3 survival trial, but it's challenging when you actually use it, because you can't assess whether it has benefited a single individual patient.<wbr> Its availability has been limited.<wbr> Its cost is not inconsequential and it's rarily been used.<wbr> The patient response to it is highly variable.<wbr> Some will want everything done, some will say, I want to know if it works, but it's really been primarily used, at least as I've seen it in patients who have relatively indolent disease who have no symptoms, who have not seen steroids or have not seen chemotherapy.<wbr> So I think it's really hard to prescribe it, I mean, discuss it.<wbr> But it's not clear again for the individual patient what it actually does.<wbr> I know Neal you have more experience with it than I do.<wbr>" </div><div style="margin-bottom: 10px;">Neal Shore:- "Well, I think you asked really the $64 question is all about combinations and sequencing.<wbr> I think I agree with everything that Howard said and he gave you a very terse and cogent answer to a very difficult question.<wbr> But I think as it relates to the Medivation drug MDV3100, I don't see there being any exclusionary therapies that would prevent concomitant therapy with MDV3100 based upon its mechanism of action, its once-a-day oral administration and its safety profile.<wbr> Of course, the big caveat is, we have to do those trials.<wbr> Those trials have to be done and that's what we have to work on Level 1 evidence, but having said that, to fast forward to 2015, my presumption is that there is nothing going to be exclusionary to MDV3100.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Q Combination Therapy - What kind of synergy do you have to observe to actually make that strong Level 1 evidence, considering the costs and everything?</STRONG> </div><div style="margin-bottom: 10px;">Howard Scher:- "I think the real question you are asking is, what signal would you want when you did an initial combinatorial study to make the investment to do a very large Phase 3 trial.<wbr> That you know again there is no regulatory endpoint.<wbr> Right now sort of survival with one exception and that has been skeletal-related events, which are very infrequent in the asymptomatic population and that would be an enormous cause.<wbr> And I'm not sure there is a clear signal right now, we've extrapolated to a degree based on the time to progression measures, but those have not themselves been approvable.<wbr> It's not clear that you would see an increase in response rate by combining the two.<wbr> So it was likely we stuck with us to see whether a biologic could prolong the response.<wbr> So it's obviously scientifically very interesting, particularly with this safety profile, but from a drug development standpoint it would be very challenging at this point in time.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Q How do you believe Zytgia and MDV3100 should be sequenced in the post chemo setting?</STRONG> </div><div style="margin-bottom: 10px;">Howard Scher:-"The steroid issue is non-trivial.<wbr> This causes skin changes, it causes muscle weakness and that's really the start, it's kind of an agent that does not require steroids, particularly long term in my view is going to be utilized first and that's the way the community has been practicing in the prechemotherapy space literally for the past 30 years when the anti-androgens were first approved.<wbr> I don't see this changing in the post-chemotherapy setting.<wbr> Couple that with the ease of administration, I think it just reinforces which one you would use first.<wbr> So the real question is, are these drugs the same and probably ask that every day, what would they look like in combination? And, as Neal mentioned, these are trials that have to be done.<wbr><STRONG> But right now, given the choice, we would use a non-steroid-containing regimen first.<wbr>"</STRONG> </div><div style="margin-bottom: 10px;">Neil Shore:-"Yeah, I would agree with that.<wbr> The safety profile, the ease of acceptance and the lack of monitoring presumably with the label based upon the safety and tolerability data that you're seeing presented today would certainly make it a more enjoyable and an ease-of-use product for the patient, first and foremost and also for the clinician in the community, there is no doubt about that.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Q Any potential limitations to use in the chemo-naive patient setting?</STRONG> </div><div style="margin-bottom: 10px;">Howard Scher:-"We really haven't seen any limitation in the pre-chemotherapy population in our own experience that precludes long-term use".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Q Over the coming months and maybe years might we be able to stratify or identify patients more likely to respond to this drug or less likely to exhibit resistance than we are currently able to do?</STRONG> </div><div style="margin-bottom: 10px;">Howard Scher:- So that's certainly a major goal of the investigations now.<wbr> There is clearly a small cohort with both Abiraterone and with MDV3100, who primarily are non-responsive to these agents.<wbr> In laboratory models there have been several, so to say, first-order targets, which are being investigated.<wbr> </div><div style="margin-bottom: 10px;">"We know that the PTEN pathway negatively inhibits when there is activated AR signaling.<wbr> And I think that's a strategy that the prostate cancer research community is aggressively looking at with multiple different agents both with the androgen receptor signaling inhibitors as well as with abiraterone.<wbr> And as you know there are a number of agents targeting virtually every aspect of the PI3-Kinase pathway.<wbr> Key is going to be having a strong enough hypothesis to test.<wbr> </div><div style="margin-bottom: 10px;">"The second requirement is going to be the development of the assays, which will be necessary in order to do this type of prediction.<wbr> The rules at the FDA level have changed now.<wbr> So in the old days, if you will, it was sufficient to do an assay in a research setting, that's no longer the case and any assay that you wish to use in the clinic in order to inform a decision to select drug A versus drug B will have to go through its own regulatory filing.<wbr> So right now what we're focusing on in our group is developing the analytical rigor, so we can do the filings and then begin the trials to actually ask the question.<wbr> But it's clearly where the field is heading.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Q: Rational for MDV3100 working in breast cancer?</STRONG> </div><div>David Hung CEO of Medivation - " So there is a fairly good evidence and a fairly bundled literature showing that AR is expressed, not only in ER positive breast cancer, but also ER negative breast cancer.<wbr> And so we've done a number of preclinical experiments, both internally as well as with some collaborators, including Jennifer Richer from the University of Colorado at Denver showing that MDV3100 inhibits not only DHT or testosterone-mediated breast cancer growth, but interestingly, it also inhibits estradiol or estrogen-mediated breast cancer growth.<wbr> So, we are very intrigued by these data.<wbr> We believe this is a potentially very large commercial opportunity and given that the, what we believe, is a very sound scientific rationale we're pushing forward aggressively to try to move into a breast cancer indication as quickly as we can.<wbr>" </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8076">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-06T17:25:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-06T17:25:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aeterna Zentaris CRPC Poster At ASCO GU</title>
	<pubDate>2012-02-06T16:22:21+01:00</pubDate>
	<wp:post_id>3209</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 14px; COLOR: rgb(26,26,26); LINE-HEIGHT: 22px; FONT-FAMILY: Helvetica, Arial, sans-serif"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 14px; COLOR: rgb(26,26,26); LINE-HEIGHT: 22px; FONT-FAMILY: Helvetica, Arial, sans-serif"><SPAN style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 14px; COLOR: rgb(26,26,26); LINE-HEIGHT: 18px; FONT-FAMILY: Helvetica, Arial, sans-serif"></SPAN></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"><B style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px"></B></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px 1em; LINE-HEIGHT: 1.6em; PADDING-TOP: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8075_2_ScreenCapture1.jpg"></P> </div><div><A href="http://www.aeternazentaris.com"></A><A href="http://www.firstwordpharma.com/node/949203"></A> </div><!-- Comment details --><a name="oncology8075attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8075_1_AEZS%2d108%20GU%20ASCO%202012%20v2.pdf">AEZS-108 GU ASCO 2012 v2.pdf</a>&nbsp;&nbsp;(202,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8075_2_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8075">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-06T16:22:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-06T16:22:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Threshold Partners its Hypoxia-Activated Prodrug TH-302</title>
	<pubDate>2012-02-06T15:42:28+01:00</pubDate>
	<wp:post_id>3210</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8073">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-06T15:42:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-06T15:42:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Expresses Concerns Over Spain's Drug Repayments</title>
	<pubDate>2012-02-06T12:08:57+01:00</pubDate>
	<wp:post_id>3211</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Our colleagues in Spain have drawn our attention to the Novartis' warning regarding the risk of the unpaid by Greece, Italy and Spain.<wbr> The latter being identified by the company as one of the most concern.<wbr> According to data supplied by Farmaindustria, autonomous communities in Spain owed more 6bn to the pharma industry at the end of 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The average payment-delay period has also increased over the last year by 135 days, reaching a peak of 525 days by December 2011.<wbr> </div><div style="margin-bottom: 10px;">Four autonomous communities—Comunidad Valenciana, Baleares, Castilla y Leon, and Cantabria—exceeded this average, reaching over 800 days in payment delays.<wbr> </div><div style="margin-bottom: 10px;">The new Spanish government needs to act quickly in order to deal with the problem of payment delays, or runs the risk of a ban on product sales from some of the largest pharma companies until debts are repaid.<wbr> </div><div>Sources: Novartis' AR; Global Insight; Europa Press </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9778">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-06T12:08:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-06T12:08:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Announces Reorganization of its Global Management Structure</title>
	<pubDate>2012-02-06T11:51:26+01:00</pubDate>
	<wp:post_id>3212</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The reorganization will be effective from April 1st.<wbr> The Global Medical Affairs (GMA) and the Global Marketing Strategy (GMS) organizations will be newly established, as well as the positions of Corporate Executives, responsible for Corporate Strategy and Finance.<wbr> Details and objectives are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Newly established positions of Corporate Executives Responsible for Corporate Strategy and Finance, reporting Directly to the President.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9777_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9777_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>Newly Establish Global Medical Affairs Structure and Global Marketing Strategy Structure</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>GMA Overview</U> </div><div style="margin-bottom: 10px;">GMA develops medical strategy and supports the execution of global medical strategy in partnership with stakeholders and in collaboration with regions to optimize medical/<wbr>scientific value across the product lifecycle.<wbr> </div><div style="margin-bottom: 10px;">Medical and scientific evaluation in the key therapeutic area of urology, oncology, transplantation, immunology and infectious diseases through the promotion of organic collaboration between various functions from the development stage onwards across various regions ・ </div><div style="margin-bottom: 10px;">Function Head: Charlotte M.<wbr> E.<wbr> Kremer, MD (Appointed January 9, 2012) </div><div style="margin-bottom: 10px;"><U>GMS Overview</U> </div><div style="margin-bottom: 10px;">Global product market launch strategy (Pre-market launch branding strategy, therapeutic area strategy, market launch planning), and post-market launch lifecycle plan creation </div><div style="margin-bottom: 10px;">Create positions of Therapeutic Area Head for the promotion of collaboration with the APGD and GMA in the key therapeutic area of urology, oncology, transplantation, immunology and infectious diseases </div><div>Function Head: VP, Product and Portfolio Strategy </div><!-- Comment details --><a name="pharmaworld9777attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9777_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9777_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(4,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9777">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-06T11:51:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-06T11:51:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Assay Using Neurons from Stem Cells for Botulinum Toxin Detection</title>
	<pubDate>2012-02-06T11:26:30+01:00</pubDate>
	<wp:post_id>3213</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:: A team from the University of Wisconsin-Madison have published data in the Toxicological science journal on a test they have developed employing stem cell derivatives to reliably and quantitatively detect botulinum neurotoxin and the antibodies that can neutralize the toxin's effects.<wbr> Data on this assay was first presented at the Toxins meeting in Santa Fe in October 2011 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6028" class="defaultlink">Neurology6028: Toxins Intelligence Part 1 - New Botulinum Toxin Assays</a>).<wbr> </div><div style="margin-bottom: 10px;">The assay is more sensitive than the mouse assay.<wbr> </div><div style="margin-bottom: 10px;">Sabine Pellett of University of Wisconsin-Madison said that the assay the team has developed is another cell based assay, one that uses normal human neurons derived from induced pluripotent stem cells, and which can be optimized for any pharmaceutical botulinum neurotoxin product.<wbr> </div><div style="margin-bottom: 10px;">Source: Toxicological Sciences journal.<wbr> </div><div>Abstract at: <A href="http://toxsci.oxfordjournals.org/content/early/2012/01/19/toxsci.kfr354.abstract?sid=35037e51-a846-4c57-9dd0-c46d35ea7399">http:/<wbr>/<wbr>toxsci.<wbr>oxfordjournals.<wbr>org/<wbr>content/<wbr>early/<wbr>2012/<wbr>01/<wbr>19/<wbr>toxsci.<wbr>kfr354.<wbr>abstract?sid=35037e51-a846-4c57-9dd0-c46d35ea7399</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6219">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-06T11:26:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-06T11:26:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Asia Key Country for Allergan</title>
	<pubDate>2012-02-03T14:53:28+01:00</pubDate>
	<wp:post_id>3214</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In an interview with Reuters, Management has reported that Allergan will rely less on the U.<wbr>S for revenues in coming year, as its products gain wider acceptance in Asia, with China to be the main driver.<wbr> </div><div style="margin-bottom: 10px;">Ian Bell (Corporate VP and President for Asia Pacific) told Reuters that cosmetic clinics in big hospitals in major Chinese cities present an opportunity for Allergan's aesthetic products.<wbr> </div><div>He outlined that Juvederm is expected to reach the Chinese market in 2014-2015.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6239c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">A<SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">llergan has currently authorised 180 Chinese hospitals nationwide to use Botox, including the major facilities of Shanghai Huamei Aesthetic in Shanghai and the Zhuhai Luda Plastic Surgery Hospital in Guangdong province.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">Ian Bell said that Allergan has d<SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">eliberately focused on physician training, working in partnership with select hospitals in key cities in China, instead of making it available everywhere in China.<wbr></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">He added that a local production plant in China is not planned because Allergan's existing facilities can meet global demand.<wbr></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN> </div><div><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 12px; font-family: Arial, Helvetica, sans-serif;">Source: Scrip 20 February 2012</SPAN></SPAN></SPAN></SPAN></SPAN></SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6217">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-03T14:53:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-03T14:53:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Richter/PregLem's Esmya® Receives Positive Opinion from the EMA/CHMP</title>
	<pubDate>2012-02-03T12:13:06+01:00</pubDate>
	<wp:post_id>3215</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Richter/<wbr>PregLem's Esmya® Receives Positive Opinion from the EMA/<wbr>CHMP</span>&nbsp;<br><span style="font-size: 12px;">Comment: PregLem is expected to receive in early 2012, a marketing authorization for Esmya® valid for all EU Member States.<wbr> The drug is indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7967">...</a><br></div><div style="margin-bottom: 10px;">A study has been published in NEJM - funded by PregLem - Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery  - with an accompanying editorial </div><div style="margin-bottom: 10px;">Access via Ipsen's subscription </div><div style="margin-bottom: 10px;"><A href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103182">http:/<wbr>/<wbr>www.<wbr>nejm.<wbr>org/<wbr>doi/<wbr>pdf/<wbr>10.<wbr>1056/<wbr>NEJMoa1103182</A> </div><div><A href="http://www.nejm.org/doi/full/10.1056/NEJMe1114043?query=featured_home">http:/<wbr>/<wbr>www.<wbr>nejm.<wbr>org/<wbr>doi/<wbr>full/<wbr>10.<wbr>1056/<wbr>NEJMe1114043?query=featured_home</A> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8072">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology7967">View thread  Oncology7967: Richter/<wbr>PregLem's Esmya® Receives Positive Opinion from the EMA/<wbr>CHMP</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-03T12:13:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-03T12:13:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Oncogenex @ ASCO GI - OGX-427 Prostate Cancer Data</title>
	<pubDate>2012-02-03T10:54:41+01:00</pubDate>
	<wp:post_id>3216</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has provided an initial read on its Ph2 study of OGX-427 + prednisone for 1st-line mCRPC.<wbr> Preliminary data provide clinical support for the role of Hsp27 in AR signalling and as a therapeutic target for prostate cancer.<wbr> Enrolment on this study continues, with final results expected to be announced by the end of 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Study Design</U> - <A href="http://clinicaltrials.gov/ct2/show/NCT01120470?term=ogx-427&amp;rank=2">NCT01120470</A> </div><div style="margin-bottom: 10px;"><STRONG>Results</STRONG> </div><div style="margin-bottom: 10px;">OGX-427 appeared to benefit patients most notably by a 71% progression-free rate in the OGX-427 + prednisone group (n=17) compared to 33% in the prednisone alone group (n=15).<wbr> </div><div style="margin-bottom: 10px;">There was a partial response rate (measured at 12 weeks) of 38% (n=8) in the OGX-427 + prednisone group compared to 0% in the prednisone group (n=9).<wbr> </div><div style="margin-bottom: 10px;">The rate of adverse events (AEs), particularly withdrawal from the study due to AEs, was higher in the OGX-427 + prednisone group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div>Randomized ph2 study of OGX-427 in combination with Zytiga (to start H2 2012).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8071">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-03T10:54:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-03T10:54:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>European Botox Sales Under Some Pressure</title>
	<pubDate>2012-02-02T18:29:10+01:00</pubDate>
	<wp:post_id>3217</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan recorded a 6.<wbr>4% increase in net earnings in the fourth quarter as higher sales of opthalmics offset what analysts considered lower than expected sales of Botox ($415m vs estimates of around $430m for Q4).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Global Botox Sales</STRONG> </div><div style="margin-bottom: 10px;">Specifically sales of Botox increased by 8.<wbr>3% in the fourth quarter in local currencies and by 7.<wbr>5% in dollars.<wbr> Full year 2011 sales grew by 10.<wbr>4% in local currencies, and 12.<wbr>4% in dollars.<wbr> Sales of Botox for therapeutic indications and cosmetic use, both grew 12% versus the prior year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Therapeutic Botox Developments</STRONG> </div><div style="margin-bottom: 10px;">Sales in the U.<wbr>S.<wbr> therapeutic business grew at a mid teens rate in Q4 driven not only by chronic migraine which is increasing steadily well in excess of this rate but also boosted by the nuerogenic overactive bladder indication (launched in the US in November) </div><div style="margin-bottom: 10px;">Pyott noted that the U.<wbr>S.<wbr> chronic migraine launch is progressing very well and better than planned with 4600 individual physicians now trained either via the web or live injector training sessions.<wbr> The reimbursement situation also continues to improve with 88% of all commercial coverage at year end.<wbr> As physicians become convinced that there is reimbursement available, the average number of units injected moves closer to the FDA indicated dose of 155 units.<wbr> </div><div style="margin-bottom: 10px;">To support uptake Allergan has been running a DTC campaign since September but from this month onwards it will be placing branded advertisements in women's magazines.<wbr> </div><div style="margin-bottom: 10px;">It claims that its surveys are indicating a high level of patient satisfaction.<wbr> </div><div style="margin-bottom: 10px;">Additional country approvals for chronic migraine in the past quarter have included Canada, Sweden, Spain, Vietnam, Bangladesh and Peru.<wbr> On the approval front the company also noted that it has received a positive opinion in France for its new cell based Botox assay and approval in the Czech republic.<wbr> </div><div style="margin-bottom: 10px;">Regarding US competition, Allergan is reporting that in the therapeutic segment the combined impact of Xeomin and Dysport is stagnating around 5%.<wbr> </div><div style="margin-bottom: 10px;">Pyott did note that its therapeutic sales in Europe have suffered from government posterity measures as well as the impact of mandated price reductions but that sales in Asia Pacific markets and the largest countries in Latin America, continue to grow at a double digit rate.<wbr> Sales from its partner GLaxosmithkline in Japan have also been on a strong growth trend.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Aesthetic Botox Growth</STRONG> </div><div style="margin-bottom: 10px;">Pyott noted that U.<wbr>S.<wbr> market conditions remain good and appear to have strengthened since the summer.<wbr> Consumer demand for Botox he suggests grew in the low double digits in Q4 and competitors market share he reports as 17% for Dysport and 8% for Xeomin.<wbr> In the Q&amp; A he claimed to be surprised by Xeomin's share but then registerd that most of that has been obtained through sampling.<wbr> He suggests it will be a different matter when they have national availability in March and have to start selling the product.<wbr> Then he claims "it will become more interesting and we will have a very robust series of measures to welcome them to our nice friendly market" </div><div style="margin-bottom: 10px;"><BR>Sales in Europe, meanwhile, have reportedly been more challenging due to economic conditions and some market share loss has occurred as Boucature (Merz) and Azzalure (Galderma) have entered new markets.<wbr> </div><div style="margin-bottom: 10px;">Asia-Pacific growth remains firm and Allergan was pleased to note that it has established a direct sales presence in Russia as of this week.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Urological Uptake</STRONG> </div><div style="margin-bottom: 10px;">Pyotts remarks about this segment were as follows:- </div><div style="margin-bottom: 10px;">"It has been almost a normal launch pattern where the first goal is getting injectors trained.<wbr> The second one is getting reimbursement in place.<wbr> And right now, there's only temporary injection codes being utilized so that's always more challenging.<wbr> We won't get a permanent code until 2013 because it takes a year until the system catches up.<wbr>" </div><div style="margin-bottom: 10px;">"So everything's going well.<wbr> There's a lot of enthusiasm but of course we'll have to kind of temper everybody's enthusiasm by saying the numbers are interesting but in 2012 still modest.<wbr> You'll see a much bigger pickup in 2013.<wbr> Once reimbursement is permanent.<wbr> And secondly once we the bigger idiopathic indication is approved.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Forecast</STRONG> </div><div style="margin-bottom: 10px;">Allergan is expecting double-digit sales growth in 2012 led by newly approved therapeutic indications.<wbr> </div><div style="margin-bottom: 10px;">Some disappointment was expressed by analysts in the rate of therapeutic versus aesthetic growth.<wbr> Pyott reassured noting that the therapeutic launches are a very long ramp but that a take-off is expected in 2012.<wbr> This should be underpinned in 2013 by the launch of the idiopathic overactive bladder indication.<wbr> </div><div style="margin-bottom: 10px;">Development plans were not discussed in detail during today's call but will be highlighted in more detail at the group's R&amp;D investor day in late March </div><div>Source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6214">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T18:29:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T18:29:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Ph3 Study with Novartis' Everolimus for NETs</title>
	<pubDate>2012-02-02T17:31:05+01:00</pubDate>
	<wp:post_id>3218</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis is to start the Radiant-4 study in March 2012, to compare the antitumor activity of everolimus plus best supportive care (BSC) vs.<wbr> placebo plus BSC in patients with advanced non-functional NET of GI or lung origin.<wbr> Primary endpoint will assess time to PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Everolimus might be more beneficial against advanced NETs than previously recognized.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://connection.asco.org/forums/forumid/22/postid/442/scope/posts.aspx#442">http:/<wbr>/<wbr>connection.<wbr>asco.<wbr>org/<wbr>forums/<wbr>forumid/<wbr>22/<wbr>postid/<wbr>442/<wbr>scope/<wbr>posts.<wbr>aspx#442</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01524783?cond=prostate+OR+hemophilia+OR+haemophilia+OR+neuroendocrine+OR+spasticity&amp;fund=2&amp;rcv_s=12%2F04%2F2011&amp;rank=15"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 279 </div><div style="margin-bottom: 10px;">The study is to complete in November 2017.<wbr> </div><div style="margin-bottom: 10px;">Dosage: everolimus 10mg once daily until disease progression, intolerable toxicity, or consent withdrawal.<wbr> </div><div><DIV class="indent2" style="MARGIN-TOP: 0.5ex">Location: U.<wbr>S</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6864">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T17:31:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T17:31:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Early Stage Prostate Cancer Data With PROVENGE At ASCO GU</title>
	<pubDate>2012-02-02T12:35:16+01:00</pubDate>
	<wp:post_id>3219</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG><SPAN class="Apple-style-span" style="font-size: medium; word-spacing: 0px; text-transform: none; color: #000000; text-indent: 0px; line-height: normal; font-style: normal; font-family: 'Times New Roman'; white-space: normal; letter-spacing: normal; border-collapse: separate; font-variant: normal; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 14px; color: #1a1a1a; line-height: 18px; font-family: Helvetica, Arial, sans-serif;"></SPAN></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div>From <A href="http://www.dendreon.com">http:/<wbr>/<wbr>www.<wbr>dendreon.<wbr>com</A>, see <A href="http://www.firstwordpharma.com/node/948405">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8068">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T12:35:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T12:35:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz' Bocouture Launched in Czec Republic</title>
	<pubDate>2012-02-02T12:10:44+01:00</pubDate>
	<wp:post_id>3220</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6212">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T12:10:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T12:10:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Development Pipeline Progress</title>
	<pubDate>2012-02-02T11:41:59+01:00</pubDate>
	<wp:post_id>3221</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Accompanying its fourth quarter results presentation, was a very detailed overview of the Roche pipeline.<wbr> This highlighted certain key developments in carcinoid disease (Avastin SWOG study), diabetes (dual GLP-1/<wbr>GIP agonist), prostate cancer (antibody drug conjugate), HCC (anti-PIGF mAb) and ulcerative colitis(RhumAb-beta7).<wbr> Also noted in the presentation was the sharp decline in Nutropin US sales in the third and fourth quarters of 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Avastin SWOG Trial</STRONG> </div><div style="margin-bottom: 10px;">In terms of forthcoming submissions there was no mention of a filing for Avastin in high risk carcinoid disease.<wbr> However, the SWOG study was featured as shown below highlighting that results are now anticipated in 2013.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Progress With Other Key Development Candidates</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Nutropin Sales Performance in 2011</STRONG> </div><div style="margin-bottom: 10px;">The chart below illustrates the marked decline in Nutropin sales that occurred in the third and fourth quarters of 2011 within the US market.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_8_ScreenCapture8.jpg"> </div><div>Source: <A href="http://www.roche.com">www.<wbr>roche.<wbr>com</A> </div><!-- Comment details --><a name="endocrinology6861attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(195,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(209,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(224,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(141,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(190,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(195,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(171,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6861_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(261,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6861">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T11:41:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T11:41:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Nordisk 2011 Results - Key Takeaways</title>
	<pubDate>2012-02-02T10:38:20+01:00</pubDate>
	<wp:post_id>3222</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NovoNordisk has lifted its sales outlook after reporting a strong increase in 2011 sales +11% in local curerncies and a 22% increase in operating profits (+18% in DKK).<wbr> The star performer has been and is expected to be the GLP-1 analogue Victoza sales of which grew by 159% to DKK5.<wbr>9bn.<wbr> Development progress with the hemophilia pipeline was also reported.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Victoza Roll-Out</STRONG> </div><div style="margin-bottom: 10px;">The global roll-out is continuing, now with 48 countries having launched Victoza&reg;, most recently Oman, Thailand, Bulgaria, Belarus, Taiwan and Jordan.<wbr> </div><div style="margin-bottom: 10px;">Victoza&reg; has achieved global market share leadership with 58% value market share in the GLP-1 segment in November 2011 compared to 30% in November 2010.<wbr> Moreover, the GLP-1 class‟s value share of the total diabetes care market increased to 4.<wbr>5% in November 2011 compared to 3.<wbr>2% in November 2010.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM>Victoza&reg; was launched in China during the fourth quarter of 2011,</EM></STRONG> and although initial market feedback has reportedly been positive, actual sales are so far limited.<wbr> </div><div style="margin-bottom: 10px;">Japan &amp; Korea Sales in Japan &amp; Korea increased, from a relatively low base in 2010, by 348% in local currencies and by 370% measured in Danish kroner in 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Hemophilia Franchise</STRONG> </div><div style="margin-bottom: 10px;">Sales of NovoSeven&reg; increased by 7% in local currencies and by 4% in Danish kroner to DKK 8,347 million compared to 2010.<wbr> All regions contributed to the sales growth although International Operations was the primary contributor to growth followed by Europe and North America.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM>Key Developments</EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><EM>Turoctocog alfa, a recombinant FVIII</EM></STRONG>, has completed its phase 3a programme.<wbr> the largest registration trial ever conducted for a factor VIII product.<wbr> </div><div style="margin-bottom: 10px;">Turoctocog alfa has been dosed to 150 haemophilia A patients with 75 exposures each.<wbr> The safety profile was reportedly positive with no patients developing an inhibitor and only few adverse events reported.<wbr> A high success rate was observed in both treatment of bleeds and in reduction of number of bleeds.<wbr> Turoctocog alfa also demonstrated a 100% success rate in preventing bleeds during surgery in both children and adults.<wbr> Equally positive results were observed in a paediatric trial of turoctocog alfa including 63 children below 12 years of age.<wbr> No inhibitory antibodies were reported in children, and a high efficacy in both treatment and prevention of bleeds was observed.<wbr> </div><div style="margin-bottom: 10px;">Based on these results, Novo Nordisk will work towards submission to regulatory authorities during the second half of 2012.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, regarding <STRONG><EM>Recombinant FXIII</EM></STRONG>, the company has received a Complete Response Letter in the US from the FDA regarding its application to market the drug for congenital factor XIII deficiency noting that the agency will require additional information prior to considering the product for approval.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Growth Hormone Performance &amp; Development</STRONG> </div><div style="margin-bottom: 10px;">Sales of Norditropin&reg; increased by 5% measured in local currencies and by 5% measured in Danish kroner to DKK 5,047 million compared to 2010.<wbr> The sales growth was driven by International Operations, North America and Japan &amp; Korea, partly offset by a decline in Europe.<wbr> Novo Nordisk remains the second-largest supplier in the global growth hormone market with a 24% share measured in volume.<wbr> After previous setbacks with a long-acting growth hormone, NovoNordisk has announced the initiation of a phI trial with a new long-acting formulation NN8640, The aim of the trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound in healthy male subjects.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Group Outlook</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6860_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="endocrinology6860attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6860_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6860">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T10:38:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T10:38:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca 2011 Results - Key Takeaways</title>
	<pubDate>2012-02-02T10:14:40+01:00</pubDate>
	<wp:post_id>3223</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Competition from generics and price cuts had a negative impact on the sales, which were down 2% to $ 33.<wbr>591bn.<wbr> 2012 guidance is for a low double-digit decline in revenues.<wbr> The group expects another $1.<wbr>6B of annual savings from third restructuring in 5 years.<wbr> The total number of positions expected to be impacted for this phase is estimated to be approx.<wbr> 7,300.<wbr> Of note the new R&amp;D orientation in neurosciences.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8066_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A focus for much of the change in R&amp;D is the neuroscience therapy area.<wbr> As a result, AstraZeneca will create a new “virtual” neuroscience Innovative Medicines unit (iMed) made up of a small team of around 40 to 50 AstraZeneca scientists conducting discovery and development externally, through a network of some of the most innovative partners in academia and industry globally.<wbr> The team will be based in major neuroscience hubs – Boston (US) and Cambridge (UK) – and work closely with innovative partners such as the Karolinska Institute in Stockholm (Sweden).<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8066_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology8066attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8066_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(26,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8066_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(54,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8066_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(43,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8066">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T10:14:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T10:14:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Octoplus Signs Formulation Dev. and MSO Contract with Ferring</title>
	<pubDate>2012-02-02T10:12:43+01:00</pubDate>
	<wp:post_id>3224</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside clinical material manufacturing services, Octoplus is specialised in injectable pharmaceutical products and liposomal/<wbr>microsphere formulations.<wbr> Although compound, activities and financial terms of the contract were not disclosed you will find below the CI considerations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Firmagon 1M</STRONG> </div><div style="margin-bottom: 10px;">A Ferring trial is currently evaluating a 1M formulation administered intramuscularly (IM) - Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7972" class="defaultlink">Oncology7972: New Degarelix Trial Evaluating New Route Of Administration</a>.<wbr>  </div><div style="margin-bottom: 10px;"><STRONG>Other</STRONG> </div><div><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9772">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T10:12:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T10:12:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Hybrid of Leuprolide Launched in Italy</title>
	<pubDate>2012-02-02T10:06:20+01:00</pubDate>
	<wp:post_id>3225</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Hybrid of Leuprolide Launched in Italy</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to Alexandra Corio's feedback we have learnt that Leptoprol was launched on January 16th, 2012.<wbr> The drug is marketed by Sandoz and developed by RegioMedica.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=109">...</a><br></div><div>The brand name used " LEPTOPROL" is surprising for me , because this brand seems currently  widely used for METROPROLOL generic tablets ( a beta adrenergic , cardio product) , see for example LEPTOPROL  from MAVI pharm .<wbr> (<A href="http://drugs-about.com/drugs-l/leptoprol.html">http:/<wbr>/<wbr>drugs-about.<wbr>com/<wbr>drugs-l/<wbr>leptoprol.<wbr>html</A>) , and could be the source of a drug product administration confusion ! </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=111">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids109">View thread  DKPHybrids109: Hybrid of Leuprolide Launched in Italy</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T10:06:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T10:06:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Switzerland Becomes the First EU Country to Approve Allergan's Non-Animal Test</title>
	<pubDate>2012-02-02T09:51:29+01:00</pubDate>
	<wp:post_id>3226</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: SwissMedic has approved Allergan’s fully in vitro, cell-based assay for use in the stability and potency testing of BOTOX® and VISTABEL®.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Allergan has disclosed it plans to work with the European medicines regulators so that this non-animal assay can be used for the commercial batch release of BOTOX® and VISTABEL® sold in Europe.<wbr> </div><div style="margin-bottom: 10px;">The company confirmed that it has already filed for approval throughout the EU.<wbr> </div><div>Source: <A href="http://www.buav.org/article/933/the-buav-welcomes-swiss-regulators-acceptance-of-non-animal-test-for-botox">http:/<wbr>/<wbr>www.<wbr>buav.<wbr>org/<wbr>article/<wbr>933/<wbr>the-buav-welcomes-swiss-regulators-acceptance-of-non-animal-test-for-botox</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6211">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T09:51:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T09:51:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J's Zytiga (abiraterone) Too Expensive for National Health Service (NHS)</title>
	<pubDate>2012-02-02T09:38:15+01:00</pubDate>
	<wp:post_id>3227</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Cost Issue</STRONG> </div><div style="margin-bottom: 10px;">Although  </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8108c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The All Wales Medicines Strategy Group has approved Zytiga (abiraterone acetate) for men with advanced castration resistant prostate cancer - s<SPAN style="letter-spacing: 0px;">pecifically, Zytiga is indicated for use alongside with prednisone or prednisolone in adult men whose disease has progressed after a docetaxel-based chemotherapy regimen.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="letter-spacing: 0px;">The AWMSG were able to approve abiraterone after assessing it as an end of life drug, meaning it will now be available on the NHS in Wales until NICE release their final guidance, which will override the AWMSG decision if abiraterone is rejected.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="letter-spacing: 0px;"><A href="http://www.wales.nhs.uk/sites3/Documents/371/Abiraterone%20%28Zytiga%29%20FAR.pdf">http:/<wbr>/<wbr>www.<wbr>wales.<wbr>nhs.<wbr>uk/<wbr>sites3/<wbr>Documents/<wbr>371/<wbr>Abiraterone%20%28Zytiga%29%20FAR.<wbr>pdf</A><BR></SPAN> </div><div><SPAN style="letter-spacing: 0px;">Source Pharmatimes 20 February 2012/<wbr>AWMSG</SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8065">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-02T09:38:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-02T09:38:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Q32011 - Key Takeaways</title>
	<pubDate>2012-02-01T17:25:54+01:00</pubDate>
	<wp:post_id>3228</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda registered strong third quarter revenue growth primarily due to the acquisition of Nycomed but operating profit/<wbr>margins and net income fell substantially.<wbr> Numbers aside the focus of its presentation was on the re-organisation of its R&amp;D and the competitive positioning of TAK-700 which it believes will be the first anti-hormonal agent for CRPC to be approved in Japan.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">In its webcast Takeda focused on the reorganisation of its R&amp;D and its guiding principals.<wbr> </div><div style="margin-bottom: 10px;">Tadataka Yamada noted:- </div><div style="margin-bottom: 10px;">"We are in a process right now structuring the R&amp;D organization somewhat differently than in the past and at another time, I will go into greater detail on how we have structured.<wbr> But for the moment, I do want to explain that the strategic product planning department of Takeda has now been amalgamated into the R&amp;D organization and has been divided into three separate groups.<wbr> One group that leads the therapeutic areas, another group called New Frontier Sciences that will explore opportunities for bringing important, early scientific platforms into the company.<wbr> And then third, that will support the office function or R&amp;D.<wbr> Mr.<wbr> Iwasaki who's currently the Head of the Strategic Product Planning Department will support me in the Chief Medical and Scientific Officer office.<wbr>" </div><div style="margin-bottom: 10px;">"Now a critical element about the new R&amp;D organization is focused on key principles that have a very narrow and pinpoint attention to patient needs.<wbr> We believe that understanding the relationship with a patient will help us greatly as we try to make new products for them.<wbr> One of the most important principles in this is to have a sense of urgency about what we're doing.<wbr> Of course there are many patients who are suffering greatly.<wbr> We understand that we can do something to relieve their suffering.<wbr> And an intrinsic appreciation of this will have a great motivating factor for our scientists.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Specific Comments on TAK-700</STRONG> </div><div style="margin-bottom: 10px;">When questioned about the competitive positioning of TAK-700 in light of the MDV3100 data Hiroshi Takahara stated:- </div><div style="margin-bottom: 10px;">"TAK-700 is a 17, 20 lyase inhibitor and it preferentially inhibits the production of testosterone without the same level of impact on the production of cortisol that a drug like Abiraterone which inhibits a different axis, which includes the 17 hydroxylase enzymes.<wbr> So, Abiraterone will always need to be taken with a steroid to supplement the cortisol.<wbr> TAK-700 has the possibility to be taken without a steroid in earlier prostate cancer.<wbr> And in the metastatic trials that we have ongoing, two Phase III global trials in prostate cancer patients whose disease has metastasized, who have either received chemotherapy and failed or have not yet received chemotherapy.<wbr> In those two settings with metastatic patients, TAK-700 is used with a steroid because the steroid actually has an anti-cancer effect in and of itself.<wbr> But as we move into earlier prostate cancer, we anticipate it would be used without a steroid with concomitant – avoiding the concomitant side effects of the steroid.<wbr> The results with MDV3100 were very good and we anticipate that these two products, TAK-700 and MDV3100, could have similar outcomes but could also potentially be used together in that the mechanisms of hormone suppression are different and therefore may be combinable for an even greater result.<wbr> <STRONG>We anticipate that TAK-700, while it will not be first to market outside of Japan, could still have the opportunity to be first to market in Japan </STRONG>and as you saw our announcement earlier, we have now included the first Japanese patients into the global Phase III trials.<wbr> I hope that gives you some background to your question" </div><div>Source: <a href="http://www.takeda.com" class="defaultlink" title="www.takeda.com">takeda.com</a> </div><!-- Comment details --><a name="oncology8062attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(159,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(206,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(86,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(151,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8062_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(184,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8062">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-01T17:25:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-01T17:25:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hybrid of Leuprolide Launched in Italy</title>
	<pubDate>2012-02-01T15:55:13+01:00</pubDate>
	<wp:post_id>3229</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Alexandra Corio's feedback we have learnt that Leptoprol was launched on January 16th, 2012.<wbr> The drug is marketed by Sandoz and developed by RegioMedica.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><B>LEPTOPROL 1 implant 3,6 mg leuprorelide acetate </B></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">SANDOZ authorization number:039814013 </DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><B>PP 133,39€</B></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><B>LEPTOPROL 1 implant 5 mg  leuprorelide acetate  </B><BR>SANDOZ authorization number: 039814052 </DIV> </div><div><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><B>PP 345,11€</B></DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="DKPHybrids111c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The brand name used " LEPTOPROL" is surprising for me , because this brand seems currently  widely used for METROPROLOL generic tablets ( a beta adrenergic , cardio product) , see for example LEPTOPROL  from MAVI pharm .<wbr> (<A href="http://drugs-about.com/drugs-l/leptoprol.html">http:/<wbr>/<wbr>drugs-about.<wbr>com/<wbr>drugs-l/<wbr>leptoprol.<wbr>html</A>) , and could be the source of a drug product administration confusion ! </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=109">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-01T15:55:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-01T15:55:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Savient CEO to Replace Dendreon CEO</title>
	<pubDate>2012-02-01T13:52:52+01:00</pubDate>
	<wp:post_id>3230</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Mitchell Gold will step down from the post, and hold that position until June 30 when <TR:CATEGORY>Johnson</TR:CATEGORY> will become CEO &amp; chairman of Dendreon.<wbr> Rationale for this change has been attributed to the disappointing launch of Dendreon's Provenge.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">J.<wbr> H.<wbr> Johnson was appointed chief executive officer of Savient Pharm.<wbr> in January 2011.<wbr> </div><div style="margin-bottom: 10px;">Prior to this appointment, he served as a senior vice president of Eli Lilly and Company and president of Lilly Oncology Business Unit, where he was responsible for multi-billion dollar franchise including a development portfolio of over 30 oncology products.<wbr> </div><div>From August 2007 to November 2009, he was CEO of ImClone Systems, and served on ImClone's board of directors until the company was acquired by Lilly in November 2008.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9770">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-01T13:52:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-01T13:52:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Q2 FY2011 Results - Key Takeaways</title>
	<pubDate>2012-02-01T11:58:04+01:00</pubDate>
	<wp:post_id>3231</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas has reported revenue growth of +4%, recording growth in all regions but with US sales notably up 18% due to a first time contribution from OSI and a strong performance from the TKI inhibitor Tarceva.<wbr> Eligard's growth remains solid and the company's R&amp;D pipeline looks to be moving into a productive phase with noteworthy MDV3100 data also reported today.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Sales in Europe grew by 6% with Vesidcare, Eligard and Mycamine strong contributors.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Highlighted below are what the group considers to be its major achievements during the first half including the registration filings (EU and US August 2011) for its new urology agent mirabegron for iOAB and steady progress with its prostate cancer drug MDV3100 and its renal cancer drug tivoaznib.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Key R&amp;D Developments</STRONG> </div><div style="margin-bottom: 10px;">Astellas continues to make good progress with its oncology pipeline having reported strong MDV3100 data today and as shown below and a survival benefit in its ph2 study with its pancreatic cancer drug AGS-1C4D4.<wbr> It is also highlighting a new prostate cancer drug in its pipeline which has entered phI development.<wbr> </div><div style="margin-bottom: 10px;"><EM><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_6_ScreenCapture6.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_7_ScreenCapture7.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_8_ScreenCapture8.jpg"></EM> </div><div><a href="http://www." class="defaultlink" title="www."></a> astellas.<wbr>com </div><!-- Comment details --><a name="oncology8057attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(253,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(273,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(690 B)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(325,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(319,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(373,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(319,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8057_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(299 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8057">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-01T11:58:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-01T11:58:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MDV3100 Post Docetaxel Data Looks Very Promising</title>
	<pubDate>2012-02-01T10:36:36+01:00</pubDate>
	<wp:post_id>3232</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas and Medivation have today released the full results of the phIII AFFIRM trial ahead of the presentation at ASCO GU tomorrow.<wbr> The data from this 1199 patient study is robust and highly statistically significant in terms of both primary and all secondary endpoints.<wbr> It fully validates the androgen signalling pathway as mechanistically important in the CRPC setting.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>In this post doceaxel setting resuts of particular note are as follows:-</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Men taking MDV3100 lived for a median of 18,4 months compared with 13.<wbr>6 months for those taking placebo (p&lt;0.<wbr>0001 HR=0.<wbr>631)
</LI>
<LI>MDV31000 also met all secondary endpoints including radiographic progression free survival *8.<wbr>3 vs.<wbr> 2.<wbr>9 months p&lt;0.<wbr>0001 HR =0.<wbr>404.<wbr>
</LI>
<LI>Soft tissue response rate 28.<wbr>9% vs.<wbr> 3.<wbr>8% p&lt;0.<wbr>0001
</LI>
<LI>Time to PSA progression 8.<wbr>3 vs.<wbr> 3.<wbr>0 months p&lt;0.<wbr>0001: HR=0.<wbr>249
</LI>
<LI>PSA declines of 50% or greater were more common in the MDV3100 group than in the placebo group (54% vs.<wbr> 1.<wbr>5% p&lt;0.<wbr>0001
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Safety Profile</STRONG> </div><div style="margin-bottom: 10px;">MDV3100 was well tolerated.<wbr> Serious AEs were lower in the MDV3100 group than in the placebo group.<wbr> Comparative Grade 3 AEs of note were fatigue (6.<wbr>3% in the MDV3100 group vs 7.<wbr>0% in the placebo arm, cardiac disorders (0.<wbr>9% vs 2.<wbr>0%), seizure (0.<wbr>6% vs 0.<wbr>0%), LFT abnormalities 0.<wbr>4% vs.<wbr> 0.<wbr>8%.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the results Professor Jonathon De Bono (Royal Marsden UK), co-principal investigator for the AFFIRM trial stated "The almost 5-month survival benefit MDV3100 showed over placeob in this trial is noteworthy, as is the fact that men with post chemotherapy prostate cancer lived for a median of a year and a half.<wbr> </div><div style="margin-bottom: 10px;">Medivation's CEO noted that based on this robust data and together with its partner Astellas it is committed to working diligently to bring MDV3100 to the market as quickly as possible.<wbr> </div><div style="margin-bottom: 10px;">The data will be highlighted in a late breaking oral presentation tomorrow at the ASCO GU Meeting (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8047" class="defaultlink">Oncology8047: Forthcoming ASCO GU Conference - Key Presentations</a>) and will be followed by a Medivation hosted conference call to discuss the results.<wbr> </div><div style="margin-bottom: 10px;">For more information on the MDV3100 please refer to Astellas's last presentation in November (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7900" class="defaultlink">Oncology7900: Highlights from Astellas' Press Conference</a>) </div><div><A href="http://www.medivation.com">www.<wbr>medivation.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8051">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-02-01T10:36:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-02-01T10:36:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Cabozantinib Study to Assess Pain Associated with Metastases in Men with CRPC</title>
	<pubDate>2012-01-31T16:33:55+01:00</pubDate>
	<wp:post_id>3233</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Exelixis has planned to start this month a Ph3 randomized, double-blind, controlled trial to assess the effect of cabozantinib vs.<wbr> mitoxantrone plus prednisone on pain response (primary endpoint).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01522443?cond=prostate+OR+hemophilia+OR+haemophilia+OR+neuroendocrine+OR+spasticity&amp;fund=2&amp;rcv_s=12%2F02%2F2011&amp;rank=7"><STRONG></STRONG></A> - COMET-2 </div><div style="margin-bottom: 10px;">Secondary endpoint will assess bone scan response.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 246 </div><div style="margin-bottom: 10px;">Est.<wbr> Primary Completion Date: June 2013.<wbr> </div><div>Location: U.<wbr>S.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8049">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-31T16:33:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-31T16:33:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's 2011 Performance - Key Takeaways</title>
	<pubDate>2012-01-31T14:59:15+01:00</pubDate>
	<wp:post_id>3234</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pfizer has reported a sharp fall in fourth quarter earnings as generic erosion of Lipitor starts to impact.<wbr> Q4 sales were marginally better than analysts predicted down by 4% set against the backdrop of a 24% decline inLipitor sales.<wbr> However, of interest was that Somavert (pegvisoment) and Sutent were amongst the group's 6 fastest growing products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Somavert Sales</STRONG> </div><div style="margin-bottom: 10px;">Whilst still small in absolute terms relative to group revenues of $67.<wbr>4bn, global Somavert revenues of $183 were up 17% with growth in the fourth quarter +19%.<wbr> Geographically, the biggest contributor to growth is ex-US notably Europe where sales grew from $109m in 2010 to $121m in 2011 (+6% ex currency).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sutent Sales</STRONG> </div><div style="margin-bottom: 10px;">Sutent Pfizer's multikinase inhibitor which received an expanded label in 2011 to include pNET on top of previous approvals for renal carcinoma and GIST generated sales of $1.<wbr>18bn +11% (l.<wbr>c.<wbr> +8%).<wbr> Q4 sales were up 7% to 317 with the fastest growth occuring in the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Genotropin</STRONG> </div><div style="margin-bottom: 10px;">W/<wbr>W sales were flat in 2011 but down in local currencies -4%.<wbr> Sales have declined in most markets with the exception of the Developed ROW which includes Australia, Canada, Japan, New Zealand, and South Korea where growth was +18%.<wbr> In a bid to rejuvinate growth and capture market share from the biosimilars, Pfizer has taken the first steps in some markets to reduce its price level to that of Omnitrope.<wbr> </div><div>Source: <a href="http://www.pfizer.com" class="defaultlink" title="http://www.pfizer.com">pfizer.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6855">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-31T14:59:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-31T14:59:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Italy: Price War Between Generics and Originators ?</title>
	<pubDate>2012-01-31T12:52:02+01:00</pubDate>
	<wp:post_id>3235</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A new law introducing stricter prescribing restrictions in Italy could save up to &euro;1 billion and lead to a price war says AssoGenerici, the Italian generic medicines association.<wbr>  However, the new law is still to pass through parliament.<wbr> </div><div style="margin-bottom: 10px;">Generic medicines have traditionally had a low market share in Italy and currently take 16% of the volume market.<wbr> The new law aims to ensure that cheaper medicines, if available, are actually dispensed.<wbr> In 90% of cases these medicines would be generics.<wbr> </div><div style="margin-bottom: 10px;">Recently, generics manufacturers have faced fierce competition from originators.<wbr> This is because originators have been lowering their prices to near generic levels in a bid to maintain their market share.<wbr> </div><div style="margin-bottom: 10px;">The R&amp;D-based industry claims that the new law will worsen market conditions, driving manufacturing abroad and forcing further plant closures.<wbr> </div><div style="margin-bottom: 10px;">See also <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9761" class="defaultlink">PharmaWorld9761: P&R End-of-Year Review 2011 and Outlook for 2012</a> </div><div>Source: Scrip 31 Janaury 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9768">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-31T12:52:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-31T12:52:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Molecular Insights ' Radiopharmaceutical to Enter Clinical for Targeted Treatment of mPC</title>
	<pubDate>2012-01-31T11:51:39+01:00</pubDate>
	<wp:post_id>3236</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company anticipates to start Ph1 in early 2013 with I-131-MIP-1466, a radiopharmaceutical radiolabeled with I-131 to enable targeted radiotherapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- MOA: systemic radiotherapy designed to deliver a therapeutic dose of radiation directly to metastatic prostate cancer </div><div style="margin-bottom: 10px;">- PC Results: the drug inhibits tumour growth in human prostate cancer xenografts </div><div style="margin-bottom: 10px;">- MSO: Centre for Probe Development and Commercialization (CPDC, Hamilton, ON).<wbr> The Centre has introduced several new radiopharmaceuticals to Ontario that are now being used in clinical trials to diagnose and stage various cancers and to monitor patient response in chemotherapy trials.<wbr> </div><div>Source: Molecular Insight PR </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8048">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-31T11:51:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-31T11:51:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Botox Study Targets Knee Pain</title>
	<pubDate>2012-01-30T18:23:35+01:00</pubDate>
	<wp:post_id>3237</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has initiated a phI/<wbr>II study to evaluate the use of Botox as a treatment for osteoarthristis knee pain </div><div style="margin-bottom: 10px;">This study will evaluate the efficacy and safety of a single 200U dose administered into the intra-articular space compared with placebo as treatment for osteoarthritis (OA) knee pain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines, Numbers, Location</STRONG> </div><div style="margin-bottom: 10px;">The study has just started recruiting and is planned to enroll 120 subjects.<wbr> Completion is planned for April 2013.<wbr> The study will be undertaken in Denmark.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Endpoints (Baseline and 12 weeks)</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="body3">Primary Outcome Measures:
<UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI style="margin-top: 0.7ex;">Change from Baseline in Daily Worst Pain Score
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">Secondary Outcome Measures:
<UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI style="margin-top: 0.7ex;">Change from Baseline in Western Ontario McMaster Arthritis Index (WOMAC&trade;) Total Index Score 
</LI>
<LI style="margin-top: 0.7ex;">Change from Baseline in WOMAC Pain Score
</LI>
<LI style="margin-top: 0.7ex;">Change from Baseline in WOMAC Physical Function Score
</LI>
<LI style="margin-top: 0.7ex;">Change from Baseline in Patient Global Impression of Change Score
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><STRONG>ClinicalTrial Identifie</STRONG>r NCT01518257 </div><div>From <A href="http://clinicaltrials.gov/">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov</A>, see <A href="http://clinicaltrials.gov/ct2/show/NCT01518257?rcv_s=01%2F16%2F2012&amp;rcv_d=14&amp;rank=232">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6207">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-30T18:23:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-30T18:23:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Forthcoming ASCO GU Conference - Key Presentations</title>
	<pubDate>2012-01-30T17:26:26+01:00</pubDate>
	<wp:post_id>3238</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This week's ASCO GU meeting will have a significant focus on new and emerging therapies for CRPC, with the full results of the MDV3100 AFFIRM trial (Medivation Astellas) and those of the Apharadin ALSYMPCA trial (Bayer) to be presented on Thursday 2nd.<wbr> </div><div style="margin-bottom: 10px;">MDVN and Astellas could report soon on the outcome of pre-NDA meeting with the FDA in early 2012 to discuss filing options.<wbr> With the recent receipt of fast-track designation, it appears likely that the US filing would receive priority review.<wbr> Hence there seems to be a good chance for MDV3100 to be approved in 2H:12.<wbr> MDVN has opted to co-promote MDV3100 in the US.<wbr> </div><div style="margin-bottom: 10px;">Turning to the congress the CRPC and Translation Science symposia on Thursday 2nd will review very comprehensively what is currently in development and what is new and pioneering.<wbr> </div><div style="margin-bottom: 10px;">Each presentor has already summarised the key points of his presentation and links to these are attached for review.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>CRPC Symposia</STRONG> </div><div style="margin-bottom: 10px;"><A href="http:///LinkClick.aspx?fileticket=VVTOjXYocQM%3d&amp;tabid=1739"><STRONG>Approved Agents and Related Trials</STRONG></A> <BR>Gary R.<wbr> MacVicar, MD – Northwestern University </div><div style="margin-bottom: 10px;">Focuses on the status of the key trials with novel hormonal agents, immunotherapy, new bone targeted therapy and cytotoxics.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://gucasym.org/LinkClick.aspx?fileticket=VVTOjXYocQM%3d&amp;tabid=1739">http:/<wbr>/<wbr>gucasym.<wbr>org/<wbr>LinkClick.<wbr>aspx?fileticket=VVTOjXYocQM%3d&amp;tabid=1739</A><BR> </div><div style="margin-bottom: 10px;"><B><A href="http:///LinkClick.aspx?fileticket=6gtkeL-YkzU%3d&amp;tabid=1739">Rational Sequencing</A><BR></B>Philip W.<wbr> Kantoff, MD – Dana-Farber Cancer Institute </div><div style="margin-bottom: 10px;">A rational framework for prescribing the new and emerging agents will be reviewed during the presentation.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://gucasym.org/LinkClick.aspx?fileticket=6gtkeL-YkzU%3d&amp;tabid=1739">http:/<wbr>/<wbr>gucasym.<wbr>org/<wbr>LinkClick.<wbr>aspx?fileticket=6gtkeL-YkzU%3d&amp;tabid=1739</A> </div><div style="margin-bottom: 10px;"><B><A href="http:///LinkClick.aspx?fileticket=ZsMOB_u1BFo%3d&amp;tabid=1739">Novel Targets, Agents, and Trials</A><BR></B>Evan Y.<wbr> Yu, MD – University of Washington Seattle Cancer Care Alliance </div><div style="margin-bottom: 10px;">Reviewed are drugs such as the VEGF- Trap agent aflibercept phIII results pending mid 2012.<wbr> Cabozanitinib (multikinase inhibitor targeting VEGF and MET).<wbr> PhII data has shown some remarkable resolution of bone scans and markers and high response rate in terms of RECIST.<wbr> The Src kinase inhibitor dasatinib which may be of value in a subset of prostate cancer that exhibit high Src kinase activity and Custirsen a second- generation phosphorothioate antisense that is complementary to the clusterin mRNA translation initiation site.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Translational Science Symposia</STRONG> </div><div style="margin-bottom: 10px;"><A href="http:///LinkClick.aspx?fileticket=Hlr8tBGDulI%3d&amp;tabid=1739"><B>Introduction to Androgen-Receptor Splice Variants and Their Significance</B> </A>Elahe A.<wbr> Mostaghel, MD, PhD – Fred Hutchinson Cancer Research Center </div><div style="margin-bottom: 10px;">This presentation focuses on the potential of the marine compound EPI-001 which it is believed may be a promising agent for disease characterised by splice variants.<wbr> The review suggests that LBD-directed agents such as MDV3100 may have more efficacy in abiraterone-naive compared with abiraterone-treated patients, and that NTD-directed agents such as EPI-001  may be required for optimal AR axis inhibition in patients whose disease recurs after abiraterone therapy.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://gucasym.org/LinkClick.aspx?fileticket=Hlr8tBGDulI%3d&amp;tabid=1739">http:/<wbr>/<wbr>gucasym.<wbr>org/<wbr>LinkClick.<wbr>aspx?fileticket=Hlr8tBGDulI%3d&amp;tabid=1739</A><BR> </div><div style="margin-bottom: 10px;"><A href="http:///LinkClick.aspx?fileticket=yrD5lkZzDDg%3d&amp;tabid=1739"><STRONG>The Androgen Receptor: New Points of Attack</STRONG></A><BR>Marianne Sadar, PhD – British Columbia Cancer Agency<BR>This presentation similarly looks as though it will focus on the potential of EPI-00 </div><div style="margin-bottom: 10px;"><A href="http://gucasym.org/LinkClick.aspx?fileticket=yrD5lkZzDDg%3d&amp;tabid=1739">http:/<wbr>/<wbr>gucasym.<wbr>org/<wbr>LinkClick.<wbr>aspx?fileticket=yrD5lkZzDDg%3d&amp;tabid=1739</A> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Androgen Receptor Adaptation and Resistance: Can We Overcome It?</STRONG><BR>Jack Schalken, PhD - Radboud University Nijmegen</LI>
</UL> </div><div style="margin-bottom: 10px;">No information forthcoming at the moment<BR> </div><div style="margin-bottom: 10px;"><A href="http:///LinkClick.aspx?fileticket=aid8aYKcL0I%3d&amp;tabid=1739"><STRONG>Redundant Molecular Pathways in Prostate Cancer</STRONG> </A> </div><div style="margin-bottom: 10px;">Brett Carver Memorial Sloane Kettering </div><div style="margin-bottom: 10px;">This will focus on how the PI3K and AKT pathways cross regulate one another by reciprocal feedback.<wbr> This reciprocal feedback regulation provides rationale for the evaluation of combination therapy targeting the PI3K and AR pathways </div><div style="margin-bottom: 10px;"><A href="http://gucasym.org/LinkClick.aspx?fileticket=aid8aYKcL0I%3d&amp;tabid=1739">http:/<wbr>/<wbr>gucasym.<wbr>org/<wbr>LinkClick.<wbr>aspx?fileticket=aid8aYKcL0I%3d&amp;tabid=1739</A> </div><div style="margin-bottom: 10px;"><STRONG>Key Posters</STRONG> </div><div style="margin-bottom: 10px;">Two other interesting poster abstracts will be those presented on ARN-509 and AEZS-108.<wbr> </div><div style="margin-bottom: 10px;">Interestingly In June, Medivation filed a breach of contract suit against The Regents of the University of California and Michael Jung, who is one of the inventors of MDV3100.<wbr> In court documents, MDVN alleges that the defendants, during the MDVN-funded discovery collaboration that led to the identification of MDV3100, produced a parallel set of closely related compounds.<wbr> MDVN's suit alleges that Dr.<wbr> Jung co-founded Aragon Pharmaceuticals with these compounds without first offering exclusive rights to MDVN, and Aragon's candidate ARN-509 (Phase I/<wbr>II) is either the same as or similar to a compound called A52, which differs in chemical structure from MDV3100 by only one atom.<wbr> </div><div style="margin-bottom: 10px;"><B>Abstract # 43 :</B> Phase I/<wbr>II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.<wbr> ( C9 )<BR><EM>Dana E.<wbr> Rathkopf , MD </EM> </div><div><B>Abstract # 60 :</B> A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.<wbr> ( D3 )<BR><EM>Stephen V.<wbr> Liu , MD </EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8047">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-30T17:26:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-30T17:26:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Aesthetics @ IMCAS (Jan. 26-29, Paris) - Key Messages</title>
	<pubDate>2012-01-30T16:08:07+01:00</pubDate>
	<wp:post_id>3239</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The two-hour sympo was mainly dedicated to the concept of "Full Face Approach".<wbr> Live injections of Bocouture and Radiesse were performed to demonstrate how to optimise treatment outcome by combining the use of Bocoture and Radiesse.<wbr> In addition two recent clinical results of Bocouture in Glabellar Lines were presented.<wbr> Interesting slides on Merz' Sales &amp; Marketing are provided below as well as key results from the company's Face Value Beauty survey.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Sales</STRONG> </div><div style="margin-bottom: 10px;">The company achieved sales of € 113,8M in 2011 (+46% vs.<wbr> 2010).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sales Force by Region</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Merz is committed to raise the bar in training.<wbr> Message was on support and relationship building.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Merz has created an exchange and training platform through the annual Merz Aesthetics European Experts Summits (MAEXS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The survey, which was commissioned in late 2010 to examine women's attitudes on beauty, confidence, aging and aesthetic procedures, has uncovered that today's women seek holistic strategies for the rejuvenation of the entire face.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Half time of the sympo was dedicated to the live injections of Bocouture and Radiesse, performed by Francine Temples (Belgium) and Fulvio Conte (Italy) respectively.<wbr> It was an interactive session with questions to the audience.<wbr> </div><div style="margin-bottom: 10px;">Welf Prager (Germany) provided an overview of recent clinical data : </div><div style="margin-bottom: 10px;"><STRONG>Comparison Study of Bocouture and Botox (data on file)</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Design: simple blind randomized trial, split face (1:1,5)</LI>
<LI>Recruitment: 25 patients </LI>
<LI>Dosage: 4U Bocouture and 6U Botox</LI>
<LI>Duration: 4 months</LI>
<LI>Results: No difference between both products over 4 months</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Bocouture Long-term efficacy in GL </STRONG><STRONG>following treatment with Bocouture &gt; 2 years (publication in process)</STRONG> </div><div>Kate Goldie (UK) dicussed the 3D vectoring lift with Radiesse, highlighting the high viscosity and elasticity properties of the filler.<wbr> </div><!-- Comment details --><a name="neurology6204attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(23,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(44,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(21,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(46,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6204_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(42,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6204">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-30T16:08:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-30T16:08:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Iran is Making Significant Progresses in the Biosimilar and Biotechnology Drugs</title>
	<pubDate>2012-01-30T12:28:44+01:00</pubDate>
	<wp:post_id>3240</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Iran is Making Significant Progresses in the Biosimilar and Biotechnology Drugs</span>&nbsp;<br><span style="font-size: 12px;">Comment: According to a press TV, Iran has the medical knowledge and facility to produce 95% of those drugs internally (with 5% being biosimilars).<wbr> The country is reported to produce 8 new medicines to treat hemophilia, cancer and osteoporosis.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=101">...</a><br></div><div style="margin-bottom: 10px;">Interestingly, in an other article published on the same subject, we have learnt that the drugs include Botulinum toxin, Factor VII , Salmeterole (asthma), Riluzole (ALS), Letrozole (breast cancer), and Zoledronic acid (osteoporosis).<wbr> </div><div>Source: Isna.<wbr>ir </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=108">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids101">View thread  DKPHybrids101: Iran is Making Significant Progresses in the Biosimilar and Biotechnology Drugs</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-30T12:28:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-30T12:28:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Once-Weekly Bydureon Approved by FDA for Type 2 DM</title>
	<pubDate>2012-01-30T09:57:50+01:00</pubDate>
	<wp:post_id>3241</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bydureon, seen as Amylin's most important new drug, will face the competition of Novo's Victoza (launched 2 years ago).<wbr> As a condition of approval, the US Agency has requested a long-term CT by 2018 to study heart-related side-effects.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6852_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6311" class="defaultlink">Endocrinology6311: Bydureon - Once Weekly Exenatide Wins European Approval</a> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Price: $323.<wbr>44 for 4 weeks of therapy

</LI>
<LI>
Availability: U.<wbr>S.<wbr> pharmacies (starting February)

</LI>
<LI>
Sales Force: Amylin plans to hire 650 sales specialists who will promote Bydureon and Byetta to doctors (starting March)

</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6852_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Efficacy: Victoza (daily injection), proved superior to Bydureon in controlling blood sugar levels </div><div style="margin-bottom: 10px;">Dosing: Bydureon may get a boost because of its more convenient dosing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6852_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="endocrinology6852attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6852_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(143,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6852_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6852_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(92 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6852">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-30T09:57:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-30T09:57:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways From Abbott's Q4 Earnings Webcast</title>
	<pubDate>2012-01-27T17:26:49+01:00</pubDate>
	<wp:post_id>3242</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Abbott's commentary included a  few brief comments on the status of elagolix for endometriosis, Duodopa for Parkinson's disease and sales of Lupron's six-month formulation.<wbr> </div><div style="margin-bottom: 10px;">Abbott is working with regulatory authorities to finalize the Phase III study design for elagolix for endometriosis and expects to initiate the global trial in coming months.<wbr> </div><div style="margin-bottom: 10px;">It also plans to present Phase III pivotal for Duodopa, an intestinal gel for advanced Parkinson's disease at an upcoming medical meeting and submit its U.<wbr>S.<wbr> regulatory application for Duodopa later in 2012.<wbr> </div><div style="margin-bottom: 10px;">Finally it was noted that U.<wbr>S.<wbr> sales of Lupron in the quarter were up 7% giving rise to full year global Lupron sales of $810 million (ahead of internal expectations).<wbr> It was stated that the recently approved six-month formulation of Lupron Depot continues to perform well driving share gains and further expanding Abbott's category leadership.<wbr> </div><div>Source:www.<wbr>abbott.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8046">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-27T17:26:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-27T17:26:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Starts Enrollment For PhIII CRPC Trials In Japan</title>
	<pubDate>2012-01-27T15:58:58+01:00</pubDate>
	<wp:post_id>3243</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda announced toady that recruitment to its two ongoing global phIII trials with TAK-700 (orteronel) will be expanded to include Japan as a means of accelerating the development programme.<wbr> </div><div style="margin-bottom: 10px;">Orteronel which is cyp 17,20 lyase inhibitor, similar to the recently approved abiraterone (J&amp;J) is being evaluated in both patients with chemotherapy-naive CRPC and post-docetaxel metastatic patients.<wbr> The trials are collectively known as the ELM-PC (Evaluation of the Lyase inhibitor in Metastatic Prostate Cancer) trials.<wbr> </div><div style="margin-bottom: 10px;">C21004 is a randomized, double-blind and multi-center trial of prednisolone plus orteronel or placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.<wbr> The primary endpoints are Overall Survival (“OS”) and Progression Free Survival (“PFS”).<wbr> </div><div style="margin-bottom: 10px;">The second (C21005) is a randomized, double-blind and multi-center trial of prednisolone plus TAK-700 or placebo in patients with mCRPC that have progressed during or following docetaxel-based therapy.<wbr> The primary endpoint is OS.<wbr> </div><div style="margin-bottom: 10px;">Commenting on this development Karen Ferrante, M.<wbr>D.<wbr>, Chief Medical Officer, Millennium stated:- </div><div style="margin-bottom: 10px;"><P class="nth-child-odd nth-child-7">“We are very pleased with the initiation of the Phase III clinical trials of orteronel in Japan.<wbr> At present, mCRPC remains an incurable disease, and novel treatments are needed.<wbr> We regard orteronel as one of our high-priority development programs, and will work to accelerate its development.<wbr>”</P> </div><div>From <A href="http://www.takeda.com/">http:/<wbr>/<wbr>www.<wbr>takeda.<wbr>com</A>, see <A href="http://www.takeda.com/press/article_44988.html">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8045">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-27T15:58:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-27T15:58:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Why the Mepha/Cephalon Acquisition Represents a" Game Changer"</title>
	<pubDate>2012-01-26T19:12:56+01:00</pubDate>
	<wp:post_id>3244</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acino's latest presentation reiterates its expectation for approval of goserelin 3M, and leuprorelin 1M &amp; 3M in 2013.<wbr> Importantly it also provides an updated picture of the company's geographic presence following the Mepha and Cephalon acquisitions.<wbr> </div><div style="margin-bottom: 10px;">Acino announced the acquisition of Swiss based Mepha and the MENA and Latin American business of Cephalon late last year (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=99" class="defaultlink">DKPHybrids99: Acino Expands  Geographically Into Latin America and Asia</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Development Pipeline Status </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_5_ScreenCapture5.jpg"> </div><div>source:www.<wbr>acino-pharma.<wbr>com </div><!-- Comment details --><a name="dkphybrids107attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(159,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(195,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(144,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(146 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_107_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(148,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=107">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-26T19:12:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-26T19:12:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen to Buy Micromet for $1.2 bln</title>
	<pubDate>2012-01-26T19:07:46+01:00</pubDate>
	<wp:post_id>3245</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Amgen, which expects to close this quarter, is betting on the Micromet's BiTE technology, which is designed to direct the body's cell-destroying T cells to attack tumor cells.<wbr> The technology has already attracted the attention of Sanofi, Boehringer Ingelheim and Bayer Schering Pharma, who have all entered into development partnerships with Micromet.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Amgen plans to pay $11 per share in cash for Micromet, a premium of nearly 33%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">BiTE antibodies are able to create a "bridge" between T-cells and tumor cells at which point, T-cells are able to cause apoptosis of thetumor cells.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8042_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">In addition to its BiTE antibody technology, Micromet also has in development several conventional antibodies in Phase 1 for the treatment of RA, MS and Melanoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Amgen is moving new attractive early-stage programs into later stages of development, including </div><div style="margin-bottom: 10px;"><UL><LI>AMG145 (anti-PCSK9 antibody for osteoporosis); </LI>
<LI>AMG785 (anti-sclerostin antibody for osteoporosis and fracture healing); and </LI>
<LI>AMG827 (anti-IL17 antibody for psoriasis).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">Additionally, Xgeva is looking to expand its labeled indication to include prevention of bone metastases in patients with prostate cancer.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8042_2_ScreenCapture2.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8042">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-26T19:07:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-26T19:07:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Points To Emerge From Novartis's 2011 Figures</title>
	<pubDate>2012-01-26T12:37:58+01:00</pubDate>
	<wp:post_id>3246</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Further detail to emerge from yesterday's webcast and press release, indicate that Sandostain LAR has now been approved for the delay of tumour progresion in patients with midgut carcinoid in 25 countries and is currently under review in more than 20 additional countries.<wbr> Additionally, it was noted that pasireotide is on-track for a US resubmission for Cushing's disease in 1H2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Key Points To Emerge</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><EM>Zometa</EM></STRONG> </div><div style="margin-bottom: 10px;">Whilst Zometa sales in Europe grew, competition in the US caused a 5% decline in sales in the fourth quarter.<wbr> We believe that the competitive situation referred to relates to the continued strong uptake of Amgen's denosumab.<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>Afinitor Sales &amp; Development Programmes</STRONG></EM> </div><div style="margin-bottom: 10px;">Afinitor sales in the fourth quarter grew by 66% to $133m with key contributions from sales in advanced renal cell carcinoma following VEGF-targeted therapy and in patients with advanced pancreatic neuroendocrine tumours.<wbr> Afinitor is now approved in 39 countries, including the US, EU and Japan, for the treatment of advanced pancreatic neuroendocrine tumors.<wbr> </div><div style="margin-bottom: 10px;">Updated results of the Afinitor Phase III study, BOLERO-2, were presented at the 2011 San Antonio Breast Cancer Symposium.<wbr> The study, examining Afinitor (everolimus) in ER+ HER2- advanced breast cancer, showed treatment with everolimus plus hormonal therapy more than doubled progression-free survival (PFS) to 7.<wbr>4 months compared to 3.<wbr>2 months with hormonal therapy alone by local investigator assessment.<wbr> An additional analysis based on an independent central radiology review showed everolimus extended PFS to 11.<wbr>0 months compared to 4.<wbr>1 months.<wbr> Worldwide regulatory submissions are underway, with FDA and EMA decisions expected in 2012.<wbr> </div><div style="margin-bottom: 10px;">In contrast results from the Phase III trial GRANITE-1, which examined the efficacy and safety of everolimus versus placebo, plus best supportive care (BSC), in patients with advanced gastric cancer did not meet the primary endpoint of overall survival.<wbr> Study results presented at the American Society of Clinical Oncology&rsquo;s 2012 Gastrointestinal Cancers Symposium showed that patients lived a median of 5.<wbr>39 months when treated with everolimus plus BSC versus 4.<wbr>34 months for those who received placebo plus BSC (p=0.<wbr>12).<wbr> However, the safety profile was consistent with previous studies of everolimus in the oncology setting.<wbr> </div><div style="margin-bottom: 10px;">When questioned about Afinitor, its patent and development strategy.<wbr> David Epstein, Divisional Head of Pharmaceuticals noted "As you know, we have several PI3 kinase inhibitors that are in the clinic that are rapidly now moving through their Phase II clinical trials across a broad range of indications.<wbr> Some of these PI3K inhibitors also inhibit mTOR directly.<wbr> We think there's a very good chance that these new medicines called BEZ, BKM and others may even be better drugs than Afinitor and our development program will either prove that or not prove that.<wbr> And these results will come out long before the Afinitor patent expires and as a result, then, we should be able to continue to grow this franchise well past that patent expiration.<wbr>" </div><div style="margin-bottom: 10px;"><EM><STRONG>Current Knowledge of Novartis's PI3K inhibitor programmes</STRONG></EM> </div><div style="margin-bottom: 10px;"><STRONG>Phase II </STRONG>- BKM120 (PI3K) in metastatic CRPC (<A href="http://clinicaltrials.gov/ct2/show/NCT01385293?term=bkm120&amp;rank=2">NCT01385293</A>), advanced endometrial cancer, NSCLC, and glioblastoma.<wbr> BEZ235 (dual mTOR/<wbr>PI3K) in endometrial cancer, metstatic breast cancer, advanced RCC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Phase 1</STRONG>- BGT226 and BYL719 in Ph1 </div><div style="margin-bottom: 10px;"><STRONG>Planned filing </STRONG>2014 for BMK120 and BEZ235 </div><div style="margin-bottom: 10px;"><STRONG>Expected Impact Of Diovan Patent Expiry</STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Despite patent expiries, Novartis currently ranks as one of the industy's fastest growing companies </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">However, Novartis does recognise that 2012 is going to be a more challenging year.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><U>Regulatory Submissions</U></STRONG> </div><div style="margin-bottom: 10px;">Novartis's planned filings from 2012 to 2016 suggest no change in filing timelines for pasireotide in acromegaly and mid-gut carcinoids compared to previous presentations.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Biosimilar Sales Growth</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="endocrinology6848attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(91,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(68,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(78,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6848_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(210,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6848">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-26T12:37:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-26T12:37:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Is Evaluating Long-Term Efficacy of Botox in Patients with Chronic Migraine</title>
	<pubDate>2012-01-25T19:17:29+01:00</pubDate>
	<wp:post_id>3247</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph4 trial started last month and will end in March 2016.<wbr> Primary outcome will assess change from baseline in the Frequency of Headaches Days.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01516892?fund=2&amp;rcv_s=01%2F11%2F2012&amp;rank=141"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 1000 with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer).<wbr> </div><div>Regimen: Patients will receive 155 U of Botox approximately every 12 weeks for 96 weeks.<wbr> Botox will be administered as 31 intramuscular injections in 7 head/<wbr>neck muscle areas.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6202">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-25T19:17:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-25T19:17:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Report Financial Results for 2011</title>
	<pubDate>2012-01-25T18:52:09+01:00</pubDate>
	<wp:post_id>3248</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The pharma segment ended 2011 to $32 508M from $30 306M (+7% vs 2010).<wbr> Sales of Sandostatin reached $374M (+6.<wbr>6% vs 2010).<wbr> Growth in emerging market was driven by China (+24%), equally followed by Russia (17%), and India (+17%).<wbr> For 2012, Novartis forecasts flat sales (vs 2011) at constant exchange rates.<wbr> No details were given for after 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9764_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sandoz delivered net sales of $9 473M (+10% vs 2010), and outperformed the market in most regions.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9764_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9764_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="pharmaworld9764attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9764_4_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9764_5_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9764_6_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(6,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9764">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-25T18:52:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-25T18:52:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz' Xeomin to Enter Ph2 for Snoring</title>
	<pubDate>2012-01-25T00:07:27+01:00</pubDate>
	<wp:post_id>3249</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph2 study of Xeomin for habitual snoring.<wbr> Primary outcome measure will assess relative change from baseline in Snoring Index at 4 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01515371?fund=2&amp;rcv_s=01%2F10%2F2012&amp;rank=98"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Design: Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-stage Dose-finding Study </div><div style="margin-bottom: 10px;">Dosage: 2.<wbr>5U, 5U or 7.<wbr>4U </div><div style="margin-bottom: 10px;">Objectives: to identify out of up to 3 doses a safe and effective dose of Xeomin for injection into one side of the soft palate to treat snoring.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 48 </div><div style="margin-bottom: 10px;">Start date: Jan 2012 - Completion date: July 2013 /<wbr> Sept 2013 </div><div>Location: Germany (1 site) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6200">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-25T00:07:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-25T00:07:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Iran is Making Significant Progresses in the Biosimilar and Biotechnology Drugs</title>
	<pubDate>2012-01-24T09:27:09+01:00</pubDate>
	<wp:post_id>3250</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Iran is Making Significant Progresses in the Biosimilar and Biotechnology Drugs</span>&nbsp;<br><span style="font-size: 12px;">Comment: According to a press TV, Iran has the medical knowledge and facility to produce 95% of those drugs internally (with 5% being biosimilars).<wbr> The country is reported to produce 8 new medicines to treat hemophilia, cancer and osteoporosis.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=101">...</a><br></div><div style="margin-bottom: 10px;">Pooyesh Darou's Microrelin 1M (triptorelin) is already available in Iran since December 24, 2011! </div><div style="margin-bottom: 10px;">We already bought 6 samples of Microrelin which are under testing/<wbr>analysis at IPB.<wbr> </div><div style="margin-bottom: 10px;">Best regards, </div><div>Matthieu </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=106">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids101">View thread  DKPHybrids101: Iran is Making Significant Progresses in the Biosimilar and Biotechnology Drugs</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-24T09:27:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-24T09:27:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Epigenetic Drug Resminostat Demonstrates Efficacy In HCC</title>
	<pubDate>2012-01-23T12:46:40+01:00</pubDate>
	<wp:post_id>3251</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"><STRONG></STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"> can be </SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 11px; FONT-FAMILY: Arial, Helvetica, verdana, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div><A href="http://www.4sc.com"></A><A href="http://www.pipelinereview.com/index.php/2012012046907/Small-Molecules/4SCs-cancer-compound-resminostat-meets-primary-endpoint-in-Phase-II-trial-in-advanced-liver-cancer-HCC-ahead-of-schedule.html"></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8033">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-23T12:46:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-23T12:46:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive HCC Cabozantinib Data To Be Presented At ASCO GU</title>
	<pubDate>2012-01-23T12:29:39+01:00</pubDate>
	<wp:post_id>3252</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8032">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-23T12:29:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-23T12:29:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Iran is Making Significant Progresses in the Biosimilar and Biotechnology Drugs</title>
	<pubDate>2012-01-23T10:51:27+01:00</pubDate>
	<wp:post_id>3253</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to a press TV, Iran has the medical knowledge and facility to produce 95% of those drugs internally (with 5% being biosimilars).<wbr> The country is reported to produce 8 new medicines to treat hemophilia, cancer and osteoporosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Current Developments of hybrids of Decapepetyl in Iran</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>DongKook's triptorelin 1M is under registration in Iran.<wbr></LI>
<LI>A Ph3 of Pooyesh Darou's Microrelin 1M (triptorelin) is currently being assessed in the Shahid Labbafinejad Medical Center in Teheran.<wbr> Launch is expected in 2013 in the country.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Regulatory Route of Hybrids in Iran</STRONG> </div><div>Dongkook is claiming that human bioequivalence and/<wbr>or pharmacoequivalence data is not required for registration purposes.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="DKPHybrids106c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Pooyesh Darou's Microrelin 1M (triptorelin) is already available in Iran since December 24, 2011! </div><div style="margin-bottom: 10px;">We already bought 6 samples of Microrelin which are under testing/<wbr>analysis at IPB.<wbr> </div><div style="margin-bottom: 10px;">Best regards, </div><div>Matthieu </div></div><a name="DKPHybrids108c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Interestingly, in an other article published on the same subject, we have learnt that the drugs include Botulinum toxin, Factor VII , Salmeterole (asthma), Riluzole (ALS), Letrozole (breast cancer), and Zoledronic acid (osteoporosis).<wbr> </div><div>Source: Isna.<wbr>ir </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120431&edate=20120101&rec=101">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-23T10:51:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-23T10:51:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pasireotide Price, Dosage & Presentation For Cushing's Disease</title>
	<pubDate>2012-01-20T15:38:32+01:00</pubDate>
	<wp:post_id>3254</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pasireotide Price, Dosage & Presentation For Cushing's Disease</span>&nbsp;<br><span style="font-size: 12px;">Comment: Whilst yet to be approved by the EMEA, Novartis has provided some pre-launch information to UK NHS customers with budgetary responsibility.<wbr> This indicates that a 28-day course of pasireotide will cost between GBP850- GBP3400 and that the drug will be supplied in a pre-filled syringe device.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6838">...</a><br></div><div style="margin-bottom: 10px;">Novartis' Signifor (pasireotide) won a green light from the European Medicines Agency (EMA) on Friday, paving the way for its formal approval in a couple of months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Committee’s recommendation has now been forwarded to the European Commission for the adoption of an opinion.<wbr> </div><div>Source: <A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002052/smops/Positive/human_smop_000326.jsp&amp;mid=WC0b01ac058001d127&amp;jsenabled=true">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>medicines/<wbr>human/<wbr>medicines/<wbr>002052/<wbr>smops/<wbr>Positive/<wbr>human_smop_000326.<wbr>jsp&amp;mid=WC0b01ac058001d127&amp;jsenabled=true</A> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6844">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6838">View thread  Endocrinology6838: Pasireotide Price, Dosage & Presentation For Cushing's Disease</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-20T15:38:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-20T15:38:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph2 Study Details of Takeda's Oral GnRH Antagonist for Endometriosis</title>
	<pubDate>2012-01-20T13:01:43+01:00</pubDate>
	<wp:post_id>3255</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In 3Q11, Takeda announced that TAK-385 entered into ph2, double-blind, comparative studies (with Leuplin) in Japan.<wbr> Details of the trials are now listed in Clinicaltrials.<wbr>gov.<wbr> The 'currently recruiting participants' trial will evaluate the efficacy and safety of 3 dose levels of TAK-385 (p.<wbr>o) for 12 weeks.<wbr> Primary outcome measure being the score for pelvic pain as measured by the Visual Analogue Scale (VAS).<wbr> A long-term extension study is expected to start this month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="header1" style="MARGIN-TOP: 3ex"><STRONG>Efficacy and Safety of TAK-385 in the Treatment of </STRONG><STRONG>Endometriosis</STRONG> - <A href="http://clinicaltrials.gov/ct2/show/NCT01458301?recr=Open&amp;cond=endometriosis&amp;fund=2&amp;rank=2">NCT01458301</A></DIV> </div><div style="margin-bottom: 10px;"><UL><LI>Recruitment: approx 495</LI>
<LI>Completion date: April 2013</LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV class="header1" style="MARGIN-TOP: 3ex"><STRONG>Long-term Extension Study of TAK-385 in the Treatment of </STRONG><STRONG>Endometriosis</STRONG> - <A href="http://clinicaltrials.gov/ct2/show/NCT01452685?recr=Open&amp;cond=endometriosis&amp;fund=2&amp;rank=3">NCT01452685</A></DIV> </div><div style="margin-bottom: 10px;"><UL><LI>Recruitment: approx.<wbr> 450</LI>
<LI>Completion date: Aug.<wbr> 2013</LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV class="header1" style="MARGIN-TOP: 3ex"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="header1" style="MARGIN-TOP: 3ex">Takeda's pipeline indicates that the drug also is in development for prostate cancer (Ph1).<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="header1" style="MARGIN-TOP: 3ex"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="header1" style="MARGIN-TOP: 3ex">TAK-385 controls the effect of LH and FSH on the ovary, reduces the level of estrogen in blood, which is known to be associated with the development of endometriosis and uterine fibroids, and is expected to improve the symptoms of these disorders.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="header1" style="MARGIN-TOP: 3ex"><STRONG></STRONG></DIV> </div><div><DIV class="header1" style="MARGIN-TOP: 3ex">TAK-385 competes with Neurocrine/<wbr>Abbott's <STRONG>elagolix</STRONG> (oral GnRH antagonist).<wbr> Abbott has worked with the FDA on the design of the pivotal Ph3 program.<wbr> Subject to agreement with the FDA on the Ph3 trial design, it was expected elagolix to enter Ph3 clinical trials in 4Q11.<wbr></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8028">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-20T13:01:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-20T13:01:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mike Crooks to Head Up Astellas' UK Operations</title>
	<pubDate>2012-01-19T13:16:24+01:00</pubDate>
	<wp:post_id>3256</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Mr Crooks will be responsible for managing and expanding Astellas' UK business with a focus on transplantation, urology, dermatology, anti-Infectives, pain management and oncology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Mr Crooks first joined Astellas in December 2007, as Marketing Director, building a strong team and developing the brand strategy for the UK portfolio of products, before being appointed Sales &amp; Marketing Director for Specialist Brands in 2010.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Before Astellas</STRONG> </div><div style="margin-bottom: 10px;">Mr Crooks joined Astellas from Novo Nordisk, where he was Marketing and Sales Director: Diabetes, Northern Europe.<wbr> </div><div>His career in the pharmaceutical industry began in 1981 as a sales representative with Ciba and he went on to hold a number of senior sales and marketing positions at Novartis and Zeneca.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8025">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-19T13:16:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-19T13:16:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pasireotide Price, Dosage & Presentation For Cushing's Disease</title>
	<pubDate>2012-01-18T17:03:08+01:00</pubDate>
	<wp:post_id>3257</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Whilst yet to be approved by the EMEA, Novartis has provided some pre-launch information to UK NHS customers with budgetary responsibility.<wbr> This indicates that a 28-day course of pasireotide will cost between GBP850- GBP3400 and that the drug will be supplied in a pre-filled syringe device.<wbr> </div><div style="margin-bottom: 10px;">Pasireotide if approved will be the first medical treatment for Cushing's Disease that targets the pituitary gland.<wbr> It will be given by subcutaneous injection twice daily, which patients can be trained to self-administer.<wbr> It is likely to be indicated only for patients with CD whose disease is not cured by surgery or who are ineligible for surgery.<wbr> </div><div style="margin-bottom: 10px;">London New Drugs Group APC/<wbr>DTC Briefing published by the Medicines Information Service at Northwick Park Hospital indicates that it will be supplied as pre-filled syringe containing either 0.<wbr>3mg, 0.<wbr>6mg or 0.<wbr>9mg of pasireotide.<wbr> </div><div>Novartis recently indicated that it expects to be in a position to launch pasireotide for Cushing's disease in May 2012 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6777" class="defaultlink">Endocrinology6777: ENEA Intelligence Update Part 1 - Pasireotide Highlights</a>).<wbr>.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology6844c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Novartis' Signifor (pasireotide) won a green light from the European Medicines Agency (EMA) on Friday, paving the way for its formal approval in a couple of months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Committee’s recommendation has now been forwarded to the European Commission for the adoption of an opinion.<wbr> </div><div>Source: <A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002052/smops/Positive/human_smop_000326.jsp&amp;mid=WC0b01ac058001d127&amp;jsenabled=true">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>medicines/<wbr>human/<wbr>medicines/<wbr>002052/<wbr>smops/<wbr>Positive/<wbr>human_smop_000326.<wbr>jsp&amp;mid=WC0b01ac058001d127&amp;jsenabled=true</A> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6838">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-18T17:03:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-18T17:03:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive Top-Line Ph2 Results from Pilot Study of PROLOR's Twice-Monthly Version of hGH in AGHD</title>
	<pubDate>2012-01-18T16:09:22+01:00</pubDate>
	<wp:post_id>3258</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The results from a pilot sudy show that 2 injections of hGH-CTP per month have significant potential to replace 30 consecutive daily injections of currently marketed hGH.<wbr> PROLOR looks forward to further study the twice-monthly regimen while advancing its ongoing clinical program for hGH-CTP administered once-weekly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>- Recruitment: 12 patients were switched from daily injections of conventional hGH to a regimen of just 2 injections of hGH-CTP</LI>
<LI>- Duration: 30 days (one month).<wbr></LI>
<LI>- Regimen: The 2 injections of hGH-CTP contained either 15% or 50% of the total cumulative dose of hGH the patients would usually inject over the 30-day period.<wbr></LI>
<LI>- Measure of efficacy: Patient IGF-1 levels.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>- the study duration was only 30 days, thus not allowing sufficient time for patients to adjust fully to the new injection regimen.<wbr></LI>
<LI>- the patients received only 15% or 50% of their regular cumulative hGH dose.<wbr></LI>
<LI>- the patients did not go through the dose titration procedure that physicians usually employ to optimize hGH dosing.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Despite the limits of the pilot study, Dr Havron reported that there was a clear correlation between dose and IGF-1 response, and patients receiving the 50% dose showed promising IGF-1 response to the twice-monthly hGH-CTP injection regimen.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Phase II results reported last year showed that hGH-CTP can potentially provide a safe and effective new therapeutic option for adults with growth hormone deficiency when injected once-weekly, versus the daily injections of conventional hGH that are currently required (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6568" class="defaultlink">Endocrinology6568: Prolor Announces Positive Results From Phase II Trial of its Long-Acting Human GH</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>From a dosage perspective, Prolor's drug competes with Hanmi's LAPS-hGH drug, which is in Ph2 and has the potential to also be administered once-a-week or twice-monthly.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6836">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-18T16:09:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-18T16:09:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>P&R End-of-Year Review 2011 and Outlook for 2012</title>
	<pubDate>2012-01-18T14:31:52+01:00</pubDate>
	<wp:post_id>3259</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In this new report, IHS Global Insight takes stock of 2011 key P&amp;R events, assesses the landscape affecting the pharma industry in 2012 and beyond, and provides an overview of austerity in advanced markets.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B>Key Findings</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>The year 2011 saw a continuation of problems from 2010.<wbr> 
</LI>
<LI>Cost-containment has once again ranked high on the agenda, with pro-generics policies, increased clawbacks/<wbr>discounts and pooled public purchasing leading to lower pharma prices—for innovative and generic drugs alike—to the public sector in the developed world.<wbr> 
</LI>
<LI>While some austerity measures have been watered down, in other cases it has not been easy, as seen in Australia, where innovative drugs have faced delayed introduction onto the positive reimbursement list on account of government efforts to subsidise new drugs only when an offset budget has been found.<wbr> 
</LI>
<LI>European payers are leading the way in increasing the quality of required outcomes data, such as France's proposal for head-to-head trials against the gold standard, and Germany's use of indirect comparators during benefit-assessment.<wbr> 
</LI>
<LI>Pharma firms have benefited from making inroads into emerging markets, although these economies are also slowing down, so an effort to reduce medicine prices in these countries has begun.<wbr> 
</LI>
<LI>Looking forward, simply increasing market presence in the developing world will not suffice, with pharma firms needing to prioritise their capital allocation and operate leaner businesses.<wbr> </LI>
</UL>
</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Introduction</B></P> </div><div style="margin-bottom: 10px;">The year 2011 has given the pharmaceutical industry very little to be thankful for on the pricing and reimbursement front.<wbr> The economic downturn that began in 2008 has reduced the ability of nations to spend, and this has trickled down to healthcare and drug spending over 2010 and 2011.<wbr> Over the course of the year this has led to price cuts, de-listing from positive reimbursement lists, greater focus on generic substitution and tougher criteria for pharmaco-economic evaluation of innovative compounds.<wbr> This report will focus on key regulatory policy changes that have occurred over the year, including the end of free pricing in Germany, NHS reforms in the United Kingdom, continuing Greek austerity measures and deficit-reduction plans in the United States.<wbr> Key developments in emerging markets will also be looked at considering the increasing importance of these markets for pharma firms looking for continued growth.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading1"><B>The Good, Bad and the Ugly: An Overview of Austerity in Advanced Markets</B></P> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>The Good…</B></P> </div><div style="margin-bottom: 10px;">As indicated before, policy changes that have occurred in the developed world over the year have largely affected the industry adversely.<wbr> In a few instances, however, the industry has managed to compromise with regulators and thereby soften the blow against top- and bottom-lines, as detailed below.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>United Kingdom</B></P> </div><div style="margin-bottom: 10px;">The Health and Social Care Bill, which is set to lead to an overhaul of the UK National Health Service (NHS), was presented to parliament in 2011, although it has not yet been passed.<wbr> This comes as no surprise, with the controversial reforms set to see Primary Healthcare Trusts (PCTs) replaced with general practitioner (GP) consortia, which will be overseen by an NHS Commissioning Board, from 2014 onwards.<wbr> Widespread concerns regarding the radical nature, pace of, and uncertainty surrounding the reforms, however, saw the coalition government engage in a "listening exercise" on the bill's contents.<wbr> The toned-down version will reduce the emphasis on competition—which would have increased the pace of privatisation of the NHS—with greater involvement of other healthcare groups in the consortia (now called commissioning consortia instead of GP consortia), greater transparency in the decision-making and spending process, and with the promise that that the consortia will assume responsibility only when ready.<wbr> The modified bill has passed the House of Commons and will be assessed by a normal committee in the House of Lords.<wbr> </div><div style="margin-bottom: 10px;">While watering down the bill reduces uncertainty surrounding the UK market for the pharma industry, the Health and Social Care Bill could prove to be beneficial in other ways.<wbr> A new cancer drug fund has been established with GBP200 million (USD314 million) in annual funding until 2014, to be used for reimbursing of drugs not recommended by the National Institute for Health and Clinical Excellence (NICE).<wbr> In addition to this, from 2014 onwards expanded access to drugs may also come in the form of value-based pricing (VBP).<wbr> While this would see an end to free pricing in the United Kingdom, details released so far on the setting of prices under the VBP seem promising, compared with NICE's current stringent GBP30,000 per quality-adjusted life year (QALY) calculation.<wbr> The latter has indirectly limited the prices of drugs in the UK, while the new VBP system instead promises a system of varied thresholds based on innovation and wider societal benefits, and thus a fairer mechanism in which truly innovative products will be rewarded.<wbr> How aspects such as societal benefits will be incorporated into the pharmac-oeconomic process remains unclear, however.<wbr> The industry, of course, runs the risk of price cuts for those drugs that Health Minister Andrew Lansley claims are not currently available at a "fair price".<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Romania</B></P> </div><div style="margin-bottom: 10px;">The pharma industry has reached a middle ground with Romanian regulators on the clawback mechanism introduced by the government in October 2011.<wbr> Viewed as unduly harsh by pharma firms, the clawback mechanism was to see those companies responsible for any drug overspend above the budgeted amount pay the Romanian National Health Insurance House (CNAS) an allocated clawback based on total market share.<wbr> Drug makers opposed this law, which was predicted would lead to the value of the Romanian pharma market falling by 30%, and would cost the industry 1.<wbr>7 billion lei (USD521.<wbr>2 million), according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).<wbr> After the industry asked the International Monetary Fund (IMF) to intercede, in December 2011 the government modified the clawback to be limited to a ceiling of 10% of total pharmaceutical expenditure, with market share within a therapeutic indication (two-thirds of calculation) and sales growth (one-third of calculation) taken into account to calculate individual rates.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>.<wbr>.<wbr>The Bad</B></P> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Australia</B></P> </div><div style="margin-bottom: 10px;">Policies discussed in 2010 took effect in 2011, with Australia's Prime Minister Julia Gillard embarking on a cost-cutting spree in order to deliver a AUD3.<wbr>1-billion (USD1.<wbr>33-billion) surplus by 2013.<wbr> From February this year, the price cuts on innovative drugs upon the listing of a generic have been increased to 16%.<wbr> Both low-volume and high-volume generics received price cuts of 2% and 5%.<wbr> In addition to this, mandatory price-disclosure policies for 248 products will see price cuts in the range of 10.<wbr>5–82.<wbr>7% for related generics reimbursable under the Pharmaceutical Benefits Scheme (PBS).<wbr> This is because price disclosure will see the end of significant discounts being offered to the pharmacist over the official reimbursable price of the PBS.<wbr> While such policies have affected the pharma industry adversely, the changes had been expected.<wbr> A memorandum of understanding (MoU) was signed between industry players and the government in May 2010 which agreed to the drug bill being slashed by USD1.<wbr>8 billion in return for no further price cuts (than those cited) for the next four years.<wbr> While Gillard did stay true to this promise, her announcement in March 2011 that subsidies for new drugs would no longer be available unless the government could find offset savings stunned pharma firms.<wbr> The government expects the measure to help save AUD200 million a year, but the industry now faces a situation where even a positive Pharmaceutical Benefits Advisory Committee (PBAC) guidance will not guarantee a product a PBS listing unless the central government allocates budget savings (accrued from other methods) for the drug.<wbr> Drug listings have thus been deferred, generating much criticism.<wbr> While industry persistence saw several drugs finally gain reimbursement in June and September, the government is still likely to defer reimbursement of drugs that cost more than AUD10 million annually over the coming 12 months.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Hungary</B></P> </div><div style="margin-bottom: 10px;">Hungary has never been an easy market for the industry to operate in due to several existing containment strategies already in place.<wbr> In spite of this, the government, as announced in 2010, rolled out an array of cuts in 2011.<wbr>The Szell Kalman/<wbr>Semmelweis Plan—the name given to the government's wider deficit-reduction plan—was approved in June 2011, and was set to see massive reductions to the drug-reimbursement budget of 26 billion Hungarian forint (USD106.<wbr>2 million) and HUF83 billion forint in 2011 and 2012 respectively, down to HUF120 billion (constituting one-third of its current reimbursement budget) by 2013.<wbr> Key measures as part of this plan include increasing the pharma turnover tax to 20%; generics prices have been cut significantly with a reference price that is a further 5% below the current reference price for new-entry generics, restriction of the positive reimbursement list to include only drugs that are no more than 5% more expensive than the cheapest generic—the reference product—and a decision by the Department of Reimbursement of the National Health Insurance Fund Administration of Hungary (OEP) to allow a product with only a 1% market share as the preferred product in a particular reference-price band.<wbr> Innovative drug firms have not been spared either, with a new system of payment-by-result under which manufacturers of high-cost therapies will be obliged to reimburse the OEP in the case of non-responders.<wbr> Separately, a change in the international reference pricing (IRP) system is also set to be introduced where drugs exceeding the average of the three lowest prices in the EU will be removed from reimbursement.<wbr> Measures already introduced as part of the Szell Kalman plan have seen average drug price cuts of 25% for several high-priced products.<wbr> Local firms like Gedeon Richter have witnessed plummeting profits and thus ceased to market certain products in the country, no doubt making patients and other stakeholders apprehensive about the reduced access to medicines in the country.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Italy</B></P> </div><div style="margin-bottom: 10px;">Italy's 2011 austerity measures began with the announcement of up to 40% cuts to generics and off-patent drugs, as part of the rolling out of 2010's austerity measures.<wbr> The price cut was reportedly on account of re-pricing generics based on the average price in EU-5 countries (Italy, France, Germany, Spain, the UK), to normalise the price of generics and yield savings of USD1 billion.<wbr> The generic pharma industry was outraged that most of the burden of the austerity was falling upon them, with the government neither modifying the extended patent exclusivity that innovative firms in Italy enjoy, nor the pharmacy margins that encourage dispensing of higher priced medicines.<wbr> As a compromise, however, the government liberalised the sale of category "C" (non-reimbursable) drugs later on in the year.<wbr> The year has also seen a transparency drive further re-emphasised by Professor Luca Pani—the new general director of the Italian Medicines Agency (AIFA) appointed in November 2011.<wbr> In mid-July a new "Transparency List" was published that showed the difference between the price of a drug and the set reference price, thus making it easier for doctors and pharmacists to identify the cheapest alternative and increasing the urgency with which pharma firms reduced the price of their respective generics.<wbr> More worrying for the industry, however, has been that AIFA has begun revealing granular details of risk-sharing agreements it has engaged in since late 2010, as these are set to affect P&amp;R of the respective drugs in other markets as well.<wbr> Over 2012, the Italian pharma industry is set to prepare for the changes set to occur in 2013 on account of austerity measures announced in 2011.<wbr> Main measures would see more "tickets"/<wbr>co-payments introduced for services and pharmaceuticals provided as part of the public health insurance system and a ceiling of 5.<wbr>2% (of total public healthcare expenditure) on medical device expenditure.<wbr> A clawback of 35% of any overspend beyond a defined ceiling for hospital-drug spending is set to take effect from mid-2012; otherwise a lower ceiling of 12.<wbr>5% on regional spending on outpatient medicines will take effect.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Greece</B></P> </div><div style="margin-bottom: 10px;">Budgetary savings for the Greek National Health Service to be accrued from drug price cuts were set to reach EUR150 million (USD190 million) for 2011, a relatively modest figure compared with 2010's savings of over EUR1 billion.<wbr> Measures announced this year, however, have not proved popular with the industry.<wbr> While the inclusion criteria for the new positive reimbursement list have been modified compared to the initial draft, it has not left the industry any better off.<wbr> While the original proposal was to mandate that all reimbursed drugs be priced equal to or lower than the reference price, the new law will see pharma firms pay insurance funds back the difference between the reference price and the actual price of their drug, if the latter is higher.<wbr> For drugs that have no other competitors in their therapeutic class, this rule does not apply, although in the case of these products, a 3–4% rebate is due.<wbr> Meanwhile, Greece has also introduced international tendering, as seen in Germany, accruing an 80% discount on previous prices and driving down generics prices.<wbr> Medicine profit margins are set to further decrease from 2012 onwards owing to the pooled purchasing power of the National Health Services Organisation (EOPYY)—a new body formed by merging the main social security funds.<wbr> Finally, receipt of account receivables from the public sector still remains a significant issue in Greece, with hospital debt continuing to mount.<wbr> Consequently, 2012 is set to see more firms follow in the steps of Bayer (Germany), Leo Pharma (Denmark), Nycomed and Novartis (both Switzerland) by implementing tough credit polices and even demanding cash upon delivery.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>….<wbr>.<wbr>And the Ugly</B></P> </div><div style="margin-bottom: 10px;">This section consists of those countries where the announced austerity measures not only adversely affect the pharma industry's top- and bottom-lines in the domestic market, but are also likely to have a knock-on impact on their performance in other markets.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>France</B></P> </div><div style="margin-bottom: 10px;">The French pharma industry began 2011 trying to adjust to the austerity measures announced for the year.<wbr> This saw the introduction of a new lower reimbursement rate of 15% for drugs with low Service Médical Rendu (SMR; measuring medical benefit).<wbr> Over the year, news on the reimbursement front only became worse with the announcement that, as part of 2012's austerity cuts, over 64 drugs with low SMR ratings would be delisted.<wbr> While not all drugs with SMR-1 ratings have been affected so far, the industry is no doubt worried as this is likely to be the medium-term plan.<wbr> It is also notable that the French government's efforts to ask the pharma industry to conduct head-to-head trials against the gold standard to demonstrate added benefit (ASMR rating, measuring innovation) were backed by the Senate in October 2011.<wbr> If this indeed becomes law, then France will be the first country to have introduced such a stringent measure for benefit assessment.<wbr> The country's health-technology assessment (HTA) process, which has often been considered fair by the industry, could lead to other EU regulators following suit, or at least using the publicly available ASMR ratings during their own price negotiations.<wbr> Finally, the industry will also suffer reduced bargaining power on the procurement side following the rolling out of hospital purchasing programmes over 2012, with regional purchasing and price negotiations set to reduce profit margins.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Germany</B></P> </div><div style="margin-bottom: 10px;">The year has been critical for the German pharma industry, with the end of free pricing in the country owing to the roll-out of the Act for the Restructuring of the Pharmaceutical Market in Statutory Health Insurance (AMNOG).<wbr> January 2011 saw the Joint Committee of Health (G-BA) unveiling the details of its early-benefit assessment for drugs, where drugs will continue to benefit from free pricing for 6 to 12 months post-market entry after which the drug will either enter the reference pricing system (if no value addition is found) or enter price negotiations with the regulator.<wbr> As occurs in France, price negotiations will be affected by the "level of innovation" of the drug compared to existing products.<wbr> In case of cancer drugs, overall survival will be favoured in measuring innovation and, in general, demonstrating a relationship between the surrogate and the clinical endpoint will be insufficient for the validation of a surrogate.<wbr> Such regulations have raised the bar for the pharmaceutical industry.<wbr> For example, AstraZeneca (UK) has decided to shelve development of ovarian cancer drug olaparib after analysis of mid-stage Phase II trials as the drug's promising progression-free survival (PFS) was unlikely to translate into overall survival (OS).<wbr> The industry has also revealed that it is struggling to cope with the unrealistic surrogate endpoint requirements, with the granularity of data required higher than ever before.<wbr> Comparators assigned to conduct benefit assessment are also widely seen as unfair, with the use of indirect comparators such as prasugrel when assessing Brilique (ticagrelor) in ST-elevation myocardial infarction (STEMI) patients.<wbr> Confidential sources have revealed to IHS Global Insight that a non-drug therapy was assigned as a comparator for a drug currently under assessment.<wbr> Such stringent comparators have seen firms such as Novartis and Boehringer Ingelheim (Germany) decide not to market their respective cardiovascular drugs, Rasilamlo (aliskiren + amlodipine) and Trajenta (linagliptin), due to the risk of being placed in the reference-pricing system.<wbr> Apart from domestic issues, the German reform will have several global knock-on effects.<wbr> Firstly, it calls for a re-thinking of Germany's place in the global launch-sequencing strategies given that the market is no longer freely priced.<wbr> Furthermore, AMNOG pricing negotiations are set to lead to an average drug price drop in Germany, therefore leading to a subsequent readjustment of prices in other European markets on account of international reference pricing (IRP).<wbr> Finally, given that all aspects of the benefit assessment and pricing negotiations are set to be transparent, it is likely that German results will affect P&amp;R discussions/<wbr>decisions in other markets as well.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Poland </B></P> </div><div style="margin-bottom: 10px;">The Polish Reimbursement Act—due to be introduced from 2012 onwards—has many healthcare stakeholders worried owing to uncertainty surrounding several of its aspects.<wbr> The act will set a 17% limit on pharmaceutical reimbursement, an amount believed to be insufficient to provide wider access to drugs as promised by the government, considering that this was closer to 20% in 2010.<wbr> Half of any overspend exceeding the ceiling will be paid back into the system by the drug industry.<wbr> An official reimbursement price is to be established based on negotiations with pharma firms.<wbr> According to Artur Fałek, the director of the drug policy and pharmacy department of the Polish Ministry of Health (MoH), the government is likely to use the lowest EU price as the benchmark during negotiations.<wbr> This is not good news for the pharma industry, as Poland joins the EU race to have the lowest price in the region; this vicious cycle means that a Polish price drop would consequently see a price reduction in other EU markets owing to IRP mechanisms.<wbr> Equally worrying is another element of the act that requires pharma firms to reveal details of risk-sharing agreements in place in other EU or EFTA countries for a product as part of its Polish risk-sharing agreement submission.<wbr> Given the confidential nature of such agreements, firms will find it difficult to part with such information for multiple reasons, including ethical issues surrounding information sharing and fear of other payers requesting similar details.<wbr> Consequently, increasing medicines access via risk-sharing agreements in Poland may not be as successful as expected by the government.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>United States</B></P> </div><div style="margin-bottom: 10px;">The US Congress passed the Budget Control Act of 2011 in August, signing off on plans to reduce the deficit by USD900 billion and creating a "super-committee" that was to find additional savings of USD1.<wbr>5 trillion by 2013.<wbr> Unfortunately, in November the committee announced that it had failed to reach a decision.<wbr> This triggered automatic budget cuts across the board, including 2% against the Medicare scheme, from 2013.<wbr> President Barack Obama has already iterated that he will veto any efforts to water down the plans.<wbr> For the drug industry, this means tougher negotiations with Medicare providers due to the latter's aim of saving monies by accruing drugs more cheaply, thus leading to indirect price cuts in spite of industry opposition to this previously.<wbr> The year 2012 is set to be a challenging one for the health insurance and pharma industry, given that they will have to deal with the repercussions of the super-committee's failures and accompanying uncertainties, concurrent with the health-reform process and its effects on value growth.<wbr> The US health spend, which is far more than any other country annually, is a reality that cannot be escaped by legislators, and will most certainly result in further cuts to spending.<wbr> While largely a domestic issue, the difficulties in the drug industry's largest market are unlikely to be contained, and will affect global pharma strategies.<wbr> The pharma industry is likely to be more desperate to increase market penetration in the emerging and less-regulated markets in order to rejuvenate dipping bottom-lines.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>The Emerging Market Safety Net?</B></P> </div><div style="margin-bottom: 10px;">The last couple of years has seen the drug industry increasingly looking to emerging markets for development.<wbr> Over the year, Pfizer (US) has been ranked the fastest growing pharma firm in India; AstraZeneca has acquired Chinese generics firm Guangdong BeiKang Pharmaceutical Co.<wbr>; and Bayer (Germany) has experienced positive growth only in its emerging markets over the third quarter of the year.<wbr> Key examples of booming emerging markets are Bulgaria and the Philippines, where average prices of medicines have increased continually owing to the increased diversity of prescription medicines available in the country and drug price increases of over 30% annually in free-priced Qatar.<wbr> With their place in the new world order, however, regulars in emerging markets are also keen to offer cheaper drugs (including innovative drugs) and create new cost-containment frameworks to rein in spending as health insurance expands.<wbr> For example, for the first time India is set to include oncology drugs that are generally outside the essential drugs list into the price-control system.<wbr> Meanwhile, China and Turkey have pursued generic price-reduction strategies; in 2011, China cut the prices of 162 drugs in cardiovascular, infectious and respiratory disease areas by an average of 21%, and 82 hormone, endocrine and central nervous system treatments by 18%.<wbr> In China, it is now no longer possible to sell drugs with the same active ingredient at different prices, with a methodology established for setting retail price.<wbr> Meanwhile, in Turkey, generics now have to be priced at a maximum of 60% (instead of 66%) of the innovator price, inflicting losses in excess of 2 billion Turkish lira (USD1.<wbr>1 billion) on the pharma sector.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Outlook and Implications</B></P> </div><div style="margin-bottom: 10px;">The year 2011 has been difficult for the pharma industry, with ongoing struggles that began in 2010 persisting.<wbr> The industry is struggling not only to cope with the increase in clawbacks, rebates, and price cuts but also mounting debts in the public sector, which has seen the loss of payment for past sales and threatening future business with these organisations.<wbr> This has led firms to ramp up their emerging markets presence more than they ever before.<wbr> This is a strategy that has benefited drug firms, with sales from these markets helping alleviate flagging profits.<wbr> </div><div style="margin-bottom: 10px;">Over the latter half of the year, however, many promising emerging markets have begun to announce their own cost-containment policies in an effort to rein in expenditure while increasing access to medical technologies.<wbr> The Brazil, Russia, India, China, Mexico and Turkey (BRIC-MT) group of markets has already begun to see slowing growth; China's GDP has shown signs of slowing down over the last three months of 2011, with 2012's GDP predicted to reach 9.<wbr>2% (compared with 9.<wbr>4% in 2011) by Deutsche Bank.<wbr> The BRIC countries' GDP growth rate is forecast to decelerate to 6.<wbr>1% in 2012 compared with 2007 rates of 9.<wbr>7%, a factor of rising wages, diminishing labour force, volatility and interest rates (source: IMF).<wbr> </div><div style="margin-bottom: 10px;">This all means that Big Pharma cannot continue to solely rely on their emerging markets strategies for future success.<wbr> With the UK also set to end free pricing and US drug prices increasingly under the spotlight, pharma firms will have to make significant changes in their launch-sequencing strategies.<wbr> Drug firms can no longer afford to have their fingers in too many pies; they will need to ruthlessly disinvest early-on from research and development assets that will not be considered truly innovative by HTA bodies at a later stage.<wbr> With increased competition from generics on account of pro-generics policies even in those markets that have traditionally preferred the innovative versions, firms will have to operate lean business models where they are able to effectively compete price-wise with their substitutable alternatives.<wbr> </div><div>A pdf copy of the report is attached </div><!-- Comment details --><a name="pharmaworld9761attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9761_1_P%26R%20End%255fof%255fReview%202011%20and%20Outlook%20for%202012.pdf">P&R End_of_Review 2011 and Outlook for 2012.pdf</a>&nbsp;&nbsp;(135 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9761">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-18T14:31:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-18T14:31:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Announces Strategic Measures to Integrate Nycomed</title>
	<pubDate>2012-01-18T11:31:39+01:00</pubDate>
	<wp:post_id>3260</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Of note among a series of upcoming measures, Takeda plans to strengthen its R&amp;D sites, invest on core areas as well as create innovative drugs.<wbr> The company will consolidate a number of sites and functions, including the potential merger (or liquidation) of subsidiaries mainly in EU (leading to approx 2,100 job reduction).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Takeda plans a reduction of the Takeda global workforce by approx.<wbr> 2,800 (2,100 mainly in Europe and 700 in the U.<wbr>S.<wbr>) positions by the end of fiscal 2015 across the functions of R&amp;D, commercial, operations and G&amp;A.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The combination of Takeda and Nycomed has brought together Takeda’s strong presence in the Japanese and U.<wbr>S.<wbr> markets with Nycomed business infrastructure in Europe and high-growth emerging markets (Russia-CIS market).<wbr> </div><div style="margin-bottom: 10px;">Emerging markets are key drivers for Takeda.<wbr> Recently, the company appointed J Davidsen, Head of Emerging Markets in addition to his current role as Area Head of Russia/<wbr>CIS.<wbr> (please See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9571" class="defaultlink">PharmaWorld9571: Takeda Appoints Head of Emerging Market</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9755_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Last December, Takeda acquired Intellikine to boost its Onco pipeline (please See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7974" class="defaultlink">Oncology7974: Takeda Boosts its Oncology Pipeline with the Acquisition of Intellikine</a>).<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9755_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld9755attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9755_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(81,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9755_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(63,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9755">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-18T11:31:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-18T11:31:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recent Study Evaluates Botox for Perioral Vertical Wrinkles</title>
	<pubDate>2012-01-18T10:53:01+01:00</pubDate>
	<wp:post_id>3261</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Joel Cohen and al have compared two doses of Botox (7.<wbr>5U or 12U) to treat 'bar code' in 60 patients.<wbr> Results tended to dissipate by 12-16 weeks of follow-up.<wbr> As expected, the rate and duration of AEs were higher in the group that got 12 U of Botox.<wbr> In daily clinical practice, Dr Cohen tends to use a total of 6-10U around the mouth (treating both the upper-and lower-lip regions).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Design: randomized trial </div><div style="margin-bottom: 10px;">All patients had moderate or severe vertical perioral lines at maximum lip contraction before being randomized to receive either 7.<wbr>5 U or 12 U of Botox in a blinded fashion.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>To make the comparison, the investigators first developed 3 photographic scales for classifying aesthetic features of the perioral area.<wbr> The scale used in this study assigns a severity grade of none, mild, moderate, or severe vertical lip-line attributes when the lips are at maximum contraction.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Results</STRONG> </div><div style="margin-bottom: 10px;"><P class="bodytext">Results were assessed for 53 patients at 4 weeks (one month), and for 51 patients at 12 weeks (three months).<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>In the 7.<wbr>5-U group, moderate or severe perioral lines were seen in 15 of 28 patients who had 4 weeks of follow-up (54%) and in 21 of 25 patients who had 12 weeks of follow-up (84%).<wbr> </LI>
<LI>In the 12-U group, 9 of 25 patients with 4 weeks of follow-up had moderate to severe perioral lines (36%), as did 11 of 26 patients with 12 weeks of follow-up (42%).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Safety</STRONG> </div><div style="margin-bottom: 10px;">Treatment-related adverse events were seen in 13 of 30 patients in the 7.<wbr>5-U group (43%) and 18 of 29 patients in the 12-U group (62%).<wbr> </div><div style="margin-bottom: 10px;">The treatment-related adverse events tended to resolve faster in the 7.<wbr>5-U group.<wbr> </div><div>Five patients in the 12-U group who had mild or moderate adverse events required follow-up, compared with no patients in the 7.<wbr>5-U group.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6198">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-18T10:53:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-18T10:53:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Forest' Management Looks at Acquisition Opportunities</title>
	<pubDate>2012-01-18T08:47:06+01:00</pubDate>
	<wp:post_id>3262</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During the Q&amp;A session of the 3Q11 financial results, Management has indicated that it is focusing on deals that bring marketed or "near-market" products.<wbr> This information is to be put in parallel with the rumour that Merz plans to transfer the U.<wbr>S marketing of Xeomin (for Neuro indications) to Forest as of Q22012.<wbr> Clearly, Forest is searching to offset the loss of Lexapro and Namenda patents, its top profit drivers (~85% of current product revenues), which will occur between 2012 &amp; 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sales of Lexapro and Namenda were $593M (+1.<wbr>1% vs 3Q11) and $340.<wbr>4M (+6.<wbr>4% vs 3Q11) respectively.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Forest anticipates launching Namenda XR, a higher dose once-a-day formulation, by early 2013.<wbr> The company has been studied the drug in combination with acetyl cholinesterase inhibitors to propel future growth of Namenda.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported that Forest " .<wbr>.<wbr>.<wbr> continue to look at acquisition opportunities" ".<wbr>.<wbr>.<wbr> that can add significant incremental value to the overall earnings potential of the business".<wbr> " .<wbr>.<wbr>.<wbr> acquisitions that come with some marketed products, or high potential, ready to launch products .<wbr>.<wbr>.<wbr>".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please refer to (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6185" class="defaultlink">Neurology6185: SOFT Intelligence -Potential Transfer of Xeomin US Therapeutic Marketing Rights To Forest Labs</a>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9752">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-18T08:47:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-18T08:47:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Algeta Appoints New President to Advance Alpharadin Through the Commercialization Phase</title>
	<pubDate>2012-01-17T15:07:39+01:00</pubDate>
	<wp:post_id>3263</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Jeffrey W.<wbr> Albers (previously with Genzyme/<wbr>Sanofi) will lead the commercial and regulatory activities of Alpharadin (treatment of bone metastases in patients with CRPC) in anticipation of the first regulatory filings, which are expected in mid 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Mr Albers joins Algeta from Genzyme (Sanofi), where he spent the past 7 years in senior commercial and corporate development positions, most recently as Vice President, US Hematology &amp; Oncology Business.<wbr> </div><div style="margin-bottom: 10px;">Prior to Genzyme, he spent 5 years (2000-2005) as an attorney at the law firm Mintz Levin Cohn Ferris Glovsky &amp; Popeo, where he focused on life sciences transactional work.<wbr> </div><div style="margin-bottom: 10px;">He has prior experience as a sales representative for Pfizer, Inc.<wbr> Mr.<wbr> Albers has a B.<wbr>Sc.<wbr> in Marketing from Indiana University, and a law degree (J.<wbr>D.<wbr>) and MBA from Georgetown University (Washington, DC).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8023_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>September 2009 - Algeta entered into a licensing and development agreement with Bayer Pharma AG.<wbr>  Under the terms of the Bayer Agreement, Algeta has a right to co-promote Alpharadin in the United States for the prevention or treatment of disease (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=5609" class="defaultlink">Oncology5609: Bayer Pay Euro 560M to Co-Dev.<wbr> Alpharadin for Bone Metastases in Symptomatic HRPC Patients</a>).<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8023_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8023attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8023_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8023_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(40,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8023">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-17T15:07:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-17T15:07:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>German's Health Technology Assessment Agency Evaluates Jevtana</title>
	<pubDate>2012-01-17T14:37:41+01:00</pubDate>
	<wp:post_id>3264</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: IQWiG has granted a significant added benefit score for the subpopulation of patients aged over 65, but is not able to quantify the added benefit in patients aged under 65.<wbr> The Common Health Board (G-BA) will decide whether Jevtana qualify for price negotiations or reference pricing by end of March 2012.<wbr> </div><div style="margin-bottom: 10px;">Jevtana has good chances of entering into price negotiations with the statutory health insurance and receiving a price premium over the appropriate comparator, based on the positive early benefit assessment issued by IQWiG.<wbr> </div><div style="margin-bottom: 10px;">The drug's price is likely to be in line with that of Zytiga (abiraterone) for which Janssen-Cilag (US) obtained a similar verdict at the beginning of January (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8000" class="defaultlink">Oncology8000: German's Health Technology Assessment Agency Evaluates Zytiga</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8022_1_ScreenCapture1.jpg"> </div><div>Source: Global Insight </div><!-- Comment details --><a name="oncology8022attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8022_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(62,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8022">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-17T14:37:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-17T14:37:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>U.S Survey Unveils Physician Confidence in Fillers and Neurotoxins</title>
	<pubDate>2012-01-17T09:27:11+01:00</pubDate>
	<wp:post_id>3265</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A new research letter published in the Jan.<wbr>/<wbr>Feb.<wbr> 2012 issue of the <EM>Archives of Facial Plastic Surgery</EM> shows that facial plastic surgeons, dermatologists, plastic surgeons and oculoplastic surgeons support the injection of neurotoxins and facial fillers for both themselves and their patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Methods</STRONG>: An anonymous survey that was sent to 6546 surgeons via e-mail.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Questionnaire</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Questions 1 and 2 inquired about the use of botulinum toxin and fillers by the participants.<wbr></LI>
<LI>Questions 3 to 5 reviewed demographics.<wbr> </LI>
<LI>Question 6 asked if the participant had ever been injected with either botulinum toxin and/<wbr>or facial fillers.<wbr> </LI>
<LI>Question 7 asked about self-injection of either product.<wbr> </LI>
<LI>Question 8 asked those who had been injected with fillers which specific products they would avoid self-injection with.<wbr> </LI>
<LI>Questions 9 and 10 asked those who do not self-inject who they enlist to inject for them.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Objectives</STRONG>: The use of botulinum toxin and the most commonly used fillers (hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, and polymethylmethacrylate).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Demographics: </STRONG>Most surgeons were male (65% vs 35% female), with the majority of participants (61%) ranging in age from 36 to 55 years.<wbr> </div><div style="margin-bottom: 10px;">Most of those responding were in the field of dermatology and dermatologic surgery (46%), the greater proportion of whom were female.<wbr> In contrast, the remaining specialties were composed mainly of male surgeons.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">98% of those who responded offer botulinum toxin in their practice, whereas 96% inject various facial fillers.<wbr> </div><div style="margin-bottom: 10px;">70% confirmed that they have been injected with botulinum toxin, whereas a lesser proportion (40%) have been injected with fillers.<wbr> </div><div style="margin-bottom: 10px;">46% of the physicians who have been injected with botulinum toxin and 21% of those injected with fillers have actually injected themselves.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6197_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Of those offering facial fillers, approx.<wbr> 100% (571 of 572) use hyaluronic acid.<wbr> In order of decreasing frequency, calcium hydroxylapatite (70% of responders), poly-L-lactic acid (50%), and polymethylmethacrylate (11%) were carried and used in the various practices.<wbr> </div><div style="margin-bottom: 10px;">Of the 102 participants who confirmed self-injection with fillers, 96 attested to which types of fillers they would inject themselves with.<wbr> Responders seemed to be least averse to hyaluronic acid as 81% of those responding would self-inject with this type of filler; 45% would use calcium hydroxylapatite, and 43% would use polymethylmethacrylate, whereas only 30% would use poly-L-lactic acid.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6197_2_ScreenCapture2.jpg"> </div><div>A copy of the full article is available on demand to Brigitte Deschamps </div><!-- Comment details --><a name="neurology6197attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6197_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(24,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6197_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(32,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6197_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(26,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6197">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-17T09:27:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-17T09:27:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Establishes Research Team to Bolster its Pipeline While Curbing Spending</title>
	<pubDate>2012-01-16T15:13:17+01:00</pubDate>
	<wp:post_id>3266</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to an article issued in the journal <EM>The Telegraph</EM>, the company has set up a 'Science and Technology Integration Office' to pursue partnerships with business, universities, governments and charities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Anders Ekblom is moving from his role as executive VP of global medicines development at AstraZeneca to head up the office.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Under a landmak agreement signed with the Medical Research Council, academics will be encouraged to explore how 22 of AstraZeneca's clinical compounds could be used to treat different diseases.<wbr> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9712" class="defaultlink">PharmaWorld9712: AZ's New Research Initiative</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9750">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-16T15:13:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-16T15:13:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis at the JP Morgan H/C Conference</title>
	<pubDate>2012-01-13T17:20:14+01:00</pubDate>
	<wp:post_id>3267</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cabozantinib is the star of the day with the presentation solely focusing on this compound.<wbr> The CEO stressed the need to be able to clearly differentiate in CRPC and believes this will be achieved with the products unique clinical profile.<wbr> </div><div style="margin-bottom: 10px;">Michael Morrissey, CEO commenced his presentation by highlighting the 2011 successes of cabozantinib: 1,500 CPRC patients evaluated, fruitful IST(Investigator Sponsored Trial) partnership with Mass General, good levels of antitumor activity have been shown.<wbr> Its unique profile will help develop a clearly differentiated commercial platform in CPRC and other cancers as well as the positive data from the EXAM trial in medullary thyroid cancer.<wbr> </div><div style="margin-bottom: 10px;">With regards to cabozantinib in CRPC, Exelixis understands that this market is a crowded one and are fully aware that differentiation is key.<wbr> He stated that they are dedicated to defining a pivotal trial plan that allows the commercial teams to best differentiate themselves from the other products soon to be on the market.<wbr> </div><div style="margin-bottom: 10px;">Decrease in bone pain seems to be the focus of early messaging, as well as a number of patients reducing the number of analgesics needed (~60% had some level of reduction with a quarter completely discontinuing).<wbr> Exelixis are aiming to file for the CRPC indication in the first half of 2012, with hope of receiving a priority review from the agencies.<wbr> </div><div style="margin-bottom: 10px;">With regards to the other pipeline products, Mr.<wbr> Morrissey stated that more news flow will be coming soon, especially at the upcoming meeting ASCO, ASCO GI and ASCO GU where they are very busy putting all the abstracts together for these events.<wbr> </div><div style="margin-bottom: 10px;">Exelixis have a financial call in February and therefore did not provide any financial details in this presentation bar that fact that Exelixis wholly owns cabozantinib and has significant options to partner and monetize the asset.<wbr> </div><div>Various trial details discussed at this meeting have already been published in Traction and can be found in the Takeaways from Exelixis 7<SUP>th</SUP> R&amp;D day in the December issue (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7944" class="defaultlink">Oncology7944: Takeaways from Exelixis 7th Annual R&D Day</a>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8019">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-13T17:20:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-13T17:20:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis To Signficantly Cut The Size Of Its US Workforce</title>
	<pubDate>2012-01-13T12:00:39+01:00</pubDate>
	<wp:post_id>3268</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><div><P style="margin: 0.5em 0px 1em; line-height: 1.6em; padding: 0px;"></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9747">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-13T12:00:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-13T12:00:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NICE Published Final Guidance Recommending Against Sanofi's Jevtana</title>
	<pubDate>2012-01-13T08:25:54+01:00</pubDate>
	<wp:post_id>3269</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NICE previously issued draft guidance in September 2011 recommending against the drug for 2nde-line treatment of HRPC.<wbr> The independent committee is concerned about the nature of the health-related QOL information provided by Sanofi.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Although the drug has been shown to be effective in extending life, it is also associated with a number of side effects (haematological AEs and diarrhoea).<wbr> </div><div>NICE CEO conclusion is that the drug would not provide enough health benefit to justify its cost (approx.<wbr> 22,200£ ($34,000) per patient).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8017">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-13T08:25:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-13T08:25:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Danish Reimbursement Body Rebuffs Sativex</title>
	<pubDate>2012-01-12T18:20:01+01:00</pubDate>
	<wp:post_id>3270</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Danish Medicines Agency has decided not to grant general or general conditional reimbursement to Almirall's Sativex.<wbr> The commission estimated that there is an abuse potential with Sativex and a risk that it could be used in other patients than those for whom it has been authorised.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">Sativex was launched in July 2011 in Denmark, only a few weeks after it was approved by Danish health authorities (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=5747" class="defaultlink">Neurology5747: Sativex® Approved in Denmark</a>).<wbr> </div><div>Denmark is the first reimbursement body to make a decision on Sativex and its verdict is in all probability likely to be looked at by other authorities.<wbr> As the drug is a cannabis-based product, reimbursement committees will be very careful and are set to apply very tight restrictions on the use of the drug if they decide to reimburse it.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6196">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-12T18:20:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-12T18:20:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astra Zeneca's Focus On Health Outcomes</title>
	<pubDate>2012-01-12T18:16:05+01:00</pubDate>
	<wp:post_id>3271</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9746">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-12T18:16:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-12T18:16:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon At The JP Morgan H/C Conference Excited By New Diabetes Data</title>
	<pubDate>2012-01-12T15:51:46+01:00</pubDate>
	<wp:post_id>3272</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lexicon's focus at today's meeting was on its diabetes programme, with some exciting data on LX4211 having been released earlier in the week demonstrating the drug's synergistic activity with the DPP-IV inhibitors.<wbr> As it gears up towards partnering and a phIII programme, the only data outstanding is that from a combination study with metformin due in June 2012.<wbr> Another notable comment was with regard to the group's partnering where there has been a shift in strategy with regard to specialist products.<wbr> Lexicon will now only look to outlicense regionally rather than globally as previously proposed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The SLGT1/<wbr>2 Competitive Environment</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">With the data it has obtained so far the emerging profile of LX4211 is of an oral drug that can produce fast effective glucose control, a drop in HBA1c within 4 weeks and a decrease in weight and b.<wbr>p within this timeframe.<wbr> Mechanistically it does this by elevating GLP-1 and PYY and in this sense it is breaking new ground.<wbr> </div><div style="margin-bottom: 10px;">Potentially what the market needs is a good combination of oral drugs that can avoid or slow down the transition to injectable therapies.<wbr> For the first time at this meeting, Lexicon highlighted data showing that LX4211 produces a synergistic effect with the DPP4 -inhibitor sitagliptin.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>LX1032 Carcinoid Syndrome Data</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Strategy</STRONG> </div><div style="margin-bottom: 10px;">Lexicon's portfolio is moving rapidly forward with three products scheduled to transition into phIII development over the next 24 months.<wbr> LX1032 (carcinoid syndrome) will be the first quickly followed by the diabetes drug.<wbr> Near term, however, the most important milestone is seen as the results from the metformin diabetes study.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_23_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;">As shown below, Lexicon is in a strong financial position following the success of the recent rights issue which raised $161m.<wbr> Its outlicensing programme continues with a lot of interest being shown in LX4211 and the intent to fully outlicense to a global partner remains.<wbr> However, for specialty products such LX1032 Lexicon wishes to retain a larger share of future sales and profits and will therefore only consider regional licensees.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_24_ScreenCapture24.jpg"> </div><!-- Comment details --><a name="endocrinology6832attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(63,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(62,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(91,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(44,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(56,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(58,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(63,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(56,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(56,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(62 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(66,6 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(69,2 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(60,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(48 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(57,3 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(67,7 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(54,4 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(64,4 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(73,9 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(52,3 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(71 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(74,4 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_6832_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(56,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6832">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-12T15:51:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-12T15:51:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS At The JP Morgan H/C Conference</title>
	<pubDate>2012-01-12T11:49:55+01:00</pubDate>
	<wp:post_id>3273</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="text-align: justify;">Comment: A critical factor in BMS having a successful 2011 was the launch of Yervoy, reaching $100 million in only 9 months on the market</P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify;">Lamberto Andreotti started off the presentation by highlighting how much BMS has changed over the past five years, divesting all of its non-pharmaceutical businesses and now focuses exclusively on innovative pharmaceuticals.<wbr> BMS now act much more like a Biotech with the money and global reach of a big Pharmaceutical.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify;">2011 was a strong year for BMS with the most notable events revolving around the launch of their Cardiovascular product ELIQUIS and their Oncology product YERVOY (ipilimumab) which has been hailed as <EM>the first therapy for metastatic melanoma to demonstrate a significant overall survival benefit into Phase </EM><EM>III</EM><EM> studies</EM>.<wbr> YERVOY was  launched in the US and in the EU, where it is currently going through the reimbursement process in various countries.<wbr> Ipilimumab is also in Phase III clinical trials for the treatment of chemotherapy-na&iuml;ve and post-docetaxel chemotherapy-recurrent forms of metastatic castration-resistant prostate cancer (mCRPC).<wbr> Data published to date also suggest that ipilimumab has significant activity in the treatment of men with much earlier forms of prostate cancer.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify;">In addition, the commercial model adopted for YERVOY has been well received as reflected by its sales - $100 million to date with peak sales forecasted to hit at as much as $6 billion.<wbr> The commercial model is defined as customer centric and includes important features such as a limited distribution model and a technology platform that allows BMS teams to provide the customer with: information that is most useful, exactly when they need it, in the format required and through channels which are most convenient.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify;">He then discussed how the late stage pipeline is a diverse mixture of small molecules and biologics and enthused about the immuno-oncology and hepatitis C franchises.<wbr>  These franchises contain four assets that have the potential to improve the standard of care for patients with high unmet medical need.<wbr>  The star of the Hep C franchise is INX-189, the highly potent pan-genotypic antiviral nuke which was procured through the acquisition of Inhibitex.<wbr>  Hep C was listed as a pillar of long-term growth forBMS.<wbr></P> </div><div><P style="text-align: justify;"> Finally, through a host of productivity initiatives (manufacturing rationalization, procurement programs etc) ,BMS managed to save $2.<wbr>5 billion with over $10 billion in cash and securities at the end of September.<wbr>BMSare about halfway through a $3 billion share repurchase program, but business development remains the top priority.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8016">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-12T11:49:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-12T11:49:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's R&D Model Highlighted @ JP Morgan H/C Conference</title>
	<pubDate>2012-01-11T10:27:12+01:00</pubDate>
	<wp:post_id>3274</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In 2011, Pfizer reduced R&amp;D spending by about $1 billion.<wbr> About 90 pre-POC studies were terminated to increase the productivity of the post-POC portfolio.<wbr> By 2015, Pfizer believes that 3 to 4 out of 5 of its POCs will be "precision medicine".<wbr> Management reported that R&amp;D model has been designed to strengthen the linkages between researchers and the commercial side.<wbr> More details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">I.<wbr> Read (Chairmand &amp; CEO) reported that " .<wbr>.<wbr>.<wbr> commercial business runs the development of POC, and Pfizer has broken the value chain into 2 distinct parts : pre-and-post POC".<wbr> </div><div style="margin-bottom: 10px;">He noted that "Researchers incentivate to get the products to POC, but only if those POCs are brought up by the business side".<wbr> </div><div style="margin-bottom: 10px;">He added "if the commercial side declines the POC, researchers are free to offer those drugs outside to external developers".<wbr> </div><div>Pfizer also changed its compensation package for research "50% of their long-term funding is now specifically tied to the results of POC starts, POC approvals, registration, and success in the market place with 30% of the total compensation tied to the value in the market place".<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9743">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-11T10:27:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-11T10:27:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Russian Pharma Market Growth Decelerating</title>
	<pubDate>2012-01-10T19:06:58+01:00</pubDate>
	<wp:post_id>3275</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12px; COLOR: #444444; LINE-HEIGHT: 18px; FONT-FAMILY: Arial; BORDER-COLLAPSE: collapse"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12px; COLOR: #444444; LINE-HEIGHT: 18px; FONT-FAMILY: Arial; BORDER-COLLAPSE: collapse"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12px; COLOR: #444444; LINE-HEIGHT: 18px; FONT-FAMILY: Arial; BORDER-COLLAPSE: collapse"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Even at this lower rate of pharmaceutical sales growth, Russia remains an attractive market in comparison to established pharmaceutical markets in Europe where growth for the full-year 2011 is expected to be in the low single-digit rate.<wbr> Efforts by the government to keep pharmaceutical prices low, particularly for reimbursable drugs, are behind the slowdown in growth.<wbr> An increase in reimbursement eligibility should, however, provide a boost to the Russian pharmaceutical market with volume sales growth over the next three years compensating for stagnating prices.<wbr> </div><div><SPAN style="FONT-SIZE: 12px; COLOR: #444444; LINE-HEIGHT: 18px; FONT-FAMILY: Arial; BORDER-COLLAPSE: collapse"><SPAN style="FONT-SIZE: 12px; COLOR: #444444; LINE-HEIGHT: 18px; FONT-FAMILY: Arial; BORDER-COLLAPSE: collapse"></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9741">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-10T19:06:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-10T19:06:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi and UCSF Collaborate to Find New Diabetes Treatments</title>
	<pubDate>2012-01-10T16:53:23+01:00</pubDate>
	<wp:post_id>3276</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The U.<wbr> of California, San Francisco (UCSF) and Sanofi will share their expertise in diabetes research for both type 1 and 2 diabetes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The $3.<wbr>1M collaboration will bring together scientists in 3 UCSF labs with Sanofi researchers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Expert Panel</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><U>Michael McManus</U>, PhD, a molecular biologist and expert in microRNA and the way genes are expressed, or turned into genetic products such as insulin and other proteins</LI>
<LI><U>Hebrok</U>, an expert on beta-cell biology and development who holds the UCSF Hurlbut-Johnson Distinguished Professorship in Diabetes Research</LI>
<LI><U>Michael German</U>, MD, an expert on beta-cell function and how cells transcribe DNA into RNA to create proteins, who is clinical director of the Diabetes Center and holds the Justine K.<wbr> Schreyer Endowed Chair in Diabetes Research.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Objectives</U> </div><div style="margin-bottom: 10px;">Together, the team will assess and validate potential drug targets from a UCSF library of approx.<wbr> 100,000 small interference RNAs (siRNA), including the gene that produces insulin.<wbr> </div><div>They also will identify Sanofi compounds that might be effective in regulating those molecules, study the impact those compounds have on UCSF laboratory models of diabetes and assess their therapeutic potential.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6829">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-10T16:53:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-10T16:53:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer Reduces The Price Of Human Growth Hormone</title>
	<pubDate>2012-01-10T10:49:13+01:00</pubDate>
	<wp:post_id>3277</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Intelligence from the field has confirmed that Pfizer has lowered the price of Genotropin in the UK and Scotland by 25%.<wbr> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse">We understand that the price reduction has been implemented in order to match the price of Omnitrope.<wbr></SPAN></SPAN> </div><div><SPAN class="Apple-style-span" style="WORD-SPACING: 0px; FONT: medium 'Times New Roman'; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BORDER-COLLAPSE: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="FONT-SIZE: 13px; COLOR: rgb(34,34,34); FONT-FAMILY: arial, sans-serif; BORDER-COLLAPSE: collapse">Please advise the CI Department and Siew-Kwan Chang if you are aware of similar developments in other markets.<wbr></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120431&edate=20120101&rec=6828">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-10T10:49:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-10T10:49:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis At The JP Morgan H/C Conference</title>
	<pubDate>2012-01-09T18:27:52+01:00</pubDate>
	<wp:post_id>3278</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Joseph Jimenez's (Novartis's CEO) focused his presentation today on how Novartis's strategy has created a diversified business capable of linking with government systems in ways that its peers simply cannot contemplate.<wbr> </div><div style="margin-bottom: 10px;">Jimenez talked about the way Novartis's strategy has evolved to address the pressures in the healthcare market both in terms of cost and innovation.<wbr> He stated that the strategy is crystal clear and very simple.<wbr> Novartis is winning through science based innovation that is focused on high growth segments of healthcare.<wbr> So it starts with the patient need, innovative medicines for breakthrough therapies, but all the way to affordable options through generics and self care through over-the-counter drugs </div><div style="margin-bottom: 10px;">He cited the $700m of savings delivered last year through the launch of enoxaparin as one example and its innovative science addressing unmet need as the other.<wbr> </div><div style="margin-bottom: 10px;">He noted that R&amp;D costs are shared across all divisions and that they all work closely together e.<wbr>g.<wbr> Pharma and Sandoz are working closely on biosimilars, whilst Animal Healths data mining exercise of NIBR's library has yeilded 35 new animal health compounds.<wbr> Talent is also moved around to gain competitive advantage.<wbr> </div><div style="margin-bottom: 10px;">He eluded to the group's strong 10-year track record in terms of double-digit operating growth, EPS and dividend growth but noted that two relatively lean years are ahead as the group looses exclusivity on its cardiovascular drug Diovan.<wbr> More will be said on this topic at the group's result meeting on the 26th January, where there will be an announcement about how the patent expiry will be "handled in a way that will surprise some people!" </div><div style="margin-bottom: 10px;">2011 was a record year for the group with 11 new approvals, the most important of which it was suggested were Gilenya for multiple sclerosis and Lucentis's new indications.<wbr> However, not all went well with some late-stage setbacks and quality issues emerging close to the year-end.<wbr> The latter requiring a $150m investment to upgrade its US generic manufacturing.<wbr> </div><div style="margin-bottom: 10px;">Looking ahead, Novartis believes that its growth will continue to be driven by blockbusters, by its generic division, by the expected approval of the first Meningitis B vaccine and by the newly acquired Alcon business.<wbr> Jimenz was very positive about the outlook for its generic division stating that it is the only company that is best positioned from both a scientific and commercial perspective - most have either one strenght or the other.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9738_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9738_2_ScreenCapture2.jpg"> </div><div>Source: <A href="http://www.novartis.com">www.<wbr>novartis.<wbr>com</A> </div><!-- Comment details --><a name="pharmaworld9738attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9738_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9738_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9738">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-09T18:27:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-09T18:27:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Polaris Is Investigating ADI-PEG 20 with Docetaxel for CRPC</title>
	<pubDate>2012-01-09T17:23:26+01:00</pubDate>
	<wp:post_id>3279</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: ADI-PEG 20 is arginine deiminase (ADI) formulated with polyethylene glycol, and is administered IM.<wbr> The primary endpoint of this PhI trial will evaluate the number of AEs as well as efficacy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01497925?cond=prostate+OR+hemophilia+OR+haemophilia+OR+neuroendocrine+OR+spasticity&amp;fund=2&amp;rcv_s=11%2F10%2F2011&amp;rank=12"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 39 </div><div style="margin-bottom: 10px;">Completion date: May 2013 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ADI-PEG 20 has been granted orphan drug status for HCC in the United States and Europe.<wbr> It has also been granted orphan drug status for melanoma in the United States.<wbr> The FDA has offered Special Protocol Assessment in the United States and the EMEA has offered Protocol Assistance in Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Mechanism of Action</STRONG> ADI-PEG 20 works by systemically depleting the external supply of arginine which causes these arginine-dependent cancer cells to die while leaving the normal cells unharmed.<wbr> </div><div style="margin-bottom: 10px;">Multiple cancers have been reported to have a high degree of arginine-dependency.<wbr> Phase 2 clinical trials have yielded positive results in patients with hepatocellular carcinoma or metastatic melanoma, and Phase 2 trials for small cell lung cancer and mesothelioma are currently ongoing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.polarispharma.com/literature/adipeg20oncprostate.html">http:/<wbr>/<wbr>www.<wbr>polarispharma.<wbr>com/<wbr>literature/<wbr>adipeg20oncprostate.<wbr>html</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Polaris Group is a privately held multinational biopharmaceutical company </div><div style="margin-bottom: 10px;">Focus: research and development of protein drugs to treat cancer and other debilitating diseases.<wbr> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8014_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8014attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8014_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(62,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8014">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-09T17:23:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-09T17:23:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan To Expand Manufacturing Plant At Westport</title>
	<pubDate>2012-01-09T12:10:22+01:00</pubDate>
	<wp:post_id>3280</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has announced today its intention to expand its manufacturing facility at its Westport Site in County Mayo creating 200 new jobs as part of a &euro;350 million investment designed to meet future demand for Botox and the next generation of biological products.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 18px; line-height: 18px;">The site which currently employs 900 people is expanding to meet the growing demand for its Botox product in treatment of migraines and incontinence.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 18px; line-height: 18px;">The planned 200 new staff will be recruited over the next four years.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 18px; line-height: 18px;">It is estimated another 250 jobs will be created indirectly locally during the construction period.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 18px; line-height: 18px;">Allergan&rsquo;s Westport facility is an important strategic site in its network and contributes more than 50 per cent of global revenues from the products it manufactures.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 18px; line-height: 18px;">Allergan has purchased the technology park next to its Westport facility to allow for the expansion.<wbr></P> </div><div><P style="margin: 0px 0px 18px; line-height: 18px;">Source:- <A href="http://www.irishtimes.com">www.<wbr>irishtimes.<wbr>com</A></P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6522c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Following the announcement in January that Allergan was to expand its biologics manufacturing capacity at its Westport facility in a $350 million investment, Allergan Pharmaceuticals have published a notice today signalling their intention to apply to Mayo County Council for permission for the development at Gortaroe, Westport (to the rear of the existing plant).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The notice outlines that the development will consist of the construction of an overall floor area of 15,677 sq meters, consisting of a three-storey office block with a floor area of 3456 sq meters and a height of 16 meters, a production hall and plant rooms with a floor area of 8,705 sq meters, and a warehouse and ancillary accommodation.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The notice also states that the works will incorporate the relocation of an existing local access road and the construction of a new circulation route to the existing Allergan facility, together with the provision of 223 car parking spaces.<wbr> Other cycle and pedestrian lanes will also be developed, along with a pedestrian link bridge of 140 sq meters and a height of 8.<wbr>8 meters to the existing multi-agency enterprise building.<wbr></SPAN> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Approximately 200 jobs will be created by Allergan when this new facility is operational, along with up to 250 indirect jobs locally, during the construction period.<wbr></SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6192">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-09T12:10:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-09T12:10:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UK's Silence Therapeutics/AZ siRNA Programme Yields Promising Results</title>
	<pubDate>2012-01-06T13:09:34+01:00</pubDate>
	<wp:post_id>3281</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Silence therapeutics has announced the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca.<wbr> The programme has resulted in three accepted unidentified therapeutic candidates which will now move into preclinical development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Evolution Of The Agreement</STRONG> </div><div style="margin-bottom: 10px;">The first collaboration between Silence and AstraZeneca was initiated in 2007 and was extended in 2010 to includes five research programs on novel small interfering RNA (siRNA) therapeutic molecules for selected targets (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=5371" class="defaultlink">PharmaWorld5371: Roche and Alnylam create major alliance to discover RNAi therapeutics</a>).<wbr> </div><div style="margin-bottom: 10px;">The second collaboration, focusing on the development of novel approaches for the delivery of siRNA molecules, was established in 2008 and was also extended in 2010.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Outcomes Of The Collaboration</STRONG> </div><div style="margin-bottom: 10px;">Under the first collaboration, which successfully identified, optimised and formulated novel siRNA molecules for selected targets and executed certain studies for five research programs.<wbr> Three of these programs have now been declared as &ldquo;Accepted Programs&rdquo; by AstraZeneca and can now be advanced into pre-clinical development.<wbr> </div><div style="margin-bottom: 10px;">AstraZeneca retains the global development and commercial rights to these Accepted Programs.<wbr> </div><div style="margin-bottom: 10px;">Silence, meanwhile will retain all rights with respect to the two research programs which did not become Accepted Programs.<wbr> However, these two programs remain subject to a two-year option with a first right of refusal in favour of AstraZeneca.<wbr> </div><div style="margin-bottom: 10px;">The second collaboration led to the development by Silence of a novel delivery system for siRNA molecules, the DACC delivery system.<wbr> Full rights to this system have been retained by Silence and can be applied to the other projects it is pursuing by itself and with partners.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Collaborations and Internal Programme</STRONG> </div><div style="margin-bottom: 10px;">Silence has other partnerships it is pursuing with Pfizer and Novartis and some in-house developments which include the liposomal siRNA product Atu027.<wbr> The drug which targets PI3K yeilded some promising results in its first phI study including responses in 2 <STRONG>neuroendocrine tumour patients</STRONG> (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7590" class="defaultlink">Oncology7590: ASCO Intelligence Part 4 - Novel Therapeutics - The PI3K inhibitor "Frenzy"</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8009_1_ScreenCapture1.jpg"> </div><div>Source: www,silencetherapeutics.<wbr>com </div><!-- Comment details --><a name="oncology8009attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8009_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8009">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-06T13:09:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-06T13:09:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Upturn In Provenge Sales Takes Market By Surprise</title>
	<pubDate>2012-01-06T09:41:58+01:00</pubDate>
	<wp:post_id>3282</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dendreon yesterday pre-announced Q4 sales of Provenge, which at $82m in the fourth quarter beat the Street's estimates by $10m.<wbr> </div><div style="margin-bottom: 10px;">The upturn appears to have been driven by unexpectedly large increase in clinics signed up to infuse Provenge for the treatment of CRPC patients (more than 840 completed in servicing, with a total of more than 590 clinics having infused Provenge at least once.<wbr> </div><div style="margin-bottom: 10px;">Analysts are suggesting that the incremental clinics represent the &ldquo;waiters&rdquo; who watched how their peers established reimbursement practices.<wbr> They do not necessarily foresee a significant uptick in &ldquo;same store sales&rdquo; and hence are predicting a return to more moderate Q/<wbr>Q growth rates of &lt;10% in the coming quarters.<wbr> </div><div style="margin-bottom: 10px;">It appears that new clinics infused patients at an estimated rate of 0.<wbr>45 per month, compared to existing clinics infusing patients at an estimated rate of 0.<wbr>5 per month, which is down from an estimated 0.<wbr>65 and 0.<wbr>74 in Q2:11 and Q1:11, respectively.<wbr> </div><div style="margin-bottom: 10px;">From a company perspective no further guidance was issued with regard to bottom line expectations for Q411 or FY2011 other than the comments that company is focused on reducing its COGS.<wbr> </div><div>Source: <a href="http://www.dendreon.com" class="defaultlink" title="www.dendreon.com">dendreon.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8007">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-06T09:41:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-06T09:41:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biogen & Idec Collaborate On Spinal Muscular Atrophy Development</title>
	<pubDate>2012-01-06T09:24:02+01:00</pubDate>
	<wp:post_id>3283</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The two companies have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize Isis&rsquo; antisense investigational drug, ISIS-SMN<SUB>Rx</SUB>, for the treatment of spinal muscular atrophy (SMA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>A Neuromuscular Disease With High Unmet Need</STRONG> </div><div style="margin-bottom: 10px;">SMA is a genetic neuromuscular disease characterized by muscle atrophy and weakness, and it is the most common genetic cause of infant mortality.<wbr> One child out of every 10,000 births worldwide is born with SMA.<wbr> Children with SMA generally appear normal at birth, with symptoms developing as early as a few months after birth, and in the most severe form of the disease, children have a significantly shortened lifespan.<wbr> The disease affects approximately 30,000-35,000 patients inthe United States,EuropeandJapan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms </STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Isis will receive an upfront payment of $29 millionand is eligible to receive up to $45 millionin milestone payments associated with the clinical development of ISIS-SMN<SUB>Rx</SUB> prior to licensing.<wbr> Biogen Idec has the option to license ISIS-SMN<SUB>Rx</SUB> until completion of the first successful Phase 2/<wbr>3 trial.<wbr> Isis could receive up to another $225 million in a license fee and regulatory milestone payments.<wbr> In addition, Isis will receive double-digit royalties on sales of ISIS-SMN<SUB>Rx</SUB>.<wbr> Isis will be responsible for global development of ISIS-SMN<SUB>Rx</SUB> through the completion of Phase 2/<wbr>3 registrational clinical trials, withBiogen Idec providing advice on the clinical trial design and regulatory strategy.<wbr> IfBiogen Idec exercises its option, it will assume global development, regulatory and commercialization responsibilities.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the development Stanley T.<wbr> Crooke, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>, Chairman of the Isis Board and Chief Executive Officer.<wbr> &ldquo;Biogen Idec&rsquo;s expertise in the global development and commercialization of innovative new therapies for neurologic diseases is a great strategic fit to advance ISIS-SMN<SUB>Rx.<wbr></SUB>This alliance is consistent with our business strategy to develop antisense drugs to proof-of-concept with a knowledgeable partner that is committed to supporting the rapid development of the drug.<wbr> Given the severity of the unmet need in SMA, our proof-of-concept studies should also serve as the registrational trials for ISIS-SMN<SUB>Rx</SUB>.<wbr> We believe that, together with Biogen Idec, we will be able to expeditiously develop this investigational drug in hopes of bringing to market an effective and desperately needed treatment to improve the lives Administration granted orphan drug status and fast track designation to ISIS-SMN<SUB>Rx</SUB> for the treatment of patients with SMA.<wbr> Isis acknowledges of children with SMA.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><STRONG>What is ISIS-SMN</STRONG><SUB><STRONG>Rx </STRONG></SUB>? </div><div style="margin-bottom: 10px;">ISIS-SMN<SUB>Rx</SUB> is an antisense molecule designed to treat all types of childhood SMA by altering the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein.<wbr> In December 2011, Isis initiated the first Phase 1 clinical study evaluating ISIS-SMN<SUB>Rx</SUB> in children with SMA (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6165" class="defaultlink">Neurology6165: Isis Trials Pioneering Therapy For SMA</a>).<wbr> The Phase 1 study is a single-dose, dose-escalation study designed to assess the safety, tolerability and the pharmacokinetic profile of the drug in children between the ages of 2 and 14 who are medically stable.<wbr> In this study, ISIS-SMN<SUB>Rx</SUB> will be administered intrathecally as a single injection directly into the spinal fluid.<wbr> Isis plans to follow this study with a Phase 1 multiple-ascending dose study.<wbr> </div><div style="margin-bottom: 10px;">ISIS-SMN<SUB>Rx</SUB> has been granted ODS status by the FDA.<wbr> </div><div>Source: <A href="http://www.biogenidec.com">www.<wbr>biogenidec.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6190">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-06T09:24:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-06T09:24:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aeterna to Develop Companion Diagnostic for AEZS-108</title>
	<pubDate>2012-01-05T16:46:12+01:00</pubDate>
	<wp:post_id>3284</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has entered into a collaboration agreement with Ventana Medical Systems (member of the Roche Group) to develop a tool to improve methods for the selection of patients to be treated with the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">AEZS-108 has successfully completed Phase 2 studies for the treatment of endometrial and ovarian cancer, and is also in Phase 2 trials in prostate and bladder cancer.<wbr> A pivotal trial in endometrial cancer is expected to be initiated in the first half of 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Ventana</STRONG> </div><div style="margin-bottom: 10px;">Together with Roche, Ventana is driving personalized medicine through accelerated drug discovery and the development of companion diagnostics to identify the patients most likely to respond favorably to specific therapies.<wbr> </div><div>Also See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=6175" class="defaultlink">PharmaWorld6175: Roche Acquires Ventana for about $3.<wbr>4 billion in Cash</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8006">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-05T16:46:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-05T16:46:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Proprietary Peptide Technology Platform Validated By Significant No Of Key Partners</title>
	<pubDate>2012-01-05T16:40:25+01:00</pubDate>
	<wp:post_id>3285</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9737_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="pharmaworld9737attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_9737_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(65,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9737">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-05T16:40:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-05T16:40:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SOFT Intelligence -Potential Transfer of Xeomin US Therapeutic Marketing Rights To Forest Labs</title>
	<pubDate>2012-01-05T15:46:49+01:00</pubDate>
	<wp:post_id>3286</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The CI Dept is picking up unsubtantiated rumours that Merz plans to transfer the marketing of Xeomin for Neurology indications in the US to its long-standing partner in the Alzheimer area Forest Labs as of Q22012 refocusing its business on aesthetics and dermatology.<wbr> </div><div style="margin-bottom: 10px;">There is speculation that as of Q2 2012, Merz will transfer the marketing of Xeomin for neurology indications to Forest.<wbr> As part of the transfer, we believe some of Merz Neuro sales reps will join forces with the Forest reps marketing the antidepressant Lexapro and the Alzheimer drug Namenda.<wbr> </div><div style="margin-bottom: 10px;">If this is true Merz's US business would essentially be refocused on aesthetics and dermatology and poised to focus its limited resources on the launch of Xeomin for Glabellar lines at a price 20% below Botox.<wbr> US approval for this indication was granted in August 2011.<wbr> </div><div style="margin-bottom: 10px;">Validation of this development is important from Ipsen's strategic perspective.<wbr> We, therefore, ask all readers to see if they can provide any further substantive intelligence on this potential collaboration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>The Logic Behind A Merz Forest Xeomin Co-marketing Agreement</U></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Merz appears to be struggling to generate therapeutic sales in the US with its current Neuro sales force, however the recent issuance of a J code for reimbursement purposes should obviate one possible constraint on sales (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6183" class="defaultlink">Neurology6183: Xeomin Obtains a Permanent J-code for Easier Reimbursement</a>): </LI>
<LI>Merz strategy as stated in its annual reports appears more focused on prospects within its aesthetic business especially following the purchase of the Californian medical aesthetic company BioForm in February 2010.<wbr> </LI>
<LI>Forest faces a potential patent cliff with two major products going off patent in 2012 and 2015.<wbr> The company pioneered in-licensing late stage assets and has come to represent the archetypal specialty pharmaceutical business model.<wbr> It has experienced strong growth throughout the last decade, however, its meteoric growth curve has not been sustainable as it has proven increasingly difficult to identify new blockbusters, and sales of Forest’s newer launches have been more modest and accompanied by typical pipeline failures and setbacks; </LI>
<LI>Whilst the company appears to have a strong pipeline of products there are some development and regulatory risks associated with these products which are making investors wary of the company's revenue prospects.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><U>Lexapro (escitalopram) </U></STRONG> </div><div style="margin-bottom: 10px;">Is an SSRI antidepressant indicated for the acute and maintenance treatment of major depressive disorder and the acute and maintenance treatment of general anxiety disorder.<wbr> The product launched in September 2002 represents ~51% of Forest’s sales.<wbr> Forest obtained the product via a partnership with Danish company Lundbeck.<wbr> </div><div style="margin-bottom: 10px;">Lexapro will go generic upon the expiration of its last patent in March 2012 and represents the most meaningful portion of Forest’s patent cliff.<wbr> </div><div style="margin-bottom: 10px;">Prescriptions of Lexapro have been declining 7% Y/<wbr>Y while sales are up approximately 4% versus the first half of Fiscal 2011.<wbr> Though sales have been boosted by price increases, continued rebating of the product combined with lower demand and a shift in promotional resources are expected to result in overall sales declines prior to generic entry.<wbr> </div><div style="margin-bottom: 10px;">Cantor Fitzgerald analysts estimate that Lexapro sales of $2.<wbr>25 billion in Fiscal 2012 will decline to $729 million in Fiscal 2013 due to generic entry in March 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Namenda (memantine)</U></STRONG> </div><div style="margin-bottom: 10px;">Is an NMDA receptor antagonist indicated for the treatment of moderate-to severe dementia of the Alzheimer’s type and was approved in October 2003.<wbr> Forest licensed Namenda from Merz, Namenda represents ~29% of Forest’s sales, and prescriptions have been growing at approximately 2.<wbr>5% Y/<wbr>Y.<wbr> Cantor Fitzgerald expects Fiscal 2012 sales of $1.<wbr>36 billion, growing to $1.<wbr>39 billion in Fiscal 2013 and $1.<wbr>40 billion in Fiscal 2014 (which includes sales from long-acting Namenda XR.<wbr> </div><div style="margin-bottom: 10px;">Namenda has been granted patent term extension such that its patent expires in April 2015.<wbr> Following a series of generic settlements, generic entry is expected to occur in January 2015, four months ahead of patent expiry.<wbr> As part of its life-cycle extension strategy Forest has developed a once-daily extended release formulation of Namenda (Namenda XR) and plans to switch existing Namenda patients to this new dosage form ahead of generic launch.<wbr> Namenda XR was FDA approved in June 2010, and the company recently announced the issuance of a patent covering this dosage form.<wbr> Forest plans to launch Namenda XR in late 2012-early 2013.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6185_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><U>Forest's Current Sales Force Structure</U></STRONG> </div><div style="margin-bottom: 10px;">There are seven sales forces within Forest.<wbr> These include four primary care forces that comprise approximately 2,000 sales reps, two specialty forces of ~550 reps, one hospital force of 250 reps, and approximately 500 sales managers.<wbr> Forest also plans to expand its sales force by another ~300 sales reps upon the approval of the constipation drug linactolide.<wbr> </div><div style="margin-bottom: 10px;">Forest's Sales Force Organisation and Sales Call Priority (Scource Cantor Fitzgerald Dec 2011) </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6185_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology6185attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6185_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(137,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6185_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6185">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-05T15:46:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-05T15:46:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Viamet Moves VT-464 Into PhI/II Development For CRPC</title>
	<pubDate>2012-01-05T14:21:49+01:00</pubDate>
	<wp:post_id>3287</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Comment: Viamet has announced that dosing has begun in a phase I/<wbr>II trial of its oral potent CYP17-lyase inhibitor VR-464 which has a differentiated profile versus the only other approved CYP17 lyase inhibitor abiraterone.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">The molecule a novel non-steroidal small molecule was discovered by Viamet using its proprietary Metallophile<SPAN class="Apple-style-span" style="font-weight: normal; word-spacing: 0px; text-transform: none; color: #000000; text-indent: 0px; line-height: normal; font-style: normal; white-space: normal; letter-spacing: normal; border-collapse: separate; font-variant: normal; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;"><SUP style="margin: 0px; padding: 0px;">&reg;</SUP> Technology.<wbr> In preclinical models VT-464 preferentially inhibits the lyase reaction of the CYP17 enzyme over the hydroxylase reaction, a key point of differentiation versus abiraterone acetate.<wbr></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: small arial,helvetica,sans-serif; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;"><STRONG>Clinical Implications of This Point Of Differentiation</STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: small arial,helvetica,sans-serif; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;"><SPAN class="Apple-style-span" style="font-weight: normal; word-spacing: 0px; text-transform: none; color: #000000; text-indent: 0px; line-height: normal; font-style: normal; white-space: normal; letter-spacing: normal; border-collapse: separate; font-variant: normal; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;">CYP17 catalyzes two distinct chemical reactions, a hydroxylase reaction and a lyase reaction.<wbr> Non-selective inhibitors can disrupt the hydroxylase reaction leading to an increase in steroids such as the mineralocorticoids and a decrease in other essential steroids such as cortisol.<wbr> This steroid imbalance results in the need to co-administer prednisone with these non-selective agents.<wbr> </SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: small arial,helvetica,sans-serif; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;"><SPAN class="Apple-style-span" style="font-weight: normal; word-spacing: 0px; text-transform: none; color: #000000; text-indent: 0px; line-height: normal; font-style: normal; white-space: normal; letter-spacing: normal; border-collapse: separate; font-variant: normal; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;">Based on preclinical research conducted by Viamet and others, it is anticipated that a lyase-selective CYP17 inhibitor, such as VT-464, would display a favorable safety and tolerability profile compared to non-selective agents and will not require co-administration of prednisone</SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: small arial,helvetica,sans-serif; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;"><SPAN class="Apple-style-span" style="font-weight: normal; word-spacing: 0px; text-transform: none; color: #000000; text-indent: 0px; line-height: normal; font-style: normal; white-space: normal; letter-spacing: normal; border-collapse: separate; font-variant: normal; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;"><STRONG>How Viamet's Technology Platform Was Used To Identify A Differentiated Molecule</STRONG></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: small arial,helvetica,sans-serif; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;"><SPAN class="Apple-style-span" style="font-weight: normal; word-spacing: 0px; text-transform: none; color: #000000; text-indent: 0px; line-height: normal; font-style: normal; white-space: normal; letter-spacing: normal; border-collapse: separate; font-variant: normal; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;"><SPAN class="Apple-style-span" style="font-weight: normal; word-spacing: 0px; text-transform: none; color: #000000; text-indent: 0px; line-height: normal; font-style: normal; white-space: normal; letter-spacing: normal; border-collapse: separate; font-variant: normal; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="color: #1a1a1a; line-height: 22px;">Viamet's disruptive Metallophile<SUP style="margin: 0px; padding: 0px;">&reg;</SUP> Technology is based on its expertise in bioinorganic chemistry and metalloenzyme biology.<wbr> This allows Viamet to identify metalloenzyme targets with high therapeutic and commercial potential, leverage existing metalloenzyme inhibitors as the basis for novel analogs, and rapidly generate potentially superior clinical candidates by optimizing the metal-binding component of known inhibitors</SPAN></SPAN></SPAN></SPAN></SPAN></SPAN> </div><div><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 14px; color: #1a1a1a; line-height: 22px; font-family: Helvetica, Arial, sans-serif;"><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="Apple-style-span" style="font-size: 14px; color: #1a1a1a; line-height: 22px; font-family: Helvetica, Arial, sans-serif;">From <A href="http://www.viamet.com">http:/<wbr>/<wbr>www.<wbr>viamet.<wbr>com</A>, see <A href="http://www.firstwordpharma.com/node/939772">original source</A>.<wbr></SPAN></SPAN></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8004">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-05T14:21:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-05T14:21:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Xeomin Obtains a Permanent J-code for Easier Reimbursement</title>
	<pubDate>2012-01-05T12:21:59+01:00</pubDate>
	<wp:post_id>3288</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6183">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-05T12:21:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-05T12:21:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>German's Health Technology Assessment Agency Evaluates Zytiga</title>
	<pubDate>2012-01-04T12:41:38+01:00</pubDate>
	<wp:post_id>3289</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=8000">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-04T12:41:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-04T12:41:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Filing of New 1st line RCC Drug Planned For 2012</title>
	<pubDate>2012-01-04T12:35:09+01:00</pubDate>
	<wp:post_id>3290</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AVEO Pharmaceuticals and its partner Astellas have announced that the TKI tivozanib has demonstrated superiority over Bayer's sorafenib in the primary endpoint of PFS in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of the drug compared to sorafenib in 517 patients with advanced renal cell carcinoma.<wbr> </div><div style="margin-bottom: 10px;">TIVO-1 is the first registration study in first-line RCC that is comparing an investigational agent against an approved VEGF therapy.<wbr> </div><div style="margin-bottom: 10px;">All patients in TIVO-1 had clear cell RCC, had undergone a prior nephrectomy, and had not previously been treated with either a VEGF or mTOR therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Top-line findings from the study have shown that:-</STRONG> </div><div style="margin-bottom: 10px;">• tivozanib demonstrated a statistically significant improvement in PFS with a median PFS of 11.<wbr>9 months compared to a median PFS of 9.<wbr>1 months for sorafenib in the overall study population </div><div style="margin-bottom: 10px;">• tivozanib demonstrated a statistically significant improvement in PFS with a median PFS of 12.<wbr>7 months compared to a median PFS of 9.<wbr>1 months for sorafenib in the pre-specified subpopulation of patients who were treatment naïve (no prior systemic anti-cancer therapy); this subpopulation was approximately 70% of the total study population </div><div style="margin-bottom: 10px;">• tivozanib demonstrated a well-tolerated safety profile consistent with the Phase 2 experience; the most commonly reported side effect was hypertension, a well established on-target and manageable effect of VEGFR inhibitors </div><div>Based on these data, AVEO and Astellas currently plan to submit for marketing approval of tivozanib in the United States and Europe in 2012, subject to final collection and analyses of all available data from the trial.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7999">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-04T12:35:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-04T12:35:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Strong Uptake Of Xgeva For Prostate Cancer</title>
	<pubDate>2012-01-04T12:28:58+01:00</pubDate>
	<wp:post_id>3291</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Strong Uptake Of Xgeva For Prostate Cancer</span>&nbsp;<br><span style="font-size: 12px;">Comment: At last week's Oppenheimer H/<wbr>C conference, Amgen provided an update on the uptake curves for Prolia and Xgeva (denosumab) and suggested that by 2015 these two drugs combined will be contributing $3-4bn in revenue.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7978">...</a><br></div><div><SPAN class="Apple-style-span" style="word-spacing: 0px; font: medium 'Times New Roman'; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; border-collapse: separate; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none;"><SPAN class="Apple-style-span" style="font-size: 12px; line-height: 14px; font-family: Arial, Helvetica, sans-serif;">Amgen has announced that the U.<wbr>S.<wbr> FDA has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb.<wbr> 2012 to discuss the sBLA for XGEVA (denosumab) to treat men with castration&ndash;resistant prostate cancer (CRPC) at high risk of developing bone metastases.<wbr></SPAN></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7998">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology7978">View thread  Oncology7978: Strong Uptake Of Xgeva For Prostate Cancer</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-04T12:28:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-04T12:28:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Apifarma Warns on Parallel Trade As Medicine Price Drop Becomes Effective in Portugal</title>
	<pubDate>2012-01-03T14:47:30+01:00</pubDate>
	<wp:post_id>3292</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Apifarma, the Portuguese branded drug industry association, issued a warning that medicine price reductions have created ruptures in the market's normal supply, according to news source Agência Lusa.<wbr> This has left patients without access to certain medicines, particularly those deemed innovative, and has also increased the possibility of counterfeiting, according to the association.<wbr> </div><div style="margin-bottom: 10px;">Apifarma issued a statement claiming that "successive administrative reduction in medicine prices that occurred in the last two years has made Portugal even more attractive to parallel trade that although legal has been causing ruptures in the normal supply".<wbr> The practice of parallel trade or exporting by pharmacies and wholesalers is legal, unless it starts to threaten the national supply of medicines.<wbr> </div><div style="margin-bottom: 10px;">The statement also added that since the start of 2011, the National Health Service (SNS) expenditure on retail medicines has been in decline.<wbr> This spending fell by 21% in October, which is "way beyond the goal delineated in the memorandum of understanding [MoU] deal", the association delineated.<wbr> The MoU was signed in May 2011 by the previous government in return for financial aid to prevent the country from following the economic footsteps of Greece.<wbr> </div><div style="margin-bottom: 10px;">Apifarma highlighted that in the hospital sector, manufacturers have made a "tremendous effort" to accommodate the SNS's accumulated debt without altering the usual supply of medicines.<wbr> According to the association's data, since December 2010, the debt of SNS hospitals to pharmaceutical manufacturers has grown by 30%, reaching EUR1.<wbr>3 million (USD 1.<wbr>7 million) in November 2011, with a payment deadline of 453 days.<wbr> </div><div style="margin-bottom: 10px;">The association also stressed that no hospital debt repayment plan or calendar has been made public, despite the fact that "the resolution of debts owed to pharmaceutical firms was deemed a priority by the MoU".<wbr> The Ministry of Health (MoH) had previously committed to establishing the aforementioned plan, in partnership with the Ministry of Finance, by the end of 2011.<wbr> The repayment plan is anticipated to be applied at the start of this year.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Medicine prices will be cheaper for patients, while the profit margin for pharmacies and distributors has reduced from today (3 January), based on legislation published yesterday (2 January) in the official gazette, <I>Diário da República</I>.<wbr> The new law has cemented a decree published at the end of November.<wbr> </div><div style="margin-bottom: 10px;">According to the latest legislation, authorised prices can be altered as long as they are lower than stipulated and in accordance with previous communications with regulator Infarmed and the Directorate General of Economic Activities, which establishes prices for the outpatient sector.<wbr> The reform crucially also delineates an annual revision of medicine prices.<wbr> </div><div style="margin-bottom: 10px;">As stated previously in the decree, the latest law defines that generic medicine prices "have to reduce until the value corresponding to 50% of the maximum price, fixed administratively, of the reference medicine with the same dosage and the same pharmaceutical form".<wbr> Exceptions are only made for generic medicines with a wholesaler price lower than EUR10, in line with the decree.<wbr> </div><div style="margin-bottom: 10px;">Pharmacies still have a deadline of three months to dispense existing medicines with the old price, but are not allowed to make new medicines available without an updated price, in line with the new legislation.<wbr> Similarly, from today, manufacturers are not allowed to provide medicines with prices different from those defined in the new way of calculating medicine prices to wholesalers or pharmacies.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">This reduction in prices is expected to provide patients with annual savings of EUR56.<wbr>8 million.<wbr> Health Secretary Manuel Teixeira told Agência Lusa that on average, medicine prices will lower by 4%, which also equates to annual savings for the SNS of EUR50 million.<wbr> The MoU signed in May 2011 has promoted a continued trend of medicine price cuts, with a greater decline expected in 2012 compared with 2011.<wbr> New generics will have to be 50% cheaper than the branded reference medicines in comparison with the 35% value used in 2011 calculations.<wbr> Furthermore, the price of many medicines is likely to be more than 50% cheaper because of the changes to countries used in the international reference-pricing system, as well as the lowering of the profit margins of wholesalers and pharmacies.<wbr> The retail price of medicines will reduce again in 1 April with the alterations to the reference-pricing system.<wbr> These administrative price cuts are unsurprisingly making Portugal an unattractive country for pharmaceutical manufacturers, who are still eagerly waiting to hear about a hospital debt repayment plan.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120431&edate=20120101&rec=9736">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-03T14:47:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-03T14:47:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Publication of the Ph2 Results of Revance's Botulinum Toxin Topical Gel for Lateral Canthal Lines</title>
	<pubDate>2012-01-03T13:50:05+01:00</pubDate>
	<wp:post_id>3293</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Top-line Ph2b results were first presented @ the ASDS (Chicago).<wbr> Published data demonstrate that RT001 appears to be a safe and well-tolerated treatment for improvement of moderate-to-severe lateral canthal lines.<wbr> More intelligence to come as Dan Browne (Revance's CEO) will be presenting 'the next frontier of non-invasive procedures' @ IMCAS (Paris Jan.<wbr> 26 to 29).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">@ <A href="http://jddonline.com/articles/dermatology/1691">http:/<wbr>/<wbr>jddonline.<wbr>com/<wbr>articles/<wbr>dermatology/<wbr>1691</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><EM style="FONT-WEIGHT: normal; FONT-SIZE: 13px; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; LINE-HEIGHT: 16px; FONT-FAMILY: Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(250,248,241); FONT-VARIANT: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></EM> </div><div style="margin-bottom: 10px;"><EM style="FONT-WEIGHT: normal; FONT-SIZE: 13px; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; LINE-HEIGHT: 16px; FONT-FAMILY: Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(250,248,241); FONT-VARIANT: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></EM> </div><div style="margin-bottom: 10px;"><EM style="FONT-WEIGHT: normal; FONT-SIZE: 13px; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; LINE-HEIGHT: 16px; FONT-FAMILY: Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(250,248,241); FONT-VARIANT: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></SPAN></EM> </div><div><EM style="FONT-WEIGHT: normal; FONT-SIZE: 13px; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; LINE-HEIGHT: 16px; FONT-FAMILY: Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(250,248,241); FONT-VARIANT: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120431&edate=20120101&rec=6180">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-03T13:50:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-03T13:50:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Plexxikon's PLX3397 to Enter Ph2 for CRPC</title>
	<pubDate>2012-01-02T11:59:20+01:00</pubDate>
	<wp:post_id>3294</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PLX3397 is a highly selective kinase inhibitor that down-modulates macrophages, osteoclasts and mast cells, as well as certain tumor cells that promote tumor growth and metastases to the bone.<wbr> Primary outcome measure will assess efficacy-biomarker profiling.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 20 </div><div style="margin-bottom: 10px;"><U>Inclusion criteria</U> </div><div style="margin-bottom: 10px;"><UL><LI>Castrate level of testosterone (&lt;50 ng/<wbr>dL).<wbr> </LI>
<LI>Baseline circulating tumor cell (CTC) count ≥10/<wbr>7.<wbr>5 mL blood.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Start date: March 2012 - Completion date: June 2013 </div><div style="margin-bottom: 10px;">Location: USA (2 sites).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Preclinical data have shown PLX3397’s antitumor effects, including a decrease in circulating tumor burden, delay of tumor metastases and inhibition of tumor growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process in conjunction with a highly specialized scaffold-like screening library, to design new drug candidates within various families of drug targets.<wbr> </div><div style="margin-bottom: 10px;">In April 2011, Plexxikon became a member of the DaiichiSankyo Group.<wbr> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_7991_1_ScreenCapture1.jpg"> </div><div>Sources: clinicaltrials.<wbr>gov; Plexxikon PR </div><!-- Comment details --><a name="oncology7991attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_7991_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(42,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120431&edate=20120101&rec=7991">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-01-02T11:59:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-01-02T11:59:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	

</channel>
</rss>
